NCT03182751	1:25:treatment,37:54:upper_bound	Coronary stent placement within the previous 6 months
NCT03182751	1:21:clinical_variable,32:41:upper_bound	Creatinine clearance less than 30 mL/min
NCT03182751	1:39:chronic_disease	Disseminated intravascular coagulation
NCT03182751	12:15:chronic_disease,17:19:chronic_disease,24:27:chronic_disease,39:55:upper_bound	History of CVA, MI, or VTE within the previous 30 days
NCT03182751	12:26:cancer,34:47:cancer	History of unprovoked VTE and/or recurrent VTE
NCT03182751	1:24:chronic_disease	Intracranial hemorrhage
NCT03182751	18:33:chronic_disease,35:57:chronic_disease,59:84:chronic_disease,86:110:chronic_disease,112:147:chronic_disease,149:167:chronic_disease	Known history of Factor V Leiden, protein C/S deficiency, prothrombin gene mutation, anti-thrombin deficiency, anti-phospholipid antibody syndrome, lupus anticoagulan
NCT03182751	46:67:treatment	Surgically treated with sliding hip screw or cephalomedullary nail (short or long)
NCT03182101	3:6:age,7:9:upper_bound	< age 12
NCT03182101	39:55:language_fluency	Patient and parent/legal guardian are English speaking
NCT03182101	36:39:chronic_disease,41:59:chronic_disease,61:75:chronic_disease,77:91:chronic_disease,96:111:chronic_disease	Primary or co-primary diagnosis of OCD, Separation Anxiety, Social Anxiety, Panic Disorder, or Specific Phobia
NCT03182101	1:10:chronic_disease,12:44:chronic_disease,49:67:chronic_disease	Psychosis, Pervasive Developmental Disorder, or Mental Retardation
NCT03180398	26:49:cancer	Histologically confirmed prostate adenocarcinoma
NCT03179449	28:49:cancer,94:103:treatment	Any patient with suspected malignant brain tumor on diagnostic MR imaging who will undergo a resection
NCT03179449	26:40:treatment	Contraindication to MRI (metal implants)
NCT03179449	1:14:chronic_disease,15:30:chronic_disease	Hemosiderosis/hemochromatosis
NCT03179449	1:14:chronic_disease,40:53:chronic_disease,57:72:chronic_disease	Iron overload from any cause (not just hemosiderosis or hemochromatosis)
NCT03179449	27:38:allergy_name	Known hypersensitivity to ferumoxytol or any of its components
NCT03179449	1:9:pregnancy	Pregnant patients
NCT03179449	1:25:chronic_disease	severe chronic hemolysis
NCT03178617	49:57:cancer,61:88:cancer	Adult primary caregiver of children treated for leukemia or lymphoblastic lymphoma (LL) and daily contact with the child
NCT03178617	21:37:treatment,51:59:upper_bound,60:74:treatment	Child has completed cancer treatment and is up to 10 years post-treatment
NCT03178617	1:26:language_fluency	Child understands English and is enrolled in school (but can be bilingual)
NCT03178617	22:36:cancer,28:36:cancer,43:77:cancer,74:76:cancer,79:107:cancer,166:170:age,171:172:lower_bound,173:181:upper_bound	Children treated for acute leukemia (e.g. acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML]), LL, or other types of leukemia (if treated intensively) aged 5-12 years and their parents/caregivers
NCT03178617	38:46:ethnicity,47:53:ethnicity	One or both parents self-identify as Hispanic/Latino
NCT03178617	36:96:treatment	Recent or current participation in educational/behavioral intervention study with similar focus
NCT03178617	11:38:chronic_disease,45:54:chronic_disease	istory of major psychiatric condition (e.g. psychosis) in parent or child
NCT03178617	43:84:language_fluency	primary participating parent/caregiver is monolingual or bilingual Spanish speaking
NCT03178617	1:35:chronic_disease,51:66:chronic_disease	severe neurodevelopmental disorder in child (e.g. Down's syndrome)
NCT03170440	12:38:chronic_disease,52:56:chronic_disease	history of severe psychiatric illness unrelated to PTSD
NCT03170375	14:25:clinical_variable,30:38:lower_bound	On-treatment systolic BP of >160 mmHg at screening visit
NCT03170375	8:14:cancer,26:71:cancer	active cancer other than non-melanoma skin or low-risk prostate cancer
NCT03170375	1:23:chronic_disease,29:65:clinical_variable,67:84:upper_bound	chronic kidney disease with estimated glomerular filtration rate <45 ml/min/ 1.73m2
NCT03170375	1:10:chronic_disease	cirrhosis
NCT03170375	1:11:clinical_variable,13:20:upper_bound	hemoglobin <9 gm/dL
NCT03170375	1:16:chronic_disease	hepatic disease
NCT03170375	1:35:clinical_variable,37:40:upper_bound	left ventricular ejection fraction <50%
NCT03170375	1:19:chronic_disease	metabolic syndrome
NCT03170375	1:42:chronic_disease	moderate or severe valvular heart disease
NCT03170375	1:22:chronic_disease,26:32:chronic_disease,44:58:upper_bound	myocardial infarction or stroke within the prior 6 months
NCT03170375	24:41:clinical_variable,43:52:upper_bound	other comorbidity with expected survival <12 months
NCT03170375	1:31:chronic_disease	severely uncontrolled diabetes
NCT03170375	12:27:chronic_disease,38:45:treatment,66:78:chronic_disease,96:105:treatment	unoperated aortic aneurysm for which surgery is indicated, prior hyperkalemia requiring urgent treatment
NCT03170375	6:9:chronic_disease	with HTN
NCT03167281	17:30:treatment,34:47:treatment	Patients taking carbamazepine or nitroglycerin
NCT03167281	25:42:treatment,49:61:chronic_disease	Patients that require a thoracostomy tube for a pneumothorax
NCT03167281	35:62:treatment,69:85:chronic_disease	Patients with an indication for a thoracostomy tube placement for a pleural effusion
NCT03167281	1:9:pregnancy,10:15:gender	Pregnant women
NCT03167281	16:20:allergy_name,25:30:allergy_name	Sensitivity to t-PA, or DNase
NCT03167281	1:4:age,5:13:lower_bound	age 18 years or older
NCT03159936	1:9:lower_bound,15:23:upper_bound,27:30:age	18 years to ≤ 65 years of age
NCT03159936	53:56:clinical_variable,75:77:lower_bound,81:110:clinical_variable,114:126:clinical_variable,145:147:lower_bound	At Screening and Visit 1 (Baseline/Day 1), have had DLE covering at least 5% of total body surface area (BSA) or SLE with DLE covering at least 2% of BSA as determined by the hand print method (one palm is equivalent to 1% BSA)
NCT03159936	66:74:treatment	Concomitant use of moderate to potent inhibitors and inducers of CYP3A4/5
NCT03159936	75:78:chronic_disease	Other skin conditions at Baseline that would interfere with evaluation of DLE
NCT03159936	1:17:treatment,72:80:lower_bound	Systemic therapy is allowed if on a stable dose and using for at least 3 months -background therapies outlined in Protocol
NCT03159936	1:23:treatment,35:47:upper_bound	Topical corticosteroid within the past 2 weeks
NCT03159936	1:6:gender,38:73:contraception_consent,101:112:treatment	Women of childbearing potential must use effective contraceptive methods in order to participate in tofacitinib clinical studies
NCT03159936	1:6:gender,11:23:pregnancy,27:50:pregnancy	Women who are pregnant or wish to become pregnant, or who are lactating
NCT03159936	28:31:chronic_disease,83:86:chronic_disease	with clinical diagnosis of DLE (and at least half of patients with a diagnosis of SLE) as determined by the Principal Investigator by medical history and physical exam
NCT03154151	1:4:gender,9:14:gender	Men and women who have worked or volunteered as rescue, recovery or clean-up workers at the WTC site following the 9/11 attacks, or who were living as a resident or working as an employee within the NYC disaster area during the 9/11 attacks
NCT03154151	46:66:chronic_disease	are currently still experiencing significant posttraumatic stress symptoms related to what they witnessed or lived through during the 9/11 attacks or their WTC recovery work
NCT03154151	22:46:treatment,48:55:treatment,59:72:treatment	are currently taking antipsychotic medication, lithium or valproic acid
NCT03154151	29:42:treatment,46:56:treatment	are not currently receiving psychotherapy or counseling
NCT03154151	13:22:chronic_disease,26:44:chronic_disease,49:65:chronic_disease	do not have psychosis, a psychotic disorder, or bipolar disorder
NCT03154151	29:44:chronic_disease,46:67:chronic_disease,120:131:chronic_disease	have a current uncontrolled medical illness, neurological disorder affecting the central nervous system, or history of head injury
NCT03150797	1:4:age,5:7:lower_bound,8:10:upper_bound	Age 10-17
NCT03150797	10:11:upper_bound,10:13:lower_bound,60:62:lower_bound,97:98:lower_bound	At least 80% compliance with headache diary (i.e. at least 23 headache diary days) during weeks 5-8 of single-blind placebo treatment pha
NCT03150797	75:81:lower_bound,130:137:lower_bound	Concomitant opioid or barbiturate overuse, wherein overuse is defined as ≥4 days per month of barbiturate containing compounds, ≥10 days per month of opioid containing compounds as these may impact sleepiness scales
NCT03150797	12:20:chronic_disease,21:29:chronic_disease	History of seizures/epilepsy
NCT03150797	67:83:chronic_disease,77:83:chronic_disease	Inability to swallow pills after teaching and practice History of nocturnal asthma, as evidenced by a having a diagnosis of asthma and symptoms that manifest as nighttime awakening due to cough, wheeze, and/or shortness of breath
NCT03150797	1:9:pregnancy	Pregnant
NCT03150004	1:29:cancer	Acute Promyelocytic Leukemia
NCT03150004	1:4:age,6:14:lower_bound	Age ≥18 years at the time of informed consent
NCT03150004	12:32:clinical_variable,34:43:lower_bound	Calculated creatinine clearance ≥30 mL/min
NCT03150004	8:17:clinical_variable,20:67:upper_bound,69:99:clinical_variable,104:136:clinical_variable,139:146:upper_bound,165:168:cancer,172:188:chronic_disease,192:201:chronic_disease	Direct bilirubin ≤ 1.5 X the upper limit of the normal range (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN unless related to AML or Gilbert syndrome or hemolysis
NCT03150004	1:60:clinical_variable,61:62:lower_bound,63:64:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance score 0-2
NCT03150004	70:117:treatment	In first or subsequent relapse or refractory status, with or without prior hematopoietic stem cell transplant (HSCT)
NCT03150004	1:5:clinical_variable,8:11:lower_bound	LVEF ≥ 45%
NCT03150004	18:33:treatment,103:110:upper_bound	Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
NCT03150004	15:18:cancer,34:37:cancer,85:98:treatment	Patients with MDS transformed to AML will be eligible even if they had not received prior therapy for AML
NCT03150004	1:9:pregnancy	Pregnant
NCT03150004	16:21:gender	breast feeding women
NCT03150004	22:27:cancer	therapy related AML (t-AML), as defined by World Health Organization (WHO) criteria
NCT03138733	1:54:chronic_disease,130:142:treatment,146:155:treatment	Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam
NCT03138733	33:42:chronic_disease	Community- or hospital-acquired pneumonia
NCT03138733	10:57:chronic_disease	Definite native-valve right-sided infective endocarditis by Modified Duke's Criteria
NCT03138733	1:5:gender	Male
NCT03138733	28:31:chronic_disease	Other forms of complicated SAB
NCT03138733	1:26:treatment,30:49:treatment	Prosthetic cardiac valves or valve support rings
NCT03138733	28:53:treatment	Requirement for continuous renal-replacement therapy
NCT03138733	1:39:chronic_disease,59:62:lower_bound,106:116:upper_bound	Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization
NCT03138733	1:10:treatment,39:58:treatment,60:92:treatment,107:111:lower_bound,123:135:upper_bound	Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization
NCT03138733	1:6:gender,15:23:pregnancy	Women who are pregnant
NCT03138733	1:7:gender,10:18:lower_bound,22:25:age	female ≥ 18 years of age
NCT03138733	1:12:chronic_disease,14:24:clinical_variable,27:33:lower_bound	tachycardia (heart rate > 90 bpm)
NCT03138733	1:23:clinical_variable,26:32:lower_bound,38:52:upper_bound,59:62:lower_bound,63:91:clinical_variable	white blood cell count > 10,000 or < 4,000 cells/µL, or > 10% immature neutrophils (bands)
NCT03137173	14:72:chronic_disease	Diagnosis of acute bacterial skin and skin structure infection (ABSSSI), with a regional or systemic sign of infection
NCT03137173	1:15:gender,17:25:lower_bound,29:32:age	Male or female ≥18 years of age
NCT03137173	9:15:chronic_disease,64:87:chronic_disease,89:97:chronic_disease,102:118:chronic_disease,120:141:chronic_disease,175:184:chronic_disease,198:212:chronic_disease,295:311:chronic_disease	Primary ABSSSI due to or associated with any of the following: diabetic foot infection, gangrene, or perianal abscess; concomitant infection at another site; infected burns; decubitus, chronic, or ischemic ulcer; evolving necrotizing process; infections at vascular catheter sites or involving thrombophlebitis
NCT03137173	17:48:treatment	Requirement for intravenous bacterial treatment
NCT03137173	1:14:chronic_disease,18:30:chronic_disease	Severe sepsis or septic shock
NCT03137173	1:48:chronic_disease	Uncomplicated skin and skin structure infection
NCT03137173	12:44:treatment,52:59:upper_bound	Use of any systemic antibacterial treatment within 14 days
NCT03132415	1:19:technology_access	Access to internet
NCT03132415	1:5:age,6:14:upper_bound,29:37:lower_bound	Aged 14 years or younger or 25 years or older at time of screening
NCT03132415	1:5:age,6:8:lower_bound,12:20:upper_bound	Aged 15 to 24 years (inclusive) at time of screening
NCT03132415	10:14:gender	Assigned male sex at birth and currently identifies as male
NCT03132415	10:14:gender	Assigned male sex at birth but identifies as transgender or gender non-conforming
NCT03132415	1:31:language_fluency	Does not speak or read English
NCT03132415	1:4:chronic_disease	HIV-positive
NCT03132415	11:15:chronic_disease	Not be on PrEP at time of enrollment
NCT03132415	42:46:gender,62:76:upper_bound	Report having consensual anal sex with a male partner in the prior 6 months
NCT03132415	16:19:chronic_disease	Self-report as HIV-negative or sero-status unaware
NCT03130543	20:29:upper_bound,33:36:age	Patients less than 12 months of age who have been admitted to the hospital after brief resolved unexplained event
NCT03130543	63:87:chronic_disease,95:116:chronic_disease,133:149:chronic_disease,157:177:chronic_disease	Patients with any pre-existing significant medical diagnosis (congenital heart disease, known neurologic impairment with or without seizure disorder, other congenital anomalies)
NCT03130543	15:19:allergy_name	Patients with food allergies such that they cannot be on a milk or rice based diet
NCT03128268	1:9:lower_bound,13:16:age	18 years of age or older
NCT03128268	1:5:treatment	ICDs implanted
NCT03128268	1:10:treatment,14:17:treatment	Pacemaker or ICD implanted
NCT03128268	1:21:treatment,28:55:treatment	Temporary Pacemakers (e.g. transvenous temporary wires)
NCT03126110	1:61:clinical_variable,62:63:lower_bound,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
NCT03126110	21:46:chronic_disease,61:86:chronic_disease	Evidence of active, noninfectious pneumonitis or history of interstitial lung disease
NCT03126110	13:30:chronic_disease,34:51:chronic_disease,52:61:chronic_disease	Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation
NCT03126110	24:31:upper_bound,54:67:treatment	Has not recovered to ≤ Grade 1 from toxic effects of prior therapy
NCT03126110	14:47:cancer,55:79:cancer	Known active central nervous system metastases and/or carcinomatous meningitis
NCT03126110	21:39:cancer	Locally advanced or metastatic disease
NCT03126110	26:40:treatment	Prior treatment with any tumor necrosis factor super family agonist
NCT03126110	12:34:treatment,38:59:treatment	Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug
NCT03124355	1:3:lower_bound,4:12:upper_bound	18-45 years
NCT03124355	1:16:gender	Female subjects
NCT03124355	37:57:chronic_disease,65:76:chronic_disease,78:89:treatment	Medical conditions that can explain postural tachycardia (e.g., dehydration, medications)
NCT03124355	1:10:pregnancy	Pregnancy
NCT03124355	6:42:chronic_disease,59:78:clinical_variable,80:86:lower_bound,106:112:upper_bound,159:182:chronic_disease,209:217:lower_bound,263:286:chronic_disease	with Postural Tachycardia Syndrome (POTS) as defined by a heart rate increase ≥30 bpm from supine within 10 min of standing or head-up tilt in the absence of orthostatic hypotension, with chronic symptoms (> 6 months), and in the absence of other acute cause of orthostatic tachycardia
NCT03118232	2:5:upper_bound,38:41:lower_bound,42:60:treatment,64:94:treatment	<15% of residents receiving at least one chlorhexidine bath or nasal decolonization treatment during their nursing home stay
NCT03118232	46:49:lower_bound,50:68:clinical_variable	Facilities with a resident population with >=20% combative patients
NCT03118232	16:37:treatment	Minimal use of chlorhexidine bathing
NCT03118232	16:36:treatment	Minimal use of nasal decolonization
NCT03118050	2:3:lower_bound	>2 falls/year
NCT03118050	8:14:cancer,18:27:chronic_disease	Active cancer or infection
NCT03118050	1:16:bmi,19:33:upper_bound	Body mass index: <40 kg/sq meter
NCT03118050	1:18:clinical_variable,21:36:lower_bound,42:58:lower_bound	Exercise training (≥2 sessions/week) or ≥10,000 steps/day
NCT03118050	1:16:treatment,30:52:chronic_disease,57:60:clinical_variable,61:63:lower_bound	Insulin therapy, significant diabetic complications, or A1c>8%
NCT03118050	22:46:chronic_disease	Non-diabetic or with Type 2 Diabetes Mellitus
NCT03118050	1:13:chronic_disease	Pre-diabetes per American Diabetes Association criteria
NCT03118050	16:24:upper_bound,26:58:treatment,60:84:treatment,88:96:treatment	Recent (within 3 months) treatment with anabolic steroids, systemic corticosteroids or estrogen
NCT03118050	8:10:lower_bound,18:55:clinical_variable	Score ≥26 on the 30-item Mini Mental State Examination
NCT03118050	13:27:chronic_disease,29:34:chronic_disease,36:41:chronic_disease,43:48:chronic_disease,53:72:chronic_disease	Significant cardiovascular, liver, renal, blood, or respiratory disease
NCT03118050	1:12:clinical_variable,14:16:lower_bound,24:37:upper_bound	weight loss >5% in the past 6 months
NCT03115424	3:18:clinical_variable,21:29:lower_bound,36:41:clinical_variable,44:48:lower_bound,78:93:chronic_disease	A fasting glucose ≥ 126mg/dl or an HbA1c ≥ 6.5% will be taken as evidence of type 2 diabetes and therefore patients will be deemed ineligible for participation
NCT03115424	16:35:chronic_disease	Active, severe psychiatric disease
NCT03115424	19:26:treatment,40:62:treatment	Concurrent use of insulin or any other GLP-1 receptor agonist
NCT03115424	1:8:gender,52:60:pregnancy,66:92:contraception_consent,132:139:treatment,140:147:treatment	Females who are sexually active and able to become pregnant must agree to use birth control for duration of study if randomized to Saxenda/Placebo
NCT03115424	21:32:allergy_name	Hypersensitivity to liraglutide or any product components
NCT03115424	31:58:cancer,62:97:cancer	Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2
NCT03115424	18:30:chronic_disease,32:46:chronic_disease,50:63:chronic_disease	Prior history of pancreatitis, cholelithiasis or cholecystitis
NCT03115424	14:41:treatment,49:63:upper_bound	Prior use of glucose lowering medication in the 3 months prior to screening
NCT03115424	74:91:treatment	Seen at Mayo Clinic Nutrition Clinic and have received authorization for bariatric surgery
NCT03115424	25:34:pregnancy,108:116:pregnancy	active consideration of pregnancy during the period of study. Subjects will be discontinued if they become pregnant during the study
NCT03113136	2:10:upper_bound	<18 years old
NCT03113136	21:30:pregnancy	breastfeeding (n.b: pregnancy status will continue to be evaluated throughout the study at each visit)
NCT03113136	1:19:pregnancy	currently pregnant
NCT03113136	12:37:chronic_disease,49:62:upper_bound	history of cardiac event or distress within the past 3 months
NCT03113136	174:187:upper_bound	never purchased or regularly used a tank system, mechanical mod, or advanced personal vaporizer EC, though previous use of cig-a-like devices will be allowed but not in the last 3 months
NCT03113136	24:38:upper_bound,66:79:upper_bound	no quit attempt in the prior 3 months and no plan to quit in the next 3 months
NCT03113136	1:28:pregnancy	planning to become pregnant
NCT03113136	1:17:language_fluency	speak in English
NCT03113136	51:62:chronic_disease,64:70:chronic_disease,75:88:chronic_disease	unstable or significant medical condition such as respiratory, kidney, or liver disease that could potentially affect biomarker data
NCT03113136	25:47:chronic_disease	unstable or significant psychiatric conditions (past and stable conditions will be allowed)
NCT03112902	1:5:age,6:8:lower_bound,9:11:upper_bound	Ages 18-80
NCT03112902	27:68:chronic_disease	Neurological diagnosis of amnestic mild cognitive impairment (aMCI)
NCT03112902	1:13:cancer	brain tumors
NCT03112902	14:34:chronic_disease	diagnosis of cognitive impairment
NCT03112902	1:7:chronic_disease	eczema or sensitive skin
NCT03112902	1:9:chronic_disease	epilepsy
NCT03112902	1:9:chronic_disease	insomnia
NCT03112902	1:11:chronic_disease	narcolepsy
NCT03112902	1:49:chronic_disease	rapid eye movement (REM)-sleep behavior disorder
NCT03112902	1:23:chronic_disease	restless legs syndrome
NCT03112902	1:12:chronic_disease	sleep apnea
NCT03112902	1:26:pregnancy	trying to become pregnant during the study period
NCT03109210	1:36:clinical_variable,39:41:lower_bound,67:75:chronic_disease	Insomnia Severity Index (ISI) score > 10 indicating at least mild insomnia
NCT03109210	8:11:treatment,28:39:treatment	accept PAP as primary/sole OSA therapy
NCT03109210	60:73:upper_bound	been given a prescription for PAP and filled it within the last 3 months
NCT03109210	11:29:treatment,91:106:upper_bound	change in thyroid medication dosage or received a new prescription for thyroid medication 3 months before the screening visit
NCT03109210	1:20:chronic_disease,22:44:chronic_disease	comorbid narcolepsy, idiopathic hypersomnia
NCT03109210	1:10:clinical_variable,13:42:lower_bound	consuming > 2 alcoholic beverages per day on a regular basis
NCT03109210	53:68:lower_bound	consuming marijuana in any form on a regular basis >1 time per week, or if used after 4:00 p.m
NCT03109210	21:24:chronic_disease,33:36:clinical_variable,39:40:lower_bound	have a diagnosis of OSA with an AHI > 5 on a diagnostic polysomnogram
NCT03109210	1:26:chronic_disease	imminent risk for suicide
NCT03109210	27:56:chronic_disease,60:77:treatment,82:90:chronic_disease,126:131:chronic_disease	lifetime diagnosis of any psychotic or bipolar disorder as sleep restriction for insomnia may precipitate hallucinations and mania
NCT03109210	21:29:lower_bound	participants must > 21 years old
NCT03109210	44:48:clinical_variable,64:75:lower_bound	periodic limb movement during sleep (known PLMS with arousal > 15 per hour)
NCT03109210	1:23:chronic_disease,35:37:lower_bound,45:49:clinical_variable	restless legs syndrome (score of >11 in the IRLS)
NCT03109210	1:17:chronic_disease,25:31:cancer,37:70:chronic_disease,78:86:chronic_disease	terminal illness (e.g., cancer), or neurological degenerative disease (e.g., dementia)
NCT03109210	11:31:chronic_disease,39:55:chronic_disease,122:132:treatment	untreated psychiatric disorder (e.g., major depression) found on structured interviews as these conditions have specific treatments and it would be inappropriate not to offer those treatments
NCT03104725	19:50:treatment,58:76:treatment,78:83:treatment	Already taking an anti-oxidant dietary supplement (e.g., Olive Leaf Extract, MitoQ)
NCT03104725	9:21:lower_bound	At least18 years old
NCT03104725	14:34:chronic_disease,49:58:treatment,66:77:treatment	History of a post-spinal headache that required treatment with a blood patch
NCT03104725	18:21:allergy_name	Known allergy to NAC
NCT03104725	1:3:chronic_disease,25:37:upper_bound	PD diagnosed within the past 5 years
NCT03104725	1:9:pregnancy	Pregnant
NCT03104725	10:43:treatment	Taking a monoamine oxidase (MAO) inhibitor
NCT03104725	8:16:treatment	Taking levodopa in any form
NCT03104413	52:68:treatment,73:75:chronic_disease	Demonstrated intolerance or inadequate response to biologic therapy for CD
NCT03104413	14:16:chronic_disease,30:44:lower_bound	Diagnosis of CD for at least 3 months prior to Baseline
NCT03104413	11:35:treatment	Having an ostomy or ileoanal pouch
NCT03104413	1:5:gender	Male
NCT03104413	19:33:treatment,41:53:treatment	Prior exposure to p19 inhibitors (e.g., risankizumab)
NCT03104413	12:27:chronic_disease,37:52:treatment,54:64:treatment,66:76:treatment,78:90:treatment,92:103:treatment,105:116:treatment,124:137:upper_bound,153:164:treatment,172:186:upper_bound	Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline)
NCT03104413	37:55:chronic_disease,59:80:chronic_disease	Subject with a current diagnosis of ulcerative colitis or indeterminate colitis
NCT03104413	45:68:treatment	Subjects with unstable doses of concomitant Crohn's disease therapy
NCT03104413	37:39:lower_bound,45:53:upper_bound,57:60:age	Where locally permissible, subjects 16 to < 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit
NCT03104413	75:82:upper_bound,86:104:upper_bound	any investigational biologic or other agent or procedure within minimally 35 days or 5 half-lives prior to Baseline, whichever is longer
NCT03104413	1:7:gender	female
NCT03098329	1:3:lower_bound,4:12:upper_bound,16:19:age	15-24 years of age
NCT03098329	31:34:lower_bound,35:40:gender,48:61:upper_bound	Had vaginal sex with at least one woman in the past 2 months
NCT03098329	15:40:ethnicity	Identifies as African American or Black
NCT03098329	1:38:language_fluency	Unable to speak or understand English
NCT03097991	21:31:clinical_variable,35:36:lower_bound	As a rule of thumb, DAS scores of 9 or higher result in automatic exclusion from the study
NCT03097991	55:58:treatment	If a potential participant reports a prior history of IPV, s/he may still be eligible for participation pending a more detailed assessment completed by trained project staff using the Danger Assessment Scale (Campbell, 2003)
NCT03097991	1:10:pregnancy	pregnancy is the mother's first with the baby's father
NCT03096548	9:17:lower_bound,21:24:age	Must be 18 years of age or older
NCT03096548	7:15:upper_bound,19:22:age	Under 18 years of age
NCT03087903	32:63:clinical_variable,64:78:lower_bound,80:90:clinical_variable,92:98:lower_bound,100:109:clinical_variable,111:120:lower_bound	Adequate hematologic function (absolute neutrophil count [ANC]≥1,500 cells/µL; hemoglobin ≥9 g/dL, platelets ≥75,000/µL)
NCT03087903	15:23:lower_bound,27:30:age	Adults > or = 18 years of age
NCT03087903	1:13:clinical_variable,24:33:lower_bound	Baseline PSA must be ≥ 0.2 ng/mL at the time of screening
NCT03087903	45:61:allergy_name	Documented hypersensitivity reaction to any product with GSE (see complete list in Appendix 1)
NCT03087903	1:61:clinical_variable,62:63:lower_bound,64:65:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status 0-2
NCT03087903	26:49:cancer	Histologically confirmed prostate adenocarcinoma
NCT03087903	20:26:cancer,118:130:upper_bound	History of another cancer is exclusionary unless it is believed to be likely cured or is unlikely to be fatal in the next 3 years
NCT03087903	30:33:allergy_name,35:53:allergy_name,83:101:allergy_name	Known allergy/intolerance to soy, phosphatidycholine or any other constituents of grape seed extract
NCT03087903	7:24:chronic_disease,30:64:chronic_disease,68:83:chronic_disease	Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis
NCT03087903	1:14:treatment,16:25:treatment,30:75:treatment,83:90:upper_bound,94:109:treatment	Major surgery, radiation, or treatment with any other investigational drug within 2 weeks of study treatment
NCT03087903	81:93:lower_bound,103:112:upper_bound	Patients must have sufficient PSA time points prior to enrollment (a minimum of 3 PSA levels within a six month period) to calculate a baseline PSA doubling time
NCT03087903	32:44:treatment,45:63:treatment,78:96:clinical_variable,99:107:lower_bound	Patients must not be on active LHRH agonist/antagonist therapy and must have testosterone level > 50 ng/dL
NCT03087903	32:53:treatment,57:85:treatment	Patients must not be on active anti-androgen therapy or 5-alpha reductase inhibitors
NCT03087903	28:56:treatment,61:89:chronic_disease,103:112:lower_bound	Patients on stable dose of 5-alpha reductase inhibitors for benign prostatic hypertrophy for at least 12 months may continue
NCT03087903	39:54:treatment	Patients who are candidates for local salvage therapy must have had this option pursued or discussed
NCT03087903	46:61:treatment	Patients who have PSA recurrence after local salvage therapy may participate in this study
NCT03087903	15:40:chronic_disease,54:88:treatment,100:131:treatment	Patients with hormone sensitive disease who received prior androgen deprivation therapy as part of primary/salvage local treatment
NCT03087903	13:28:cancer,76:100:treatment	Symptomatic prostate cancer as determined by cancer-related pain requiring narcotic pain medication
NCT03087903	11:14:clinical_variable,42:49:upper_bound,76:83:lower_bound	Very fast PSA doubling time of less than 4 weeks, if the absolute PSA is > 2 ng/mL
NCT03087903	35:50:treatment	patient must have either declined salvage therapy or was deemed not to be a candidate for salvage therapy
NCT03087903	20:61:treatment	patients receiving intermittent androgen deprivation therapy will be allowed to participate
NCT03085147	5:21:treatment,75:87:upper_bound	Any surgical therapy in the area of the oral cavity or pharynx within the last 2 weeks
NCT03085147	5:10:cancer	Any tumor stage, any N, M0
NCT03085147	1:24:clinical_variable,25:26:lower_bound,30:31:upper_bound	ECOG performance status 0 or 1
NCT03085147	27:35:allergy_name	Known hypersensitivity to Olaparib
NCT03085147	14:22:lower_bound	Patient is ≥ 18 years old
NCT03085147	35:50:treatment	Prior or ongoing treatment with a PARP1 inhibitor
NCT03084640	3:18:clinical_variable,35:43:lower_bound	A life expectancy of greater than 24 weeks at Screening
NCT03084640	48:62:chronic_disease	Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the Investigator
NCT03084640	1:61:clinical_variable,65:66:lower_bound,70:71:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
NCT03084640	44:89:cancer	Histopathologically confirmed diagnosis of metastatic or unresectable malignant melanoma
NCT03084640	22:56:chronic_disease,58:81:chronic_disease,85:108:chronic_disease	Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
NCT03084640	1:28:clinical_variable,31:48:upper_bound	Lactate dehydrogenase (LDH) <=2.0 times the ULN range of each institution
NCT03084640	1:16:cancer	Ocular melanoma participants
NCT03084640	1:9:pregnancy	Pregnant
NCT03084640	10:97:treatment,105:118:upper_bound	Received treatment with anti- cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody within 30 days prior to the start of CMP-001 dosing on Week 1 Day 1
NCT03084640	41:56:treatment,87:96:lower_bound,97:107:treatment	Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day prednisone
NCT03084640	75:90:treatment,92:99:treatment,103:128:treatment,146:161:cancer	Requires prohibited treatment that is, non-protocol specified anticancer. pharmacotherapy, surgery or conventional radiotherapy for treatment of malignant tumor)
NCT03084640	21:36:chronic_disease,44:52:upper_bound,109:121:chronic_disease,123:138:chronic_disease,140:166:chronic_disease,170:200:chronic_disease	Severe uncontrolled cardiac disease within 6 months of screening, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA)
NCT03084640	1:6:gender,42:106:contraception_consent	Women of child-bearing potential who are unable or unwilling to use an acceptable method of contraception
NCT03084640	40:72:treatment	currently receiving treatment with the anti-PD-1 antibody pembrolizumab either alone or in combination
NCT03084640	32:51:chronic_disease,55:79:chronic_disease,112:125:treatment	have a best response of either Stable Disease (SD) or Progressive Disease (PD) per RECIST Version 1.1 while on pembrolizumab
NCT03084640	1:17:clinical_variable,49:78:lower_bound	neutrophil count greater than or equal to (>/=) 1,000/cubic millimeter (mm^3)
NCT03084640	1:15:clinical_variable,19:30:lower_bound	platelet count >/=75,000/mm^3
NCT03084640	20:27:treatment,29:43:treatment,48:69:treatment	replacement doses, topical, ophthalmologic and inhalational steroids
NCT03084640	1:17:clinical_variable,20:37:upper_bound	serum creatinine <=1.5 times the ULN range of each institution
NCT03084640	1:16:clinical_variable,44:85:upper_bound	total bilirubin less than or equal to (<=) 1.5 times the upper limit of normal (ULN) of each institution
NCT03084640	29:37:treatment,53:62:upper_bound	who are currently receiving steroids at a dose of <=10 mg/day do not need to discontinue steroids prior to enrollment
NCT03084640	15:35:chronic_disease,47:48:upper_bound,100:101:upper_bound,135:152:treatment,179:209:lower_bound,223:230:lower_bound	who developed autoimmune disorders of Grade <=3 may enroll if the disorder has resolved to Grade <=1 and the participant has been off systemic steroids at doses greater than (>) 10 milligrams per day (mg/day) for at least 2 weeks
NCT03084640	23:44:chronic_disease	who have a history of adrenal insufficiency
NCT03084640	35:48:treatment,62:70:lower_bound	who have had SD must have been on pembrolizumab for at least 12 weeks
NCT03084640	34:57:treatment	who have previously received any anti-PD-1/PD-L1 therapy, alone or in combination
NCT03084146	1:9:lower_bound,13:16:age	12 years of age or older
NCT03084146	25:34:chronic_disease,38:56:chronic_disease	History of drug-induced psoriasis or pustular psoriasis
NCT03084146	1:9:pregnancy	Pregnant
NCT03084146	23:47:chronic_disease,91:99:lower_bound,132:135:lower_bound,202:207:lower_bound	Psoriatic group only: Chronic plaque psoriasis (patients must have diagnosis for at least 6 months) or guttate psoriasis involving 2 % or greater total body surface area or 2 plaques, each measuring > 8 cm2
NCT03084146	23:32:chronic_disease,126:144:treatment,172:190:clinical_variable,196:205:lower_bound	Psoriatic group only: Psoriasis is untreated (as defined in Exclusion criteria 4) or subject has been on a stable topical or systemic treatment with no dose alteration or regimen alteration for >12 months
NCT03084146	30:48:treatment,53:62:chronic_disease,70:78:upper_bound	Psoriatic group only: Use of biologic treatment for psoriasis within 3 months of baseline
NCT03084146	12:29:chronic_disease	history of diabetes mellitus
NCT03084146	1:16:chronic_disease,20:46:chronic_disease	thyroid disease or inflammatory bowel disease
NCT03084146	8:44:treatment,49:58:chronic_disease,66:73:upper_bound,97:114:treatment,136:143:upper_bound	use of systemic immunosuppressive treatment for psoriasis within 4 weeks of baseline, or use of topical treatment for psoriasis within 2 weeks
NCT03083977	20:56:language_fluency	Individuals who do not read or speak proficient English
NCT03078088	1:6:clinical_variable,8:11:lower_bound,13:26:clinical_variable,28:31:lower_bound,112:125:upper_bound	FEV1% >35%, O2 saturation >90% on room air, clinically stable with no significant changes in health status for 14 days prior to Day 1
NCT03078088	1:9:pregnancy	Pregnant
NCT03078088	97:110:upper_bound	Use of any investigational drug and/or participated in any interventional clinical trial within 28 days prior to screening
NCT03078088	1:5:age,6:8:lower_bound,9:11:upper_bound	aged 16-80
NCT03078088	68:81:upper_bound	clinically stable with no significant changes in health status for 14 days prior to Day 1
NCT03078023	1:3:lower_bound,7:15:upper_bound,19:22:age	18 to 70 years of age
NCT03078023	8:10:lower_bound,11:18:clinical_variable	> than 15 Eos phf
NCT03078023	69:78:chronic_disease,85:96:chronic_disease,98:101:chronic_disease,103:109:chronic_disease	Clinical evidence of infectious process potentially contributing to dysphagia (e.g. candidiasis, CMV, herpes)
NCT03078023	1:28:clinical_variable,31:36:upper_bound,40:68:treatment	Esophageal minimal diameter < 13 mm on structured barium esophagram
NCT03078023	16:25:chronic_disease,40:49:treatment,56:74:chronic_disease,76:85:chronic_disease,87:90:chronic_disease,92:96:chronic_disease,98:107:chronic_disease,109:128:cancer	Other cause of dysphagia identified at endoscopy (e.g. reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm)
NCT03074877	86:90:upper_bound	Child must be recipient of needs based Medicaid or family income must be at or below 150% Health and Human Services (HHS) Poverty Guidelines
NCT03074877	27:44:chronic_disease	Having moderate to severe mental disability (based on medical records)
NCT03074877	1:26:language_fluency	Inability to read English
NCT03073811	1:21:chronic_disease	Cognitive impairment
NCT03073811	1:27:treatment	Elective abdominal surgery
NCT03073811	1:23:technology_access	No access to telephone
NCT03073811	137:146:upper_bound	Unwillingness to be randomized to either intervention arm, submit to study testing, or continuously participate in the intervention for six weeks
NCT03067818	1:31:chronic_disease	Brainstem or cerebellar stroke
NCT03067818	1:31:chronic_disease,55:61:chronic_disease	Central nervous system disease or disorder other than stroke
NCT03062111	1:3:clinical_variable,5:29:lower_bound	FR >15ml/Indwelling catheter
NCT03062111	12:27:cancer	History of prostate cancer
NCT03062111	1:5:clinical_variable,7:8:upper_bound	IPSS <8
NCT03062111	1:63:language_fluency	Language: English, Spanish, Haitian Creole, French, Portuguese
NCT03062111	1:5:gender	Male
NCT03062111	1:19:chronic_disease	Neurogenic bladder
NCT03062111	1:4:clinical_variable,6:9:upper_bound	PVR <250
NCT03062111	1:38:chronic_disease	Untreated or uncorrected coagulopathy
NCT03060772	1:18:pregnancy	Current pregnancy
NCT03060772	14:36:treatment	Currently on pioglitazone treatment for another reason
NCT03060772	1:4:chronic_disease	HIV-positive
NCT03060772	12:26:cancer	History of bladder cancer
NCT03060772	12:34:chronic_disease	History of cirrhosis of the liver
NCT03060772	12:20:chronic_disease	History of diabetes
NCT03060772	12:25:chronic_disease	History of heart failure
NCT03060772	1:21:language_fluency	Non-English speaking
NCT03060772	1:28:pregnancy,36:49:upper_bound	planning to become pregnant in the next 6 months
NCT03059355	3:5:upper_bound,29:37:upper_bound	< 85 (less than or equal to 85 years at the time of signing the Informed Consent Form
NCT03059355	1:27:chronic_disease	Advanced pulmonary disease
NCT03059355	14:23:chronic_disease	Apple shaped adiposity
NCT03059355	6:12:gender,20:28:pregnancy	Be a female who is pregnant
NCT03059355	7:23:treatment	Be an organ transplant recipient
NCT03059355	23:26:chronic_disease	Be serum positive for HIV
NCT03059355	1:23:chronic_disease	Elevated triglycerides
NCT03059355	1:16:gender,32:56:pregnancy,86:100:upper_bound	Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion
NCT03059355	1:4:clinical_variable,19:21:upper_bound	GFR < or equal to 35
NCT03059355	28:38:cancer,46:53:upper_bound	Have a clinical history of malignancy within 3 years
NCT03059355	52:66:upper_bound	Have a history of drug or alcohol abuse within the past 24 months
NCT03059355	25:35:allergy_name,39:51:allergy_name	Have known allergies to penicillin or streptomycin
NCT03059355	1:15:clinical_variable,29:30:lower_bound	Hemoglobin A1C greater than 7
NCT03059355	21:46:allergy_name	Hypersensitivity to dimethyl sulfoxide (DMSO)
NCT03059355	1:14:chronic_disease	Liver disease
NCT03059355	1:35:chronic_disease	Proliferative diabetic retinopathy
NCT03059355	1:23:chronic_disease,24:31:lower_bound	chronic kidney disease stage 3 or higher
NCT03059355	21:41:cancer	curatively- treated basal cell carcinoma
NCT03059355	1:14:chronic_disease	heart failure patients
NCT03059355	1:15:chronic_disease,19:38:chronic_disease	hepatitis BsAg or Viremic hepatitis C
NCT03059355	11:12:upper_bound,22:31:clinical_variable	less than 1 expected life span
NCT03059355	1:17:cancer,21:39:cancer	melanoma in situ or cervical carcinoma
NCT03059355	25:41:upper_bound	participated within the previous 30 days
NCT03059355	1:24:cancer	squamous cell carcinoma
NCT03059355	15:31:cancer	subjects with prior malignancy must be disease free for 3 years
NCT03058991	14:18:age,19:27:lower_bound	Adolescents (ages 12 years or older)
NCT03058991	1:21:language_fluency,46:126:language_fluency	Non-English speaking (operationalized as the inability to read and understand the consent form and converse in spoken English)
NCT03058991	170:187:gender	Reflecting the demographics of the community in which we are recruiting, we expect approximately 70% of the sample to be at or below the poverty level, balanced between males and females, with the majority from an ethnic minority background
NCT03055377	1:4:age,5:7:lower_bound,10:18:upper_bound	Age 14 - 21 years
NCT03055377	27:43:allergy_name	Allergy or intolerance to N-acetylcysteine
NCT03055377	16:32:treatment	Current use of N-acetylcysteine or any supplement containing N-acetylcysteine (must agree not to take any such supplement throughout study participation)
NCT03055377	1:8:gender,14:60:contraception_consent,89:108:contraception_consent,110:129:contraception_consent,131:160:contraception_consent,162:184:contraception_consent,186:213:contraception_consent,215:258:contraception_consent,263:298:contraception_consent	Females must agree to use appropriate birth control methods during study participation: oral contraceptives, contraceptive patch, barrier (diaphragm or condom), levonorgestrel implant, medroxyprogesterone acetate, complete abstinence from sexual intercourse, or hormonal contraceptive vaginal ring
NCT03055377	1:8:gender,17:25:pregnancy	Females who are pregnant or lactating
NCT03055377	27:39:upper_bound,60:81:chronic_disease	Must meet current (within last 30 days) DSM-5 criteria for cannabis use disorder
NCT03055377	8:21:treatment,25:38:treatment,46:53:upper_bound	Use of carbamazepine or nitroglycerin within 14 days of randomization or expectation of future use during protocol participation
NCT03055377	7:15:upper_bound,16:19:age	under 18 years old
NCT03050801	13:55:chronic_disease,85:91:chronic_disease,93:110:chronic_disease,112:129:chronic_disease,131:144:chronic_disease,148:164:chronic_disease	Any current major neurological or psychiatric disorder such as (but not limited to) stroke, Parkinson disease, Alzheimer disease, schizophrenia or major depression
NCT03050801	13:31:chronic_disease,35:55:chronic_disease,69:72:chronic_disease,103:109:chronic_disease,111:128:chronic_disease,130:147:chronic_disease,149:162:chronic_disease,166:182:chronic_disease	Any current major neurological or psychiatric disorder unrelated to TBI, such as (but not limited to) stroke, Parkinson disease, Alzheimer disease, schizophrenia or major depression
NCT03050801	12:32:chronic_disease	History of mild to moderate TBI
NCT03049033	14:33:chronic_disease	Diagnosis of Parkinson's Disease using the UK Brain Bank Criteria
NCT03049033	40:52:chronic_disease,64:87:chronic_disease	Features suggestive of other causes of parkinsonism, including cerebrovascular disease or history of major head trauma
NCT03049033	32:39:lower_bound	Medication stable for at least 30 days
NCT03049033	45:65:treatment	Participants whose insurance does not cover Occupational Therapy costs or who have no insurance
NCT03048838	9:37:language_fluency	able to speak English and/or Spanish
NCT03048838	13:21:lower_bound	be at least 18 years old
NCT03048838	32:36:treatment,82:85:chronic_disease	either partner is currently on PrEP and fully adherent, or enrolled in any other HIV prevention study
NCT03048838	79:92:upper_bound	either partner is planning on ending the relationship with his partner in the next 8 months
NCT03048838	65:73:upper_bound	either partner is planning to move outside the area in the next 8 months
NCT03048838	30:34:gender,54:66:upper_bound,89:92:gender	report having a main/primary male partner during the past 90 days (operationalized as a man with whom he has had a sexual relationship during the past 90 days and has a strong emotional bond)
NCT03048838	32:44:upper_bound	reports sexual activity in the past 90 days as described in the screening instrument
NCT03048838	18:33:ethnicity	self-identify as Latino/Hispanic or identify as having a main partner who identifies as Latino/Hispanic
NCT03044054	1:9:lower_bound	18 years or older
NCT03044054	1:8:clinical_variable,11:21:lower_bound,68:80:upper_bound	Anxiety ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days
NCT03044054	17:31:treatment,54:58:lower_bound,82:94:cancer	Focal point for HIFU treatment must also be at least 3 mm from any border of the fibroadenoma
NCT03044054	4:9:gender,12:20:upper_bound,40:49:treatment	In women ≤ 35 years old, a single view mammogram of the affected breast is sufficient for evaluation of calcification
NCT03044054	1:5:clinical_variable,8:18:lower_bound,31:34:clinical_variable,65:77:upper_bound	Pain ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days
NCT03044054	32:39:treatment	Patient is a candidate for the surgery
NCT03044054	12:20:pregnancy	Patient is pregnant
NCT03044054	25:38:cancer,53:79:treatment	Patient with history of breast cancer or history of laser or radiation therapy to the target breast
NCT03044054	11:23:cancer	Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit
NCT03044054	11:28:clinical_variable,52:58:lower_bound,73:78:upper_bound,102:112:treatment	Patient's fibroadenoma size is greater or equal to 0.2 cc and less than 10 cc in volume (measured by ultrasound on the day of the procedure)
NCT03044054	23:35:cancer	Presence of calcified fibroadenoma
NCT03044054	5:17:cancer,21:25:lower_bound,79:85:upper_bound,135:145:treatment	The fibroadenoma is 1 cm or greater at its largest dimension and no less than 7.5 mm in the anterior-posterior dimension (measured by ultrasound)
NCT03044054	173:178:lower_bound	The rib cage should not be in the prefocal ultrasound path or behind the target fibroadenoma (minimum distance from the posterior wall of the fibroadenoma must be at least 10 mm)
NCT03044054	61:66:gender	Ultrasound image alone for patients under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound
NCT03040778	30:44:treatment,49:58:treatment	A patient who has taken both bisphosphonate and Denosumab
NCT03040778	12:28:cancer	Absence of tumor in the jaw at the time of recruitment
NCT03040778	1:16:gender,25:33:pregnancy	Female patients who are pregnant
NCT03040778	24:38:treatment,59:74:treatment,78:95:treatment	History of exposure to antiresorptive medications such as bisphosphonates or RANK-L inhibitors
NCT03040778	25:40:cancer	Patient with history of prostate cancer
NCT03040778	17:34:treatment	Patients taking CYP1A2 inhibitors
NCT03040778	22:36:treatment	Patients taking oral anticoagulants
NCT03040778	54:59:allergy_name,67:80:upper_bound	Patients who underwent any surgical intervention for MRONJ in the past 4 months
NCT03040778	17:37:chronic_disease	Patients with a vitamin K deficiency due to any cause
NCT03040778	46:60:allergy_name,62:71:allergy_name,76:86:allergy_name	Patients with allergy or hypersensitivity to pentoxifylline, xanthines, or tocopherol
NCT03040778	18:35:clinical_variable,46:52:upper_bound	Patients with an expected survival less than 1 year
NCT03040778	26:52:treatment	Patients with history of external radiation therapy to the jaws
NCT03040778	15:38:chronic_disease	Patients with ischemic heart diseases
NCT03040778	21:57:chronic_disease	Patients with known hemorrhagic and coagulation disorder
NCT03040778	15:41:chronic_disease	Patients with serious cardiac arrhythmia
NCT03040778	22:35:chronic_disease	Patients with severe liver disease
NCT03040778	15:35:chronic_disease	Patients with severe renal failure
NCT03040778	1:8:lower_bound,16:17:upper_bound,18:23:chronic_disease	Stage 1, 2, or 3 MRONJ as defined by the AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update (Ruggiero 2014)
NCT03040778	1:14:treatment	ciprofloxacin
NCT03040778	1:29:chronic_disease	extensive retinal hemorrhage
NCT03040778	8:29:chronic_disease	recent myocardial infarction
NCT03038620	1:4:age,7:15:lower_bound	Age ≥ 35 years
NCT03038620	27:42:chronic_disease	Any lifetime history of a suicide attempt
NCT03038620	1:33:chronic_disease,46:50:clinical_variable,51:60:upper_bound	Chronic kidney disease stage III or greater (eGFR<60 mL/min)
NCT03038620	23:32:treatment,97:110:upper_bound,150:174:treatment,222:223:lower_bound,225:232:upper_bound,235:261:treatment,263:285:treatment,290:306:treatment,314:324:treatment,326:339:treatment,341:352:treatment,354:364:treatment,366:376:treatment,378:391:treatment,393:405:treatment,407:416:treatment,418:428:treatment,430:443:treatment,469:476:treatment	Current or history of treatment with medications that may cause significant weight gain, within 1 month prior to screening for this trial, including systemic corticosteroids (except for a short course of treatment, i.e., 7- 10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g., imipramine, amitryptiline, mirtazapine, paroxetine, phenelzine, clorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium)
NCT03038620	39:63:treatment,78:96:upper_bound	Current participation in an organized weight reduction program or within the last 1 month prior to screening for this trial
NCT03038620	79:92:upper_bound	Diet attempts using herbal supplements or over-the-counter medications within 1 month prior to screening for this trial
NCT03038620	42:68:chronic_disease,81:108:cancer	Familial or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma
NCT03038620	1:8:gender,39:51:pregnancy,81:96:pregnancy,104:144:contraception_consent	Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
NCT03038620	12:37:chronic_disease,49:61:upper_bound	History of Major Depressive Disorder within the last 2 years
NCT03038620	12:32:chronic_disease,36:65:chronic_disease	History of chronic pancreatitis or idiopathic acute pancreatitis (current or prior history)
NCT03038620	12:31:chronic_disease,33:47:chronic_disease,51:64:chronic_disease	History of gallbladder disease (cholelithiasis or cholecystitis)
NCT03038620	18:46:chronic_disease,54:67:chronic_disease,69:85:chronic_disease	History of other severe psychiatric disorders, e.g., schizophrenia, bipolar disorder
NCT03038620	40:78:allergy_name	Known or suspected hypersensitivity to trial product(s) or related product(s)
NCT03038620	1:8:chronic_disease,26:50:chronic_disease,57:73:chronic_disease	Obesity induced by other endocrinologic disorders (e.g. Cushing Syndrome)
NCT03038620	46:59:upper_bound	Participation in a clinical trial within the last 3 months prior to screening for this trial
NCT03038620	16:47:treatment,55:68:upper_bound	Receipt of any anti-obesity drug or supplement within 1 month prior to screening for this trial
NCT03038620	78:87:lower_bound,92:98:clinical_variable,106:120:upper_bound	Self-reported or clinically documented history of significant fluctuations (>5% change) in weight within 3 months prior to screening for this trial
NCT03038620	1:8:treatment	Surgery scheduled for the trial duration period
NCT03038620	1:15:clinical_variable,18:29:lower_bound,36:45:treatment,50:62:chronic_disease	blood pressure > 130/85 mmHg or on treatment for hypertension
NCT03038620	1:16:clinical_variable,19:28:lower_bound	fasting glucose > 100 mg/dL
NCT03038620	11:28:chronic_disease,30:36:lower_bound,40:41:upper_bound,64:88:treatment	istory of diabetes mellitus (type 1 or 2) or on treatment with anti-diabetes medication
NCT03038620	1:26:treatment	minor surgical procedures
NCT03038620	1:14:clinical_variable,17:26:lower_bound,47:67:chronic_disease	triglycerides > 150 mg/dL or on treatment for hypertriglyceridemia
NCT03038620	1:20:clinical_variable,23:37:lower_bound,41:44:gender,49:62:lower_bound,66:71:gender	waist circumference > 102 cm (40 in) in men and 88 cm (35 in) in women
NCT03034863	44:61:chronic_disease	evidence of current (within the past week) suicidal ideation
NCT03034863	1:28:language_fluency	limited English proficiency
NCT03034863	71:87:upper_bound	participation in another family-based psychosocial intervention trial six months prior to study
NCT03034863	23:70:clinical_variable,106:107:upper_bound,115:136:clinical_variable,170:185:chronic_disease,193:206:upper_bound	plan or intent on the Columbia Suicide Severity Rating Scale (C-SSRS), but scoring less than or equal to 4 on the C-SSRS Behavior Scale, and without history of a lethal suicide attempt in the last 3 months
NCT03034863	27:36:chronic_disease	untreated or un-medicated psychosis
NCT03030118	1:60:chronic_disease	Active bacterial, viral, fungal, or opportunistic infection
NCT03030118	1:34:clinical_variable,38:42:lower_bound	Anti-nuclear antibody (ANA) titer of 1:80, or greater, as determined by immunofluorescence assay (IFA)
NCT03030118	9:11:lower_bound,16:24:upper_bound,28:31:age	Between 15 and 49 years of age
NCT03030118	26:57:treatment,35:49:treatment,71:76:lower_bound,80:90:treatment,161:175:upper_bound	Co-morbidities requiring systemic corticosteroid therapy greater than 10 mg of prednisone per day, or equivalent, or a change in corticosteroid dose within the 3 months prior to Visit 1
NCT03030118	28:62:chronic_disease,64:75:chronic_disease,80:91:chronic_disease	Evidence of infection with human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C
NCT03030118	12:36:chronic_disease	History of primary immunodeficiency
NCT03030118	33:36:lower_bound	Participants must have at least one (but not three or more) additional clinical or laboratory criterion from the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria
NCT03030118	1:9:pregnancy,29:64:contraception_consent	Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
NCT03030118	78:124:treatment,132:150:upper_bound	Starting, stopping, or changing the dose of over the counter or prescription non-steroidal anti-inflammatory drugs (NSAIDs) in the three months prior to Visit 1
NCT03030118	45:64:chronic_disease,77:106:chronic_disease	The subject has been diagnosed with another autoimmune disorder, other than autoimmune thyroid conditions
NCT03030118	44:77:treatment,101:115:chronic_disease,117:135:chronic_disease,137:146:chronic_disease,148:157:chronic_disease,177:190:allergy_name	The subject has other contraindications to treatment with hydroxychloroquine including pre-existing ocular disease, hepatic impairment, psoriasis, porphyria, or allergy to the drug or class
NCT03030118	68:92:treatment,103:121:treatment,110:121:treatment,139:149:treatment	The subject has previously been or is currently being treated with oral antimalarial agents including hydroxychloroquine, chloroquine, or quinacrine
NCT03030118	41:69:treatment,145:163:treatment	The subject has significant findings on ophthalmological examination that, in the opinion of the examining Ophthalmologist, prevent safe use of hydroxychloroquine
NCT03030118	51:68:treatment,70:86:treatment,91:112:treatment	The subject is currently or has been treated with immunosuppressive, immune modifying, or cytotoxic medications as listed in Section 7.2
NCT03027388	1:4:age,29:37:lower_bound	Age greater than or equal to18 years
NCT03027388	84:91:lower_bound	At the time of registration, all subjects must be removed greater than or equal to 28 days from any investigational agents
NCT03027388	1:10:clinical_variable,36:39:lower_bound	Karnofsky greater than or equal to 60%
NCT03027388	27:45:treatment,49:65:treatment,73:86:upper_bound,143:159:treatment	Patients may not have had prior chemotherapy or biologic therapy in the 4 weeks prior to study entry. For patients who have been treated with targeted therapy, 5 half-lives of that therapy (or 28 days, whichever is shorter) must have passed prior to enrollment in the study
NCT03027388	74:84:treatment	Patients must be in adequate general medical health to safely tolerate a craniotomy
NCT03027388	45:57:cancer,58:69:cancer	Patients must have histologically confirmed glioblastoma/gliosarcoma confirmed by the Laboratory of Pathology, NCI
NCT03027388	31:41:treatment	Patients unwilling to undergo craniotomy
NCT03027388	1:9:pregnancy,10:15:gender,67:82:treatment	Pregnant women are excluded from this study because the safety of PP2A inhibition on a developing fetus has not been established
NCT03027388	16:21:treatment,82:87:gender,84:87:gender,128:163:contraception_consent,165:173:contraception_consent,177:208:contraception_consent,210:220:contraception_consent,297:302:gender,303:318:pregnancy,310:318:pregnancy	The effects of LB100 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
NCT03027388	14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:158:chronic_disease,159:177:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
NCT03027388	1:20:chronic_disease	psychiatric illness/social situations that would limit compliance with study requirements
NCT03026816	1:9:lower_bound,13:16:age	22 years of age or older
NCT03026816	1:27:treatment,35:52:upper_bound	Botulinum toxin injections in the previous 6 months
NCT03026816	24:38:chronic_disease	Clinically significant mental illness
NCT03026816	9:18:pregnancy	Current Pregnancy
NCT03026816	34:57:treatment	Current and anticipated need for opioid pain medications or pain that would prevent full participation in the rehabilitation program
NCT03026816	76:102:treatment,109:124:chronic_disease	Diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery (e.g. cardiopulmonary issues)
NCT03026816	23:58:treatment	Inability to withhold antiplatelet/anticoagulation agents perioperatively
NCT03026816	11:34:chronic_disease,49:60:treatment	Recurrent urinary tract infection refractory to antibiotics
NCT03026816	9:34:chronic_disease	Stable, motor-complete paraplegia
NCT03026816	1:23:treatment,29:36:chronic_disease,38:48:chronic_disease,53:56:clinical_variable,59:61:upper_bound,66:69:lower_bound	single tilt table test with syncope, presyncope, or SBP < 50 or >200
NCT03023332	34:50:chronic_disease	Does not have family member with bipolar disorder
NCT03023332	1:17:language_fluency	English-speaking
NCT03023332	44:57:upper_bound	Have cared/supported them for at least the last 6 months in the last year
NCT03019367	1:3:lower_bound,7:9:upper_bound,13:28:clinical_variable	23 to 32 +6 Gestational age
NCT03019367	1:17:chronic_disease	Bleeding Accreta
NCT03019367	1:21:chronic_disease	Congenital anomalies
NCT03019367	1:14:chronic_disease	Cord prolapse
NCT03019367	1:8:chronic_disease	Hydrops
NCT03019367	1:22:chronic_disease	Major cardiac defects
NCT03019367	1:30:chronic_disease,36:46:chronic_disease	Placental abruption or previa with hemorrhage
NCT03014687	1:17:chronic_disease	Active sinusitis
NCT03014687	26:44:treatment,62:78:cancer,98:105:cancer,107:117:chronic_disease,122:134:cancer	Adult patient undergoing endoscopic surgery for resection of pituitary tumors for nonfunctioning adenoma, acromegaly, or prolactinoma
NCT03014687	5:27:treatment,31:53:treatment	Any solid organ transplant or bone marrow transplant
NCT03014687	1:10:chronic_disease	Cirrhosis
NCT03014687	54:77:chronic_disease	Concurrent antibiotics for another indication (i.e., urinary tract infection)
NCT03014687	1:18:chronic_disease	Cushing's disease
NCT03014687	1:17:language_fluency	English speaking
NCT03014687	12:29:chronic_disease	History of chronic sinusitis
NCT03014687	1:17:chronic_disease	Immunodeficiency
NCT03014687	1:10:pregnancy	Pregnancy
NCT03014687	10:23:treatment	Previous sinus surgery
NCT03014687	1:20:chronic_disease,24:38:chronic_disease	Rathke's Cleft cyst or pituitary cyst
NCT03014687	24:36:clinical_variable,41:48:clinical_variable	able to understand the ASK Nasal-12 and SNOT-22 scales
NCT03014687	1:10:chronic_disease	hepatitis
NCT03008070	8:18:cancer	Active malignancy
NCT03008070	1:22:bmi,24:32:lower_bound	Body mass index (BMI) >45 kg/m2
NCT03008070	13:26:chronic_disease	Compensated liver disease
NCT03008070	22:34:treatment	Contra-indication to liver biopsy
NCT03008070	1:22:chronic_disease	Diabetic ketoacidosis
NCT03008070	29:42:chronic_disease	Evidence of another form of liver disease
NCT03008070	1:11:clinical_variable,13:14:lower_bound,16:57:clinical_variable,89:102:chronic_disease,158:165:lower_bound,168:181:chronic_disease	HB antigen >0, HCV Polymerase chain reaction (PCR) tests >0 (patients with a history of HCV infection can be included if HCV PCR is negative since more than 3 years), HIV infection
NCT03008070	78:117:allergy_name	Have a known hypersensitivity to any of the ingredients or excipients of the Investigational medicinal product (IMP)
NCT03008070	15:21:clinical_variable,32:44:treatment,85:88:lower_bound,105:116:clinical_variable	Have a stable weight since the liver biopsy was performed defined by no more than a 5 % loss of initial body weight
NCT03008070	1:21:chronic_disease,48:62:treatment	Hemostasis disorders or current treatment with anticoagulants
NCT03008070	12:60:treatment,78:85:upper_bound,153:168:treatment,170:189:treatment,191:203:treatment,205:217:treatment,221:231:treatment,239:256:upper_bound	History of gastrointestinal malabsorptive bariatric surgery within less than 5 years or ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months
NCT03008070	24:44:chronic_disease,65:87:chronic_disease,105:126:chronic_disease	History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease event, including myocardial infarction, except patients with only well controlled hypertension
NCT03008070	1:5:chronic_disease,93:98:chronic_disease,150:156:clinical_variable,159:161:lower_bound,244:256:treatment,269:277:upper_bound	NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree ≥ 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed ≤ 6 months before screening in the study or at screening and confirmed by central reading during the screening period
NCT03008070	20:41:chronic_disease,43:53:chronic_disease,55:82:chronic_disease,84:107:chronic_disease,109:132:chronic_disease,134:142:chronic_disease,144:170:chronic_disease,172:187:chronic_disease	No other causes of chronic liver disease (autoimmune, primary biliary cholangitis, Hepatitis B virus (HBV), hepatitis C virus (HCV), Wilson's, α-1-antitrypsin deficiency, hemochromatosis, etc…)
NCT03008070	41:53:chronic_disease	Osteopenia or any other well documented Bone disease
NCT03008070	63:71:upper_bound	Participation in any other clinical study within the previous 3 months
NCT03008070	1:10:pregnancy	Pregnancy
NCT03008070	1:19:clinical_variable,23:24:lower_bound,28:29:upper_bound,32:33:lower_bound	SAF Activity score of 3 or 4 (>2)
NCT03008070	1:19:clinical_variable,22:23:upper_bound	SAF Fibrosis score < 4
NCT03008070	1:20:clinical_variable,23:24:lower_bound	SAF Steatosis score ≥ 1
NCT03008070	26:38:treatment,55:63:lower_bound	Subject agrees to have a liver biopsy performed after 24 weeks of treatment
NCT03008070	1:27:chronic_disease,48:55:treatment	Type 1 diabetes and type 2 diabetic patient on insulin
NCT03008070	10:29:chronic_disease	Unstable metabolic condition
NCT03008070	17:20:lower_bound,28:45:upper_bound,47:55:chronic_disease,84:89:clinical_variable,92:96:lower_bound,118:130:chronic_disease,140:157:treatment,158:171:chronic_disease,175:196:treatment,211:218:treatment,231:245:upper_bound	Weight change > 5kg in the last three months, diabetes with poor glycemic control (HbA1c > 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening
NCT03008070	1:4:age,6:14:lower_bound	age ≥18 years
NCT03008070	1:33:cancer	cutaneous basocellular carcinoma
NCT03008070	15:30:chronic_disease,22:30:chronic_disease,43:48:clinical_variable,51:55:upper_bound,60:76:clinical_variable,78:87:upper_bound,121:138:upper_bound,206:223:upper_bound	have a stable type 2 diabetes, defined as HbA1c < 8.5% and fasting glycemia <10 mmol/L, no changes in medication in the previous 6 months, and no new symptoms associated with decompensated diabetes in the previous 3 months
NCT03008070	24:46:contraception_consent,50:55:gender	inability to adhere to adequate contraception in women of child-bearing potential
NCT02996227	1:3:lower_bound,4:12:upper_bound	18-85 years old
NCT02996227	1:20:clinical_variable,21:22:lower_bound,23:24:upper_bound	ASA Physical Status 1-3
NCT02996227	1:15:treatment,56:64:treatment,68:78:treatment	Anticoagulants considered to be a contraindication for epidural or TAP blocks
NCT02996227	1:12:allergy_name	Bupivacaine sensitivity
NCT02996227	26:44:treatment,58:66:lower_bound	Expected requirement for parenteral opioids for at least 72 hours for postoperative pain
NCT02996227	1:16:chronic_disease	Hepatic disease, e.g. twice the normal levels of liver enzymes
NCT02996227	1:10:treatment	Surgeries with high port sites
NCT02996227	1:6:gender,11:23:pregnancy	Women who are pregnant
NCT02996227	1:31:treatment	laparoscopic abdominal surgery
NCT02991248	1:16:treatment,24:32:upper_bound	Botox injection within 6 months of starting the study
NCT02991248	98:107:lower_bound	ability to ambulate without orthotics or with orthotics that do not cross the knee for more than 10 meters
NCT02991248	46:56:lower_bound,70:81:clinical_variable	ability to walk on a treadmill for more than 20 minutes with partial body weight support as needed and short sitting/standing breaks
NCT02991248	1:4:age,13:15:lower_bound,20:28:upper_bound	age between 18 and 65 years
NCT02991248	24:54:chronic_disease,61:82:chronic_disease,86:124:chronic_disease	concomitant central or peripheral neurological injury (e.g. traumatic head injury or peripheral nerve damage in lower limbs)
NCT02991248	19:45:treatment	current receiving physical therapy treatment
NCT02991248	1:22:chronic_disease,27:44:chronic_disease	severe cardiovascular and pulmonary disease
NCT02982772	1:9:lower_bound,13:16:age	18 years of age and older
NCT02982772	1:9:chronic_disease,20:27:treatment	Diabetes requiring insulin
NCT02982772	1:18:language_fluency,22:29:language_fluency	Fluent in English or Spanish
NCT02982772	29:45:allergy_name	History of allergies to the nicotine patches
NCT02982772	1:9:pregnancy,10:15:gender	Pregnant women
NCT02982772	1:10:chronic_disease,14:45:chronic_disease	Psychotic or disabling psychiatric disorders
NCT02982772	1:34:chronic_disease	Temporal-mandibular joint disease
NCT02982772	1:32:treatment	Treatment for vascular problems
NCT02982772	1:15:chronic_disease	kidney disease
NCT02982772	1:6:gender	women that are breastfeeding
NCT02982564	18:31:cancer,47:48:lower_bound,52:55:upper_bound	Be classified in breast cancer stage grouping 0 to III according to the American Joint Committee on Cancer Classification of Malignant Tumors (TNM) Staging System (2013)
NCT02982564	16:29:cancer	Diagnosed with breast cancer
NCT02982564	1:12:lower_bound,16:19:age	Fifty years of age or older
NCT02982564	16:41:treatment,51:61:lower_bound,65:78:upper_bound	Have completed adjuvant curative therapy at least two months to 5 years prior to recruitment
NCT02982564	1:6:gender,62:82:lower_bound	Women who already meet the national standard for exercise (≥ 150 minutes per week of moderate exercise)
NCT02982564	1:6:gender,37:45:allergy_name,74:80:chronic_disease,91:106:chronic_disease,121:129:chronic_disease,144:156:chronic_disease,158:172:chronic_disease	Women who have contraindications to exercise, such as extreme fatigue or anemia, unstable cardiac disease; uncontrolled diabetes; uncontrolled hypertension; coagulopathies; inability to ambulate independently
NCT02982564	1:6:gender,12:22:cancer,26:43:cancer	Women with metastasis or secondary cancers
NCT02979574	10:26:treatment,28:35:treatment,37:49:treatment,58:70:treatment,81:96:lower_bound,140:157:treatment	Complete active treatment (surgery, chemotherapy, and/or radiotherapy) at least one month prior to study initiation (patients on continued hormone treatment will not be excluded)
NCT02979574	1:17:language_fluency	English speaking
NCT02979574	6:40:chronic_disease,218:248:chronic_disease	Have non-musculoskeletal pain syndromes (headache, facial pain, chest pain, visceral abdominal pain) if these are the sole source of pain, but can be present as co-morbid conditions as long as a patient has a primary musculoskeletal pain condition defined s above
NCT02979574	25:26:lower_bound,57:58:lower_bound,59:61:upper_bound	Having a pain rating of 4 or greater in worst pain on a 1-10 numerical rating scale in the preceding week (Patients with a neuropathic component to their pain that involves the extremities or back will be eligible)
NCT02979574	1:23:chronic_disease,37:60:treatment,67:87:chronic_disease	Inflammatory arthritis that require disease modifying drugs (e.g. rheumatoid arthritis)
NCT02979574	28:45:cancer	Patients with a history of metastatic cancer who are not currently NED
NCT02979574	14:20:cancer,98:116:cancer	diagnosis of cancer with no restrictions placed on type of cancer, other than that patients with metastatic disease will be excluded
NCT02978885	1:4:age,7:15:upper_bound	Age < 18 years
NCT02978885	47:65:treatment	Patients with normal lung function undergoing Whipple procedures
NCT02978885	1:34:clinical_variable,29:33:clinical_variable,35:62:clinical_variable,64:68:upper_bound,78:80:lower_bound,81:84:upper_bound,132:147:treatment	forced expiratory volume 1 (FEV1)/forced vital capacity (FVC) <0.70 and FEV1 50-79% normal) undergoing Whipple procedures or other major surgeries
NCT02978885	7:32:treatment	other major abdominal surgeries
NCT02975986	1:4:bmi,13:16:upper_bound	BMI (within 10%)
NCT02975986	22:27:treatment,25:27:treatment,32:41:pregnancy,58:79:chronic_disease,81:85:clinical_variable,88:104:upper_bound,107:118:treatment,120:150:treatment,170:186:chronic_disease,203:216:chronic_disease,248:263:clinical_variable,288:291:clinical_variable,293:296:clinical_variable,301:321:clinical_variable,368:374:chronic_disease,380:447:treatment,456:480:treatment	Contraindications to SPECT/CT, pregnancy, breastfeeding, chronic renal disease (eGFR < 60 ml/min/1.73m2), proteinuria, genetic diseases of the kidney, inborn defects of lipid metabolism, alcohol abuse, liver disease (patients with highly elevated total bilirubin, elevated liver enzymes AST, ALT and alkaline phosphatase and those with an established liver disease), anemia, and pharmacological treatment with insulin or insulin-sensitizing drugs such as thiazolidinediones (TZD)
NCT02975986	76:89:chronic_disease,102:105:age,114:121:upper_bound	In the Control group (N=10), we will include volunteers with no history of stone disease matched for age (within 5 years)
NCT02975986	1:4:age,7:15:lower_bound	age > 21 years
NCT02975986	1:9:chronic_disease	diabetes status
NCT02975869	16:51:cancer	A diagnosis of acute promyelocytic leukemia (APML)
NCT02975869	1:26:chronic_disease,30:49:chronic_disease	Major psychiatric illness or comorbid conditions prohibiting compliance with study procedures
NCT02975869	31:34:cancer,37:45:lower_bound,49:52:age	Newly diagnosed patients with AML ≥ 60 years of age
NCT02975869	33:36:cancer	Newly diagnosed therapy-related AML
NCT02975869	1:23:cancer	Primary refractory AML
NCT02964897	15:23:chronic_disease,33:60:chronic_disease	No history of dementia or other serious cognitive condition that would prevent them from being interviewed or completing a survey questionnaire
NCT02964741	16:39:treatment	Current use of opioid pain medications
NCT02964741	1:18:chronic_disease,46:54:lower_bound,105:125:upper_bound	Episodic migraine (ICHD-3-beta) for at least 6 months, with at least one attack per month and less than 15 attacks per month
NCT02964741	12:33:chronic_disease,40:48:chronic_disease,50:56:chronic_disease,58:68:chronic_disease,70:86:chronic_disease	History of neurological disorder (e.g. epilepsy, stroke, neuropathy, neuropathic pain)
NCT02964741	34:52:chronic_disease,59:72:chronic_disease,94:101:chronic_disease,105:128:chronic_disease,146:167:clinical_variable,173:175:lower_bound	History or current evidence of a psychotic disorder (e.g. schizophrenia) or substance abuse; bipolar or severe major depression, as evidenced by Beck Depression score of ≥ 30
NCT02964741	14:31:treatment,40:55:upper_bound	No intake of opiate medication for the past six months
NCT02964741	15:35:treatment,67:84:lower_bound,99:107:lower_bound	No overuse of analgesic medication, defined as regular intake on ≥15 days per month for more than 3 months
NCT02964741	35:56:chronic_disease	Presence of any other systemic or chronic pain disorder
NCT02964741	1:18:treatment	Prior use of tDCS
NCT02959632	1:3:lower_bound,4:12:upper_bound,16:19:age	18-80 years of age
NCT02959632	10:12:lower_bound,13:21:upper_bound,25:28:age	Patients 18-80 years of age
NCT02959632	1:9:pregnancy,10:15:gender	Pregnant women (as verbalized by participant)
NCT02958462	1:49:chronic_disease	Clonal cytopenias of unclear significance (CCUS)
NCT02958462	1:53:chronic_disease	Idiopathic cytopenias of unclear significance (ICUS)
NCT02958462	1:35:chronic_disease,37:40:chronic_disease	Low Risk Myelodysplastic Syndromes (MDS)
NCT02958462	1:25:chronic_disease,31:49:cancer,66:86:cancer,88:118:chronic_disease	Marrow failure syndromes with myeloid malignancy predisposition- telomere dysfunction, chromosomal breakage disorders, etc
NCT02950233	1:3:lower_bound,4:12:upper_bound,16:19:age	18-75 years of age
NCT02950233	22:40:chronic_disease	Current diagnosis of Cushing's syndrome
NCT02950233	12:25:chronic_disease,29:45:chronic_disease	History of schizophrenia or bipolar disorder
NCT02950233	7:24:cancer,28:45:chronic_disease	Known intracranial mass or cerebral aneurysm or raised intraocular pressure
NCT02950233	18:42:treatment	Planned elective VATS pulmonary lobectomy
NCT02950233	1:10:pregnancy	Pregnancy
NCT02950233	1:24:chronic_disease,26:56:clinical_variable,61:69:upper_bound	Severe renal impairment (creatinine clearance based GFR of <30ml/min)
NCT02950233	1:18:treatment,21:29:lower_bound,33:45:treatment,70:77:lower_bound,89:102:upper_bound	Steroid treatment > 10mg/day of Prednisolone or its equivalent for > 3 weeks within the last 3 months
NCT02946268	1:4:bmi,6:14:upper_bound	BMI ≤40 kg/m2
NCT02946268	54:71:allergy_name	Contraindications to or known drug interactions with local anesthetics
NCT02946268	1:5:gender	Male
NCT02946268	31:58:treatment,104:136:treatment,138:151:treatment,153:169:treatment,175:201:treatment	Patients scheduled to undergo unilateral shoulder surgery at Duke University Medical Center, including arthroscopic rotator cuff repair, acromioplasty, hemiarthroplasty, and total shoulder replacement
NCT02946268	15:27:chronic_disease,59:67:lower_bound	Patients with chronic pain (pain existing for longer than 6 months)
NCT02946268	1:9:pregnancy,10:15:gender	Pregnant women
NCT02946268	14:21:chronic_disease	Uncontrolled anxiety
NCT02946268	1:18:chronic_disease	abnormal clotting
NCT02946268	1:7:gender	female
NCT02946268	1:21:chronic_disease,23:27:clinical_variable,28:31:upper_bound,56:64:clinical_variable,67:71:upper_bound	moderate-severe COPD (FEV1<80% of normal values and/or FEV1/FVC < 0.70)
NCT02946268	7:27:chronic_disease	other psychiatric disorder
NCT02946268	13:35:chronic_disease,39:61:chronic_disease	presence of neurological disorders or cervical spine disease
NCT02946268	1:15:chronic_disease	skin infection involving the neck
NCT02946268	8:23:treatment,38:69:lower_bound,82:89:treatment	taking chronic opioids (greater than 60 morphine equivalents per day) at time of surgery
NCT02946268	2:10:lower_bound,14:17:age	≥18 years of age
NCT02937402	22:63:treatment,51:54:treatment,68:72:cancer,76:81:cancer,102:114:treatment	Candidate to undergo immune checkpoint inhibitor (ICI) therapy for SCLC or NSCLC (ICI as any line of chemotherapy is acceptable) as deemed by individual's treating oncologist
NCT02937402	1:13:chronic_disease,19:55:clinical_variable,58:61:lower_bound	Coagulopathy with international normalized ratio (INR) > 2.0 or
NCT02937402	1:13:treatment,19:34:clinical_variable,37:41:upper_bound	Coagulopathy with platelets (Plt) < 10 k
NCT02937402	24:58:cancer,62:91:cancer	Confirmed diagnosis of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)
NCT02937402	53:87:treatment	Enrollment into this study may occur in tandem with other clinical therapeutics trials occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does not violate protocol or inclusion criteria of that study
NCT02937402	50:82:chronic_disease	Inability to perform informed consent due to any medical or psychiatric condition
NCT02937402	1:29:treatment,31:41:treatment,43:53:treatment,55:65:treatment,70:90:treatment,102:112:treatment,166:172:cancer	Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
NCT02937402	1:20:chronic_disease,44:49:lower_bound,50:74:treatment,78:91:treatment,95:117:treatment,129:143:upper_bound	Respiratory failure requiring greater than 6 Lpm supplemental oxygen (O2) by nasal cannula or mechanical ventilation within the past six weeks
NCT02937402	67:85:chronic_disease,109:117:chronic_disease,157:186:treatment	Subjects with an active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids/immunosuppressive medications
NCT02937272	6:72:clinical_variable,76:77:lower_bound,81:82:upper_bound	Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1
NCT02937272	16:45:chronic_disease	Have a serious concomitant systemic disorder
NCT02937272	25:47:chronic_disease	Have moderate or severe cardiovascular disease
NCT02937272	67:73:cancer	The participant must have histological or cytological evidence of cancer
NCT02933034	14:35:treatment,39:62:treatment	are taking a digitalis preparation or calcium channel blocker
NCT02933034	10:18:lower_bound,22:25:age	at least 18 years of age
NCT02933034	12:22:chronic_disease	develop an arrhythmia prior to or during either of the exercise tests; SeeMore should not be administered
NCT02933034	6:33:chronic_disease	have NYHA Grade IV heart failure
NCT02933034	19:27:chronic_disease,31:56:clinical_variable	have a history of torsades or prolonged QT/QTc interval
NCT02933034	55:65:clinical_variable,76:83:upper_bound	have abnormal baseline potassium or calcium values or hemoglobin less than 10 g/dl
NCT02933034	6:29:chronic_disease,52:65:chronic_disease	have abnormal liver function tests or a history of liver disease
NCT02933034	32:43:allergy_name,63:95:allergy_name	have known hypersensitivity to ondansetron or other selective serotonin 5HT3 receptor blockers
NCT02933034	6:31:chronic_disease,33:56:clinical_variable,59:62:lower_bound,66:78:clinical_variable,81:83:lower_bound	have uncontrolled hypertension (Systolic Blood Pressure > 140 or Diastolic BP > 90 consistently at baseline)
NCT02933034	4:10:gender,15:26:pregnancy,51:60:pregnancy,70:120:contraception_consent	if female, be nonpregnant as evidenced by a serum pregnancy test and using a medically-approved method of birth control, or post-menopausal or surgically sterile
NCT02933034	51:64:upper_bound	received an investigational drug or device within 30 days prior to administration of SeeMore
NCT02927639	19:27:chronic_disease,42:55:upper_bound	Have been seen in diabetes clinic in the last 6 months
NCT02927639	1:6:clinical_variable,32:34:lower_bound,49:52:upper_bound	HbA1c greater than or equal to 8% but less than 14%
NCT02927639	1:17:chronic_disease	Hemolytic anemia
NCT02927639	1:21:language_fluency	Non-English speaking
NCT02927639	13:33:chronic_disease	Significant cognitive disability
NCT02926248	1:4:age,30:38:lower_bound	Age greater than or equal to 18 years
NCT02926248	1:11:treatment,13:27:treatment,29:38:treatment,40:52:treatment,54:66:treatment,68:78:treatment,80:90:treatment,92:101:treatment,103:113:treatment,115:128:treatment,130:140:treatment,142:152:treatment,154:163:treatment,165:177:treatment,179:190:treatment,192:205:treatment,225:234:treatment	Atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, verapamil
NCT02926248	1:11:clinical_variable,14:17:lower_bound,36:56:clinical_variable,67:76:upper_bound	Creatinine > 1.5, and/or estimated creatinine clearance less than 30 mL/min
NCT02926248	1:13:treatment,15:25:treatment	Cyclosporine, ranolazine
NCT02926248	1:4:treatment,22:23:lower_bound,27:35:upper_bound,39:54:treatment	MUA indicated within 5 to 12 weeks of primary surgery
NCT02926248	1:30:language_fluency	Non-English speaking patients
NCT02926248	69:77:chronic_disease,82:96:chronic_disease	Patients concurrently taking medications that increase the risk for myopathy and rhabdomyolysis
NCT02926248	20:33:treatment	Patients requiring bilateral MUA
NCT02926248	15:30:chronic_disease,38:51:chronic_disease,53:62:chronic_disease,71:78:clinical_variable,79:81:lower_bound	Patients with hepatic disease (known liver disease, cirrhosis, and/or AST/ALT>60)
NCT02926248	25:35:upper_bound,41:60:treatment	Patients with less than 10 degrees of a flexion contracture
NCT02926248	15:28:chronic_disease	Patients with renal disease
NCT02926248	35:45:allergy_name	Patients with reported allergy to colchicine
NCT02926248	1:9:pregnancy	Pregnant patients
NCT02926248	22:24:chronic_disease,29:32:treatment	Primary Diagnosis of OA for TKA
NCT02926248	1:13:treatment	Revision TKA
NCT02926248	1:13:treatment,15:26:treatment,28:39:treatment,41:52:treatment,54:62:treatment,64:75:treatment,77:84:treatment	atorvastatin, fluvastatin, pravastatin, simvastatin, fibrates, gemfibrozil, digoxin
NCT02926248	1:19:clinical_variable,30:33:upper_bound	knee flexion angle less than 90°
NCT02925923	1:9:treatment	Apixaban
NCT02925923	1:15:treatment	Clarithromycin
NCT02925923	1:11:treatment	Dabigatran
NCT02925923	1:9:treatment	Edoxaban
NCT02925923	1:10:treatment	Indinavir
NCT02925923	1:13:treatment	Itraconazole
NCT02925923	1:13:treatment	Ketoconazole
NCT02925923	1:10:treatment	Lopinavir
NCT02925923	1:7:chronic_disease,54:62:clinical_variable,65:76:lower_bound	NSTEMI as evidenced by elevation of troponin levels (Troponin > 0.034 ng/ml)
NCT02925923	1:11:treatment	Nelfinavir
NCT02925923	15:30:chronic_disease	Patients with unstable angina
NCT02925923	1:10:treatment	Ritonavir
NCT02925923	1:12:treatment	Rivaroxaban
NCT02925923	1:14:treatment	Telithormycin
NCT02925923	1:13:treatment	Voriconazole
NCT02925923	19:41:treatment	administration of GP IIb/IIIa inhibitors
NCT02925923	1:7:chronic_disease,13:16:clinical_variable,17:20:upper_bound	anemia with HCT<30%
NCT02925923	1:23:treatment	anti-retroviral agents
NCT02925923	1:18:treatment,28:39:treatment	antifungal agents and some antibiotics
NCT02925923	34:50:clinical_variable	associated therapy with a strong cytochrome P-450 inhibitors
NCT02925923	19:30:chronic_disease	increased risk of bradycardia
NCT02925923	31:38:upper_bound	major bleeding episode within 2 weeks
NCT02925923	10:38:treatment	need for oral anticoagulation therapy
NCT02925923	10:21:treatment,25:41:treatment	need for vasopressor or inotropic agents
NCT02925923	1:8:treatment,9:16:upper_bound	surgery<4 weeks
NCT02925923	1:17:chronic_disease,19:33:clinical_variable,36:42:upper_bound	thrombocytopenia (Platelet count < 100000)
NCT02925923	19:22:chronic_disease	troponin negative ACS
NCT02925923	12:27:treatment,29:40:treatment,42:51:treatment,53:65:upper_bound	use of any thienopyridines (Clopidogrel, Prasugrel) 7 days prior to randomization
NCT02923167	1:2:lower_bound,6:14:upper_bound,18:21:age	9 to 14 years of age
NCT02923167	21:53:treatment,102:145:treatment,178:184:chronic_disease,195:207:chronic_disease	Contraindication to robotic-assisted manual training such acute and pronounced pain symptoms despite conventional pain therapy of the upper-limb, lack of compliance, high-grade ataxia, advanced osteoporosis, and fractures of the upper-limb
NCT02923167	14:16:chronic_disease	Diagnosis of CP with upper-limb impairment
NCT02923167	1:52:clinical_variable	Manual Ability Classification Scale Level II or III
NCT02923167	1:30:clinical_variable	Modified Ashworth Scale (MAS) of 4 in the upper-limb
NCT02923167	15:51:treatment,63:76:upper_bound	Recent use of upper-limb robotic-assisted training within the last 3 months
NCT02922335	1:40:chronic_disease,44:62:chronic_disease	Pervasive Developmental Disorders (PDD) or mental retardation
NCT02922335	1:4:age,5:7:lower_bound,8:10:upper_bound	age 17-21
NCT02922335	65:79:upper_bound	recent arrest or release from jail/prison/detention (within the past 18 months
NCT02922023	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT02922023	1:15:clinical_variable,20:31:lower_bound,55:63:upper_bound	Blood pressure of >140/90 mmHg for patients less than 60 years
NCT02922023	1:21:chronic_disease	Cognitively impaired persons
NCT02922023	17:43:chronic_disease,45:79:chronic_disease,81:89:chronic_disease,91:112:chronic_disease	Conditions with visual field deterioration (Anterior Ischemic Optic Neuropathy, Glaucoma, Optic Nerve Disorders)
NCT02922023	23:47:treatment,67:75:treatment,90:98:upper_bound	Currently receiving 3 anti-hypertensive agents, one of which is a diuretic, for at least 3 months
NCT02922023	1:9:pregnancy,10:15:gender	Pregnant women
NCT02920866	1:4:bmi,27:29:upper_bound	BMI less than or equal to 40
NCT02920866	1:13:chronic_disease,17:35:chronic_disease	Neurological or pulmonary problems that severely limit function
NCT02920866	7:38:chronic_disease	Other unstable orthopaedic conditions that limit function
NCT02920866	1:28:clinical_variable,33:37:lower_bound	Severe contralateral leg OA (>= 5/10 pain with stair climbing)
NCT02920710	14:34:allergy_name	Allergies to pig-derived proteins
NCT02920710	31:46:allergy_name,53:77:chronic_disease	Contraindication to high-dose corticosteroids (e.g. uncontrolled blood sugar)
NCT02920710	18:48:chronic_disease	Diagnosis of any underlying neurologic disorder that would potentially confound interpretation of the study results
NCT02920710	21:38:chronic_disease	Evidence of current serious infection, or a history of chronic or recurring infections
NCT02920710	12:22:cancer	History of malignancy
NCT02920710	1:14:chronic_disease	Hydrocephalus
NCT02920710	1:20:chronic_disease,32:54:chronic_disease,56:67:chronic_disease,75:87:chronic_disease	Neurologic deficits related to intraparenchymal brain, spinal cord and/or cauda equina involvement
NCT02920710	14:25:chronic_disease	Patient with sarcoidosis as defined by ATS/ERS/WASOG (American Thoracic Society/European Thoracic Society/World Association for Sarcoidosis and Other Granulomatous Disorders)
NCT02920710	54:66:upper_bound,77:105:treatment,117:130:upper_bound	Significant change in corticosteroid dose within the past 4 weeks, or other immunosuppressive medication within the past 6 months
NCT02920710	17:46:treatment	Stable baseline immunosuppressive medications
NCT02914171	1:9:lower_bound	10 years and older
NCT02914171	1:4:age,5:13:lower_bound,17:25:upper_bound	Age 6 months to 30 years
NCT02914171	1:18:chronic_disease	Cardiac condition requiring emergency procedure
NCT02914171	1:16:gender	Female subjects
NCT02914171	29:49:treatment,102:116:treatment	Individuals able to undergo bone marrow aspirate according to clinical consultation with Hematology (cell treatment group only)
NCT02914171	23:42:treatment,58:74:treatment	Individuals requiring cavopulmonary shunt at the time of surgical Ebstein repair
NCT02914171	156:179:treatment	Individuals who have other clinical concerns as documented by a site investigator that could reasonably increase the risk of complications during or after surgical Ebstein repair
NCT02914171	17:22:clinical_variable,33:38:lower_bound	Individuals who weigh more than 90 kg
NCT02914171	18:36:chronic_disease	Individuals with bleeding disorders
NCT02914171	26:37:treatment	Individuals with current IV inotrope requirements
NCT02914171	29:51:chronic_disease	Individuals with history of ventricular arrhythmia or new onset ventricular arrhythmia after enrollment that requires medical management
NCT02914171	18:53:chronic_disease	Individuals with preoperative ventricular arrhythmia requiring medical management
NCT02914171	18:35:chronic_disease,39:67:chronic_disease,73:103:chronic_disease	Individuals with pulmonary atresia or atrioventricular discordance with ventriculoarterial discordance
NCT02914171	18:41:chronic_disease	Individuals with severe chronic diseases
NCT02914171	50:63:upper_bound,67:89:treatment	Individuals with the following conditions within 60 days prior to Ebstein repair surgery
NCT02914171	1:27:chronic_disease,38:68:chronic_disease	Multi-system organ failure including acute or chronic renal failure
NCT02914171	11:34:chronic_disease	extensive extra-cardiac syndromes
NCT02914171	16:22:cancer	history of any cancer
NCT02914171	12:22:chronic_disease	history of thrombosis
NCT02913404	1:4:bmi,13:15:lower_bound,16:18:upper_bound	BMI between 18-35
NCT02913404	1:9:pregnancy,10:17:gender	Pregnant females
NCT02913404	76:102:treatment	Subjects will be of generally good health and will have decided to undergo ACL reconstruction surgery and agreed to participate in the study (following informed consent procedures)
NCT02913404	10:27:treatment,31:40:treatment	Use of a quad tendon graft or BTB graft
NCT02913404	9:12:age,16:18:lower_bound,19:21:upper_bound	between age of 14-40
NCT02913404	11:40:clinical_variable,46:50:lower_bound	display a quantitative pivot shift test of >=3 mm lateral translation
NCT02913404	46:55:upper_bound	have a contralateral healthy knee and within 12 months of grade 3 injury to the ipsilateral ACL
NCT02913404	17:24:upper_bound	no greater than grade 2 injury to MCL or LCL and absence of PCL injury
NCT02912845	39:53:treatment,57:92:treatment	History of previous administration of rabies vaccine or human rabies immune globulin (HRIG)
NCT02912845	1:5:gender	male
NCT02907983	26:36:chronic_disease	12 months of spontaneous amenorrhea
NCT02907983	25:35:chronic_disease,41:57:clinical_variable,60:68:lower_bound	6 months of spontaneous amenorrhea with serum FSH levels ≥ 40 IU/ml
NCT02907983	1:4:clinical_variable,6:9:lower_bound	INR >1.3
NCT02907983	1:55:clinical_variable,57:59:lower_bound	Personal Health Questionnaire Depression Scale (PHQ-8)> 15
NCT02907983	1:5:age,6:8:lower_bound,12:20:upper_bound	aged 40 to 65 years
NCT02907983	11:24:treatment	all other anti-platelet
NCT02907983	1:28:treatment	anticoagulation medications will be discontinued with the permission of the participant's prescribing physician
NCT02907983	28:47:chronic_disease,76:92:chronic_disease,94:110:chronic_disease,115:148:chronic_disease	conditions that can affect depressive symptoms (e.g., current diagnosis of major depression, bipolar disorder, or other Axis I Psychiatric disorder)
NCT02907983	28:51:chronic_disease	contralateral (left-sided) phrenic nerve paralysis
NCT02907983	1:11:clinical_variable,14:21:lower_bound	creatinine ≥ 2 mg/ml
NCT02907983	1:9:chronic_disease,10:35:chronic_disease,37:66:clinical_variable,89:91:upper_bound	dementia/mild cognitive impairment, Mini-Mental State Exam (MMSE) less than or equal to 27) at baseline
NCT02907983	35:42:chronic_disease,44:48:chronic_disease,53:59:chronic_disease	diaphragmatic paresis; history of seizure, coma, or stroke
NCT02907983	10:25:treatment	for whom hormone therapy is contraindicated
NCT02907983	5:10:gender,26:37:treatment	for women who refuse any oral therap
NCT02907983	1:11:clinical_variable,12:15:upper_bound	hemoglobin<9.0
NCT02907983	12:22:chronic_disease	history of neurologic deficit to the brachial plexus
NCT02907983	54:61:chronic_disease,68:82:chronic_disease	inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia)
NCT02907983	30:57:treatment	including oral (2 months) or transdermal hormone therapy(1 month), botanicals
NCT02907983	18:41:treatment,45:66:treatment	most but not all spinal cord stimulators or deep brain stimulator, ferrous-containing metals within the body (e.g., braces, aneurysm clips, shrapnel/retained particles)
NCT02907983	21:29:upper_bound	oral contraceptives(2 months)
NCT02907983	1:10:clinical_variable,12:19:upper_bound,21:24:clinical_variable,27:34:lower_bound	platelets <100,000, BUN ≥ 30mg/dl
NCT02907983	17:22:gender,75:90:treatment,98:113:treatment,117:127:treatment	post-menopausal women whose vasomotor symptoms are refractory to approved oral treatments (i.e., hormone therapy or paroxetine)
NCT02907983	1:11:treatment,13:22:treatment,64:84:treatment	pregabalin, clonidine, selective estrogen receptor modulators, aromatase inhibitors, tissue selective estrogen complexes
NCT02907983	20:27:upper_bound,31:34:treatment	safety labs within 30 days of SGB intervention
NCT02907983	1:52:treatment	serotonin norepinephrine reuptake inhibitors (SNRI)
NCT02907983	1:47:treatment	serotonin selective reuptake inhibitors (SSRI) (2 weeks)
NCT02907983	1:21:clinical_variable,24:27:upper_bound,33:42:lower_bound,88:104:allergy_name,108:120:allergy_name	serum potassium (K+) ≤ 3.5 or ≥ 5.0 mEq/L allergic reactions or contraindications to a local anesthetic or contrast dye
NCT02907983	1:15:treatment	sham treatment
NCT02907983	1:7:chronic_disease	stroke
NCT02907983	1:30:clinical_variable,32:41:lower_bound,45:75:clinical_variable,77:85:lower_bound	systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg
NCT02907983	1:23:chronic_disease	traumatic brain injury
NCT02907983	1:7:clinical_variable,10:17:lower_bound	weight > 300 lbs. unless height is sufficiently high [e.g., + 5'11] so that waist and shoulder circumference do not prevent her from fitting in the scanner
NCT02907983	24:35:treatment	willingness to undergo fluoroscopy-guided SGB
NCT02905370	1:9:lower_bound,13:16:age	65 years of age and older
NCT02905370	1:22:treatment	Acute cardiac surgery
NCT02905370	1:20:chronic_disease	Atrial fibrillation
NCT02905370	4:20:language_fluency	Be English-speaking
NCT02905370	1:26:chronic_disease	Chronic ulcerative wounds
NCT02905370	1:25:chronic_disease	Congestive Heart Failure
NCT02905370	1:48:chronic_disease	Deep vein thrombosis/pulmonary embolus (DVT/PE)
NCT02905370	1:25:chronic_disease	Depression/mental health
NCT02905370	1:9:chronic_disease	Diabetes
NCT02905370	1:35:treatment	Elective joint replacement surgery
NCT02905370	1:23:chronic_disease	Gastrointestinal Bleed
NCT02905370	15:16:lower_bound	Have at least 3 comorbid conditions
NCT02905370	1:14:chronic_disease	Heart Disease
NCT02905370	1:7:chronic_disease	Hernia
NCT02905370	1:13:chronic_disease	Hypertension
NCT02905370	1:18:chronic_disease	Hypo/Hyperthyroid
NCT02905370	1:28:chronic_disease	Peripheral Arterial Disease
NCT02905370	1:10:chronic_disease	Pneumonia
NCT02905370	1:22:treatment	Post-op bowel surgery
NCT02905370	9:27:treatment	Post-op pancreatic surgery
NCT02905370	13:40:chronic_disease,47:58:chronic_disease,60:62:chronic_disease,64:67:chronic_disease	Progressive neurodegenerative diagnosis (e.g. Parkinson's, MS, ALS)
NCT02905370	23:39:treatment	Referred to home care physical therapy following acute medical deconditioning
NCT02905370	1:14:chronic_disease,19:27:treatment	Renal Failure (no dialysis)
NCT02905370	11:13:upper_bound	Score of <20 on SLUMS
NCT02905370	1:17:chronic_disease	Terminal illness
NCT02905370	1:24:chronic_disease	Urinary Tract Infection
NCT02901314	27:29:chronic_disease,31:43:chronic_disease,47:82:chronic_disease,84:108:chronic_disease,112:136:chronic_disease	A non-traditional form of HF (hypertrophic or restrictive forms of cardiomyopathy, congenital heart disease or Takotsubo cardiomyopathy)
NCT02901314	1:22:chronic_disease	Chronic renal failure
NCT02901314	23:61:treatment	Currently enrolled in another experimental HF research study
NCT02901314	9:12:age,13:21:lower_bound	Minimum age 18 years (no upper age limit)
NCT02901314	18:41:treatment	Not referred for cardiac transplantation
NCT02901314	38:49:chronic_disease,61:69:chronic_disease,71:84:chronic_disease,92:104:chronic_disease	adhere to self-care recommendations (Alzheimer's condition, dementia, schizophrenia, other neurological history that impairs memory)
NCT02901314	1:9:chronic_disease,11:34:chronic_disease,38:44:cancer,48:123:chronic_disease	cachexia, end stage liver disease or cancer or non-ambulatory New York Heart Association functional class IV heart failure
NCT02901314	1:21:chronic_disease	cognitive conditions that limit ability to understand
NCT02901314	46:52:upper_bound	has a medical condition reflecting less than 1 year of survival
NCT02901314	67:85:chronic_disease	unable to carry out physical activity, including walking,due to a chronic disability or documented medical condition
NCT02891564	1:4:age,5:7:lower_bound,11:13:upper_bound	Age 45 to 75
NCT02891564	1:33:clinical_variable,36:38:lower_bound	Hamilton Depression Rating Scale > 20
NCT02891564	27:30:treatment	ability to participate in MRI
NCT02891564	1:9:chronic_disease,13:16:chronic_disease	dementia or MCI
NCT02891564	67:97:chronic_disease,113:120:chronic_disease	history or presence of psychiatric diagnoses other than unipolar, non-psychotic major depression or generalized anxiety disorder
NCT02891564	1:9:chronic_disease,11:40:chronic_disease	unipolar, nonpsychotic major depression (by SCID, DSM-V)
NCT02891564	8:26:treatment,30:55:treatment,81:96:treatment	use of psychotropic drugs or cholinesterase inhibitors other than mild doses of benzodiazepines
NCT02890979	204:219:treatment,223:245:treatment	Patients must be scheduled for a procedure capable of providing a definitive pathologic diagnosis and evaluating for complications of the esophageal sponge on the same day as the study procedure, either upper endoscopy or surgical esophagectomy
NCT02890979	21:38:cancer,40:54:cancer,58:81:cancer	Subjects with known esophageal cancer (adenocarcinoma or squamous cell carcinoma)
NCT02890979	34:52:chronic_disease	Subjects with known or suspected esophageal varices
NCT02890979	32:53:cancer,64:71:chronic_disease,88:126:chronic_disease	Subjects with risk factors for esophageal malignancy including Barrett?s esophagus and gastroesophageal reflux disease (GERD)
NCT02890979	1:34:chronic_disease	Uncontrolled intercurrent illness
NCT02890979	1:19:chronic_disease	cardiac arrhythmia
NCT02890979	12:28:chronic_disease	ongoing or active infection
NCT02890979	1:38:chronic_disease	psychiatric illness/social situations that would limit compliance with study requirements
NCT02881515	1:6:gender	Women
NCT02881515	12:34:chronic_disease	history of cardiovascular disease
NCT02881515	12:20:chronic_disease	history of diabetes
NCT02881515	12:26:chronic_disease	history of kidney disease
NCT02881515	1:4:gender	men
NCT02881515	1:8:chronic_disease,10:13:bmi,16:24:lower_bound	obesity (BMI > 30 kg/m2)
NCT02877875	1:17:chronic_disease,27:42:chronic_disease	Active psychosis and/or a suicide attempt in the previous year
NCT02877875	1:17:chronic_disease	Eating disorders
NCT02877875	13:21:lower_bound,22:23:upper_bound	Enrolled in grades 3-7
NCT02877875	49:56:chronic_disease,58:68:chronic_disease,82:102:chronic_disease	Have a primary clinical problem in the areas of anxiety, depression, conduct, or posttraumatic stress
NCT02877875	1:33:chronic_disease	Pervasive developmental disorder
NCT02874898	13:16:age,20:22:lower_bound,27:29:upper_bound	Between the age of 18 and 65
NCT02874898	22:38:chronic_disease,40:74:chronic_disease,40:50:chronic_disease,125:146:treatment,154:169:chronic_disease	Current diagnosis of bipolar disorder, depression with psychotic features, or depression severe enough to require immediate psychiatric treatment (i.e., serious suicide risk with intent and plan)
NCT02874898	10:33:chronic_disease,45:46:upper_bound	No clear trauma memory or trauma before age 3
NCT02874898	18:42:treatment,50:64:upper_bound	Unstable dose of psychotropic medications in the prior 3 months
NCT02874898	44:72:treatment	Unwilling or unable to discontinue current trauma-focused psychotherapy
NCT02860988	1:5:gender	Male inmates at specific eastern Kentucky jail sites
NCT02857218	1:11:clinical_variable,50:70:clinical_variable,74:92:lower_bound,111:128:clinical_variable	Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for subjects with creatinine levels above institutional normal
NCT02857218	1:61:clinical_variable,65:66:upper_bound,68:77:clinical_variable,81:84:lower_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
NCT02857218	1:11:clinical_variable,15:23:lower_bound,78:94:clinical_variable	Hemoglobin >= 8.0 g/dl (The use of transfusion or other invention to achieve Hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
NCT02857218	18:28:cancer,36:48:upper_bound	History of other malignancy in the past 2 years
NCT02857218	1:35:chronic_disease,57:91:treatment,136:164:treatment,170:181:treatment	Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
NCT02857218	30:43:treatment	Medical contraindications to esophagectomy
NCT02857218	45:72:cancer	Pathologically confirmed, locally advanced, malignancy of the esophagus
NCT02857218	20:39:chronic_disease	Patients must have regional adenopathy
NCT02857218	15:34:chronic_disease	Patients with renal insufficiency
NCT02857218	1:38:treatment	Positron emission tomography (PET)/CT of the whole-body or skull base to mid-thigh
NCT02857218	1:9:pregnancy,10:15:gender,53:70:treatment,93:104:treatment	Pregnant women are excluded from this study because chemoradiotherapy has the potential for teratogenic or abortifacient effects
NCT02857218	7:28:treatment,33:50:cancer	Prior systemic chemotherapy for esophageal cancer
NCT02857218	1:15:clinical_variable,18:59:upper_bound	Serum ferritin < 2.0 X institutional upper limit of normal
NCT02857218	42:45:allergy_name	Subjects who have a contraindication for MRI
NCT02857218	15:23:cancer,27:57:cancer,126:135:treatment,147:188:treatment,201:214:treatment	Subjects with cervical or Siewert 3 esophageal carcinoma, that are recommended by the multi-disciplinary tumor board to have treatment other than tri-modality chemo-radiation therapy (RT) followed by esophagectomy
NCT02857218	27:40:chronic_disease	Subjects with evidence of iron overload
NCT02857218	1:16:clinical_variable,20:61:upper_bound	Total bilirubin =< 1.5 X institutional upper limit of normal
NCT02857218	1:23:clinical_variable,27:38:lower_bound	White blood cell count >= 3.0 K/cu mm
NCT02857218	40:51:allergy_name	a known history of hypersensitivity to ferumoxytol
NCT02857218	29:34:cancer,81:103:treatment	based on multi-disciplinary tumor board discussion, patients are candidates for tri-modality treatment
NCT02857218	110:121:treatment	because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother
NCT02857218	1:39:cancer	breast ductal carcinoma in situ (DCIS)
NCT02857218	20:53:allergy_name	have an allergy to gadolinium (Gd) contrast material
NCT02857218	16:33:treatment,39:66:treatment	have undergone endoscopic biopsy with endoscopic ultrasound (EUS)-proven peri-esophageal nodal involvement
NCT02857218	10:33:cancer	low-risk prostate adenocarcinoma
NCT02857218	1:4:gender,33:100:contraception_consent	men who are sexually active and not willing/able to use medically acceptable forms of contraception
NCT02857218	1:29:cancer	non-melanomatous skin cancer
NCT02857218	12:28:chronic_disease	ongoing or active infection
NCT02857218	1:38:chronic_disease	psychiatric illness/social situations that would limit compliance with study requirements
NCT02857218	1:10:treatment,15:32:cancer	radiation for esophageal cancer
NCT02857218	1:18:chronic_disease	severely agitated
NCT02857218	51:87:allergy_name	subjects who have had an allergic reaction to any intravenous iron replacement product
NCT02857218	1:37:chronic_disease	symptomatic congestive heart failure
NCT02857218	1:25:chronic_disease	unstable angina pectoris
NCT02851888	1:3:lower_bound,7:15:upper_bound	18 to 50 years old
NCT02851888	1:69:clinical_variable,73:74:lower_bound,78:80:upper_bound	American Society of Anesthesiologists Physical Status (ASA PS) score of I or II
NCT02851888	1:29:pregnancy	Current or planned pregnancy
NCT02851888	23:37:chronic_disease,41:54:lower_bound	Radiographic signs of osteoarthritis (> Tonis grade 1)
NCT02851888	15:41:treatment,58:80:treatment	Scheduled for arthroscopic labral repair with or without osteoplasty of the hip
NCT02851303	41:54:treatment	Primary substance exposure in-utero was buprenorphine, or was not opioids
NCT02847988	13:34:chronic_disease	Acute-onset neuromuscular disease
NCT02847988	1:16:chronic_disease	Cardiopulmonary Instability
NCT02847988	13:35:clinical_variable,37:44:lower_bound	Duration of mechanical ventilation >14 days
NCT02847988	1:35:treatment	Lower-extremity amputee or paresis
NCT02847988	1:20:clinical_variable,22:23:lower_bound	Pitting edema grade ≥3
NCT02845453	19:27:lower_bound	For participants >17 years—unable or unwilling to identify emergency contact
NCT02845453	45:75:treatment,83:90:upper_bound,103:106:lower_bound,157:163:lower_bound,188:195:upper_bound	If subject in restricted setting/care (e.g. detox or residential treatment) for ≤ 2 weeks, then use ≥ 50% of days while outside of restricted setting (e.g. 7 days of substance use out of 14 days in unrestricted setting)
NCT02845453	1:5:gender	Male
NCT02845453	26:42:chronic_disease,46:84:chronic_disease,108:125:chronic_disease	Meets DSM-5 criteria for bipolar disorder or disruptive mood dysregulation disorder or DSM IV criteria for mood disorder NOS
NCT02845453	41:46:treatment,50:71:treatment,79:86:lower_bound,99:112:upper_bound	Placement in a restricted setting (e.g. detox or residential treatment) for ≥ 2 weeks out of past 28 days prior to screening visit, or placement in a restricted setting at anytime during study participation
NCT02845453	68:75:upper_bound	Subjects need to have been in an unrestricted setting for at least 2 weeks prior to screening
NCT02845453	18:41:clinical_variable,45:72:clinical_variable,74:77:lower_bound	Symptoms of SMD: Youth Self Report (YSR) or Adult Self Report (ASR) AAA ≥180
NCT02845453	1:4:age,5:7:lower_bound,11:13:upper_bound	age 15 to 24
NCT02845453	1:7:gender	female
NCT02844751	3:25:clinical_variable,39:42:lower_bound,66:75:treatment,79:94:treatment	A varus/valgus deformity of more than 10o, a deformity requiring osteotomy or complex surgery
NCT02844751	19:25:treatment,33:41:upper_bound	Consistent use of NSAIDs within 48 hours of procedure
NCT02844751	1:25:treatment,51:58:upper_bound	Corticosteroid injection at treatment site within 1 month
NCT02844751	49:63:upper_bound	Diagnosis of a transient ischemic attack in the 6 months prior to screening
NCT02844751	14:22:lower_bound	Greater than 6 months knee pain on the index side (left or right knee)
NCT02844751	1:18:cancer,26:39:upper_bound	Neoplastic cancer within 5 years prior to screening
NCT02844751	24:38:chronic_disease,42:45:chronic_disease	Patients infected with hepatitis B, C or HIV
NCT02844751	21:23:lower_bound,24:32:upper_bound,36:39:age	Patients range from 18-90 years of age
NCT02844751	15:36:bmi,39:46:lower_bound	Patients with Body Mass Index (BMI) > 40kg/m2
NCT02844751	52:59:clinical_variable,62:65:upper_bound,67:71:clinical_variable	Patients with adequate blood coagulation activity, PT(INR) < 1.5, APTT
NCT02844751	15:56:chronic_disease	Patients with adequate cardiac and respiratory function
NCT02844751	40:50:clinical_variable,53:62:upper_bound	Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl
NCT02844751	29:43:chronic_disease	Patients with indication of Osteoarthritis
NCT02840643	14:24:chronic_disease	Diagnosis of hemiplegia
NCT02840643	1:12:clinical_variable,35:45:lower_bound	Wrist range of motion of at least 10 degrees
NCT02838797	12:13:lower_bound,31:53:clinical_variable,76:165:clinical_variable	A score of 5 or higher on the gastroparesis subscale or 5 or higher on the constipation subscale of the Gastrointestinal Symptoms in Neurodegenerative Disease Scale
NCT02838797	18:19:lower_bound,37:74:clinical_variable	A total score of 2 or higher on the Gastroparesis Cardinal Symptoms Index (total score equals average of scores on the 3 subscales)
NCT02838797	1:9:chronic_disease,11:34:clinical_variable,37:39:upper_bound	Dementia (Mini Mental Status Exam < 25)
NCT02838797	1:13:clinical_variable,14:22:lower_bound,23:24:upper_bound	Hoehn & Yahr stages 1-3
NCT02838797	1:31:chronic_disease	Idiopathic Parkinson's Disease (UK Brain Bank Criteria)
NCT02838797	1:34:chronic_disease	abnormal liver or kidney function
NCT02838797	1:17:chronic_disease,19:36:chronic_disease	active psychosis, severe depression (score of 4 on question 1.3 of the Movement Disorder Society-United Parkinson Disease Rating Scale)
NCT02838797	1:19:chronic_disease,49:71:clinical_variable,75:76:lower_bound,80:81:upper_bound,89:136:clinical_variable	active suicidality as measured by a most severe suicide ideation score of 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT02838797	12:21:allergy_name,23:26:allergy_name,28:32:allergy_name,37:42:allergy_name	allergy to spirulina, egg, milk, or wheat
NCT02838797	1:19:chronic_disease	cardiac arrhythmia (past or present)
NCT02838797	1:9:chronic_disease	diabetes
NCT02838797	1:7:gender,29:37:pregnancy	female participants who are pregnant or lactating
NCT02838797	2:30:chronic_disease	gastroesophageal reflux disease
NCT02838797	16:40:treatment,81:92:treatment,102:113:treatment,115:131:treatment,136:169:treatment,174:193:chronic_disease	history of any gastrointestinal surgery that might impact drug absorption (e.g. gastrectomy), use of apomorphine, anticholinergics, or carbidopa/levodopa intestinal gel for Parkinson's Disease
NCT02838797	26:45:language_fluency	individuals with limited English proficiency
NCT02838797	1:5:gender,9:28:gender,45:48:age,57:125:contraception_consent	male or female participants of childbearing age who are not willing, or whose partners are not willing, to use contraception during the study
NCT02838797	24:37:treatment,39:56:treatment,58:88:treatment,90:129:treatment,135:145:treatment,414:430:treatment,435:454:chronic_disease	participants may be on oral levodopa, dopamine agonists, monoamine oxidase-B inhibitors, catechol-O-methyltransferase inhibitors, and amantadine, but doses must have remained stable for 28 days prior to enrollment and should be anticipated to remain stable throughout the study, participants may have deep brain stimulation (though stimulator settings must be expected to remain constant throughout the study) or ablative surgery for Parkinson's Disease
NCT02838797	82:115:chronic_disease	patients who, in the opinion of the investigator, present a risk of suicide, any chronic gastrointestinal diseases
NCT02838797	1:19:chronic_disease	symptomatic anemia
NCT02838394	1:22:chronic_disease,24:34:chronic_disease,36:44:chronic_disease	neurologic conditions (neuropathy, myopathy)
NCT02838394	22:25:lower_bound	presence of at least one painful trigger point in the gluteals (gluteus maximus or medius) and infraspinatus on the same side
NCT02838394	20:35:treatment,37:44:treatment,94:110:chronic_disease,112:128:chronic_disease	use of medication (antidepressants, opioids) and/or acute cervico-thoracic injury (whiplash, facet irritation, acute discopathy) that could directly influence normal somatosensory processing at the C5 segment [Srbely]
NCT02829060	8:17:pregnancy	Active pregnancy
NCT02829060	10:13:age,15:17:upper_bound	Patients age <18
NCT02829060	20:36:treatment,86:96:upper_bound,107:114:treatment	Patients receiving antibiotic doses (other than prescribed for the study) within the seven days preceding surgery
NCT02829060	44:52:upper_bound	Positive preoperative urine culture within 3 months
NCT02829060	1:12:chronic_disease,35:39:treatment	Renal stone of any size for which PCNL is recommended
NCT02829060	6:9:gender,14:19:gender	both men and women
NCT02826681	8:41:chronic_disease	Active acute or known chronic infections
NCT02826681	240:250:cancer,252:277:chronic_disease,279:310:chronic_disease,315:345:chronic_disease	Any other pre-existing laboratory abnormality, medical condition, or disease that, in the opinion of Investigator, may cause the subject to be unsuitable for the study or place the subject at potential risk from being in the study, e.g. a malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus
NCT02826681	42:57:upper_bound	Chronic alcohol or drug abuse within the past six months
NCT02826681	24:27:chronic_disease	Confirmed diagnosis of RLS based on the Cambridge-Hopkins Diagnostic Questionnaire (CHDQ) and the Hopkins-Hening Telephone Diagnostic Interview (HDTI)
NCT02826681	10:22:upper_bound,61:64:chronic_disease,71:78:treatment,80:117:treatment,119:135:treatment,137:172:treatment,177:208:treatment	Current (past 4 weeks) use of drugs that may cause or treat RLS, e.g. opioids, calcium channel alpha-2-delta ligands, anti-depressants, dopaminergic agonist or antagonists, or centrally-acting antihistamines
NCT02826681	69:72:chronic_disease	Disorders that require treatment with the same medications used for RLS
NCT02826681	12:27:chronic_disease,29:42:chronic_disease,50:72:chronic_disease,76:101:chronic_disease	History of hemochromatosis, hemosiderosis, other iron storage disorders or iron metabolism disorders
NCT02826681	1:12:clinical_variable,2:5:chronic_disease,14:16:lower_bound,48:56:lower_bound,82:99:lower_bound	IRLSS score ≥15 plus RLS symptoms for at least 3 months and currently occurring ≥2 nights per week
NCT02826681	1:23:chronic_disease,38:41:clinical_variable,43:50:upper_bound,58:66:clinical_variable,68:76:upper_bound,91:94:upper_bound,100:104:clinical_variable,109:112:upper_bound	Iron-deficiency anemia defined as an Hgb <12 g/dl with a ferritin <20 ng/mL, or ferritin <100 when TSAT is <18%
NCT02826681	53:63:allergy_name,66:87:allergy_name	Known hypersensitivity reaction to any component of Injectafer® (ferric carboxymaltose)
NCT02826681	16:21:chronic_disease,25:41:chronic_disease	Known positive HIV-1 or HIV-2 antibodies (anti-HIV)
NCT02826681	16:44:chronic_disease,99:122:treatment,139:171:chronic_disease,189:205:chronic_disease,213:216:clinical_variable,217:220:clinical_variable,234:251:lower_bound	Known positive Hepatitis B antigen (HBs Ag), unless positive test can be attributed to receipt of Hepatitis B vaccination in childhood or Hepatitis C viral antibody (HCV) with evidence of active hepatitis (i.e., AST/ALT greater than two times the ULN)
NCT02826681	1:33:clinical_variable,47:88:lower_bound	Liver transaminases (AST or ALT) greater than two times the upper limit of normal (ULN)
NCT02826681	1:5:gender	Male
NCT02826681	1:16:treatment,18:50:treatment,58:75:treatment,83:98:upper_bound	Parenteral iron, erythropoiesis stimulating agent use or blood transfusion within six weeks prior to the screening visit
NCT02826681	9:25:treatment	Planned elective surgery during the study year
NCT02826681	1:9:pregnancy,24:29:gender	Pregnant and lactating women
NCT02826681	26:36:treatment,39:42:treatment,46:52:treatment,59:73:treatment	Previously randomized to Injectafer® (FCM or VIT-45) in a clinical trial
NCT02826681	1:21:chronic_disease	Rheumatoid arthritis with symptoms or signs of active inflammation
NCT02826681	1:14:chronic_disease,22:45:chronic_disease,49:60:chronic_disease	Secondary RLS due to neurological conditions or head trauma
NCT02826681	22:31:pregnancy,44:62:pregnancy,88:134:contraception_consent,147:159:contraception_consent,163:177:contraception_consent,195:217:pregnancy,227:282:contraception_consent,296:311:lower_bound,328:351:contraception_consent,353:376:contraception_consent,378:397:contraception_consent,402:419:contraception_consent	Subjects at risk for pregnancy must have a negative pregnancy test at screening and be practicing an acceptable form of birth control, have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide with barrier, intrauterine device, or partner sterility
NCT02826681	13:29:treatment,68:82:upper_bound	Subjects on sleep medication must be on a stable dose for at least 6 months prior screening
NCT02826681	1:7:gender	female
NCT02826681	1:22:chronic_disease,27:54:chronic_disease,61:80:chronic_disease,84:92:chronic_disease	peripheral neuropathy and neurodegenerative disorders (i.e. Parkinson's disease or dementia)
NCT02826681	10:18:lower_bound,22:25:age	subject ≥18 years of age who is able to give informed consent
NCT02819141	1:16:chronic_disease,20:33:chronic_disease,35:51:clinical_variable,53:60:lower_bound	Acute hepatitis or liver failure (direct bilirubin >5 mg/dL)
NCT02819141	1:28:chronic_disease,36:50:upper_bound	Acute myocardial infarction within 48 hours prior to enrollment
NCT02819141	1:13:chronic_disease	Acute stroke
NCT02819141	1:19:treatment,27:41:upper_bound	General anesthesia within 12 hours prior to enrollment
NCT02819141	1:12:chronic_disease,14:37:clinical_variable,40:47:upper_bound,96:110:treatment,99:110:treatment,145:156:clinical_variable,159:177:lower_bound	Hypotension (systolic blood pressure < 85 mmHg) requiring a vasopressor at a dose greater than norepinephrine or epinephrine 0.15 mcg/kg/min or vasopressin > 2.4 units per hour
NCT02819141	10:19:pregnancy	Positive pregnancy test
NCT02819141	1:35:chronic_disease,39:50:chronic_disease,52:62:clinical_variable,65:77:upper_bound	Second or third degree heart block or bradycardia (heart rate < 50 beats/min)
NCT02819141	8:43:chronic_disease,53:57:chronic_disease,59:67:chronic_disease	Severe cognition or communication problems (such as coma, deafness without signing literacy, physician-documented dementia)
NCT02819141	34:89:treatment	currently receiving a continuous intravenous infusion of a sedative/opioid medication(s)
NCT02819141	80:120:clinical_variable,121:123:lower_bound,127:129:upper_bound	must pass pre-Patient-Controlled Sedation (PCS) screening test and be assessed Richmond Agitation-Sedation Scale (RASS) -2 to +1
NCT02819141	19:22:lower_bound,85:102:upper_bound,104:112:treatment,114:127:treatment,129:137:treatment,139:147:treatment,149:158:treatment,160:168:treatment,170:179:treatment,181:189:treatment,191:202:treatment,204:219:treatment	received at least one intravenous bolus dose of a sedative/opioid medication in the previous 24 hours (fentanyl, hydromorphone, ketamine, morphine, midazolam, diazepam, lorazepam, propofol, haloperidol, dexmedetomidine)
NCT02819141	14:22:chronic_disease	uncontrolled seizures
NCT02819141	1:12:treatment,34:48:treatment,37:48:treatment,81:92:treatment,95:113:lower_bound,115:128:treatment,130:142:lower_bound,144:152:treatment,154:167:lower_bound	vasopressor dose was higher than norepinephrine or epinephrine 0.15 mcg/kg/min, vasopressin > 2.4 units per hour, phenylephrine >3 mcg/kg/min, dopamine >10 mcg/kg/min or dobutamine at any dose in the prior 6 hours
NCT02816697	1:34:language_fluency	Able to read and write in English
NCT02816697	1:27:chronic_disease	Acute respiratory distress
NCT02816697	66:79:upper_bound	Current or recent former smoker (defined as having smoked within past 6 months)
NCT02816697	28:36:lower_bound	Former smoker greater than 6 months
NCT02816697	1:12:chronic_disease	Hypotension
NCT02816697	1:37:technology_access	Must have an active telephone number
NCT02811939	51:63:allergy_name	Individuals with a documented reaction/allergy to Pregnenolone
NCT02808468	1:2:lower_bound,3:11:upper_bound	2-10 weeks post sexual assault
NCT02808468	1:22:technology_access	Access to a telephone
NCT02808468	1:4:age,7:15:lower_bound	Age > 18 years
NCT02808468	20:21:lower_bound,76:79:lower_bound	Drinking more than 3 drinks on one occasion in the last month and at least two reported negative consequences of alcohol use
NCT02808468	17:26:chronic_disease	Exhibit current psychosis
NCT02808468	15:21:gender	Identifies as female
NCT02808468	45:46:lower_bound,68:102:treatment	Previous non-response to an adequate trial (8 or more sessions) of Cognitive Processing Therapy (CPT)
NCT02808442	1:45:cancer	Active Central Nervous System (CNS) leukemia
NCT02808442	1:17:cancer	Burkitt leukemia
NCT02808442	1:30:cancer	CD19-negative B-cell leukemia
NCT02808442	11:26:clinical_variable,29:37:lower_bound	Estimated life expectancy ≥ 12 weeks
NCT02808442	51:90:cancer	Patient with relapsed or refractory CD19-positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options
NCT02808442	7:56:chronic_disease,67:87:treatment	ctive acute or chronic Graft-versus-Host Disease (GvHD) requiring systemic use therapy
NCT02803359	12:21:allergy_name	Allergy to Lidocaine
NCT02803359	12:25:allergy_name	Allergy to Oxymetazoline
NCT02803359	29:65:treatment	Healthy Subjects undergoing thyroid or other open neck surgeries
NCT02803359	12:25:treatment	History of Brain Surgery
NCT02803359	12:29:chronic_disease	History of Diabetes Mellitus
NCT02803359	12:24:treatment	History of Neck Surgery
NCT02803359	12:30:chronic_disease	History of Neurologic Disease
NCT02803359	12:18:chronic_disease	History of Stroke
NCT02803359	1:33:chronic_disease	Laryngopharyngeal Reflux Disease
NCT02803359	8:25:treatment,34:43:upper_bound	Recent Laryngeal Surgery (within one month)
NCT02781519	8:28:treatment,32:56:contraception_consent,62:67:gender	taking estrogen supplements or oral contraceptive pills (for women)
NCT02779244	1:4:bmi,5:7:lower_bound	BMI>40
NCT02779244	1:16:chronic_disease	Pilon fractures
NCT02779244	1:11:chronic_disease	Polytrauma patients
NCT02776891	40:60:clinical_variable,62:71:lower_bound	Adequate renal function with estimated creatinine clearance ≥50 mL/min (by the Cockcroft Gault equation)
NCT02776891	73:90:chronic_disease	Any serious and/or unstable pre-existing medical, psychiatric, or other medical condition that could interfere with subject's safety, provision of informed consent, or compliance with study procedures
NCT02776891	47:59:upper_bound	Available prior CT or PET/CT scan done in the last 8 weeks for comparison
NCT02776891	1:12:clinical_variable,18:28:lower_bound	Body weight over 300 pounds
NCT02776891	1:6:cancer	DLBCL without myc translocation or overexpression by the above methods
NCT02776891	12:20:cancer	Double hit lymphoma
NCT02776891	26:31:cancer,35:39:cancer	Histologically confirmed DLBCL or BCLU
NCT02776891	25:28:treatment,35:44:treatment,46:60:treatment,69:83:chronic_disease	No contraindications to MRI (e.g. pacemaker, aneurysm clips, severe claustrophobia)
NCT02776891	73:79:lower_bound	Presence of palpable or radiographically measurable disease of at least 1.5 cm in longest dimension
NCT02776891	1:10:treatment,16:36:clinical_variable,38:40:upper_bound	Prior MRI with gadolinium performed <24 hours before the study scan
NCT02776891	1:19:treatment,23:32:treatment,85:98:lower_bound	Prior chemotherapy or radiation to the measurable lesion must be completed at least 14 days prior
NCT02776891	16:26:treatment	intolerance to gadolinium
NCT02776761	42:53:chronic_disease,55:64:chronic_disease,66:80:chronic_disease,85:92:chronic_disease,96:124:chronic_disease	Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical exam, and/or laboratory screening test
NCT02776761	49:56:lower_bound,58:76:treatment	Administration of chronic (defined as more than 14 days) immunosuppressants
NCT02776761	5:42:chronic_disease,54:62:chronic_disease,67:75:chronic_disease	Any chronic or active neurologic disorder, including seizures and epilepsy
NCT02776761	27:53:chronic_disease	Any confirmed evidence of hepatitis B or C infection
NCT02776761	28:45:chronic_disease,49:74:chronic_disease,86:130:chronic_disease	Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection
NCT02776761	5:20:treatment,37:47:clinical_variable,89:102:lower_bound	For corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day
NCT02776761	15:19:gender	Healthy adult male
NCT02776761	54:65:allergy_name	History of severe local or systemic reactions to any vaccination
NCT02776761	34:69:chronic_disease,99:125:treatment	History or serologic evidence of prior infection with any hantavirus or prior participation in an HTNV or PUUV vaccine trial
NCT02776761	1:42:treatment	Intranasal, inhaled, and topical steroids
NCT02776761	10:20:chronic_disease,10:26:treatment,21:26:treatment	Negative hantavirus PsVNA test result at screening
NCT02776761	26:48:treatment	Ongoing participation in another clinical trial (subjects continuing through Day 365 will not join other new studies until their final visit)
NCT02776761	1:9:pregnancy	Pregnant
NCT02776761	12:29:treatment,37:44:upper_bound,61:73:treatment,75:82:upper_bound,87:100:treatment	Receipt of licensed vaccines within 14 days before or after immunization (30 days for live vaccines)
NCT02776761	1:5:age,6:8:lower_bound,9:11:upper_bound	ages 18-49 (inclusive) at the time of screening
NCT02776761	15:23:treatment,28:37:treatment,41:47:chronic_disease	daily inhaled steroids for treatment of asthma
NCT02776761	1:7:gender,12:38:pregnancy	female who intends to become pregnant during the study period
NCT02776761	12:37:chronic_disease	history of severe allergic reactions
NCT02776761	11:17:gender	lactating female
NCT02776761	143:150:upper_bound	planned administration during the study period Blood donation for human use (eg, American Red Cross or other similar blood drives) within the 56 days preceding study entry
NCT02776761	8:23:chronic_disease	single febrile seizure as a child
NCT02776761	12:52:contraception_consent,58:80:contraception_consent,92:120:contraception_consent,122:131:contraception_consent,133:145:contraception_consent,147:166:contraception_consent,168:174:contraception_consent,179:199:contraception_consent,303:311:lower_bound	willing to use an effective method of contraception (eg, hormonal contraception to include oral and implantable options, diaphragm, cervical cap, intrauterine device, condom, or anatomical sterility [self or partner]) for the duration of study participation (from the date of screening) until at least 3 months after the last injection
NCT02776059	50:87:clinical_variable,89:91:lower_bound	A clinical diagnosis of alcoholic hepatitis with Maddrey's discriminant function score ≥32
NCT02776059	1:4:age,5:13:lower_bound	Age 18 years or older
NCT02776059	1:10:clinical_variable,12:19:upper_bound	Bilirubin <5 mg/dL
NCT02776059	7:20:chronic_disease	Known HIV infection
NCT02776059	1:14:chronic_disease	Renal failure
NCT02776059	1:23:chronic_disease	Uncontrolled infection
NCT02776059	1:9:pregnancy	pregnant
NCT02776059	27:52:chronic_disease	uncontrolled recent upper gastrointestinal bleeding
NCT02769156	13:16:age	18 years of age
NCT02769156	34:42:allergy_name	Patients with a known allergy to Benadryl
NCT02762032	5:28:chronic_disease	Any dermatological disorder that may interfere with the accurate evaluation of the subject's skin
NCT02762032	1:8:treatment	Aspirin
NCT02762032	24:50:chronic_disease	Clinically significant unstable medical disorders
NCT02762032	1:16:gender	Female subjects
NCT02762032	13:21:chronic_disease,23:46:chronic_disease	History of, diabetes, heart or kidney disease
NCT02762032	1:19:treatment	Hydochlorothiazide
NCT02762032	1:20:treatment	Immunosuppressant's
NCT02762032	1:6:gender	Males
NCT02762032	1:17:treatment	Muscle relaxants
NCT02762032	21:24:age,21:25:age,29:31:lower_bound,35:43:upper_bound	must be between the ages of 30 to 65 years of age
NCT02762032	1:21:pregnancy	planning a pregnancy
NCT02762032	10:19:upper_bound	starting two weeks before onset of study and also during the study
NCT02759211	1:3:lower_bound,4:12:upper_bound,16:19:age	18-65 years of age
NCT02759211	75:77:lower_bound,92:96:clinical_variable	Cognitively able to understand directions and complete protocol (score of 22 or greater on MMSE)
NCT02759211	33:35:chronic_disease	Confirmed clinical diagnosis of MS
NCT02759211	26:42:treatment	Current participation in physical therapy
NCT02759211	42:57:chronic_disease,59:92:chronic_disease,111:145:chronic_disease,147:185:chronic_disease,187:210:chronic_disease,214:234:chronic_disease,247:250:chronic_disease,252:269:chronic_disease,273:285:chronic_disease,287:311:chronic_disease,313:338:chronic_disease,344:365:chronic_disease	Current self-reported medical history of unstable angina, uncontrolled cardiac dysrhythmias causing symptoms, symptomatic severe aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus or pulmonary infarction, history of DVT, acute myocarditis or pericarditis, acute systemic infection, uncontrolled hypertension, and uncontrolled diabetes [11]
NCT02759211	1:11:clinical_variable,15:16:lower_bound,20:21:upper_bound,33:47:upper_bound	PDDS score of 3 to 5 during the past 12 months
NCT02759211	103:113:lower_bound	Requires constant bilateral assistance (canes or crutches) for ambulation and/or cannot walk at least 100 meters without resting
NCT02759211	1:15:language_fluency	Speaks English (in order to safely complete intervention
NCT02759120	32:45:allergy_name,50:62:allergy_name,64:76:allergy_name	Allergy or intolerance to both tetracyclines AND trimethoprim, sulfonamides or their combination
NCT02759120	27:40:allergy_name,51:66:clinical_variable,69:76:lower_bound,84:96:upper_bound	Allergy or intolerance to tetracyclines AND known potassium level > 5 mEq/L in the past 90 days
NCT02759120	27:40:allergy_name,85:117:clinical_variable,120:125:upper_bound,137:153:upper_bound	Allergy or intolerance to tetracyclines AND known renal insufficiency (defined as a glomerular filtration rate (GFR) < 30 ml within the previous 90 days)
NCT02759120	1:30:treatment,36:48:treatment,50:63:treatment,65:81:treatment,86:98:treatment	Concomitant immunosuppression with azathioprine, mycophenolate, cyclophosphamide, or cyclosporine
NCT02759120	21:39:allergy_name	Contraindicated for antibiotic therapy
NCT02759120	38:55:chronic_disease	If the enrolling physician feels the renal dysfunction has resolved, documentation to that effect must be provided
NCT02759120	1:9:pregnancy	Pregnant
NCT02759120	10:31:treatment,39:51:upper_bound	Received antimicrobial therapy in the past 30 days
NCT02759120	11:38:treatment,43:54:treatment,66:78:upper_bound,86:97:treatment	Use of an investigational study agent for IPF therapy within the past 30 days, or an IV infusion with a half-life of four (4) weeks
NCT02759120	1:29:pregnancy	anticipate becoming pregnant
NCT02759120	3:11:lower_bound,15:18:age	≥ 40 years of age
NCT02753283	12:16:gender	Ambulatory male
NCT02753283	116:123:upper_bound	Institutionalized residents with subacute illnesses who are not expected to survive or who will be discharged in < 2 years
NCT02753283	41:56:treatment,61:76:treatment	Patients will be allowed to continue on glucocorticoids and anticonvulsants because their use is common in this population
NCT02753283	20:27:treatment,39:53:treatment,55:64:treatment,69:81:treatment,126:131:lower_bound,143:159:upper_bound,173:188:treatment	Those currently on therapy (including bisphosphonate, denosumab, or teriparatide) or who have been on a bisphosphonate for > 1year during the previous 2 years because some bisphosphonates are long acting
NCT02753283	10:25:treatment,30:45:treatment	Those on glucocorticoids and anticonvulsants will be allowed to continue in the study because their use is common in this population
NCT02753283	10:43:treatment,45:55:treatment,60:90:treatment,182:191:treatment	Those on hormone replacement therapy (HRT), raloxifene, or prescribed protective hip pads by their Primary Care Physician (PCP) will be allowed to participate and continue on these therapies
NCT02753283	62:71:treatment	Those with a history of hypocalcemia or contraindication for treatment
NCT02753283	12:28:clinical_variable,12:21:treatment,31:38:upper_bound	Those with vitamin D levels < 25ng/mL will be treated with vitamin D 50,000 IU/wk for 8 weeks
NCT02753283	50:60:clinical_variable,106:112:cancer	We will suggest that participants stop long-term calcitonin as it has been discontinued in Europe due to cancer concerns
NCT02753283	124:127:lower_bound,154:156:lower_bound	Would be treated based on FRAX® and the National Osteoporosis Foundation (NOF) treatment thresholds of a 10 year risk of ≥ 20% for a major fracture or ≥ 3% for hip fracture suing femoral neck BMD
NCT02753283	40:74:clinical_variable,77:81:upper_bound	by bone density [spine, hip or forearm Bone Mineral Density (BMD) T-score ≤ -2.5]
NCT02753283	16:28:chronic_disease,32:45:chronic_disease,69:73:age,74:76:lower_bound	residents with osteoporosis or low bone mass (at risk for fracture) ages 65 and older
NCT02744053	22:37:allergy_name	Has known allergy to Tc99m sestamibi
NCT02744053	32:35:clinical_variable	Has known contraindications to MRI
NCT02744053	4:12:pregnancy	Is pregnant (confirmed by the patient as imaging clinic standard of care)
NCT02744053	24:28:cancer,84:106:clinical_variable,111:137:clinical_variable,141:144:upper_bound,145:150:cancer,178:216:treatment,217:250:clinical_variable,253:254:upper_bound	The patient has proven TNBC, defined by standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (< 10% tumor staining) and negative for human epidermal growth factor 2 (HER2) (immunohistochemistry [IHC] score < 3, gene copy number not amplified)
NCT02743728	1:50:chronic_disease	Disorders of Cellular Migration and Proliferation
NCT02743728	1:20:chronic_disease	Metabolic Disorders
NCT02743728	1:9:cancer	Neoplasm
NCT02743728	7:27:chronic_disease,41:47:chronic_disease	Other neurologic disorders unrelated to stroke
NCT02743728	1:32:clinical_variable,11:26:clinical_variable	Small for gestational age (SGA): Infants are smaller in size than normal for the gestational age
NCT02743728	1:4:age,13:14:lower_bound,19:28:upper_bound	age between 3 and 12 months of age
NCT02738398	15:20:cancer,69:92:treatment	Patients with NSCLC diagnosis who have been referred for a clinical FDG PET/CT staging scan as part of their standard of care
NCT02738398	1:5:age,6:8:lower_bound	aged 18 or over
NCT02738398	10:18:lower_bound,22:25:age	at least 18 years of age
NCT02737475	32:44:treatment	All subjects must have a fresh tumor biopsy
NCT02737475	13:25:cancer	Concomitant malignancies
NCT02737475	1:14:clinical_variable,25:32:upper_bound	Major surgery less than 4 weeks before the start of the study
NCT02737475	34:46:allergy_name,48:56:allergy_name,61:75:allergy_name	Patients with known allergies to egg products, neomycin, or tetanus toxoid
NCT02737475	27:61:allergy_name	Prior adverse reaction to tetanus toxoid-containing vaccines
NCT02734771	1:31:clinical_variable,35:67:clinical_variable,86:129:upper_bound	Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be less than 3 times the upper limit of the normal range
NCT02734771	13:22:chronic_disease,13:30:chronic_disease,103:130:chronic_disease	Carriers of hepatitis B virus should be closely monitored for clinical and laboratory signs of active hepatitis B virus infection and for signs of hepatitis throughout study participation
NCT02734771	1:19:cancer	Composite lymphoma containing both indolent and large cell features will be included
NCT02734771	1:61:clinical_variable,65:66:lower_bound,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
NCT02734771	17:30:treatment,35:40:cancer,44:46:chronic_disease,81:91:treatment,117:123:upper_bound,134:142:cancer,179:198:cancer,219:257:treatment	Has received no prior therapy for DLBCL or HT with the exception of a course of prednisone of less than or equal to 7 days given for lymphoma related symptoms; prior therapy for follicular lymphoma is accepted, but no prior anthracycline-containing therapy
NCT02734771	12:39:treatment,44:88:chronic_disease	History of solid organ transplantation, or post-transplant lymphoproliferative disorder
NCT02734771	36:73:cancer	History of, or clinically apparent central nervous system (CNS) lymphoma
NCT02734771	1:27:clinical_variable,28:51:chronic_disease,55:72:clinical_variable,86:89:upper_bound,93:107:treatment,111:146:treatment	New York Heart Association class III heart failure or ejection fraction of less than 30% on echocardiogram or Multi Gated Acquisition Scan (MUGA)
NCT02734771	38:58:clinical_variable,63:75:upper_bound,83:90:upper_bound	Patient has a calculated or measured creatinine clearance of <30 mL/minute within 14 days before enrollment
NCT02734771	15:29:clinical_variable,34:44:upper_bound,52:59:upper_bound	Patient has a platelet count of ≤50,000/mm3 within 14 days before enrollment
NCT02734771	16:41:clinical_variable,47:56:upper_bound,64:71:upper_bound	Patient has an absolute neutrophil count of < 1,000/mm3 within 14 days before enrollment
NCT02734771	25:42:cancer	Patient has concomitant active malignancy that the treating physician or PI feels may interfere with the ability to measure the primary or secondary outcomes
NCT02734771	55:62:upper_bound	Patient has received other investigational drugs with 14 days before enrollment
NCT02734771	14:21:lower_bound,22:43:clinical_variable,51:58:upper_bound	Patient has ≥Grade 2 peripheral neuropathy within 14 days before enrollment
NCT02734771	24:27:chronic_disease	Patient is known to be HIV positive (test result not required for enrollment)
NCT02734771	22:41:treatment,45:57:treatment	Patient is receiving peritoneal dialysis or hemodialysis
NCT02734771	15:17:chronic_disease,44:57:treatment	Patients with HT must not have received an anthracycline-containing regimen in the past
NCT02734771	57:89:cancer,93:121:cancer,125:156:cancer	Patients with a history of curative, surgically treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible
NCT02734771	17:27:cancer,55:62:treatment,176:185:treatment,192:205:lower_bound	Patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded, unless the malignancy has been in documented remission without treatment for ≥ 3 years prior to enrollment
NCT02734771	19:32:treatment	Prior exposure to anthracycline
NCT02734771	1:39:chronic_disease	Serious medical or psychiatric illness likely to interfere with participation in this clinical study
NCT02734771	7:16:clinical_variable,35:76:upper_bound,120:136:chronic_disease	Total bilirubin must be less than 1.5 times the upper limit of normal (ULN) unless the elevation is known to be due to Gilbert syndrome
NCT02734771	1:4:age,1:5:age,31:39:lower_bound	aged greater than or equal to 75 years of age
NCT02734771	1:6:gender	women
NCT02734602	1:3:lower_bound,4:12:upper_bound	18-55 years old
NCT02734602	23:34:upper_bound	Blood donation within eight weeks of the start of the study
NCT02734602	1:15:clinical_variable,17:23:lower_bound	Blood pressure >140/80
NCT02734602	21:24:treatment,44:58:chronic_disease	Contraindication to MRI scanning including claustrophobia and presence of a ferromagnetic object, including orthodontic braces
NCT02734602	22:25:treatment,62:68:cancer	Contraindications to PET (e.g., past or current diagnosis of cancer, poor venous access for placement of venous lines)
NCT02734602	22:25:chronic_disease,29:33:chronic_disease	Current diagnosis of MDD or PTSD with psychotic features
NCT02734602	9:18:chronic_disease,39:57:chronic_disease	Current psychosis, active suicidal or homicidal ideation
NCT02734602	1:17:language_fluency	English speaking
NCT02734602	45:63:chronic_disease	First degree relative with a diagnosis of a psychotic disorder
NCT02734602	12:14:clinical_variable,26:28:upper_bound	Full scale IQ lower than 70
NCT02734602	12:27:treatment	History of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure
NCT02734602	21:43:chronic_disease,66:77:chronic_disease	Lifetime history of neurologic abnormality including significant head trauma
NCT02734602	37:62:chronic_disease	Meet DSM-IV diagnostic criteria for Major Depressive Disorder, and for a current depressive episode
NCT02734602	31:37:chronic_disease	No current, or history of any DSM-IV diagnosis
NCT02734602	42:51:chronic_disease,53:57:chronic_disease,62:78:chronic_disease	No first-degree relative with history of psychotic, mood, or anxiety disorder
NCT02734602	59:67:upper_bound	Previous or anticipated radiation exposure at work within one year of the proposed research PET scans that precludes study participation
NCT02734602	1:16:cancer,20:37:cancer	cerebrovascular or neoplastic lesion
NCT02734602	1:27:chronic_disease	neurodegenerative disorder
NCT02728050	4:7:lower_bound	>= 10% blasts in marrow or blood
NCT02728050	1:4:cancer,16:50:cancer,56:73:clinical_variable,170:186:cancer	AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO) classification; patients with biphenotypic AML
NCT02728050	8:23:chronic_disease,87:96:treatment,226:249:chronic_disease,251:285:chronic_disease	Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)])
NCT02728050	1:10:clinical_variable,14:57:upper_bound,123:126:cancer,128:146:chronic_disease,151:160:chronic_disease,178:191:upper_bound	Bilirubin =< 2 times institutional upper limit of normal unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (assessed within 10 days prior to study day 0)
NCT02728050	1:20:chronic_disease,60:66:upper_bound	Concomitant illness associated with a likely survival of < 1 year
NCT02728050	1:10:pregnancy	Pregnancy
NCT02728050	12:23:treatment	The use of hydroxyurea prior to study registration
NCT02728050	1:6:gender,3:6:gender,46:81:contraception_consent,137:145:lower_bound	Women of childbearing potential and men must agree to use adequate contraception beginning at the signing of the consent until at least 3 months after the last dose of study drug
NCT02728050	11:38:cancer	high-risk myeloproliferative neoplasm
NCT02728050	99:101:lower_bound,102:116:upper_bound,191:210:chronic_disease	patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24-48 hours prior to study day 0, unless fever is thought to be secondary to the underlying hematologic disease
NCT02728050	1:10:treatment	sorafenib
NCT02728050	16:19:chronic_disease,23:26:chronic_disease,63:66:cancer,129:145:treatment	such high-risk MDS or MPN have natural history much closer to AML than to lower risk MDS or MPN and have responded similarly to AML-type therapy
NCT02724540	1:17:chronic_disease,31:40:chronic_disease,45:61:chronic_disease	Active infection (Symptomatic bacterial and fungal infection - newly diagnosed and/or requiring treatment)
NCT02724540	1:7:treatment,15:35:cancer	Biopsy-proven neuroendocrine tumor
NCT02724540	22:35:allergy_name,59:74:allergy_name	Contraindications to arteriography and selective visceral catheterization
NCT02724540	22:49:treatment	Contraindications to hepatic artery embolization
NCT02724540	1:4:clinical_variable,7:10:upper_bound	INR ≤ 1.5
NCT02724540	12:31:cancer,46:59:lower_bound,62:68:lower_bound	Measurable metastasis to liver with at least one dimension ≥ 1.0 cm
NCT02724540	14:22:lower_bound	Participants 18 years and older
NCT02724540	27:36:lower_bound,44:62:treatment,64:68:treatment,70:78:treatment,82:89:treatment,119:148:treatment	Patients must be at least one month beyond prior chemotherapy, PRRT, ablation or surgery, and have recovered from all therapy-associated toxicities
NCT02724540	1:19:clinical_variable,20:21:lower_bound,22:23:upper_bound,27:56:clinical_variable	Performance status 0-2 on Zubrod/ECOG Performance Scale
NCT02724540	1:15:clinical_variable,18:33:lower_bound	Platelet count > 50 thousands/uL
NCT02724540	1:9:pregnancy	Pregnant
NCT02724540	7:31:treatment	Prior hepatic arterial therapy
NCT02724540	1:25:treatment,29:37:treatment,41:57:cancer	Prior surgical resection or ablation of liver metastases is acceptable
NCT02724540	1:16:clinical_variable,19:28:upper_bound	Serum Bilirubin ≤ 2.0 mg/dL
NCT02724540	1:14:clinical_variable,17:25:lower_bound	Serum albumin ≥ 3.0 g/dL
NCT02724540	1:17:clinical_variable,20:29:upper_bound	Serum creatinine < 2.0 mg/dL
NCT02724540	57:76:treatment,91:109:treatment	There must be no plans for the patient to receive other concomitant therapy while on this protocol treatment (other than somatostatin analogs or bone-strengthening agents)
NCT02724540	1:6:cancer	Tumor burden dominant in the liver
NCT02724540	1:10:gender,74:121:contraception_consent	Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
NCT02724540	1:19:chronic_disease,54:61:treatment	bleeding diathesis not correctable by usual forms of therapy
NCT02724540	26:47:clinical_variable,49:52:lower_bound	criteria in the liver OR baseline tumor burden >25% of the liver volume
NCT02724540	1:23:chronic_disease	hepatic encephalopathy
NCT02724540	1:26:treatment	hepatic radiation therapy
NCT02724540	16:30:allergy_name	intolerance to contrast media
NCT02724540	11:16:gender,71:89:treatment	lactating women may not participate due to the embryotoxic effects of protocol treatment
NCT02724540	1:12:cancer,42:45:upper_bound,53:71:clinical_variable	liver tumor burden less than or equal to 70% of the total liver volume by visual estimate
NCT02724540	1:34:cancer	morphologically progressive tumor by RECIST
NCT02724540	1:10:treatment	narcotics
NCT02724540	1:20:chronic_disease	portal hypertension with hepatofugal flow
NCT02724540	1:22:chronic_disease,75:86:treatment	portal vein occlusion without hepatopedal collateral flow demonstrated by angiography
NCT02724540	1:10:treatment	sedatives
NCT02724540	1:35:chronic_disease,47:62:treatment	severe peripheral vascular disease precluding catheterization
NCT02724540	1:29:treatment	transpapillary biliary stent
NCT02712229	1:8:clinical_variable	ECOG PS of 3
NCT02712229	1:64:clinical_variable,70:71:upper_bound	Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤ 2
NCT02712229	1:21:chronic_disease	cognitive impairment or inability to consent to treatment, as determined by the patient's oncologist
NCT02712229	28:31:lower_bound	confined to bed or chair > 50% of waking hours
NCT02712229	1:23:cancer	hematologic malignancy
NCT02710968	1:21:chronic_disease,106:113:clinical_variable,116:119:lower_bound	Diaphragmatic hernia: right-sided or bilateral, major associated anomalies, isolated left-sided with the O/E LHR ≥ 30%
NCT02710968	12:32:allergy_name	History of natural rubber latex allergy
NCT02710968	12:32:chronic_disease	Left sided diaphragmatic hernia with liver up
NCT02710968	30:48:allergy_name,52:85:allergy_name,89:98:pregnancy	Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy
NCT02710968	1:20:chronic_disease,38:69:clinical_variable,95:97:lower_bound	Maternal depression as assessed by a Beck Depression Inventory score equal to or greater than 17
NCT02710968	1:9:pregnancy,10:15:gender	Pregnant women
NCT02710968	11:20:pregnancy	Singleton pregnancy
NCT02710968	34:52:treatment	Technical limitations precluding fetoscopic surgery
NCT02710968	1:6:gender,23:28:allergy_name	Women with allergy to Latex
NCT02710968	1:4:age,5:13:lower_bound	age 18 years and older
NCT02708394	1:4:bmi,5:9:lower_bound,10:19:upper_bound	BMI 18.5-24.9kg/m2
NCT02708394	12:21:allergy_name,25:40:allergy_name	allergy to lidocaine or drug excipients
NCT02708394	1:19:pregnancy	currently pregnant
NCT02708394	28:54:treatment	history of difficulty with intravenous line placement
NCT02708394	9:23:clinical_variable,26:41:upper_bound	minimal alcohol intake (<1 drink per day)
NCT02708394	31:50:chronic_disease,54:62:chronic_disease	personal or family history of cardiac arrhythmias or seizures
NCT02708394	1:50:contraception_consent	unwilling to take acceptable birth control method
NCT02702492	1:17:chronic_disease,37:60:treatment,62:72:treatment,77:88:treatment,96:110:upper_bound	Active infection with completion of therapeutic antibiotics, antivirals, or antifungals within one week prior to C1D1
NCT02702492	1:28:chronic_disease,38:68:chronic_disease	Active peptic ulcer disease or other active gastrointestinal bleeds
NCT02702492	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT02702492	1:16:clinical_variable,22:30:lower_bound	Life expectancy of ≥ 3 months
NCT02702492	1:20:treatment,52:64:upper_bound	Palliative steroids for disease related symptoms < 7 days prior to C1D1
NCT02702492	1:25:treatment,27:37:treatment,41:52:treatment	Prophylactic antibiotics, antivirals or antifungals are permitted
NCT02702492	21:34:treatment,39:48:treatment,61:79:cancer,83:86:cancer	Time since the last prior therapy for treatment of advanced solid malignancies or NHL
NCT02693262	9:39:chronic_disease	Current persistent atrial fibrillation
NCT02693262	1:9:pregnancy	Pregnant patients
NCT02693262	10:18:lower_bound	at least 18 years old
NCT02693145	73:81:upper_bound	Clinic definition: did not have a visit with a prescribing provider for 6 months
NCT02693145	74:87:chronic_disease,131:138:upper_bound	Residents within the health department jurisdiction with newly diagnosed HIV infection who have not linked to medical care within 90 days
NCT02692651	33:46:treatment	Patients anticipated to receive metronidazole after enrollment
NCT02692651	22:23:lower_bound,44:54:treatment,59:68:treatment,96:99:chronic_disease,134:140:lower_bound	Patients receiving ≥ 1 high or medium risk antibiotic for treatment of an infection other than CDI, for an anticipated duration of ≥ 5 days from the time of enrollment
NCT02692651	36:46:treatment,50:63:treatment,80:91:treatment,99:107:lower_bound,129:137:upper_bound	Patients who already received oral vancomycin or metronidazole (either oral or intravenous) for > 24 hours within the preceding 72 hours at the time of enrollment
NCT02692651	64:76:treatment,78:90:chronic_disease,101:127:chronic_disease,129:138:chronic_disease	Patients with severe-complicated disease that would compromise oral therapy (hypotenstion or shock, ileus or bowel obstruction, megacolon)
NCT02692651	7:8:lower_bound	with >3 unformed stools/24 hours with positive stool test for C
NCT02687906	1:55:clinical_variable,58:64:lower_bound,74:83:clinical_variable,86:94:lower_bound	Aspartate aminotransferase or alanine aminotransferase ≥ 3X ULN or total bilirubin ≥ 1.5X ULN
NCT02687906	1:4:bmi,34:48:upper_bound,62:77:lower_bound	BMI outside the range (below the 5th percentile or above the 95th percentile) for height
NCT02687906	1:39:chronic_disease,56:72:clinical_variable,76:103:clinical_variable,106:116:lower_bound,120:129:clinical_variable,132:164:upper_bound	Disseminated intravascular coagulation as evidenced by prothrombin time or partial thromboplastin time ≥ 2X the ULN or platelets < 50% of the lower limit of normal
NCT02687906	25:40:chronic_disease,73:94:chronic_disease,98:120:chronic_disease	Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis or hepatic encephalopathy
NCT02687906	1:27:gender,32:44:pregnancy,72:102:pregnancy	Female adolescent subjects who are pregnant or breastfeeding or have a positive serum β-hCG pregnancy test at screening and at pre-dose Day 1
NCT02687906	1:8:gender	Females who are of childbearing potential and unwilling to practice abstinence or use at least two methods of contraception (oral contraceptives, barrier methods, approved contraceptive implant) during the entire study period
NCT02687906	1:12:chronic_disease,14:30:clinical_variable,33:40:upper_bound,44:51:upper_bound	Hypothermia (core temperature < 35.6 ºC or 96.1 ºF)
NCT02687906	4:10:gender,140:176:contraception_consent	If female and has reached menarche, or has reached Tanner Stage 3 breast development (even if not having reached menarche), the subject is practicing appropriate birth control or is sexually abstinent
NCT02687906	43:65:allergy_name	Known significant hypersensitivity to any beta-lactam antibiotic
NCT02687906	1:5:gender	Male
NCT02687906	1:6:gender	Males who are unwilling to practice abstinence or use an acceptable method of broth control during the entire study period (i.e. condom with spermicide)
NCT02687906	18:49:clinical_variable,52:65:upper_bound	Neutropenia with absolute neutrophil count (ANC) < 500 cells/mm3
NCT02687906	19:30:treatment,34:42:treatment	Prior exposure to vaborbactam or Vabomere
NCT02687906	76:89:upper_bound	Receipt of any investigational medication or investigational device within 30 days prior to enrollment
NCT02687906	10:23:chronic_disease	Signs of severe sepsis
NCT02687906	59:66:lower_bound	The subject will be observed in the hospital for at least 6 hours after the study drug is administered
NCT02687906	8:17:treatment,25:33:upper_bound,69:77:upper_bound	Use of meropenem within 48 hours of administration of study drug or 12 hours after study drug administration
NCT02687906	1:4:age,9:15:clinical_variable,38:45:upper_bound	age and weight except for children < 2 years of age
NCT02687906	17:25:upper_bound,29:32:age	from birth to < 18 years of age
NCT02687906	55:66:treatment	subjects receiving peri-operative prophylactic use of antibiotics
NCT02681211	23:46:treatment,58:67:treatment,77:83:treatment	Patients who received ED migraine medications (including ibuprofen or other NSAIDS) prior to study evaluation
NCT02681211	102:110:chronic_disease	Patients with underlying abnormal brain pathology (e.g. mass or bleed) as the potential cause of the migraine
NCT02674529	3:6:gender	A man
NCT02674529	56:81:chronic_disease	Currently experiencing a depressive episode as part of Major Depressive Disorder
NCT02674529	55:67:treatment	Have a history of inadequate response/tolerability to escitalopram
NCT02674529	43:70:treatment	Have a medical condition that contradicts treatment with escitalopram
NCT02674529	47:60:upper_bound	Meet criteria for substance dependence in the last 6 months
NCT02674529	1:9:pregnancy	Pregnant
NCT02674529	22:32:chronic_disease	history of resistant depression
NCT02674529	7:33:chronic_disease	other Axis I psychotic disorders
NCT02674529	1:16:chronic_disease	schizoaffective
NCT02674529	1:14:chronic_disease	schizophrenic
NCT02674529	24:37:upper_bound	substance abuse in the last 2 months
NCT02674529	1:6:gender	woman
NCT02661724	1:17:language_fluency	English speaking due to feasibility of providing the web-based intervention only in English at this time
NCT02661724	9:29:technology_access	Lack of access to a computer that is connected to the worldwide web
NCT02661724	13:32:clinical_variable,64:65:lower_bound,67:68:lower_bound,69:71:upper_bound	Reporting a pain severity score on the Brief Pain inventory of 4 (0-10) or higher
NCT02661724	28:36:lower_bound	Reporting pain of at least 3 months duration
NCT02661724	13:25:chronic_disease,29:50:chronic_disease	Significant neurological or psychiatric condition precluding informed consent
NCT02657993	9:31:language_fluency	Able to speak and read English (to allow for participation in study intervention sessions)
NCT02657993	1:22:treatment,50:68:upper_bound	Bone fracture/surgery of an extremity during the preceding 6 months
NCT02657993	16:31:treatment,44:48:treatment,50:66:treatment,71:100:treatment,108:120:upper_bound	Current use of corticosteroids, defined as oral, intravenous (IV), or injections of corticosteroids in the past 4 weeks
NCT02657993	113:123:treatment	Experiencing ongoing pain and/or stiffness in one or more joints, which started or worsened after initiation of AI therapy
NCT02657993	1:7:gender	Female
NCT02657993	1:13:chronic_disease	Fibromyalgia
NCT02657993	62:102:clinical_variable,108:109:lower_bound,115:116:lower_bound,120:122:upper_bound	Having a baseline worst pain score over the past week on the Brief Pain Inventory-Short Form (BPI-SF) of ≥ 3 on a 0 to 10 scale
NCT02657993	1:36:cancer	Metastatic (Stage IV) breast cancer, as their treatment and outcomes typically follow a different course
NCT02657993	1:30:treatment,42:55:upper_bound	Non-steroidal joint injection within the last 3 months
NCT02657993	10:12:lower_bound	Over age 18
NCT02657993	6:12:cancer	Past cancer
NCT02657993	16:25:treatment	Regular use of narcotics
NCT02657993	53:67:cancer,69:97:cancer	patients will be eligible if they have a history of non-metastatic, non-melanomatous skin cancer
NCT02643381	2:10:upper_bound	<18 years old
NCT02643381	16:30:gender,52:75:treatment	Adult patient (male or female) requiring emergency endotracheal intubation
NCT02643381	55:64:treatment	Any patient who has been previously randomized in the EvK Trial
NCT02643381	1:6:gender,11:35:pregnancy	Women who are known to be pregnant
NCT02643381	13:36:treatment	who require endotracheal intubation without sedative medication
NCT02643381	25:33:allergy_name,37:46:allergy_name	with a known allergy to ketamine or etomidate
NCT02640950	9:16:chronic_disease	Current suicide risk
NCT02640950	12:23:chronic_disease,25:33:chronic_disease,37:53:chronic_disease,55:86:treatment	History of head injury, epilepsy or seizure disorder, non-removable metallic implants or objects in or around the head
NCT02640950	76:83:chronic_disease	It is the judgment of the investigator that the patient may be at risk for suicide
NCT02640950	16:32:chronic_disease	Presence of an Axis II disorder felt by the investigator to potentially interfere with study compliance
NCT02640950	59:62:treatment,66:69:treatment	Should not have a lifetime history of lack of response to ECT or VNS
NCT02640950	29:47:chronic_disease,65:72:lower_bound,92:99:upper_bound	The duration of the current depressive episode must be at least 4 weeks and no longer than 3 years in length
NCT02640950	5:20:treatment,59:75:lower_bound,85:98:treatment	The mood stabilizer must be at a stable dose for at least four days before starting TMS treatment
NCT02640950	17:34:chronic_disease,46:66:upper_bound	The patient has attempted suicide within the past 12 months prior to Screening
NCT02640950	1:6:gender	Women of child-bearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse
NCT02640950	10:18:lower_bound	at least 18 years old
NCT02640950	1:7:gender	female of childbearing potential
NCT02640950	8:19:clinical_variable,32:34:lower_bound	have a MADRS score of at least 20 at screening
NCT02640950	8:32:pregnancy	have a negative urine pregnancy test at screening
NCT02640950	29:38:chronic_disease,83:99:upper_bound	have no previous history of psychosis or substance dependence or abuse within the six months prior to Screening
NCT02640950	25:32:chronic_disease,50:60:chronic_disease	meet DSM-5 criteria for bipolar (either I or II) depression by clinical interview and M.I.N.I
NCT02640950	1:21:pregnancy	planning a pregnancy
NCT02640950	1:6:gender,15:23:pregnancy	women who are pregnant
NCT02636530	54:66:lower_bound	able to travel to the exercise facility a minimum of 3 times/week
NCT02636530	1:7:chronic_disease,27:52:chronic_disease	angina and/or evidence of acute myocardial ischemia during a treadmill test
NCT02636530	1:21:treatment,38:45:upper_bound	anti-resorptive drug use in the last 2 years
NCT02636530	15:25:treatment,111:125:upper_bound	initiation of treatments that could impact bone metabolism (diuretics, hormones, bine anabolic agents) in the prior 6 months
NCT02636530	34:44:upper_bound	not physically active (less than 60 minutes of purposeful exercise/week)
NCT02636530	9:23:clinical_variable,30:38:lower_bound,39:47:clinical_variable,51:58:lower_bound,59:68:clinical_variable	resting blood pressure above 150 mmHg systolic of 90 mmHg diastolic
NCT02636530	1:30:clinical_variable,32:40:upper_bound	serum vitamin D concentration <20 ng/mL
NCT02636530	8:23:treatment	use of glucocorticoids
NCT02631850	59:86:treatment	Concurrent participation in other experimental trials for motor dysfunction treatment
NCT02631850	93:106:chronic_disease,117:126:pregnancy,128:136:chronic_disease,151:182:chronic_disease	Have medical conditions that would place volunteers at higher risk of adverse events (e.g., renal disease, frailty, pregnancy, dementia, severe pain, end-stage/degenerative diseases)
NCT02631850	79:86:treatment	Have preserved ability to comprehend and participate in basic elements of the therapy
NCT02631850	15:55:treatment,77:88:chronic_disease	Have received intensive upper-extremity rehabilitation in the chronic phase post-stroke
NCT02631850	1:6:gender	Males
NCT02631850	11:24:treatment,45:58:upper_bound	Receiving Botox therapy currently or in the past 3 months
NCT02631850	21:29:lower_bound,33:36:age	any gender identity 18 years of age or older
NCT02631850	1:8:gender	females
NCT02627495	26:27:lower_bound,76:79:clinical_variable,94:95:lower_bound,99:101:upper_bound	Average pain of at least 4 on a numeric rating scale in the previous week (NRS; ranging from 0 to 10)
NCT02627495	1:12:chronic_disease,61:67:lower_bound,71:92:chronic_disease,110:118:lower_bound	Head injury resulting in loss of consciousness for at least 30 min or pos-traumatic amnesia for greater than 24 hours, as self-reported
NCT02627495	12:24:treatment	History of neurosurgery, as self-reported
NCT02627495	93:105:upper_bound	History of unexplained fainting spells or loss of consciousness as self-reported during the last 2 years
NCT02627495	79:86:lower_bound	If the subject is taking any medications, dosages must be stable for at least 2 weeks prior to the enrollment of the study
NCT02627495	210:227:treatment	Presence of the following contraindication to transcranial direct current stimulation Ferromagnetic metal in the head (e.g., plates or pins, bullets, shrapnel) Implanted head electronic medical devices (e.g., cochlear implants)
NCT02627495	23:31:lower_bound	Subject is older than 18 years
NCT02627495	23:33:chronic_disease,61:63:lower_bound,71:96:clinical_variable	Suffering from severe depression (as defined by a score of >30 in the Beck Depression Inventory)
NCT02627495	14:22:chronic_disease	Uncontrolled Epilepsy
NCT02627495	10:28:chronic_disease,35:56:chronic_disease,58:86:chronic_disease,88:101:chronic_disease,105:142:chronic_disease	Unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues, heart failure or chronic obstructive pulmonary disease)
NCT02615353	1:4:age,6:8:lower_bound,9:11:upper_bound	Age: 12-16
NCT02615353	11:21:chronic_disease	Diagnosed depression or other condition that may impact QoL
NCT02615353	1:7:ethnicity	Latino: self-report
NCT02615353	8:11:bmi,24:39:lower_bound,44:47:age,67:76:lower_bound	Obese: BMI percentile ≥95th percentile for age and gender or BMI ≥30 kg/m22
NCT02615353	1:16:chronic_disease,18:33:clinical_variable,35:50:lower_bound,48:62:lower_bound,64:73:lower_bound	Type 2 diabetes: Fasting glucose ≥126 mg/dl or 2-hour glucose ≥200 mg/dl
NCT02608840	94:95:upper_bound,119:122:age	Healthy Older Adults Group: Intact cognitive profile based on neuropsychology testing within 1 standard deviation for age and education status
NCT02608840	1:4:age,6:14:lower_bound	age ≥60 years
NCT02608840	12:19:chronic_disease,12:20:chronic_disease,31:42:treatment	history of seizures or taking medications that may lower the seizure threshold
NCT02608840	17:28:chronic_disease,40:60:clinical_variable,62:76:lower_bound,80:108:clinical_variable,110:117:lower_bound,135:150:treatment	moderate-severe sleep apnea defined by apnea-hypopnea index ≥15 events/hour or periodic limb movement index ≥15/hour on the screening home sleep test
NCT02608840	10:41:chronic_disease	unstable medical or psychiatric disorder
NCT02608840	1:6:gender	women
NCT02607514	3:4:lower_bound,102:115:upper_bound	> 6 one hour classes of meditation or other mind-body disciplines (e.g., Tai chi or yoga) within the last 6 months
NCT02607514	66:74:chronic_disease,76:90:chronic_disease	Active conditions which may also cause depressive symptoms (e.g. epilepsy, hypothyroidism)
NCT02607514	8:23:chronic_disease	Active suicidal intent within the past year (yes on item 4 or 5 on the Columbia-Suicide Severity Rating Scale)
NCT02607514	1:29:language_fluency	English language proficiency
NCT02607514	1:19:chronic_disease,62:79:chronic_disease,81:103:chronic_disease,105:117:chronic_disease,120:123:lower_bound,124:132:clinical_variable,144:153:clinical_variable,156:167:chronic_disease,190:192:upper_bound,223:246:chronic_disease,328:348:chronic_disease,350:360:cancer,365:386:chronic_disease	Medical conditions that may make participation unsafe (e.g., diabetes [I & II], cardiovascular disease, hypertension [>140 systolic and/or >90 diastolic], hypotension [<90 systolic and/or <60 diastolic, during screening], orthostatic hypotension [systolic drop of 20 points or 10 point diastolic or heart rate increase by 10], autoimmune disorders, malignancy, or autonomic dysfunction)
NCT02607514	1:10:pregnancy	Pregnancy
NCT02607514	1:24:treatment,55:63:upper_bound	Psychotropic medication use that has been stable for <3 months
NCT02607514	11:13:lower_bound,21:86:clinical_variable	Score of >23 on the Inventory of Depressive Symptomatology - Clinician Rated (IDS-CR)
NCT02607514	1:22:chronic_disease,46:49:treatment	Unsafe cardiac status as defined by abnormal ECG reading at screening visit
NCT02607514	1:6:gender	Women of childbearing potential must use an acceptable form of birth control
NCT02607514	1:5:age,6:8:lower_bound,9:11:upper_bound	ages 18-60
NCT02607514	1:17:chronic_disease	bipolar disorder
NCT02607514	1:17:chronic_disease	eating disorders
NCT02607514	1:21:chronic_disease	neurologic disorders
NCT02607514	1:18:pregnancy	planned pregnancy during study
NCT02607514	1:20:chronic_disease	psychotic disorders
NCT02607514	43:52:upper_bound	substance abuse or dependence (within the last year)
NCT02607033	8:14:cancer	Active cancer
NCT02607033	9:17:clinical_variable,18:25:lower_bound	Already exercise 2x/week or more
NCT02607033	1:4:bmi,6:14:lower_bound	BMI >30 kg/m2
NCT02607033	21:47:treatment	No current plan for surgical revascularization
NCT02607033	1:16:chronic_disease,29:41:chronic_disease	Unstable angina or a recent heart attack
NCT02600156	1:9:lower_bound,13:16:age	45 years of age or older
NCT02600156	14:42:clinical_variable,55:57:lower_bound	A documented Karnofsky performance status of at least 70
NCT02600156	1:26:cancer	Clinical stage T1c or T2a
NCT02600156	1:19:clinical_variable,23:30:lower_bound	Estimated survival of 5 years or greater, as determined by treating physician
NCT02600156	1:14:clinical_variable,21:24:lower_bound,28:31:upper_bound	Gleason score of 7 (3+4 or 4+3) or less
NCT02600156	1:17:treatment,95:108:clinical_variable,112:126:upper_bound	MR-guided biopsy confirmation of one or more radiographically visible prostate lesion(s) with Gleason score of 7 (3+4 or 4+3) or less
NCT02600156	16:22:treatment,34:49:cancer	Three or fewer biopsy cores with prostate cancer
NCT02599922	13:32:chronic_disease	Evidence of degenerative myopia regardless of the refractive error in the study eye
NCT02599922	5:12:gender,42:60:pregnancy,73:79:upper_bound	For females of childbearing potential: A negative pregnancy test within 2 days before administration of study agent
NCT02599922	1:17:clinical_variable,23:37:lower_bound,64:70:chronic_disease	Refractive error of ≥ -8.00 diopters (spherical equivalent) of myopia in the study eye
NCT02595866	12:23:chronic_disease,47:68:treatment,197:210:chronic_disease	A positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B surface antibody [HBsAb] positive and hepatitis B core antibody [HBcAb] negative), or a fully resolved acute HBV infection
NCT02595866	1:5:chronic_disease,14:34:cancer	AIDS-related non-Hodgkin lymphoma and other non-Hodgkin lymphoma
NCT02595866	1:25:chronic_disease	Active tuberculosis (TB)
NCT02595866	1:10:chronic_disease	Cirrhosis with Child-Pugh score of B or C
NCT02595866	22:30:chronic_disease	Clinical evidence of vitiligo or other forms of depigmenting illness
NCT02595866	18:31:chronic_disease,54:70:cancer,90:112:cancer,136:157:cancer	Extensive active brain disease including symptomatic brain metastases or the presence of leptomeningeal disease, and all patients with infratentorial tumors
NCT02595866	28:35:treatment	Failed standard first-line therapy
NCT02595866	54:78:treatment	Grade 3 or 4 immune related toxicity associated with prior ipilimumab therapy that has not resolved to grade 0 or 1
NCT02595866	77:86:chronic_disease	Mild autoimmunity not impacting the function of major organs (e.g., limited psoriasis)
NCT02595866	38:60:treatment,65:71:cancer	Patients who are receiving any other investigational agents for cancer
NCT02595866	44:51:treatment,53:57:treatment,84:86:chronic_disease	Patients who are undergoing first month of therapy (RIPE or equivalent) for active TB
NCT02595866	49:52:chronic_disease,64:71:treatment	Patients who have been successfully treated for HCV as long as therapy for HCV has been completed
NCT02595866	15:48:chronic_disease,66:81:treatment	Patients with TB immune reconstitution syndrome (IRIS) requiring corticosteroids
NCT02595866	23:26:chronic_disease,53:75:treatment	Patients with chronic HBV suppressed by appropriate antiretroviral therapy with activity against HBV, as outlined in DHHS guidelines
NCT02595866	10:13:chronic_disease,86:99:chronic_disease	Positive HCV serology but no detectable HCV RNA, indicative of spontaneously cleared HCV infection
NCT02595866	40:58:chronic_disease,111:116:chronic_disease	The presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody [ANA] titer or lupus anticoagulant) without associated symptoms
NCT02595866	14:47:chronic_disease,33:36:chronic_disease	Uncontrolled hepatitis B virus (HBV) infection, defined as plasma HBV DNA detectable by polymerase chain reaction (PCR)
NCT02595866	14:25:chronic_disease,33:36:chronic_disease	Uncontrolled hepatitis C virus (HCV) infection, defined as plasma HCV RNA detectable by PCR
NCT02595866	8:23:chronic_disease	active angina pectoris
NCT02595866	1:25:chronic_disease,27:59:clinical_variable,60:63:lower_bound,67:69:upper_bound	congestive heart failure (New York Heart Association class III or IV)
NCT02595866	28:35:treatment,43:52:lower_bound,56:71:treatment,92:99:chronic_disease,110:132:treatment,153:162:treatment,167:186:chronic_disease	patients who are receiving therapy beyond month one of initial therapy with no evidence of TB IRIS requiring corticosteroid therapy, or those receiving treatment for latent tuberculosis (INH or alternative) may be eligible after discussion with the protocol P.I
NCT02595866	8:29:chronic_disease,42:55:upper_bound	recent myocardial infarction (within the last 6 months)
NCT02595372	1:4:clinical_variable,7:12:lower_bound	ANC > 1,000
NCT02595372	29:42:treatment,47:67:treatment	Adequate organ function for anthracycline and taxane based therapy
NCT02595372	1:11:clinical_variable,14:17:upper_bound	Creatinine < 1.5
NCT02595372	1:27:treatment	Dexlansoprazole (Dexilant)
NCT02595372	1:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	ECOG Performance Status 0-1
NCT02595372	1:3:clinical_variable,8:10:clinical_variable,13:16:upper_bound	ER and PR < 10%
NCT02595372	1:22:treatment	Esomeprazole (Nexium)
NCT02595372	7:18:clinical_variable,21:24:upper_bound,28:50:clinical_variable,52:53:upper_bound	HER2: CEP17 ratio < 2.0 or HER2 total copy number <6
NCT02595372	49:70:upper_bound	Has not had menses at any time in the preceding 24 consecutive months
NCT02595372	1:4:clinical_variable,7:10:lower_bound	Hgb > 8.5
NCT02595372	1:4:clinical_variable,5:6:lower_bound,10:12:upper_bound	IHC 0 or 1+
NCT02595372	1:4:clinical_variable,5:6:lower_bound,12:16:treatment,49:70:treatment	IHC 2+ and FISH equivocal and no indication for HER2 targeted therapy based on the treating investigators discretion
NCT02595372	1:4:treatment,12:16:treatment	IHC 2+ and FISH negative
NCT02595372	75:89:allergy_name	Known hypersensitivity to any component of the formulation or substituted benzimidazoles
NCT02595372	1:5:clinical_variable,21:33:treatment,37:41:treatment	LVEF > LLN based on cardiac ECHO or MUGA
NCT02595372	1:13:treatment,15:23:treatment	Lansoprazole (Prevacid)
NCT02595372	17:53:cancer,54:68:clinical_variable,69:71:lower_bound,80:83:upper_bound	Newly diagnosed triple negative breast cancer (TNBC) clinical stage Ic, II, or III
NCT02595372	1:11:treatment,13:21:treatment,23:30:treatment	Omeprazole (Prilosec, Zegerid)
NCT02595372	1:24:treatment	Pantoprazole (Protonix)
NCT02595372	9:30:treatment,36:49:treatment,54:60:treatment,72:84:treatment	Planned neoadjuvant treatment with anthracycline and taxane containing chemotherapy
NCT02595372	1:10:clinical_variable,13:20:lower_bound	Platelets > 100,000
NCT02595372	1:19:treatment	Prior hysterectomy
NCT02595372	7:28:chronic_disease	Prior osteoporotic fracture
NCT02595372	1:12:treatment,14:21:treatment	Rabeprazole (Aciphex)
NCT02595372	1:8:clinical_variable,11:14:upper_bound	T. bili < 1.3
NCT02595372	8:16:treatment,24:38:upper_bound	Use of OTC PPIs within 6 months prior to study entry
NCT02595372	8:16:treatment,36:50:treatment,58:72:upper_bound	Use of Orlistat or any other known FASN inhibitor within 6 months prior to study entry
NCT02595372	21:25:treatment,33:48:upper_bound	Use of prescription PPIs within 12 months prior to study entry
NCT02595372	1:6:gender,56:74:pregnancy,87:94:upper_bound	Women of childbearing potential definition must have a negative pregnancy test within 14 days of registration
NCT02595372	1:23:treatment	bilateral oophorectomy
NCT02595372	3:11:lower_bound	≥ 18 years old at the time of informed consent
NCT02592551	28:46:chronic_disease,58:70:upper_bound	Active or prior documented autoimmune disease within the past 2 years
NCT02592551	28:54:chronic_disease,62:77:chronic_disease,79:97:chronic_disease	Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
NCT02592551	1:4:age,9:17:lower_bound	Age >/= 18 years at time of study entry
NCT02592551	5:8:cancer,20:30:cancer,39:50:cancer	Any MPM histology (epithelial, mixed, sarcomatoid)
NCT02592551	106:115:treatment	Any condition that, in the opinion of the investigator, would interfere with the evaluation of the study treatment or interpretation of subject safety or study results
NCT02592551	14:23:treatment,31:34:treatment,38:53:treatment,65:73:treatment	Any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736
NCT02592551	18:19:lower_bound,20:55:clinical_variable,50:54:clinical_variable,85:104:treatment,130:137:lower_bound	Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
NCT02592551	27:40:lower_bound,56:75:treatment	Any unresolved toxicity (>CTCAE grade 2) from previous anti-cancer therapy
NCT02592551	1:14:clinical_variable,26:37:clinical_variable,41:44:lower_bound,47:50:age,52:54:lower_bound,57:73:clinical_variable	Creatinine CL (mL/min) = Weight (kg) × (140 - Age) 72 × serum creatinine (mg/dL)
NCT02592551	1:23:clinical_variable,26:37:clinical_variable,47:50:age,64:88:clinical_variable	Creatinine CL (mL/min) = Weight (kg) × (140 - Age) × 0.85 72 × serum creatinine (mg/dL)
NCT02592551	25:53:treatment,61:68:upper_bound,80:129:treatment	Current or prior use of immunosuppressive medication within 28 days before the infusion with MEDI4736 or MEDI4736 + tremelimumab and through 90 days post infusion
NCT02592551	1:61:clinical_variable,65:66:lower_bound,70:71:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
NCT02592551	1:16:gender,98:106:lower_bound,107:110:age,132:138:lower_bound	Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: ≥60 years old and no menses for >/=1 year without an alternative medical cause
NCT02592551	1:16:gender,25:33:pregnancy,53:76:gender,111:161:contraception_consent	Female subjects who are pregnant, breastfeeding, or male or female subjects of reproductive potential who are not employing an effective method of birth control
NCT02592551	1:11:clinical_variable,14:22:lower_bound,23:54:clinical_variable,57:68:lower_bound,72:84:lower_bound,86:100:clinical_variable,103:114:lower_bound,117:132:lower_bound,134:149:clinical_variable,152:198:upper_bound,198:201:clinical_variable,202:205:upper_bound,206:226:clinical_variable,228:236:lower_bound,237:265:clinical_variable,270:296:clinical_variable,299:308:upper_bound,301:308:upper_bound,334:350:cancer	Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count (ANC) ≥ 1.5 × 109/L (> 1500 per mm3) Platelet count ≥ 100 × 109/L (>100,000 per mm3) Serum bilirubin ≤ 1.5× institutional upper limit of normal (ULN)AST<3.0 Creatinine clearance >50mL/miN Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN if documented liver metastasis are present)
NCT02592551	12:39:treatment	History of allogeneic organ transplant
NCT02592551	32:40:allergy_name	History of hypersensitivity to MEDI4736 or any excipient
NCT02592551	32:44:allergy_name,67:90:allergy_name	History of hypersensitivity to tremelimumab or the combination of MEDI4736 + tremelimumab
NCT02592551	12:37:chronic_disease,38:49:chronic_disease	History of interstitial lung disease/pneumonitis
NCT02592551	12:41:cancer	History of leptomeningeal carcinomatosis
NCT02592551	12:36:chronic_disease	History of primary immunodeficiency
NCT02592551	49:61:chronic_disease	Known history of previous clinical diagnosis of tuberculosis
NCT02592551	7:23:chronic_disease,38:60:treatment,68:74:treatment	N0 or N1 nodal disease as present on perioperative chest CT and/or PET CT
NCT02592551	1:17:cancer,54:75:treatment	N2 nodal disease if no progression after 2 cycles of standard chemotherapy
NCT02592551	1:17:chronic_disease	N3 nodal disease
NCT02592551	40:52:treatment	No tissue is obtainable at the time of thoracoscopy
NCT02592551	18:72:treatment,84:97:upper_bound	Participation in another clinical study with an investigational product during the last 3 months
NCT02592551	9:28:treatment,33:36:cancer,38:70:treatment,74:109:treatment	Planned resectional surgery for MPM [extrapleural pneumonectomy (EPP) or pleurectomy and decortication (P/D)]
NCT02592551	46:62:chronic_disease,78:90:treatment	Progression will be considered if additional N1 or N2 disease develop during chemotherapy
NCT02592551	23:31:treatment,98:105:upper_bound,119:127:treatment,131:150:treatment	Receipt of drugs with laxative properties and herbal or natural remedies for constipation within 90 days of receiving MEDI4736 or MEDI + tremelimumab
NCT02592551	12:39:treatment,47:60:upper_bound,86:94:upper_bound,108:116:treatment,120:139:treatment	Receipt of live attenuated vaccination within 30 days prior to study entry or within 6 months of receiving MEDI4736 or MEDI + tremelimumab
NCT02592551	12:21:treatment,29:37:upper_bound	Receipt of sunitinib within 3 months of receiving tremelimumab
NCT02592551	29:48:treatment,50:62:treatment,64:77:treatment,79:96:treatment,98:114:treatment,116:132:treatment,134:152:treatment,206:219:upper_bound,334:344:treatment,352:361:treatment,377:387:treatment,400:407:upper_bound,427:438:treatment	Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 30 days prior to the first dose of study drug, and 30 days prior to the first dose of study drug for subjects who have received prior TKIs [e.g., erlotinib, gefitinib and crizotinib] and within 6 weeks for nitrosourea or mitomycin C)
NCT02592551	1:17:clinical_variable,20:29:upper_bound,33:64:clinical_variable,67:76:lower_bound	Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance ≥ 50 mL/min as determined by the Cockcroft-Gault equation
NCT02592551	28:36:chronic_disease	Subjects with uncontrolled seizures
NCT02592551	15:23:chronic_disease,25:40:chronic_disease,45:54:chronic_disease,69:87:treatment,100:112:upper_bound	Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years)
NCT02592551	23:26:cancer	Surgically resectable MPM with no disease extension beyond the ipsilateral hemithorax
NCT02592551	29:45:cancer,56:76:treatment,110:117:treatment,119:128:treatment,137:152:treatment	Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids
NCT02592551	77:93:chronic_disease,107:131:chronic_disease,146:158:chronic_disease,160:184:chronic_disease,186:204:chronic_disease,213:233:chronic_disease,237:246:chronic_disease,255:273:chronic_disease,322:350:chronic_disease,352:363:chronic_disease,367:401:chronic_disease,406:443:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
NCT02592551	22:34:treatment	history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry
NCT02592551	12:36:treatment	history of bilateral tubal ligation
NCT02592551	12:24:treatment	history of hysterectomy
NCT02592551	1:11:treatment,16:39:treatment,24:38:treatment,43:67:treatment,116:125:upper_bound,129:139:treatment	intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
NCT02589938	1:26:chronic_disease,30:44:chronic_disease	Active systemic infection or skin infection at or near the acupuncture sites
NCT02589938	7:8:lower_bound	Grade 0 - None
NCT02589938	11:19:chronic_disease	Grade 4 - Fibrosis
NCT02589938	19:43:treatment,55:67:upper_bound	Have received any investigational new drug within the past 30 days or planning to receive such during the study period
NCT02589938	12:22:chronic_disease,24:41:chronic_disease,95:114:treatment	History of xerostomia, Sjogren's disease or other illness known to affect salivation prior to head/neck radiation
NCT02589938	11:34:clinical_variable,38:39:lower_bound,40:41:upper_bound	Must have ECOG performance status of 0-2
NCT02589938	21:33:treatment,43:58:lower_bound	Must have completed radiotherapy at least 12 months prior to entry
NCT02589938	20:43:treatment,71:76:lower_bound	Must have received external beam radiation at a mean dose of at least 24 Gy to one of the parotid glands
NCT02589938	36:57:treatment	Over the counter products used for salivary substitution
NCT02589938	11:23:treatment	Receiving chemotherapy during study period
NCT02589938	39:44:upper_bound	The other gland can receive less than 24 Gy
NCT02589938	65:78:lower_bound	Treatment known to affect salivation should be stopped at least 14 days prior to enrollment
NCT02589938	1:43:language_fluency	able to read, write and understand English
NCT02589938	21:36:cancer	have a diagnosis of head/neck cance
NCT02589938	15:42:treatment	have received bilateral radiation therapy, and subsequently developed grade 2 or 3 xerostomia, according to modified RTOG scale
NCT02589938	7:15:lower_bound,19:22:age	least 18 years of age
NCT02589938	43:57:lower_bound	will need to be discontinued for at least 24 hours prior to saliva and questionnaire data collection
NCT02589600	19:24:gender,78:85:upper_bound	Institutionalized women with subacute illnesses surviving or discharged in < 3 years
NCT02589600	1:4:gender,13:25:chronic_disease,44:47:gender	Men because osteoporosis is less common in men
NCT02589600	17:48:clinical_variable,51:60:upper_bound	Patients with a calculated creatinine clearance < 35 ml/min
NCT02589600	1:6:gender,20:34:treatment,36:45:treatment,50:70:treatment,125:131:lower_bound,143:159:upper_bound,168:183:treatment	Women currently on bisphosphonate, denosumab, or teriparatide therapy or who have been on a bisphosphonate for greater than 1 year during the previous 2 years because bisphosphonates are long acting
NCT02589600	1:4:age,6:14:lower_bound	age ≥65 years
NCT02589600	29:44:treatment,55:67:chronic_disease	have a contraindication for bisphosphonates (allergy, hypocalcemia)
NCT02589600	36:41:gender	initial ZEST 1 study only included women
NCT02589600	1:13:chronic_disease,59:93:clinical_variable,97:103:upper_bound	osteoporosis by axial bone density (spine, hip or forearm bone mineral density (BMD) T-score ≤ -2.5 SD)
NCT02589600	1:6:gender	women
NCT02589600	115:118:lower_bound,158:160:lower_bound,184:200:treatment	would be treated based on FRAX National Osteoporosis Foundation (NOF) treatment thresholds of a 10 year risk of ≥ 20% for a major osteoporotic fracture or ≥ 3% for hip fracture using femoral neck BMD
NCT02589340	16:39:chronic_disease	Currently have severe renal impairment
NCT02589340	45:72:chronic_disease	Currently receiving any other treatment for levodopa-induced dyskinesia, including but not exclusive to deep brain stimulation
NCT02589340	20:28:treatment,55:74:chronic_disease	Currently taking a levodopa containing medication for Parkinson's disease
NCT02589340	26:29:lower_bound,30:36:upper_bound,40:50:treatment,61:70:treatment,74:101:chronic_disease	Currently taking between 200-500 mg of amantadine daily for treatment of levodopa-induced dyskinesia with insufficient suppression levodopa-induced dyskinesia
NCT02589340	19:37:chronic_disease	Have a history of hepatic impairment
NCT02589340	6:29:chronic_disease	Have proprioceptive deficits
NCT02589340	16:26:chronic_disease	Mild to Severe dyskinesia
NCT02589340	68:87:chronic_disease,92:102:chronic_disease	Not able to answer a patient questionnaire about their symptoms of Parkinson's disease and dyskinesia
NCT02589340	44:54:lower_bound	Not able to stand unsupported for at least 60 seconds
NCT02589340	1:20:chronic_disease	Parkinson's disease diagnosis
NCT02589340	1:10:pregnancy	Pregnancy
NCT02589340	1:33:chronic_disease	Significant cognitive impairment
NCT02589340	1:26:treatment,40:53:lower_bound	Stable medication regimen for at least 4 weeks prior to study
NCT02589340	19:29:treatment	Unable to swallow study drug (capsule)
NCT02587598	1:5:age,6:14:lower_bound	Aged 18 years or older
NCT02587598	1:8:chronic_disease,20:36:chronic_disease,47:66:treatment,68:78:treatment,83:102:treatment	Chronic or current active infection requiring systemic antibiotic, antifungal, or antiviral treatment
NCT02587598	31:50:cancer	Confirmed diagnosis of select advanced malignancy
NCT02587598	21:29:lower_bound,52:55:cancer,64:73:treatment,94:116:treatment	Elderly subjects (≥ 65 years) with newly diagnosed AML must be treatment naive and unfit for intensive chemotherapy
NCT02587598	1:16:clinical_variable,19:27:lower_bound,33:41:lower_bound	Life expectancy > 12 weeks or ≥ 24 weeks for Part 3 and Part 4 MF subjects
NCT02587598	1:14:cancer,52:63:treatment,70:78:lower_bound,104:111:lower_bound	Myelofibrosis subjects must have been treated with ruxolitinib for ≥ 6 months with a stable dose for ≥ 8 weeks (acceptable doses are 5 mg twice daily [BID] to 25 mg BID)
NCT02587598	31:49:treatment	Not currently a candidate for curative treatment
NCT02587598	20:33:treatment	Prior receipt of a PIM inhibitor
NCT02587598	1:13:treatment,25:38:upper_bound,56:65:treatment	Radiotherapy within the 2 weeks prior to initiation of treatment
NCT02587598	13:34:treatment,42:54:upper_bound,125:135:treatment	Received an investigational agent within 5 half-lives or 14 days, whichever is longer, prior to receiving the first dose of study drug
NCT02587598	10:44:treatment,52:70:upper_bound,102:112:treatment,121:128:upper_bound,133:144:treatment,148:160:treatment,170:177:upper_bound,186:196:treatment,200:220:treatment	Received non-biologic anticancer medication within 5 half-lives prior to receiving the first dose of study drug (within 6 weeks for mitomycin-C or nitrosoureas), within 28 days for any antibodies or biological therapies
NCT02587598	11:47:clinical_variable,50:66:lower_bound	Screening corrected QT interval (QTc) interval > 470 milliseconds
NCT02587598	35:38:cancer,65:87:treatment,99:121:treatment,126:145:chronic_disease	Subjects with relapsed/refractory AML must have received either induction chemotherapy for AML or hypomethylating agents for hematologic disease before AML
NCT02587598	37:44:treatment	Unresponsive to currently available therapy and there is no standard-of-care therapy available in the judgment of the investigator
NCT02587598	26:57:treatment,65:73:treatment,135:142:treatment	Willingness to undergo a pretreatment bone marrow biopsy and/or aspirate, or archival sample obtained since completion of most recent therapy (as appropriate to subjects with existing bone marrow disease or for whom bone marrow examination is a component of disease status assessment)
NCT02587312	1:18:pregnancy	Current pregnancy
NCT02587312	26:48:clinical_variable,62:67:lower_bound	Participants must meet a breath carbon monoxide criterion of 6 ppm or higher
NCT02587312	29:47:language_fluency	Participants must speak and comprehend English well enough to complete study procedures
NCT02587312	30:39:treatment,116:128:upper_bound	Participants who are seeking treatment for their smoking or who report that they intend to quit smoking within the next 30 days and have made a 24-hour quit attempt in the past year
NCT02587312	33:50:chronic_disease	Participants who report current suicidal ideation on the MINI suicide subscale questions 4 & 5
NCT02587312	24:25:lower_bound,61:74:upper_bound	current daily smoking (1 or more cigarettes per day for the past 6 months or longer)
NCT02581982	2:23:chronic_disease	(Bacillus tuberculosis)
NCT02581982	1:32:clinical_variable,36:46:lower_bound	Absolute neutrophil count (ANC) >= 1,500 /mcL
NCT02581982	8:26:chronic_disease,45:63:treatment,71:83:upper_bound,102:126:treatment,128:143:treatment,147:170:treatment,173:192:treatment,199:208:treatment,210:217:treatment,222:268:treatment,273:280:chronic_disease,284:307:chronic_disease	Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
NCT02581982	1:17:chronic_disease,28:44:treatment	Active infection requiring systemic therapy
NCT02581982	1:8:clinical_variable,12:21:lower_bound	Albumin >= 2.5 mg/dL
NCT02581982	1:38:treatment,46:53:lower_bound,46:59:upper_bound,110:117:upper_bound	Anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
NCT02581982	1:33:clinical_variable,35:81:clinical_variable,87:117:clinical_variable,119:163:clinical_variable,168:177:upper_bound,170:177:upper_bound,210:226:cancer	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
NCT02581982	10:11:lower_bound,12:59:treatment,63:74:treatment	At least 1 prior chemotherapy regimen containing cisplatin or carboplatin
NCT02581982	1:13:treatment,15:46:treatment,51:68:treatment,76:89:upper_bound,140:147:upper_bound	Chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent
NCT02581982	32:41:treatment,50:71:treatment,83:105:treatment,113:120:upper_bound	Currently receiving or has had treatment with an investigational agent or used an investigational device within 4 weeks of study day 1
NCT02581982	14:30:chronic_disease,47:71:treatment,93:118:treatment,126:138:upper_bound,160:175:treatment	Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
NCT02581982	1:16:gender,53:119:contraception_consent,195:209:upper_bound,233:243:treatment,370:376:lower_bound	Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
NCT02581982	1:11:clinical_variable,15:21:lower_bound	Hemoglobin >= 9 g/dL without transfusion dependency
NCT02581982	47:54:treatment	History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate
NCT02581982	21:34:allergy_name,47:57:treatment,59:69:treatment	Hypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipients
NCT02581982	14:53:cancer,61:85:cancer,120:136:cancer,235:251:lower_bound,273:288:treatment,418:426:treatment,440:452:lower_bound	Known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
NCT02581982	7:25:chronic_disease,14:25:chronic_disease,88:99:chronic_disease	Known active hepatitis B (e.g., hepatitis B virus surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
NCT02581982	18:28:cancer,61:77:treatment,98:118:cancer,134:157:cancer,201:217:treatment,221:244:cancer	Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
NCT02581982	18:27:chronic_disease	Known history of active TB
NCT02581982	18:52:chronic_disease,48:51:chronic_disease	Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
NCT02581982	38:44:chronic_disease,46:72:chronic_disease	Known history of, or any evidence of active, non-infectious pneumonitis
NCT02581982	7:18:chronic_disease	Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
NCT02581982	1:14:gender,22:70:contraception_consent,109:116:treatment,125:139:upper_bound	Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
NCT02581982	65:69:treatment,73:90:treatment,96:108:cancer,165:173:upper_bound,207:216:treatment	Patient must be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion; newly-obtained is defined as a specimen obtained up to 12 weeks (84 days) prior to initiation of treatment on day 1; archived specimen can be used for subjects in whom newly-obtained samples cannot be provided
NCT02581982	25:73:cancer	Patients diagnosed with platinum-refractory metastatic urothelial cancer that is measureable based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
NCT02581982	1:19:clinical_variable,23:24:lower_bound,28:29:upper_bound,37:96:clinical_variable	Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale
NCT02581982	1:10:clinical_variable,14:26:lower_bound	Platelets >= 80,000 / mcL
NCT02581982	1:10:pregnancy,176:184:upper_bound,208:223:treatment	Pregnancy or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
NCT02581982	1:58:treatment,60:103:treatment,108:157:treatment	Prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death-ligand 1 (PD-L1), or anti-programmed cell death-ligand 2 (PD-L2) agent
NCT02581982	12:24:treatment,32:39:upper_bound,66:73:treatment	Received a live vaccine within 30 days of planned start of study therapy
NCT02581982	1:17:clinical_variable,7:17:clinical_variable,21:54:upper_bound,103:135:clinical_variable,179:212:clinical_variable,216:225:lower_bound,243:260:clinical_variable,263:286:lower_bound	Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance rate [CrCl]) >= 35 mL/min for subject with creatinine levels > 1.5 X institutional ULN
NCT02581982	1:22:clinical_variable,26:35:upper_bound,39:55:clinical_variable,81:103:clinical_variable,106:113:lower_bound	Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN
NCT02579096	1:4:age,5:13:lower_bound	Age 18 years
NCT02579096	12:29:chronic_disease	Any severe medical condition that, in the enrollee's opinion, is likely to compromise the participant's ability to complete the trial
NCT02579096	1:8:chronic_disease	Ascites
NCT02579096	1:10:clinical_variable,11:18:lower_bound	Bilirubin 2 mg/dL
NCT02579096	16:28:treatment,30:44:treatment,46:56:treatment,58:74:treatment,79:89:treatment	Current use of azathioprine, mercaptopurine, didanosine, cyclophosphamide, or probenecid
NCT02579096	1:15:chronic_disease	Encephalopathy
NCT02579096	12:16:chronic_disease	History of gout - crystal proven or historical as defined by ACR criteria listed above
NCT02579096	17:33:treatment	INR 1.7, not on Warfarin therapy
NCT02579096	60:84:treatment,86:96:treatment,98:106:treatment,110:125:treatment	Patients who are not candidates for any of the recommended prophylactic medications (colchicine, naprosyn or glucocorticoids)
NCT02579096	34:77:treatment	Patients with a history of prior solid organ / hematopoietic transplantation
NCT02579096	15:36:chronic_disease	Patients with chronic liver disease
NCT02579096	15:27:cancer	Patients with malignancies that are currently active
NCT02579096	15:29:clinical_variable,34:44:clinical_variable,50:58:upper_bound	Patients with myelodysplasia and hemoglobin of < 8.5 g/dL
NCT02579096	15:37:clinical_variable,39:47:lower_bound	Patients with serum uric acid levels >15 mg/dl
NCT02579096	36:47:allergy_name,51:61:allergy_name	Previous allergy or intolerance to allopurinol or febuxostat
NCT02579096	70:94:treatment,105:115:lower_bound	Previous history of failure to reach target uric acid levels despite therapy with allopurinol at dose > 300 mg/day
NCT02579096	7:17:treatment	Prior febuxostat use
NCT02579096	1:14:clinical_variable,16:24:upper_bound	Serum albumin <3.5 g/dL
NCT02579096	1:18:clinical_variable	Serum urate level 6.8 mg/dl
NCT02579096	1:42:chronic_disease,56:60:clinical_variable,65:74:upper_bound	Stage 4 or 5 Chronic Kidney Disease (CKD) - defined as eGFR of <30 ml/min
NCT02579096	1:6:gender	Women
NCT02579096	11:19:upper_bound,23:26:age	less than 50 years of age
NCT02579096	1:25:cancer	non-melanoma skin cancer
NCT02577731	14:32:chronic_disease	Blunt and/or penetrating trauma patient
NCT02577731	1:28:clinical_variable,54:56:lower_bound	Injury Severity Score (ISS) greater than or equal to 15
NCT02577731	1:8:clinical_variable,11:12:lower_bound	Lactate ≥ 2
NCT02577731	20:39:treatment	Patient undergoing elective hip repair for non-infectious reasons
NCT02577731	47:55:lower_bound	Patients not expected to survive greater than 48 hours
NCT02577731	28:43:treatment,47:74:treatment	Patients receiving chronic corticosteroids or immunosuppression therapies
NCT02577731	15:38:chronic_disease	Patients with End Stage Renal Disease
NCT02577731	32:53:chronic_disease	Patients with any pre-existing hematological disease
NCT02577731	33:55:chronic_disease,57:63:cancer,76:79:chronic_disease,95:120:chronic_disease	Pre-existing conditions such as pathological fractures, cancer, history of HIV, or history of connective tissue disease
NCT02577731	1:10:pregnancy	Pregnancy
NCT02577731	1:22:treatment,26:35:treatment	Previous Chemotherapy or Radiation
NCT02577731	10:37:treatment	Previous bone marrow transplantation
NCT02577731	1:4:age,6:8:lower_bound	age ≥18
NCT02577731	1:4:age,6:8:lower_bound,12:14:upper_bound	age ≥18 to 54
NCT02577731	1:18:clinical_variable,21:26:lower_bound	base deficit (BD) ≥ 5 meq
NCT02577731	1:18:chronic_disease	hemorrhagic shock
NCT02577731	1:23:clinical_variable,25:32:upper_bound	mean arterial pressure≤ 65 mmHg
NCT02577731	1:18:clinical_variable,21:28:upper_bound	systolic BP (SBP) ≤ 90 mmHg
NCT02564744	92:95:cancer,97:102:cancer,104:106:cancer,108:116:cancer,118:121:cancer,149:152:cancer	For Part 1 of the study, participants must have histopathologically confirmed diagnosis of R/R, DLBCL, FL, MZL/MALT, MCL, or other Sponsor approved NHL subtypes according to the World Health Organization (WHO) classification 2008 for which standard measures do not exist or are no longer effective
NCT02564744	127:132:cancer	For Part 2 and Part 3 of the study, participants must have histopathologically and clinically confirmed diagnosis of relapsed DLBCL
NCT02564744	79:97:treatment	For Part 2 and Part 3 of the study, participants that are eligible to undergo first time HD-ASCT
NCT02564744	51:75:chronic_disease,118:126:upper_bound	For Part 2 and Part 3 of the study, patients with primary refractory DLBCL (defined as progression of disease within 24 weeks after first line of treatment)
NCT02564744	24:84:clinical_variable,85:86:lower_bound,89:90:upper_bound	Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2
NCT02564744	122:130:cancer	Participants must have evaluable or measurable disease in accordance with the International Working Group Guidelines for Lymphoma
NCT02564744	42:45:lower_bound,63:66:upper_bound	Participants must have received at least one but no more than six prior treatment regimens
NCT02564744	22:67:chronic_disease	Participants who are Hepatitis B surface antigen positive (HBsAg+) (must be PCR negative) who are taking antivirals, are allowed to enroll
NCT02564744	29:51:cancer,53:62:cancer,67:83:cancer,94:110:cancer	Participants who have known central nervous system, meningeal, or epidural disease including brain metastases
NCT02564744	32:45:treatment,51:84:treatment	Participants who have received prior therapy with other anti-CD37-targeting therapy
NCT02564744	41:44:lower_bound,53:69:treatment,62:69:treatment,90:112:clinical_variable,116:137:treatment,151:159:lower_bound,268:280:treatment,286:332:treatment	Participants who received at least only one line of previous therapy and achieved either complete response (CR) or partial response (PR) for at least 24 weeks (from the last day of the last cycle) after their first line of therapy, but are not eligible for high dose chemotherapy with autologous stem cell transplantation (HD-ASCT)
NCT02564744	58:65:treatment,77:84:treatment,129:131:treatment,135:137:treatment,151:158:lower_bound	Participants who received more than one line of previous therapy (including HD-ASCT), and have achieved a duration of response (CR or PR) of at least 8 weeks (from the last day of the last cycle) after their last line of therapy
NCT02564744	110:118:lower_bound,131:152:treatment	Participants will be considered to have a relapsed disease if they showed a duration of response of at least 24 weeks after their first line of therapy
NCT02564744	34:68:cancer,72:104:cancer	Participants with a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
NCT02564744	26:55:chronic_disease	Participants with active hepatitis A, B or C infection
NCT02564744	19:44:chronic_disease,48:86:chronic_disease	Participants with impaired cardiac function or clinically significant cardiac disease
NCT02564744	25:40:treatment	Prior treatment with an anti-CD20 agent, either alone or in combination, is allowed
NCT02564744	42:47:cancer	The following participants with relapsed DLBCL will be enrolled
NCT02564744	1:6:gender,11:23:pregnancy	Women who are pregnant or breast feeding
NCT02562066	11:28:chronic_disease	Any other medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confound the assessment of the patient
NCT02562066	5:23:chronic_disease,33:42:chronic_disease,153:164:treatment	Any systemic bacterial or other infection, which is clinically significant in the opinion of the investigator and has not been treated with appropriate antibiotics
NCT02562066	6:12:clinical_variable,14:19:lower_bound	Body weight ≥10 kg
NCT02562066	26:57:chronic_disease,59:80:chronic_disease,82:97:chronic_disease,103:121:chronic_disease	CMS subtype diagnosis of acetylcholinesterase deficiency, slow-channel syndrome, LRP4 deficiency, and plectin deficiency
NCT02562066	1:27:chronic_disease,41:44:treatment	Cardiac conduction defects on Screening ECG
NCT02562066	1:16:gender,55:73:pregnancy	Female patients of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin [HCG] at Screening)
NCT02562066	23:26:chronic_disease,37:66:chronic_disease,68:85:chronic_disease,87:102:chronic_disease,104:120:chronic_disease,122:137:chronic_disease,138:156:chronic_disease,162:183:chronic_disease	Genetically-confirmed CMS involving acetylcholine receptor defect, Rapsyn deficiency, MuSK deficiency, Dok-7 deficiency, SYT2 deficiency,SNAP25B deficiency, and fast channel syndrome
NCT02562066	32:62:allergy_name,70:93:allergy_name	History of drug allergy to any pyridine-containing substances or any amifampridine phosphate excipient(s)
NCT02562066	22:29:treatment,33:56:treatment,74:77:lower_bound,81:102:clinical_variable	In patients naïve to 3,4-DAP or amifampridine phosphate, improvement of >20% in MFM20 or MFM32 scores after open label period of up titration of dose
NCT02562066	38:72:treatment	In patients previously stabilized on 3,4-DAP or amifampridine phosphate, history of meaningful improvement in motor function (in opinion of investigator)
NCT02562066	1:4:clinical_variable,39:41:lower_bound,45:47:lower_bound	MFM 20 or 32 score equal or less than 48 or 76, respectively, at Screening
NCT02562066	1:5:gender	Male
NCT02562066	1:10:pregnancy	Pregnancy
NCT02562066	1:17:chronic_disease	Seizure disorder
NCT02562066	1:39:treatment,52:75:treatment,78:84:treatment,89:105:treatment,113:120:upper_bound	Treatment with an investigational drug (other than amifampridine phosphate), device, or biological agent within 30 days before Screening or while participating in this study
NCT02562066	35:49:treatment,51:61:treatment,63:72:treatment,74:83:treatment,88:98:treatment,135:146:treatment	Willingness of patients receiving pyridostigmine, prednisone, albuterol, ephedrine, or fluoxetine to remain on a stable dose of these medications throughout the study interval
NCT02562066	1:4:age,5:6:lower_bound	age 2 and above
NCT02562066	1:7:gender	female
NCT02562066	6:56:contraception_consent	must practice effective, reliable contraceptive regimen during the study
NCT02562066	20:28:pregnancy	planning to become pregnant at any time during the study
NCT02552186	1:4:age,45:53:treatment,117:133:treatment	Age and gender matched patients who undergo chest CT at the ACH JHM Radiology Department for indications other than Pectus Excavatum
NCT02552186	159:198:treatment	All patients evaluated in the ACH JHM Pediatric Surgery or Cardiac Surgery Clinics, as well as in the outpatient clinic system at Johns Hopkins Hospital, for surgical correction of Pectus Excavatum
NCT02548546	11:19:lower_bound,23:26:age	Patients >18 years of age
NCT02548546	35:46:allergy_name,66:91:chronic_disease	Patients with contraindication to IV contrast such as allergy or severe kidney dysfunction
NCT02548546	50:53:chronic_disease,68:83:clinical_variable,86:106:lower_bound	Patients with either symptomatic or asymptomatic AAA as defined by aortic diameter ≥ 1.5x normal diameter
NCT02548546	15:36:chronic_disease	Patients with non-aneurysmal aortas who require aortic contrast imaging or echocardiography for preoperative planning or other reason
NCT02548546	54:69:clinical_variable,75:83:upper_bound	Terminally ill patients, and patients with estimated life expectancy of ≤ 6 months
NCT02542956	3:20:chronic_disease	A medical condition that could interfere with study participation
NCT02542956	1:12:clinical_variable,23:28:upper_bound	Body weight less than 50 kg
NCT02542956	45:71:treatment	Participating in another study involving an investigational medication
NCT02542956	12:26:treatment,30:61:treatment	Undergoing abdominoplasty or TRAM flap breast reconstruction
NCT02542202	1:26:clinical_variable,30:37:lower_bound	Absolute neutrophil count >= 500/mcL
NCT02542202	1:16:chronic_disease,20:36:chronic_disease,47:70:treatment	Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
NCT02542202	1:4:age,5:13:lower_bound	Age 18 years or older
NCT02542202	1:17:cancer	Brain metastases must be treated prior to enrollment in the study
NCT02542202	1:3:treatment,7:39:treatment,89:107:chronic_disease	CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms
NCT02542202	1:51:chronic_disease,61:80:chronic_disease,121:134:treatment,142:155:upper_bound	Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
NCT02542202	6:25:clinical_variable,37:41:upper_bound,58:62:treatment,66:83:treatment	Each extracranial lesion must be =< 6 cm and amenable to SBRT or surgical excision
NCT02542202	1:61:clinical_variable,64:65:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status =<2
NCT02542202	1:4:chronic_disease	HIV testing is not required for eligibility for this protocol
NCT02542202	1:11:clinical_variable,15:23:lower_bound	Hemoglobin >= 8.0 g/dL
NCT02542202	1:35:chronic_disease,77:88:clinical_variable,91:111:upper_bound	Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter
NCT02542202	23:33:cancer,45:65:cancer,73:97:cancer	Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer
NCT02542202	1:16:clinical_variable,23:31:lower_bound	Life expectancy of >= 3 months
NCT02542202	35:62:treatment,66:94:treatment,102:119:treatment	Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
NCT02542202	33:44:treatment,71:96:chronic_disease,138:150:treatment	Patients may not have had prior bevacizumab, based on case reports of tracheoesophageal fistula in patients treated with bevacizumab and radiotherapy
NCT02542202	32:55:treatment	Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose
NCT02542202	20:21:upper_bound,31:47:cancer,52:56:clinical_variable,60:64:upper_bound	Patients must have 3 or fewer brain metastases, of size =< 4 cm
NCT02542202	28:29:lower_bound,33:34:upper_bound,75:89:cancer,104:111:treatment	Patients must have between 1 to 5 new or recurrent lesions suspicious for metastatic RCC on diagnostic imaging
NCT02542202	35:59:treatment,101:108:upper_bound	Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial
NCT02542202	27:39:treatment,32:39:treatment,41:54:treatment,56:68:treatment,112:124:upper_bound	Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month
NCT02542202	62:72:cancer,86:89:cancer	Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)
NCT02542202	60:67:upper_bound	Patients must have normal organ and marrow function within 30 days of registration
NCT02542202	40:53:cancer,79:98:treatment,103:120:treatment	Patients who have an intact unresected primary tumor should be considered for radical nephrectomy and primary resection prior to enrollment in the study
NCT02542202	27:44:treatment,132:144:treatment	Patients who have had any prior bevacizumab, due to case reports suggesting a possible risk of severe toxicity in combination with radiotherapy
NCT02542202	23:41:treatment,43:56:treatment,58:74:treatment,79:91:treatment,99:106:upper_bound	Patients who have had prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy within 1 month of enrollment
NCT02542202	52:75:chronic_disease,79:100:chronic_disease,146:156:cancer	Patients with radiographic or clinical findings of spinal cord compression or cauda equina syndrome with neurologic deficit thought to be due to malignancy
NCT02542202	1:10:clinical_variable,14:24:lower_bound	Platelets >= 50,000/mcL
NCT02542202	1:10:pregnancy,14:19:gender,74:141:contraception_consent,158:167:treatment,184:192:lower_bound	Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatment
NCT02542202	8:23:chronic_disease,51:61:clinical_variable,121:139:cancer	Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease if the liver is involved with metastatic disease
NCT02542202	1:33:chronic_disease,45:58:upper_bound	Transmural myocardial infarction within the last 6 months prior to registration
NCT02542202	1:16:chronic_disease,24:48:chronic_disease,59:74:treatment,86:105:upper_bound	Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration
NCT02542202	1:6:gender,45:63:pregnancy,76:83:upper_bound	Women of childbearing potential must have a negative pregnancy test within 14 days of registration
NCT02542202	18:21:chronic_disease,69:128:treatment,140:149:clinical_variable,153:173:lower_bound,181:194:upper_bound	patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration
NCT02542202	17:26:treatment,30:46:cancer,59:77:treatment,79:103:treatment,105:130:treatment	the modality of treatment of brain metastases can include surgical resection, whole brain radiotherapy, stereotactic radiosurgery, or any combination of the above
NCT02542202	27:40:cancer,43:48:upper_bound,114:115:lower_bound	this will be defined as a primary tumor < 10 cm in size or a primary lesion which can be treated to a dose of >= 8 Gy x 5 without excessive perceived risk of toxicity
NCT02535936	25:41:chronic_disease,53:87:treatment	Children diagnosis with Spastic Diplegia and having Selective Dorsal Rhizotomy surgery
NCT02535936	4:38:treatment	No Selective Dorsal Rhizotomy surgery
NCT02529644	115:131:lower_bound	Attend church at least once a month or use church outreach services, such as food and clothing programs, at least 4 times per year
NCT02529644	8:10:upper_bound,143:146:chronic_disease	Minors 18 and under are intentionally excluded since the intervention study has been designed specifically for adults with information of how HIV affects the African American adult population
NCT02529644	1:5:age,6:8:lower_bound,12:14:upper_bound	aged 18 to 64
NCT02527564	137:164:chronic_disease,166:194:chronic_disease,199:215:chronic_disease,266:274:chronic_disease,286:311:chronic_disease	Adult outpatients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder (296.70), bipolar II disorder (296.89), or bipolar disorder not otherwise specified (296.80), with concurrent insomnia related to bipolar disorder (307.42)
NCT02527564	68:97:treatment,99:118:treatment,120:164:treatment,166:193:treatment	Clinically significant abnormalities on baseline laboratory tests (comprehensive metabolic panel, fasting lipid panel, Complete Blood Count (CBC) with differential, thyroid stimulating hormone)
NCT02527564	10:23:upper_bound	Current (past 6 months) alcohol or substance use disorder
NCT02527564	50:93:clinical_variable,96:98:lower_bound	Current hypo/manic symptoms, as evidenced by the Young Mania Rating Scale (YMRS) total score ≥ 12
NCT02527564	9:18:chronic_disease	Current psychosis
NCT02527564	20:21:lower_bound,35:58:treatment,60:75:treatment,77:88:treatment,90:113:treatment,115:131:treatment,140:155:treatment,175:191:chronic_disease	Currently taking ≥ 1 prescription psychotropic medication (hypnotic agents, anxiolytics, atypical antipsychotics, mood stabilizers, and/or antidepressants) for management of bipolar disorder
NCT02527564	27:35:chronic_disease	Patients who are actively suicidal or evaluated as being a high suicide risk
NCT02527564	57:69:chronic_disease,77:93:chronic_disease	Presence of any unstable and/or potentially confounding neurological and/or medical disorder
NCT02527564	1:35:clinical_variable,38:45:upper_bound,51:52:lower_bound	Subjective total sleep time (sTST) < 6 hours on ≥ 1 night during the prior week
NCT02527564	1:6:gender,15:33:pregnancy	Women who are currently pregnant
NCT02523443	1:10:chronic_disease	Cirrhotic patients
NCT02523443	21:38:allergy_name,59:77:chronic_disease,79:104:chronic_disease,106:141:chronic_disease,143:165:chronic_disease,171:188:chronic_disease,191:215:chronic_disease,217:235:chronic_disease,237:268:chronic_disease,272:315:chronic_disease,318:348:treatment,352:374:chronic_disease,397:411:treatment,499:525:chronic_disease,527:530:clinical_variable,544:547:lower_bound,555:563:clinical_variable,567:570:clinical_variable,584:586:lower_bound,589:598:clinical_variable,609:619:upper_bound	Contraindication to epidural catheter placement including bleeding diathesis (essential thrombocythemia, idiopathic thrombocytopenic purpura, von Willebrand disease, and hemophilia A or B), neurological dysfunction (multiple sclerosis, subacute myelo-opticoneuropathy or preexisting lower limb neurological deficit), prior extensive spinal surgery or major spinal deformity, pre-operative use of anti-coagulant with planned use of therapeutic dose of anti-coagulant in post-operatively, documented pre-operative coagulopathy (INR greater than 1.3 not on Coumadin or PTT greater than 42), platelets less than 100,000/μL, or evidence of infection at potential epidural site
NCT02523443	30:37:treatment,88:92:lower_bound,96:104:clinical_variable	Patients receiving high dose opioids on a chronic basis (greater than or equivalent to 60mg of morphine per day)
NCT02523443	21:35:treatment,36:57:treatment,64:77:treatment	Patients taking any opioid agonist/antagonist medication (i.e. Buprenorphine)
NCT02523443	21:50:treatment,114:138:cancer,170:201:treatment,211:231:treatment,235:255:treatment,306:323:treatment,325:344:chronic_disease,346:356:chronic_disease,361:387:treatment	Patients undergoing open elective liver resection for primary liver pathology (benign or malignant) or secondary metastatic liver disease, including patients undergoing concomitant surgical procedures (such as colorectal resection or debulking procedures), with no contraindication to the insertion of an epidural catheter (localized infection, septicemia, or pre-operative coagulopathy)
NCT02523443	162:170:allergy_name,172:180:allergy_name,186:197:allergy_name	Patients with a history of documented anaphylaxis or contraindication to any of the study medications or standardized intra-operative medications. These include dilaudid, fentanyl, and bupivacaine
NCT02523443	57:60:clinical_variable,62:63:lower_bound	Patients with pain at rest or with movement measured by NRS >2
NCT02523443	22:66:chronic_disease,81:85:clinical_variable,87:90:upper_bound	Patients with severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 <50%
NCT02523443	27:47:chronic_disease,62:84:chronic_disease	Patients with significant cognitive impairment or documented psychologic impairment
NCT02523443	1:4:age,5:13:lower_bound	age 18 years or older
NCT02521103	15:36:clinical_variable,39:41:lower_bound	Patient has a Body Mass Index (BMI) > 45
NCT02521103	22:49:treatment	Patient has a failed unicondylar knee prosthesis
NCT02521103	36:52:allergy_name	Patient has a known sensitivity to device materials
NCT02521103	15:28:chronic_disease,32:55:chronic_disease	Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device
NCT02521103	36:52:chronic_disease,106:125:treatment	Patient has an active or suspected latent infection in or about the affected knee joint at time of study device implantation
NCT02521103	79:101:treatment	Patient is a candidate for revision of all femoral and tibial components of a total knee replacement
NCT02521103	14:18:gender,26:34:pregnancy,35:41:gender	Patient is a male or non-pregnant female
NCT02521103	29:45:chronic_disease,52:71:chronic_disease,78:96:chronic_disease,103:118:chronic_disease	Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration
NCT02521103	52:60:treatment,116:123:lower_bound	Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. > 30 days)
NCT02521103	23:26:age,27:35:lower_bound	skeletally mature and age 18 years or older at time of study device implantation
NCT02519738	28:31:age	Any patient falling within age group with granulation tissue around G tube site
NCT02519738	29:32:age	Patients falling outside of age group range
NCT02512718	8:26:chronic_disease,32:46:chronic_disease	Active/acute pancreatitis with hyperlipidemia
NCT02512718	12:15:allergy_name,17:21:allergy_name,26:29:allergy_name,30:45:allergy_name	Allergy to egg, fish, or soy/legume products
NCT02512718	16:40:cancer,51:65:chronic_disease	Diagnosis of a hematological malignancy including myelodysplasia
NCT02512718	1:5:chronic_disease,6:17:treatment,32:41:treatment	GVHD prophylaxis that includes rapamycin
NCT02512718	12:59:treatment	History of parenteral nutrition use with SOLE prior to HCT
NCT02512718	1:16:chronic_disease	Lipid nephrosis
NCT02512718	27:29:treatment,33:51:treatment	Other contraindication to PN or intravenous lipids
NCT02512718	14:28:chronic_disease,44:71:clinical_variable,74:83:lower_bound	Pathological hyperlipidemia (2 consecutive fasting triglyceride levels > 500 mg/dL)
NCT02512718	132:156:treatment,170:173:chronic_disease,175:198:clinical_variable,200:208:lower_bound,213:221:treatment,243:266:treatment	Planned myeloablative allogeneic bone marrow, cord, or peripheral blood stem cell (from any donor, including haploidentical donor) HCT conditioning regimen using either TBI (planned cumulative dose >1100 cGy) or busulfan in addition to other chemotherapeutic agents
NCT02512718	79:81:upper_bound,82:111:clinical_variable,118:123:clinical_variable,126:127:clinical_variable,130:131:clinical_variable,134:138:clinical_variable,145:147:clinical_variable	Planned related or unrelated bone marrow donor matched at a minimum of out of 10 human leukocyte antigen (HLA) loci (HLA-A, -B, -C, -DRB1, and -DQ)
NCT02512718	8:14:chronic_disease,16:34:chronic_disease,38:46:chronic_disease	Recent stroke, cardiac infarction or embolism
NCT02512718	10:27:chronic_disease	Unstable diabetes mellitus
NCT02512718	8:26:chronic_disease,32:46:chronic_disease	active/acute pancreatitis with hyperlipidemia
NCT02512718	12:15:allergy_name,17:21:allergy_name,26:29:allergy_name,30:45:allergy_name	allergy to egg, fish, or soy/legume products
NCT02512718	24:55:treatment	co-enrollment in other interventional clinical studies
NCT02512718	1:16:chronic_disease	lipid nephrosis
NCT02512718	27:29:treatment,33:51:treatment	other contraindication to PN or intravenous lipids
NCT02512718	14:28:chronic_disease,44:71:clinical_variable,74:83:lower_bound	pathological hyperlipidemia (2 consecutive fasting triglyceride levels > 500 mg/dL)
NCT02512718	71:72:lower_bound,80:81:upper_bound,82:90:clinical_variable,92:97:clinical_variable,99:101:clinical_variable,108:112:clinical_variable	planned related or unrelated cord blood donor matched at a minimum of 4 out of 6 HLA loci (HLA-A, -B, and -DRB1)
NCT02512718	8:14:chronic_disease,16:34:chronic_disease	recent stroke, cardiac infarction or embolism
NCT02512718	10:27:chronic_disease	unstable diabetes mellitus
NCT02512497	30:58:chronic_disease,60:89:chronic_disease,91:109:chronic_disease,114:128:chronic_disease,164:219:treatment	A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
NCT02512497	8:19:chronic_disease,44:49:chronic_disease,56:63:chronic_disease,65:72:clinical_variable,76:92:lower_bound,101:112:lower_bound	Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA >/=10,000 copies/mL, or >/= 2,000 IU/mL)
NCT02512497	8:30:chronic_disease,32:37:chronic_disease,41:58:chronic_disease	Active uncontrolled bacterial, viral or fungal infections
NCT02512497	1:4:age,5:7:lower_bound,11:19:upper_bound,23:26:age	Age 18 to 70 years of age
NCT02512497	50:66:chronic_disease,68:81:clinical_variable,100:104:lower_bound,120:136:clinical_variable,144:154:clinical_variable	An EKG recorded at screening showing evidence of cardiac ischemia (ST depression depression of >/= 2 mm, measured from isoelectric line to the ST segment)
NCT02512497	5:23:chronic_disease,37:63:treatment	Any cardiac arrhythmia requiring an anti-arrhythmic medication
NCT02512497	20:37:treatment,97:107:treatment	Concomitant use of CYP3A4 inhibitors where the interaction is thought too great to proceed with romidepsin
NCT02512497	1:23:chronic_disease,25:28:clinical_variable,30:36:lower_bound	Congenital QT syndrome, QTc >500 ms
NCT02512497	1:31:chronic_disease,111:128:clinical_variable,130:133:upper_bound,137:146:clinical_variable,151:154:upper_bound,158:172:treatment,180:183:treatment	Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI
NCT02512497	21:46:cancer,48:73:cancer,75:104:cancer,106:139:cancer,144:170:cancer,172:202:cancer,212:248:treatment	Diagnosis of either Cutaneous T-Cell Lymphoma; T-Prolymphocytic Leukemia; T-Large Granulocytic Leukemia; T-Lymphoblastic Leukemia/lymphoma; or Peripheral T-Cell Lymphoma, Natural Killer/T-cell lymphoma for whom allogeneic stem cell transplantation is indicated
NCT02512497	1:3:clinical_variable,7:10:lower_bound,14:23:treatment,27:41:treatment	EF>/= 50% on MUGA scan or Echocardiogram
NCT02512497	20:29:chronic_disease,33:40:lower_bound,41:42:upper_bound,43:57:chronic_disease,75:94:chronic_disease,83:94:chronic_disease	Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
NCT02512497	19:40:treatment,48:55:upper_bound	Exposure to other investigational drugs within 4 weeks before enrollment
NCT02512497	1:5:clinical_variable,7:10:clinical_variable,25:29:clinical_variable,34:37:lower_bound	FEV1, FVC and corrected DLCO >/= 40%
NCT02512497	1:15:gender,70:122:contraception_consent,132:154:contraception_consent,156:176:contraception_consent,178:203:contraception_consent,205:227:contraception_consent,232:242:contraception_consent,275:287:gender,288:340:contraception_consent	Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study
NCT02512497	11:12:lower_bound,13:37:clinical_variable,43:59:treatment,89:96:upper_bound	Grade >/= 3 non-hematologic toxicity from previous therapy that has not resolved to </= grade 1
NCT02512497	1:14:chronic_disease	HIV infection
NCT02512497	1:52:clinical_variable,54:55:lower_bound,158:166:treatment	Hematopoetic Transplant Co-Morbidity Index (HCT-CI) >4 unless deemed clinically insignificant by primary investigator for patients receiving Time-Sequential Busulfan (total exposure 20000 umol-min
NCT02512497	1:26:chronic_disease,30:56:chronic_disease,62:77:treatment	Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
NCT02512497	1:14:gender,46:92:contraception_consent	Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study
NCT02512497	1:22:chronic_disease,30:36:upper_bound	Myocardial infarction within 1 year of study entry
NCT02512497	19:36:chronic_disease,47:94:chronic_disease,96:115:chronic_disease,120:131:chronic_disease,133:149:clinical_variable,160:168:upper_bound	Other significant EKG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)
NCT02512497	21:32:chronic_disease	Patient with active CNS disease
NCT02512497	46:61:clinical_variable,113:123:treatment	Patients taking drugs leading to significant QT prolongation where the interaction is too great to proceed with romidepsin
NCT02512497	1:10:pregnancy,40:45:gender,126:157:treatment,245:266:treatment,267:272:gender	Pregnancy (positive Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women
NCT02512497	1:21:treatment,29:44:upper_bound	Prior autologous SCT in the prior 12 months
NCT02512497	1:30:treatment	Prior whole brain irradiation
NCT02512497	1:18:treatment	Radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment
NCT02512497	28:49:clinical_variable,58:59:lower_bound,64:79:upper_bound	Subjects with a history of myocardial infarction between 6 and 12 months prior to study entry who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate
NCT02512497	1:26:chronic_disease,14:26:chronic_disease,34:53:clinical_variable,61:67:lower_bound,127:137:treatment	Uncontrolled hypertension, i.e., blood pressure (BP) of >/= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose and meet all other inclusion criteria
NCT02512497	17:30:treatment	stable doses of beta-blockers
NCT02508467	1:26:clinical_variable,28:35:upper_bound	Absolute neutrophil count <1000/mL
NCT02508467	1:34:cancer	Central nervous system metastases
NCT02508467	1:19:clinical_variable	Child-Pugh class A with no clinically apparent ascites
NCT02508467	24:27:cancer	Confirmed diagnosis of HCC by histological examination
NCT02508467	1:61:clinical_variable,65:66:lower_bound,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
NCT02508467	35:55:chronic_disease,93:102:treatment	For Part 1 and 2, the patient has unresectable disease and has been previously treated with sorafenib
NCT02508467	65:68:treatment	For Part 3, the patient has not received prior treatment with a TKI
NCT02508467	1:11:clinical_variable,13:19:upper_bound	Hemoglobin <8 g/dL
NCT02508467	1:37:clinical_variable,39:42:lower_bound	International normalized ratio (INR) >2.3
NCT02508467	1:15:clinical_variable,17:26:upper_bound	Platelet count <75,000/mL
NCT02508467	7:16:clinical_variable,18:27:lower_bound	Total bilirubin >2.5 mg/dL
NCT02508467	1:31:clinical_variable,33:67:lower_bound	alanine aminotransferase (ALT) >5x the upper limit of normal (ULN)
NCT02508467	25:34:treatment	does not have access to sorafenib
NCT02508467	14:38:treatment	has declined treatment with sorafenib
NCT02508467	10:30:clinical_variable,32:41:upper_bound	measured creatinine clearance <40 mL/min
NCT02508467	1:22:clinical_variable,24:33:lower_bound	prothrombin time (PT) >6 seconds above control
NCT02508467	1:32:clinical_variable	spartate aminotransferase (AST)
NCT02503358	1:9:lower_bound	18 years and older
NCT02503358	34:45:treatment,77:85:treatment,89:93:treatment	A history of hypersensitivity to selumetinib, or any excipient agents (e.g. Captisol or TPGS- a water soluble form of Vitamin E)
NCT02503358	40:56:chronic_disease,100:116:chronic_disease,125:143:chronic_disease,147:163:treatment,201:212:chronic_disease,214:225:chronic_disease,230:263:chronic_disease	Any evidence of severe or uncontrolled systemic disease, including, but not limited to, ongoing or active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV
NCT02503358	5:61:treatment,66:74:cancer,78:94:cancer	Any prior treatment with either a MEK, RAS, or RAF inhibitor for advanced or metastatic NSCLC
NCT02503358	16:24:clinical_variable,27:40:lower_bound,76:104:treatment,117:125:chronic_disease,134:146:upper_bound	Any unresolved toxicity > CTCAE grade 2 despite optimal care/support, from previous anti-cancer therapy, except for alopecia, within 7 days prior to Cycle 1, day 1
NCT02503358	1:17:cancer,21:44:treatment,66:118:treatment,132:139:lower_bound	Brain metastases or spinal cord compression unless asymptomatic, treated and stable off steroids and anti-convulsants for at least 30 days
NCT02503358	48:66:treatment,86:95:treatment,119:131:treatment,142:163:treatment,165:177:treatment,179:189:treatment,191:202:treatment,204:214:treatment,216:225:treatment,227:237:treatment,239:248:treatment,253:263:treatment,281:291:treatment,293:306:treatment,308:317:treatment,319:328:treatment,333:343:treatment,421:432:treatment	Caution should be exercised when administering paclitaxel (Taxol) concomitantly with medicines known to inhibit (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir and nelfinavir) OR induce (e.g. rifampicin, carbamazepine, phenytoin, efavirenz and nevirapine) either CYP2C8 or CYP3A4. Based on the in vitro data and SimCYP simulations, selumetinib is considered unlikely to perpetrate clinically significant drug-drug interaction via inhibition or induction of CYP enzymes
NCT02503358	21:30:treatment	Conception while on treatment must be avoided
NCT02503358	28:54:chronic_disease,58:80:chronic_disease	Current or past history of central serous retinopathy or retinal vein occlusion
NCT02503358	1:24:clinical_variable,28:29:lower_bound,33:34:upper_bound	ECOG Performance Status of 0 or 1
NCT02503358	1:26:clinical_variable,94:103:treatment,107:115:lower_bound	Estimated life expectancy, in the judgment of the investigator, which will permit receipt of treatment of 12 weeks or more
NCT02503358	1:16:gender,25:33:pregnancy,86:98:pregnancy,112:130:pregnancy,121:130:pregnancy,203:208:gender	Female patients who are pregnant or breast-feeding (confirmation that the patient is not pregnant must be by a negative pregnancy test result obtained during screening; pregnancy testing is required of women of childbearing potential but not required for post-menopausal or surgically, sterilized women)
NCT02503358	1:8:gender,66:153:contraception_consent,174:211:contraception_consent,266:279:upper_bound	Females of child bearing potential that are sexually active must agree to either practice 2 medically accepted highly effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 30 days after the last dose of study drug
NCT02503358	11:34:treatment,95:104:treatment	For other targeted therapy agents, the washout period will be 5 half-lives, prior to start of treatment on study
NCT02503358	48:82:cancer,86:100:cancer	Histologically and/or cytologically confirmed, non-small cell lung cancer (NSCLC) of adenocarcinoma histology at the time of initial diagnosis
NCT02503358	1:22:clinical_variable,25:32:lower_bound,50:58:chronic_disease	Intra-ocular pressure > 21 mmHg, or uncontrolled glaucoma (irrespective of intra-ocular pressure)
NCT02503358	35:39:clinical_variable,41:44:clinical_variable,46:50:clinical_variable,86:95:treatment	Known actionable mutations (e.g., EGFR, ALK, ROS1), against which there is available treatment
NCT02503358	1:15:treatment,33:46:upper_bound	Major surgical procedure within 21 days prior to enrollment
NCT02503358	1:6:gender,39:88:contraception_consent,113:122:treatment,142:150:lower_bound,197:202:gender,203:224:treatment,238:252:treatment	Males of child bearing potential must agree to practice effective barrier contraception during the entire study treatment period and through 6 months) after the last dose of study drug, (includes males surgically sterilized (i.e. status post vasectomy)
NCT02503358	96:99:cancer,141:154:upper_bound	Measurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment
NCT02503358	1:13:cancer	Mixed tumors will be categorized by the predominant cell type
NCT02503358	19:28:pregnancy,45:51:gender,45:52:gender,124:129:gender,268:280:treatment,284:306:treatment,365:386:lower_bound,428:459:upper_bound,463:471:upper_bound	Negative test for pregnancy is required for females of child-bearing potential; A female of child bearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1. has not undergone a hysterectomy or bilateral oophorectomy; or 2. has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months or 730 days)
NCT02503358	1:28:chronic_disease	Ophthalmological conditions
NCT02503358	33:42:treatment	Patients who progressed on such treatment, i.e., have developed acquired resistance and are no longer reasonably expected to derive therapeutic benefit are eligible for the trial
NCT02503358	1:34:treatment,38:51:treatment,59:72:upper_bound	Prior treatment with chemotherapy or immunotherapy within 14 days prior to enrollment
NCT02503358	13:33:treatment,41:48:upper_bound,61:70:treatment	Received an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drug
NCT02503358	9:16:chronic_disease,20:49:chronic_disease,136:145:treatment	Serious medical or psychiatric illness/condition likely in the judgment of the Investigator to interfere with compliance with protocol treatment/research
NCT02503358	1:11:lower_bound,12:14:upper_bound,36:46:cancer,97:108:cancer	Stage IIIB-IV, locally advanced or metastatic disease according to the 7 th edition of the AJCC lung cancer TNM classification system
NCT02503358	20:40:treatment,44:55:chronic_disease,63:69:upper_bound	Subjects receiving palliative radiation to CNS disease within 7 days may be eligible with PI approval
NCT02502006	7:10:gender	Adult men
NCT02502006	1:16:gender,25:33:pregnancy	Female subjects who are pregnant
NCT02502006	24:37:treatment,41:62:treatment	Has ever taken the any anti-platelet or anti-coagulant agents
NCT02502006	11:17:treatment,21:42:treatment,44:66:treatment,70:93:treatment,102:115:upper_bound	Has taken NSAIDs or anti-secretory agents (proton pump inhibitors or H2 receptor antagonists) within 14 days prior to study drug administration
NCT02502006	15:38:treatment,50:69:treatment,50:77:treatment,89:94:gender,187:215:treatment,217:243:treatment,248:277:treatment,266:277:treatment	Has taken any prescription medication other than hormone replacement therapy (including males taking testosterone as a hormone replacement to treat a documented low testosterone level), thyroid replacement hormones, anti-hyperlipidemic agents, or anti-hypertensive medications. Individuals taking other/additional chronic stable medications can be considered on a case-by-case basis for inclusion in the study if agreed upon by judgment of the investigators
NCT02502006	12:18:cancer,30:42:upper_bound	History of cancer within the last 5 years
NCT02502006	24:46:chronic_disease,58:64:chronic_disease	History of significant cardiovascular disease (including stroke or TIA), renal, hepatic, respiratory
NCT02502006	6:35:treatment,17:35:treatment,47:58:treatment,60:69:treatment,71:79:treatment,121:128:upper_bound	Used dietary or herbal supplements containing salicylates, Vitamin E, fish oil, or any other herbal supplements, within 14 days of study drug administration
NCT02502006	39:51:chronic_disease,56:70:chronic_disease	Volunteers with adequately controlled hypertension and hyperlipidemia
NCT02502006	1:12:chronic_disease,14:22:chronic_disease,26:41:chronic_disease	coagulation, bleeding or blood disorders
NCT02502006	1:21:cancer,25:45:cancer,58:66:treatment,71:102:cancer	cutaneous basal cell or squamous cell cancer resolved by excision, or carcinoma in situ of the cervix adequately treated
NCT02502006	27:53:chronic_disease,65:80:chronic_disease	documented history of any gastrointestinal disorders, including bleeding ulcers
NCT02502006	14:22:lower_bound,26:29:age	greater than 18 years of age
NCT02502006	45:58:upper_bound	history of drug or alcohol abuse within the last 6 months
NCT02502006	1:7:chronic_disease,9:18:chronic_disease,20:42:chronic_disease,46:68:chronic_disease	immune, endocrine, hematopoietic disorder or neurological disorders
NCT02502006	27:41:lower_bound	infections which longer > 6 months prior to screening
NCT02502006	13:33:treatment,80:93:upper_bound,142:145:lower_bound,158:171:upper_bound	received an investigational drug or used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening
NCT02502006	26:33:allergy_name,43:49:allergy_name	sensitive or allergic to aspirin or other NSAIDs
NCT02502006	26:46:allergy_name,50:69:allergy_name	sensitive or allergic to celecoxib (Celebrex) or naproxen (Naprosyn) or their components
NCT02502006	1:18:clinical_variable,23:32:upper_bound	total cholesterol of ≤270 mg/dL
NCT02502006	1:6:gender	women
NCT02492867	17:55:contraception_consent,59:65:gender	Patient must be willing to use effective contraception if female with reproductive capability
NCT02492867	37:49:treatment	Patients cannot tolerate concurrent chemotherapy
NCT02492867	18:26:lower_bound,30:33:age	Patients must be 18 years of age or older
NCT02492867	55:64:lower_bound,65:69:upper_bound,70:96:cancer	Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer
NCT02492867	32:57:cancer	Patients with any component of small cell lung carcinoma
NCT02492867	29:70:cancer	Patients with evidence of a malignant pleural or pericardial effusion
NCT02492867	1:9:pregnancy,10:15:gender	Pregnant women
NCT02492867	1:19:treatment,54:63:treatment	Prior radiotherapy to the thorax such that composite radiation would significantly overdose critical structures, either per estimation of the treating radiation oncologist or defined by failure to meet normal tissue tolerance constraints
NCT02488967	1:32:clinical_variable,44:53:lower_bound	Absolute neutrophil count (ANC) must be >= 1200/mm^3
NCT02488967	8:23:chronic_disease	Active cardiac disease
NCT02488967	8:19:chronic_disease,23:34:chronic_disease	Active hepatitis B or hepatitis C with abnormal liver function tests
NCT02488967	8:17:chronic_disease,21:38:chronic_disease,69:80:treatment	Active infection or chronic infection requiring chronic suppressive antibiotics
NCT02488967	43:56:upper_bound,101:117:clinical_variable,140:171:clinical_variable,174:183:lower_bound	Adequate renal function determined within 6 weeks prior to randomization defined as the most recent serum creatinine =< ULN or measured or calculated creatinine clearance > 60 mL/min
NCT02488967	1:21:clinical_variable,33:42:upper_bound	Alkaline phosphatase must be =< 2.5 x ULN for the lab
NCT02488967	1:16:chronic_disease,50:73:treatment	Angina pectoris that requires the current use of anti-anginal medication
NCT02488967	22:42:treatment,50:69:treatment,71:106:treatment	Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy
NCT02488967	46:59:cancer,75:79:cancer	Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS
NCT02488967	1:33:clinical_variable,45:54:upper_bound	Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab
NCT02488967	1:64:treatment	Axillary lymphadenectomy with or without SN isolation procedure
NCT02488967	27:40:cancer	By pathologic evaluation, primary tumor must be pT1-3
NCT02488967	1:16:chronic_disease,109:127:treatment	Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens
NCT02488967	1:13:treatment,55:68:cancer	Chemotherapy administered for the currently diagnosed breast cancer prior to randomization
NCT02488967	1:45:treatment,64:73:lower_bound,74:92:treatment,115:131:treatment	Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)
NCT02488967	50:65:treatment	Conditions that would prohibit administration of corticosteroids
NCT02488967	36:45:treatment	Conduction abnormality requiring a pacemaker
NCT02488967	47:65:cancer,124:137:upper_bound	Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 90 days prior to randomization
NCT02488967	12:26:chronic_disease	Documented cardiomyopathy
NCT02488967	1:61:clinical_variable,65:66:lower_bound,70:71:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
NCT02488967	26:36:treatment,106:120:cancer,125:156:cancer	For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist
NCT02488967	26:36:treatment,81:86:cancer	For patients who undergo mastectomy, the margins must be free of residual gross tumor
NCT02488967	1:11:clinical_variable,23:30:lower_bound	Hemoglobin must be >= 10 g/dL
NCT02488967	12:27:chronic_disease	History of cardiac disease
NCT02488967	23:53:chronic_disease	History of documented congestive heart failure (CHF)
NCT02488967	31:45:upper_bound,50:77:chronic_disease,81:134:chronic_disease	History of hospitalization in past 12 months for diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic nonketotic syndrome (HHNS)
NCT02488967	12:35:cancer,48:63:cancer,80:94:treatment,99:109:cancer,114:150:cancer,159:172:upper_bound	History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization
NCT02488967	1:4:treatment,12:39:treatment,78:116:clinical_variable,119:122:upper_bound,141:170:clinical_variable,173:188:upper_bound	IHC 2+ and in situ hybridization (ISH) non-amplified with a ratio of HER2 to centromere enumerator probe 17 (CEP17) < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells
NCT02488967	1:4:chronic_disease,43:48:clinical_variable,51:54:upper_bound,73:102:clinical_variable,105:120:upper_bound	ISH non-amplified with a ratio of HER2 to CEP17 < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells
NCT02488967	1:27:clinical_variable,28:29:lower_bound,30:31:upper_bound	Immunohistochemistry (IHC) 0-1+
NCT02488967	1:23:chronic_disease,37:44:chronic_disease	Intrinsic lung disease resulting in dyspnea
NCT02488967	38:49:treatment,53:63:treatment,71:85:treatment,90:103:treatment	Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80 and Cremophor® EL
NCT02488967	1:42:clinical_variable,37:41:clinical_variable,79:92:upper_bound,141:173:treatment,197:232:treatment,309:312:lower_bound	Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [D] echocardiogram is preferred; however, multi gated acquisition [MUGA] scan may be substituted based on institutional preferences;) the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal
NCT02488967	1:22:chronic_disease	Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricle (LV) function
NCT02488967	1:24:clinical_variable,26:37:chronic_disease,39:66:chronic_disease,71:100:chronic_disease,105:112:lower_bound	Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0
NCT02488967	7:37:cancer,85:100:treatment	Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
NCT02488967	22:56:chronic_disease,109:120:clinical_variable,126:140:upper_bound,162:204:chronic_disease	Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions
NCT02488967	15:18:clinical_variable,22:42:clinical_variable,107:131:treatment,133:165:treatment,167:204:treatment,209:217:treatment,236:249:upper_bound,288:306:cancer	Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements above are met
NCT02488967	15:35:clinical_variable,57:66:upper_bound,137:146:treatment,148:159:treatment,164:172:treatment,190:203:upper_bound,242:260:cancer	Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease
NCT02488967	1:15:clinical_variable,27:39:lower_bound	Platelet count must be >= 100,000/mm^3
NCT02488967	1:10:pregnancy	Pregnancy or lactation at the time of study entry
NCT02488967	10:17:treatment,23:37:treatment,41:48:treatment,57:67:cancer	Previous therapy with anthracyclines or taxanes for any malignancy
NCT02488967	1:12:chronic_disease,16:35:chronic_disease	Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements
NCT02488967	1:25:treatment	Sentinel lymphadenectomy alone
NCT02488967	28:39:chronic_disease,52:61:treatment,85:95:treatment	Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication
NCT02488967	13:25:chronic_disease	Symptomatic pericarditis
NCT02488967	25:61:cancer	Synchronous or previous contralateral invasive breast cancer
NCT02488967	1:10:cancer,21:47:cancer	T4 tumors including inflammatory breast cancer
NCT02488967	31:38:treatment,43:56:cancer,131:138:lower_bound	The interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 60 days
NCT02488967	42:52:treatment,97:107:treatment	The patient must have undergone either a mastectomy (total, skin-sparing, or nipple-sparing) or lumpectomy
NCT02488967	5:10:cancer,39:67:cancer	The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination
NCT02488967	5:10:cancer	The tumor must have been determined to be estrogen receptor (ER)-and progesterone receptor (PgR)-negative assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
NCT02488967	5:10:cancer,43:90:cancer	The tumor must have been determined to be human epidermal growth factor receptor 2 (HER2)-negative
NCT02488967	1:16:clinical_variable,106:125:clinical_variable,135:144:upper_bound,152:169:chronic_disease	Total bilirubin must be =< upper limit of normal (ULN) for the laboratory (lab) unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin
NCT02488967	1:26:chronic_disease,48:76:clinical_variable,79:87:lower_bound,91:103:clinical_variable,106:113:lower_bound	Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg
NCT02488967	1:17:chronic_disease	Valvular disease with documented compromise in cardiac function
NCT02488967	1:24:chronic_disease,43:77:chronic_disease	Ventricular arrhythmias except for benign premature ventricular contractions
NCT02488967	17:19:upper_bound,20:22:clinical_variable,27:30:clinical_variable,43:46:clinical_variable	patients with < 1% ER and PgR staining by IHC are considered negative
NCT02488967	36:68:cancer,101:110:treatment	patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection
NCT02488967	15:43:cancer,68:106:treatment	patients with microscopic positive margins are eligible as long as post-mastectomy radiation therapy [RT] of the chest wall will be administered
NCT02488967	43:61:cancer,65:69:cancer	patients with synchronous and/or previous contralateral DCIS or LCIS are eligible)
NCT02488967	39:55:cancer	patients with synchronous or previous ipsilateral LCIS are eligible
NCT02488967	1:10:pregnancy,60:65:gender,117:130:upper_bound	pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to randomization
NCT02484937	1:9:lower_bound,13:16:age	18 years of age or older
NCT02484937	10:25:chronic_disease,27:50:chronic_disease	Advanced medical illness (severe systemic disease)
NCT02484937	12:52:chronic_disease,54:82:chronic_disease	History of psychosis or psychiatric hospitalization, suicidal ideation or attempt
NCT02484937	62:70:lower_bound	Non-structural non-specific chronic low back pain of a least 3 months duration
NCT02484937	49:62:chronic_disease,64:80:chronic_disease,85:102:chronic_disease	Significant psychiatric history: a diagnosis of schizophrenia, bipolar disorder, or severe depression
NCT02484287	35:43:pregnancy	Prisoners and/or those who may be pregnant
NCT02481713	1:9:lower_bound	18 years old or older
NCT02481713	11:34:treatment,38:50:upper_bound	change in psychiatric medications in past 30 days
NCT02481713	14:32:chronic_disease	diagnosis of psychotic disorder
NCT02481713	13:37:chronic_disease	evidence of developmental disability
NCT02481713	52:64:upper_bound	meeting criteria for substance abuse/dependence in past 30 days
NCT02481713	1:28:treatment,32:44:upper_bound	psychiatric hospitalization in past 30 days
NCT02481713	8:34:chronic_disease	severe auditory/visual impairment
NCT02481349	1:31:language_fluency	Able to read and speak English
NCT02481349	26:32:cancer,63:70:lower_bound,74:86:treatment,101:103:lower_bound	Diagnosed with a primary glioma and going to receive at least 4 weeks of radiotherapy with at least 20 fractions
NCT02481349	1:35:clinical_variable,39:41:lower_bound	Karnofsky performance status (KPS) of 80 or above
NCT02481349	35:50:clinical_variable,64:72:upper_bound	for phase 1 only, physician-rated life expectancy of less than 6 months
NCT02481349	88:106:treatment	for phase 1 only, regularly (self-defined) participated in a yoga practice in the year prior to diagnosis
NCT02481245	22:33:treatment	Agrees not to change medications during the study
NCT02481245	1:11:chronic_disease	Bipolar II
NCT02481245	1:12:chronic_disease	Bipolar NOS,
NCT02481245	36:50:chronic_disease,69:87:treatment,119:133:lower_bound	Clinical or laboratory evidence of hypothyroidism (if maintained on thyroid medication must be euthyroid for at least 1 month before Visit 1)
NCT02481245	48:69:treatment,79:100:chronic_disease	Conditions which may be negatively affected by bezafibrate treatment, such as hepatobiliary disease
NCT02481245	18:25:treatment,80:88:treatment	Current use of a fibrate or history of anaphylactic reaction or intolerance to fibrates or any component of the preparation
NCT02481245	19:33:treatment,35:42:treatment,48:62:treatment	Current use of of MAO Inhibitors, statins, and anticoagulants
NCT02481245	1:12:chronic_disease	Cyclothymia
NCT02481245	21:44:chronic_disease	DSM IV diagnosis of Bipolar Disorder Type I
NCT02481245	12:38:chronic_disease	History of Type 1 or Type II Diabetes
NCT02481245	24:33:treatment	History of significant treatment non-adherence or situations where the subjects is unlikely to adhere to treatment, in the opinion of the investigator
NCT02481245	12:18:chronic_disease,22:45:chronic_disease	History of stroke or cerebrovascular disease
NCT02481245	30:54:chronic_disease,93:97:clinical_variable,107:118:clinical_variable,123:125:lower_bound	Meets criteria for a current major depressive episode as defined and operationalized by the MINI and by a MADRS score of >18 at screen and baseline (randomization)
NCT02481245	1:4:gender	Men
NCT02481245	1:4:chronic_disease,8:30:chronic_disease	OCD or OCD-spectrum disorders
NCT02481245	20:35:chronic_disease,39:52:chronic_disease	Patients who are a serious suicide or homicide risk
NCT02481245	1:9:pregnancy,10:15:gender	Pregnant women
NCT02481245	22:39:chronic_disease,22:38:chronic_disease,103:112:treatment	Primary diagnosis of anxiety disorders or patients where the anxiety disorder is the primary focus of treatment
NCT02481245	1:25:chronic_disease	Schizoaffective Disorder
NCT02481245	24:27:lower_bound,46:61:treatment	Subjects having failed two or more trials of somatic therapy
NCT02481245	40:65:chronic_disease,76:84:chronic_disease,96:113:chronic_disease,115:130:chronic_disease,139:145:chronic_disease,161:172:chronic_disease	Suspected or known clinically unstable systemic medical disorder including epilepsy, untreated endocrine disease, unstable angina, recent ulcers or significant esophagitis
NCT02481245	45:66:treatment,80:95:lower_bound	Taking an adequate dose of any FDA-approved anti-manic medication for at least two weeks prior to enrollment
NCT02481245	1:5:age,9:11:lower_bound,16:18:upper_bound	ages of 18 and 65
NCT02481245	1:20:chronic_disease	delusional disorder
NCT02481245	1:20:chronic_disease	psychotic disorders not elsewhere classified
NCT02481245	1:14:chronic_disease	schizophrenia
NCT02481245	8:18:chronic_disease,22:53:chronic_disease	severe borderline or antisocial personality disorder
NCT02481245	63:71:upper_bound	substance use disorders, including alcohol, active within the 3 months
NCT02481245	1:6:gender	women
NCT02481245	1:6:gender,42:95:contraception_consent	women of child bearing potential who are not using a medically accepted means of contraception
NCT02474667	1:16:bmi,19:21:upper_bound	Body mass index < 35 based on dry weight
NCT02474667	12:18:chronic_disease,22:48:chronic_disease	Concurrent sepsis or active bacterial infection
NCT02474667	54:74:treatment,78:92:treatment,106:113:upper_bound,117:137:upper_bound	Currently participating in or has participated in an investigational drug or medical device study within 30 days or five drug half-lives, whichever is longer, prior to enrollment into this study
NCT02474667	50:62:upper_bound	Dry weight and height parameters obtained within 7 days prior to study entry may be used
NCT02474667	1:41:clinical_variable,52:60:upper_bound,66:77:clinical_variable,88:96:upper_bound	Estimated donor organ cold ischemia time less than 30 hours (for PMP kidneys less than 40 hours)
NCT02474667	1:7:gender	Female who is breastfeeding
NCT02474667	1:8:gender	Females of childbearing potential
NCT02474667	8:25:cancer,40:45:cancer,47:57:cancer,61:83:cancer,106:111:cancer,115:158:cancer	Has an active malignancy or history of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma in situ of the skin that has been adequately treated
NCT02474667	74:89:treatment,99:114:treatment,142:167:treatment	Has measurable donor-specific antibody or positive cross-match requiring desensitization prior to transplantation or deviation from standard immunosuppressive therapy
NCT02474667	21:49:chronic_disease	History of positive human immunodeficiency virus test
NCT02474667	1:14:gender,20:40:contraception_consent,68:77:pregnancy,97:107:contraception_consent,127:133:lower_bound	Male patients must agree to use condoms or other suitable means of pregnancy prevention such as abstinence during the initial 30-day study period
NCT02474667	1:6:gender,11:18:gender	Males and females
NCT02474667	6:61:contraception_consent,72:90:contraception_consent,111:117:upper_bound	Must agree to use 2 forms of effective birth control regimen (at least one-barrier method) during the initial 30-day study period OR agree to maintain total abstinence throughout the initial 30-day study period
NCT02474667	13:37:pregnancy,43:67:treatment	Must have a negative serum pregnancy test prior to transplantation
NCT02474667	1:27:chronic_disease,39:45:upper_bound,71:83:treatment,87:106:treatment,126:140:lower_bound,144:159:treatment	Oligo-anuric renal failure (less than 200 mL of UO per day) requiring hemodialysis or peritoneal dialysis initiated at least 3 months prior to transplantation
NCT02474667	46:54:upper_bound,55:70:treatment,55:75:treatment,88:98:clinical_variable,112:117:upper_bound,136:155:upper_bound,210:218:treatment,236:242:upper_bound,276:290:treatment	Patient has poor renal function in the first 24 hours post-transplantation based on an average UO of less than 50 mL per hour over any 8 consecutive hours, to maximize the likelihood that the patient requires dialysis within the first 7 days post-transplant, irrespective of pre-transplant donor and recipient risk factors
NCT02474667	43:60:treatment	Patient is to be the recipient of a first kidney transplant from a deceased donor
NCT02474667	34:55:treatment	Patients cannot be given another investigational agent during the course of this study (through Day 360)
NCT02474667	29:53:treatment	Patients may participate in another concurrent study only if that study is a non-interventional, observational investigation
NCT02474667	16:18:clinical_variable	Reason for low UO is not due to structural or vascular abnormalities which, when indicated should be confirmed with a renal ultrasound with Doppler study and/or vascular or urinary tract contrast studies
NCT02474667	36:76:treatment	Recipient of a kidney preserved by normothermic pulsatile machine perfusion
NCT02474667	17:40:treatment	Recipient of an ABO-incompatible kidney
NCT02474667	10:46:treatment,48:61:treatment,69:80:treatment	Requires treatment with the CYP1A2 inhibitors, ciprofloxacin and/or fluvoxamine
NCT02474667	15:45:treatment,49:88:treatment	Scheduled for multiple organ transplantation or prior recipient of a transplanted organ
NCT02474667	23:39:chronic_disease	Signs and symptoms of volume depletion
NCT02474667	1:11:treatment,48:56:upper_bound	Study drug can be administered starting within 30 hours after restoration of blood flow to the engrafted kidney
NCT02474667	26:31:gender,71:77:upper_bound	including perimenopausal women who have had a menstrual period within 1 year
NCT02474667	3:11:lower_bound,15:18:age	≥ 18 years of age
NCT02473354	9:11:lower_bound,16:24:upper_bound,28:31:age	between 18 and 50 years of age
NCT02473354	82:95:upper_bound	currently participating in, or has recently participated in (discontinued within 30 days prior to this study) in an investigational drug study [self-reported]
NCT02473354	1:7:gender,15:55:contraception_consent	female and is unwilling to use effective birth control between the time of screening and study procedure
NCT02473354	5:22:chronic_disease	has Rayanud's disease
NCT02473354	7:10:bmi,19:23:lower_bound,28:32:upper_bound	has a BMI between 18.0 and 30.0 [calculated from measured height & weight]
NCT02473354	7:11:clinical_variable,25:27:lower_bound,32:37:clinical_variable,51:53:lower_bound,67:98:treatment	has a COHb greater than 3%, or MetHb greater than 2% [measured by venous blood sample co-oximetry]
NCT02473354	30:42:chronic_disease	has a clinically significant abnormal EKG [assessment by PI or delegate]
NCT02473354	30:62:treatment,67:77:treatment	has a clinically significant abnormal pulmonary function test via spirometry [assessment by PI or delegate]
NCT02473354	18:37:chronic_disease	has a history of sickle cell disease [self-reported]
NCT02473354	33:42:allergy_name,46:74:allergy_name	has a prior or known allergy to lidocaine or similar pharmacologic agents
NCT02473354	5:11:chronic_disease	has anemia [measured by venous blood gas sample]
NCT02473354	101:113:treatment	has completed the appropriate fasting periods for solids and liquids prior to the administration of remifentanil
NCT02473354	53:59:lower_bound,82:95:lower_bound	has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure [self-reported]
NCT02473354	10:24:clinical_variable,35:38:upper_bound	has room air saturation less than 95% by pulse oximetry [measurement by PI or delegate]
NCT02473354	4:52:clinical_variable	is American Society Anesthesiologist (ASA) status 1 [assessment by PI or delegate]
NCT02473354	4:10:gender,18:36:pregnancy	is female with a positive pregnancy test [serum or urine]
NCT02473354	1:48:contraception_consent	unwilling or unable to provide informed consent or comply with the study procedures
NCT02473354	21:33:lower_bound	weighs greater than 40 kilograms
NCT02472834	8:20:cancer,70:91:chronic_disease	Active malignancies or other serious concurrent or recent medical or psychiatric condition which, in the opinion of the Investigator, makes the patient unsuitable for participation in this study
NCT02472834	1:22:bmi,24:26:upper_bound,31:33:lower_bound	Body Mass Index (BMI) <18 or >30
NCT02472834	1:29:clinical_variable,32:44:lower_bound	Carbamylated albumin (C-Alb) > 7.7 mmol/mol
NCT02472834	16:25:clinical_variable,27:33:upper_bound	Condition with prognosis <1 year at time of study entry
NCT02472834	9:25:treatment,37:58:treatment,116:129:upper_bound	Current active treatment in another investigational study or participation in another investigational study in the 1 month prior to screening
NCT02472834	1:9:treatment,31:36:clinical_variable,39:42:lower_bound	Dialysis adequacy recorded as Kt/ V > 1.2
NCT02472834	1:4:chronic_disease	HIV positive
NCT02472834	27:37:allergy_name	History of allergy to any amino acid compound
NCT02472834	4:31:treatment,15:23:treatment,45:59:lower_bound,149:153:chronic_disease	On stable hemodialysis therapy for at least 90 days before the study entry, defined as receiving thrice weekly dialysis and carrying a diagnosis of ESRD
NCT02472834	11:26:treatment,34:53:upper_bound,117:128:treatment	On stable medical therapy in the last 30 days before the study entry, defined as no change, addition, or removal of medications
NCT02472834	19:31:chronic_disease,33:56:clinical_variable,59:67:lower_bound,75:99:clinical_variable,102:110:lower_bound,129:157:treatment	Poorly controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg during any of the previous 3 dialysis sessions (confirmed by repeat)
NCT02472834	14:32:treatment	Prescribed a dialysis treatment time of 4 hours per session
NCT02472834	13:19:chronic_disease	Presence of asthma
NCT02472834	10:30:treatment,38:50:upper_bound	Received parenteral nutrition within last 90 days
NCT02472834	1:14:clinical_variable,17:34:lower_bound	Serum albumin ≥ 3.0 g/dL (30 g/L)
NCT02472834	8:26:chronic_disease	Severe hepatic impairment
NCT02472834	20:46:treatment,58:70:upper_bound	Taking any type of amino acid supplementation within the last 90 days
NCT02472834	90:108:treatment	Willing and able to adhere to all study-related procedures, including adherence to study medication regimen
NCT02472834	1:6:gender,41:81:contraception_consent,107:130:treatment	Women of childbearing potential must be practicing barrier or oral contraception, for the duration of the study-related treatment, or be documented as surgically sterile or one year post-menopausal
NCT02472834	2:10:lower_bound	≥18 years old
NCT02469389	34:47:chronic_disease,51:75:chronic_disease	5th edition (DSM 5) diagnosis of schizophrenia or schizoaffective disorder
NCT02469389	49:50:lower_bound,67:68:lower_bound,69:70:upper_bound	A minimum average rating of a moderate deficit (3 or greater on a 0-4 scale) on any symptom domain within the affect motivation factor of the Clinical Assessment Interview for Negative Symptoms (CAINS)
NCT02469389	1:4:age,13:15:lower_bound,20:28:upper_bound	Age between 18 and 75 years
NCT02469389	1:21:chronic_disease	Cognitive impairment
NCT02469389	31:52:chronic_disease	Documented history of serious neurological disorder
NCT02469389	1:10:chronic_disease	anhedonia
NCT02469389	1:10:chronic_disease	avolition
NCT02469389	14:28:clinical_variable,39:41:upper_bound	defined as a total IQ score less than 70 as measured by the Wechsler Test of Adult Reading or as indicated by chart review
NCT02469389	1:12:chronic_disease	head trauma with loss of consciousness
NCT02469389	13:23:chronic_disease	symptoms of asociality
NCT02468778	8:26:chronic_disease,37:46:treatment,52:63:treatment	Active systemic infection requiring treatment with antibiotics
NCT02468778	31:36:allergy_name,41:64:allergy_name,66:80:allergy_name,85:111:allergy_name	Any allergy or intolerance to ionic and nonionic contrast media, anticoagulants, or antiplatelet therapy drugs that cannot be adequately premedicated
NCT02468778	5:37:treatment,49:62:upper_bound	Any prior coronary revascularization within the last 6 months
NCT02468778	10:18:lower_bound,22:25:age	At least 18 years of age
NCT02468778	1:15:chronic_disease,23:31:upper_bound,55:90:treatment,94:108:treatment	Cardiac arrest within 24 hours of procedure requiring cardiopulmonary resuscitation (CPR) or defibrillation
NCT02468778	1:18:chronic_disease,20:23:clinical_variable,25:32:upper_bound,38:44:lower_bound,111:124:clinical_variable,126:138:upper_bound	Cardiogenic shock (SBP <90 mmHg for >1 hour with either cool clammy skin OR oliguria OR altered sensorium AND cardiac index <2.2 L/min/m2)
NCT02468778	24:39:chronic_disease,41:53:clinical_variable,57:63:upper_bound	Documented presence of aortic stenosis (orifice area of 1.5cm2 or less)
NCT02468778	11:14:treatment	Emergency PCI
NCT02468778	1:52:treatment	Hemodynamic support with the HeartMate PHP post-PCI is anticipated
NCT02468778	26:28:chronic_disease,43:60:clinical_variable,62:90:clinical_variable,94:102:clinical_variable,104:105:lower_bound,104:134:lower_bound,178:182:treatment,249:256:lower_bound	Hemodynamically unstable MI with elevated cardiac biomarker (creatinine kinase-MB (CK-MB) or troponin >1X upper limit of normal (ULN)) and no evidence of at least 1 consecutive CKMB or troponin value trending downward from previous value (at least 4 hours apart)
NCT02468778	12:36:treatment,40:46:treatment	History of aortic valve replacement or repair
NCT02468778	54:61:treatment,73:82:chronic_disease	Known abnormalities of the aorta that would preclude surgery, including aneurysms and significant tortuosity or calcifications
NCT02468778	1:18:chronic_disease,37:50:clinical_variable,55:71:clinical_variable,77:83:lower_bound,87:127:clinical_variable,129:130:lower_bound,134:161:clinical_variable,164:172:lower_bound	Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3X ULN or Internationalized Normalized Ratio (INR) ≥2 or lactate dehydrogenase (LDH) > 2.5X ULN
NCT02468778	20:40:chronic_disease,44:61:treatment	Moderate to severe aortic insufficiency by echocardiographic assessment
NCT02468778	1:37:chronic_disease	Mural thrombus in the left ventricle
NCT02468778	18:77:treatment	Participation in another clinical study of an investigational drug or device that has not met its primary endpoint
NCT02468778	23:31:treatment,35:65:treatment	Patient is undergoing elective or urgent high risk PCI procedure and is hemodynamically stable
NCT02468778	1:24:clinical_variable,32:46:upper_bound,97:114:clinical_variable	ST Elevation MI (STEMI) within 72 hours prior to the index procedure regardless of the level of cardiac biomarker
NCT02468778	8:35:chronic_disease,68:85:treatment,130:152:treatment	Severe peripheral vascular disease that will preclude the use of a 14F access sheath, which is required for the insertion of the HeartMate PHP catheter
NCT02468778	8:11:treatment,30:37:upper_bound	Staged PCI is planned within 90 days following device removal
NCT02468778	1:7:chronic_disease,11:42:chronic_disease,50:58:upper_bound	Stroke or transient ischemic attack (TIA) within 6 months of procedure
NCT02468778	15:27:treatment	Subject is on hemodialysis
NCT02468778	12:20:pregnancy,28:42:gender,72:81:pregnancy,112:119:upper_bound	Subject is pregnant (For a female subject of childbearing potential, a pregnancy test must be performed within 14 days (≤14 days) prior to the index procedure per site standard test)
NCT02468778	25:54:chronic_disease,61:84:chronic_disease,130:149:chronic_disease	The presence of complex coronary artery disease (CAD) makes hemodynamic instability resulting from repeat episodes of reversible myocardial ischemia during PCI likely
NCT02468778	48:62:clinical_variable,64:73:upper_bound,77:80:clinical_variable,89:99:clinical_variable,101:108:upper_bound	Uncorrectable abnormal coagulation parameters (platelet count ≤75000/mm3 or INR ≥2.0 or fibrinogen ≤1.5 g/l)
NCT02468778	20:48:chronic_disease	intervention of an unprotected left main artery
NCT02466009	1:26:clinical_variable,29:34:lower_bound	Absolute neutrophil count ≥ 1,500
NCT02466009	34:49:chronic_disease	Active or clinically significant cardiac disease
NCT02466009	1:4:age,9:11:lower_bound	Age +/> 70
NCT02466009	1:53:clinical_variable,56:83:upper_bound	Alanine aminotransferase & Asparate aminotransferase ≤ 2.5 x upper limit or normal
NCT02466009	5:15:clinical_variable,19:33:clinical_variable,36:43:lower_bound,51:58:upper_bound	Any hemorrhage or bleeding event ≥ grade 3 within 4 weeks
NCT02466009	5:18:chronic_disease	Any malabsorption condition
NCT02466009	21:43:treatment,48:76:cancer	Currently receiving other systemic therapy for metastatic colorectal cancer
NCT02466009	1:12:clinical_variable,15:22:lower_bound	Dehydration ≥ grade 1
NCT02466009	24:42:chronic_disease,46:58:chronic_disease	Evidence or history of bleeding diathesis or coagulopathy
NCT02466009	1:27:clinical_variable,30:39:lower_bound	Glomerular filtration rate ≥ 60 ml/min
NCT02466009	26:51:cancer	Histologically confirmed colorectal adenocarcinoma
NCT02466009	12:27:treatment,38:56:treatment	History of organ allograft including corneal transplant
NCT02466009	25:35:cancer,43:55:upper_bound	History of other active malignancy within past 2 years
NCT02466009	1:31:clinical_variable,32:48:clinical_variable,51:78:upper_bound	International normalized ratio/prothrombin time ≤ 1.5 x upper limit or normal
NCT02466009	18:56:chronic_disease,83:109:chronic_disease	Known history of human immunodeficiency virus infection or current chronic/active hepatitis B or C infection
NCT02466009	55:65:allergy_name	Known or suspected allergy or hypersensitivity to the study drug
NCT02466009	1:16:clinical_variable,21:29:lower_bound	Life expectancy >/= 12 weeks
NCT02466009	12:30:chronic_disease	Measurable metastatic disease
NCT02466009	36:52:treatment	Must be able to swallow and retain oral medications
NCT02466009	9:18:clinical_variable,21:28:lower_bound	Ongoing infection > grade 2
NCT02466009	15:32:cancer	Patients with phaeochromocytoma
NCT02466009	15:31:chronic_disease,42:52:treatment	Patients with seizure disorder requiring medication
NCT02466009	1:23:clinical_variable,26:33:lower_bound,34:59:chronic_disease	Persistent proteinuria ≥ grade 3 Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
NCT02466009	1:15:clinical_variable,18:25:lower_bound,27:37:clinical_variable,40:46:lower_bound	Platelet count ≥ 100,000, hemoglobin ≥ 9 g/dL
NCT02466009	1:17:chronic_disease,21:28:chronic_disease,65:80:chronic_disease	Pleural effusion or ascites that causes respiratory compromise, grade 2 dyspnea
NCT02466009	13:30:chronic_disease,32:49:chronic_disease	Presence of non-healing wound, non-healing ulcer, or bone fracture
NCT02466009	24:33:treatment	Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study
NCT02466009	16:32:treatment,62:74:treatment	Progression on standard therapy, not a candidate for further chemotherapy or patient declines other options
NCT02466009	1:14:chronic_disease,25:29:treatment,34:53:treatment	Renal failure requiring hemo- or peritoneal dialysis
NCT02466009	1:17:clinical_variable,20:47:upper_bound	Serum creatinine ≤ 1.5 x upper limit or normal
NCT02466009	41:76:contraception_consent,139:153:lower_bound,171:181:treatment	Subjects of childbearing potential must agree to use adequate contraception beginning at the signing informed consent form until at least 3 months after the last dose of study drug
NCT02466009	72:96:chronic_disease,98:118:chronic_disease,122:139:chronic_disease,147:155:upper_bound	Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, deep vein thrombosis or pulmonary embolus within 6 months of informed consent
NCT02466009	27:40:chronic_disease	Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study
NCT02466009	1:29:cancer,33:49:cancer	Symptomatic metastatic brain or meningeal tumors
NCT02466009	1:11:clinical_variable,14:41:upper_bound	Total bili ≤ 1.5 x upper limit or normal
NCT02466009	1:26:chronic_disease,35:61:treatment	Uncontrolled hypertension despite optimal medical management
NCT02464696	3:10:lower_bound,11:28:clinical_variable,34:42:lower_bound,43:53:clinical_variable	> 20cc/hr sputum production or > 100 cc's hemoptysis/24 hrs
NCT02464696	8:27:chronic_disease,35:47:chronic_disease,51:70:chronic_disease	Active myocardial ischemia (acute ST elevation or non ST elevation MI
NCT02464696	1:4:age,9:17:lower_bound	Age >/= 18 years old
NCT02464696	1:7:chronic_disease,11:24:chronic_disease	Airway or facial trauma that would hinder the use of a NIPPV mask
NCT02464696	1:20:chronic_disease	Atrial fibrillation with rapid ventricular response
NCT02464696	1:17:treatment,21:28:treatment,40:54:upper_bound,85:92:cancer,96:130:cancer,134:147:cancer,174:199:chronic_disease	Chest radiograph or CT scan within </= 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency
NCT02464696	22:40:chronic_disease	Clinical evidence of left heart failure as the main etiology for respiratory compromise
NCT02464696	22:35:treatment	Contraindications to NIPPV therapy
NCT02464696	20:68:cancer,130:155:chronic_disease	Evidence of active intrathoracic malignancy (primary or metastatic) in the lungs or pleural space that is a significant cause of respiratory insufficiency
NCT02464696	1:4:clinical_variable,7:8:upper_bound	GCS < 8 or inadequate airway protective reflexes
NCT02464696	1:3:clinical_variable,6:13:lower_bound	HR > 120 bpm
NCT02464696	18:28:cancer	Have a diagnosed malignancy
NCT02464696	29:34:treatment	Inability to cooperate with NIPPV
NCT02464696	10:29:chronic_disease	Oliguric acute renal failure
NCT02464696	1:5:clinical_variable,6:10:clinical_variable,6:16:clinical_variable,21:29:upper_bound,35:39:clinical_variable,49:52:upper_bound	PaO2:FiO2 ratio </= 300 mmHg OR a SpO2:FiO2 </= 357
NCT02464696	20:25:treatment	Patient already on NIPPV at the time of screening
NCT02464696	15:61:chronic_disease	Patients with acute chronic obstructive disease exacerbation as the primary etiology for respiratory failure
NCT02464696	16:24:clinical_variable,37:45:lower_bound	Probability of survival is at least 6 months
NCT02464696	1:44:treatment,53:60:upper_bound	Recent esophageal, gastric or bowel surgery (within 3 weeks of study enrollment)
NCT02464696	20:25:treatment	Refusal to receive NIPPV
NCT02464696	1:19:chronic_disease	Respiratory arrest
NCT02464696	10:28:treatment,34:39:chronic_disease,41:51:chronic_disease,55:72:chronic_disease	Risk for gastric aspiration (ie; ileus, esophageal or bowel obstruction, active vomiting)
NCT02464696	1:6:chronic_disease	Shock
NCT02464696	1:29:chronic_disease	Supraventricular tachycardia
NCT02464696	1:25:chronic_disease	Third degree heart block
NCT02464696	14:19:chronic_disease,23:38:chronic_disease,49:68:chronic_disease	Uncontrolled tachy or bradyarrhythmia or active myocardial ischemia
NCT02464696	11:23:chronic_disease,24:41:chronic_disease	Undrained pneumothorax/pneumomediastinum
NCT02464696	1:24:chronic_disease,28:64:chronic_disease	Ventricular tachycardia or nonsustained ventricular tachycardia
NCT02464696	5:15:clinical_variable,26:32:upper_bound	any heart rate less than 40 bpm
NCT02464696	10:29:treatment,39:41:upper_bound	need for vasopressor therapy or MAP < 60 despite fluid administration
NCT02464696	1:3:clinical_variable,5:9:upper_bound,13:17:clinical_variable,19:21:lower_bound	pH <7.30 or pCO2 >50 (if available)
NCT02464696	1:13:clinical_variable,16:26:upper_bound	urine output < 500 ml/day
NCT02459769	4:12:lower_bound,16:19:age	Be 21 years of age or older
NCT02459769	12:24:language_fluency	Be able to read English
NCT02459769	62:68:cancer	For caregivers, be currently undergoing active treatment for cancer
NCT02459769	25:31:cancer	Have had a diagnosis of cancer
NCT02459769	1:7:cancer	cancer survivors
NCT02459769	11:29:treatment	continued adjuvant treatment
NCT02459769	16:31:treatment,33:45:treatment,54:63:treatment	have completed primary surgery, chemotherapy, and/or radiation
NCT02459769	1:9:cancer,14:39:cancer	squamous and basal cell [skin cancers]
NCT02459769	1:12:gender	transgender
NCT02452645	1:45:language_fluency	ability to read and speak English or Spanish
NCT02452645	41:48:lower_bound	child care will be closed for more than 1 month at a time in the forthcoming year
NCT02452645	43:47:age,51:52:lower_bound,57:64:upper_bound	has no children in their care between the ages of 2 and 5 years old
NCT02452645	1:21:technology_access	have a working phone
NCT02452645	15:16:lower_bound	have at least 1 children in their care
NCT02452645	15:25:technology_access,29:70:technology_access	have either a DVD player or internet access through computer or phone
NCT02452645	18:19:lower_bound	provide at least 2 meals/snacks to the children
NCT02452645	7:15:lower_bound,19:22:age	under 18 years of age
NCT02452268	1:8:clinical_variable,10:19:upper_bound	AST/ALT ≤2.5 × ULN
NCT02452268	1:4:age,6:14:lower_bound	Age ≥18 years
NCT02452268	12:30:treatment,48:70:treatment	Concurrent anticancer therapy (including other investigational agents)
NCT02452268	1:8:clinical_variable,13:17:clinical_variable,20:23:lower_bound	DLCO/VA and FEV1 ≥ 50% of predicted on PFTs
NCT02452268	1:24:clinical_variable,26:27:upper_bound,29:38:clinical_variable,40:43:lower_bound	ECOG performance status ≤1 (Karnofsky ≥70%)
NCT02452268	14:32:chronic_disease	Evaluable or measurable disease, defined as by Response Evaluation Criteria in Solid Tumors (RECIST)
NCT02452268	1:4:chronic_disease	HIV positive patients
NCT02452268	26:37:cancer,38:48:cancer,57:67:cancer,116:123:lower_bound,124:131:treatment	Histologically confirmed solid tumor malignancy that is metastatic or unresectable and have progressed on at least 1 prior therapy and for whom standard curative or palliative measures do not exist or are associated with minimal subject survival benefit
NCT02452268	45:110:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to hetIL-15
NCT02452268	12:30:chronic_disease	History of autoimmune disease
NCT02452268	19:25:chronic_disease,70:96:treatment	History of severe asthma or absolute requirement for chronic inhaled corticosteroid medications
NCT02452268	1:16:clinical_variable,19:27:lower_bound	Life expectancy > 3 months
NCT02452268	10:21:chronic_disease,25:26:chronic_disease	Positive hepatitis B or C serology
NCT02452268	9:22:cancer,33:47:cancer	Primary brain cancers or active CNS metastases
NCT02452268	1:22:treatment,26:43:treatment,45:58:treatment,60:72:treatment,74:87:treatment,89:107:treatment,111:132:treatment,140:153:upper_bound,191:202:treatment,206:220:treatment,224:236:treatment,240:251:treatment,256:269:upper_bound	Prior IL-15 treatment or cytotoxic therapy, immunotherapy, radiotherapy, major surgery, antitumor vaccines or monoclonal antibodies in the 4 weeks prior or for checkpoint inhibitors such as anti-CTLA-4 or anti PD1/PD-L1 or nitrosoureas or mitomycin C for 6 weeks prior to C1D1
NCT02452268	16:23:upper_bound,24:33:clinical_variable,63:81:treatment,85:101:treatment,125:132:lower_bound	Recovered to ≤ grade 1 NCI CTCAE version 4.0 from toxicity of prior chemotherapy or biologic therapy administered more than 4 weeks earlier
NCT02452268	13:28:treatment,37:43:cancer,50:65:treatment,58:65:treatment,70:85:cancer	Subjects on bisphosphonates for any cancer or on hormone therapy for prostate cancer may continue this therapy
NCT02452268	24:63:cancer	Subjects with inactive central nervous system (CNS) metastasis
NCT02452268	77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,179:199:chronic_disease,228:247:chronic_disease,325:334:treatment	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, cognitive impairment, active substance abuse, or psychiatric illness/social situations that, in the view of the Investigator, would preclude safe treatment or the ability to give informed consent and limit compliance with study requirements
NCT02452268	1:6:gender,3:6:gender,47:82:contraception_consent,116:125:treatment,155:169:upper_bound	Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during the treatment portion of the study and for 4 months after completion of hetIL-15 administration
NCT02452268	1:32:clinical_variable,34:43:lower_bound	absolute neutrophil count (ANC) ≥1,500/mcL
NCT02452268	34:72:treatment,121:134:lower_bound	autoimmune event associated with prior ipilimumab (anti-CTLA-4) therapy that has been completely resolved for more than 4 weeks prior to C1D1
NCT02452268	1:11:clinical_variable,13:36:upper_bound	creatinine <1.5 × institutional ULN
NCT02452268	1:21:clinical_variable,23:40:lower_bound,59:82:clinical_variable,84:105:lower_bound	creatinine clearance ≥60 mL/min/1.73 m2 for subjects with serum creatinine levels >1.5 × higher than ULN
NCT02452268	1:16:treatment,21:36:cancer	hormone therapy for prostate cancer
NCT02452268	1:11:clinical_variable,13:22:lower_bound	leukocytes ≥3,000/mcL
NCT02452268	1:10:clinical_variable,12:23:lower_bound	platelets ≥100,000/mcL
NCT02452268	1:16:clinical_variable	total bilirubin within normal institutional limits
NCT02452203	18:29:treatment,74:92:treatment,100:115:treatment,117:124:treatment,126:165:treatment,167:184:treatment,186:198:treatment,200:204:treatment,206:209:treatment,211:221:treatment,223:229:treatment,231:244:treatment,246:254:treatment	Certain drugs or medications consumed within the past week including any psychoactive drugs (e.g., benzodiazepines, opiates, selective serotonin reuptake inhibitors, dopamine agonists, barbiturates, MDMA, LSD, psilocybin, peyote, phencyclidine, ketamine)
NCT02452203	1:4:treatment,34:51:treatment,53:97:treatment,99:120:treatment,122:132:treatment,134:171:treatment,173:184:treatment,186:209:treatment,211:240:treatment,242:252:treatment,254:285:treatment,290:323:treatment,399:410:treatment,529:531:lower_bound,532:543:upper_bound,545:563:treatment,653:662:pregnancy	MRI contraindications including: cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/ wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a professional metal worker/welder, history of eye surgery/eyes washed out because of metal, vision problems uncorrectable with lenses, inability to lie still on one's back for 60-120 minutes; prior neurosurgery; tattoos or cosmetic makeup with metal dyes, unwillingness to remove body piercings, and pregnancy
NCT02452203	30:47:chronic_disease	Participant endorses current suicidal ideation with intent or plan
NCT02452203	39:44:chronic_disease,48:67:chronic_disease,69:77:chronic_disease,79:87:chronic_disease,114:121:chronic_disease,123:131:chronic_disease,133:142:chronic_disease,144:160:chronic_disease,162:171:chronic_disease,173:183:chronic_disease,185:196:chronic_disease,198:211:chronic_disease,216:237:chronic_disease	Participant has a history of unstable liver or renal insufficiency; glaucoma; diabetes; significant and unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbance; or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments
NCT02452203	16:30:chronic_disease,32:35:bmi,38:40:lower_bound	Participant is morbidly obese (BMI > 40)
NCT02452203	34:54:chronic_disease	Participant meets criteria for a DSM5 Axis-1 disorder
NCT02452203	1:10:pregnancy	Pregnancy as detected by a urine test
NCT02452203	64:115:language_fluency	They must be able to provide written informed consent and must have sufficient proficiency in the English language to understand and complete interviews, questionnaires, and all other study procedures
NCT02452203	9:11:lower_bound,12:20:upper_bound,24:27:age	between 18-55 years of age
NCT02452203	29:64:chronic_disease	free of any current or past neurological or psychiatric illness, and capable of performing all tasks during each session of the experiment
NCT02452203	118:125:lower_bound	we require the participant to be stably medicated prior to participation (defined as having taken the medication for 6 weeks or longer)
NCT02442297	1:4:age,7:14:lower_bound	Age ≥ 3 years
NCT02442297	11:46:clinical_variable,77:80:lower_bound,95:99:clinical_variable,195:198:lower_bound,202:220:treatment	Available autologous transduced T lymphocytes with greater than or equal to 15% expression of HER2 CAR determined by flow-cytometry and killing of HER2-positive targets greater than or equal to 20% in cytotoxicity assay
NCT02442297	1:10:clinical_variable,33:42:upper_bound,44:47:clinical_variable,70:72:upper_bound,70:79:upper_bound,81:84:clinical_variable,111:127:clinical_variable,150:174:upper_bound,179:182:age,188:191:clinical_variable,217:220:upper_bound	Bilirubin less than or equal to 3x normal, AST less than or equal to 5x normal, ALT less than or equal to 5x, serum creatinine less than or equal to 2x upper limit of normal for age, and Hgb greater than or equal to 7.0
NCT02442297	1:14:treatment,37:49:upper_bound	Dexamethasone up to a total dose of 2 mg per day will be allowed if medically indicated
NCT02442297	14:18:cancer	Diagnosis of DIPG
NCT02442297	20:26:cancer,30:33:clinical_variable,69:76:lower_bound,75:76:lower_bound,109:124:clinical_variable	HER2 expression in tumors on IHC should be greater than or equal to grade 1 and greater than or equal to 1+ intensity score
NCT02442297	42:76:allergy_name	History of hypersensitivity reactions to murine protein-containing products
NCT02442297	1:27:treatment,31:37:treatment	Immunohistochemistry (IHC) or RT-PCR will be used to determine HER2 positivity. Results will be compared to standard controls
NCT02442297	1:10:clinical_variable,11:23:clinical_variable,52:54:lower_bound	Karnofsky/Lansky score of greater than or equal to 60
NCT02442297	1:23:clinical_variable,26:28:lower_bound	Karnofsky/Lansky score ≥ 60
NCT02442297	7:10:chronic_disease	Known HIV positivity
NCT02442297	1:16:clinical_variable,19:26:lower_bound	Life expectancy ≥ 6 weeks
NCT02442297	1:9:pregnancy	Pregnant or lactating
NCT02442297	1:15:clinical_variable,44:47:lower_bound	Pulse oximetry of greater than or equal to 90% on room air
NCT02442297	25:81:cancer,71:74:cancer,85:115:cancer	Recurrent or refractory HER2 positive primary central nervous system (CNS) tumor or HER2 positive tumor metastatic to the CNS
NCT02442297	25:38:cancer	Recurrent or refractory HER2-positive
NCT02442297	8:30:chronic_disease	Severe intercurrent infection
NCT02442297	53:56:lower_bound,124:139:treatment	Sexually active subjects must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusion
NCT02442297	17:30:treatment,44:48:lower_bound	Steroid dose of dexamethasone greater than 2 mg per day (or equivalent)
NCT02442297	19:34:treatment	Subjects having a tumor resection if medically feasible
NCT02442297	53:75:treatment,80:95:upper_bound	Subjects should have been off other investigational antineoplastic therapy for two weeks prior to entry in this study
NCT02442297	1:13:treatment,36:44:upper_bound	Temozolomide will be allowed up to 48 hours preinfusion
NCT02442297	5:9:gender	The male partner should use a condom
NCT02442297	60:61:lower_bound,65:68:upper_bound,79:81:lower_bound,82:85:upper_bound,99:101:lower_bound,102:106:upper_bound,128:132:cancer,189:218:treatment	Wherein grades are defines as: Grade 0: no staining; Grade 1: 1-25%; Grade 2: 26-50% and Grade 3: 51-100% of cell staining for HER2 and intensity scores are: negative; 1+; 2+ and 3+ using breast cancer standard arrays as a guide for intensity
NCT02442297	1:18:cancer,22:58:cancer	primary CNS tumor or HER2-positive solid tumor metastatic to the CNS
NCT02441062	3:21:pregnancy,52:67:gender	A negative pregnancy test will be required for all female subjects with child bearing potential
NCT02441062	1:4:age,7:15:lower_bound	Age ≥ 6 months
NCT02441062	16:33:chronic_disease,43:63:chronic_disease	Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
NCT02441062	1:7:gender	Female must also be non-lactating
NCT02441062	26:46:cancer,41:46:cancer	Histologically diagnosed neuroendocrine tumor or other tumor with probable somatostatin receptors subtype 2
NCT02441062	12:21:pregnancy,148:165:pregnancy	If a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is not capable of becoming pregnant
NCT02441062	121:135:chronic_disease,137:153:chronic_disease	Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
NCT02441062	74:83:chronic_disease	Inability to lie still for the entire imaging time (due to cough, severe arthritis, etc.)
NCT02441062	1:29:clinical_variable,33:57:clinical_variable,63:65:lower_bound	Karnofsky performance status or Lansky Play Scale status of ≥ 60 (or ECOG/WHO equivalent)
NCT02441062	1:21:treatment,29:36:upper_bound,40:60:treatment	Lanreotide injection within 8 weeks of Ga-68 DOTATOC PET/CT (+/-5%)
NCT02441062	1:45:treatment,53:60:upper_bound,78:81:treatment,82:89:treatment	Peptide receptor radionuclide therapy (PRRT) within 4 weeks of Ga-68 DOTATOC PET/CT scan
NCT02441062	1:13:clinical_variable,22:30:upper_bound	SQ Octreotide within 12 hours
NCT02441062	12:16:gender	Subject is male
NCT02441062	9:15:clinical_variable,26:36:lower_bound	Subject weighs more than 450 pounds
NCT02441062	14:19:clinical_variable,30:40:lower_bound	Subjects who weigh more than 450 pounds will not be able to fit inside the imaging machines
NCT02441062	1:31:treatment,39:46:upper_bound	Treatment with Sandostatin LAR within 4 weeks
NCT02441062	1:7:gender,73:85:treatment,104:116:treatment	female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy)
NCT02441062	19:26:lower_bound	postmenopausal (> 1 years without menses)
NCT02441062	2:10:lower_bound,55:64:pregnancy,103:126:treatment	≥60 years old,or of childbearing potential for whom a pregnancy test (with the results known prior to investigational product administration) is negative
NCT02434809	14:61:treatment,99:111:upper_bound	Able to have bronchoscopic placement of Calypso transponders as confirmed on a recent (within the past 8 weeks) CT scan
NCT02434809	35:45:treatment,47:61:treatment,67:86:treatment,112:136:treatment	Active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown
NCT02434809	1:4:age,7:19:lower_bound	Age ≥ 18 years old
NCT02434809	22:27:cancer,84:86:treatment	At least part of the tumor must be visible as observed in a diagnostic or planning CT
NCT02434809	1:15:chronic_disease	Bronchiectasis in the region of the intended implantation
NCT02434809	45:66:treatment	Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines
NCT02434809	1:7:gender,21:33:pregnancy	Female patients who are pregnant
NCT02434809	21:31:cancer,45:71:treatment	Histologic proof of malignancy suitable for thoracic radiation therapy
NCT02434809	32:38:allergy_name	History of hypersensitivity to nickel
NCT02434809	43:52:treatment	Implantation of transponders will degrade MR images
NCT02434809	1:29:clinical_variable,32:35:lower_bound	Karnofsky Performance Status ≥ 60%
NCT02434809	32:49:treatment	Patient is planning to undergo radiation therapy for primary
NCT02434809	16:27:cancer	Patients whose lung tumors are being monitored by MR imaging as part of standard clinical care
NCT02434809	38:55:chronic_disease	Patients with clinically significant active infections
NCT02434809	34:39:lower_bound	Posterior lesions that would be >19 cm distance from Calypso detector plate
NCT02434809	20:30:treatment,34:42:treatment	Unable to tolerate anesthesia or sedation
NCT02434809	11:35:cancer,39:74:cancer	recurrent malignancies of the lung or metastatic malignancies to the lung
NCT02433626	1:32:clinical_variable,34:45:lower_bound	Absolute neutrophil count (ANC) ≥1.5 x 109/L
NCT02433626	1:7:chronic_disease,9:31:chronic_disease,33:38:chronic_disease,40:46:chronic_disease,57:80:chronic_disease,91:107:treatment	Active, uncontrolled bacterial, viral, fungal, or other opportunistic infection requiring systemic therapy
NCT02433626	1:27:clinical_variable,32:60:clinical_variable,68:94:upper_bound	Alanine transaminase (ALT) and aspartate transaminase (AST) within 1.5x upper limit of normal
NCT02433626	1:16:chronic_disease	Angina pectoris
NCT02433626	51:62:chronic_disease,97:115:chronic_disease,154:165:chronic_disease,169:187:chronic_disease	Any serious and/or unstable pre-existing medical, psychiatric, or other condition (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
NCT02433626	1:32:clinical_variable,34:43:lower_bound	Calculated creatinine clearance >50 mL/min
NCT02433626	1:7:cancer,27:37:cancer	Cancer that is recurrent, metastatic, or unresectable and for which no effective or curative measures exist
NCT02433626	1:25:chronic_disease,29:62:clinical_variable,70:71:lower_bound	Congestive heart failure of New York Heart Association (NYHA) Grade >2
NCT02433626	1:62:clinical_variable,63:64:lower_bound,68:69:upper_bound	European Cooperative Oncology Group (ECOG) performance status 0 or 1
NCT02433626	1:4:chronic_disease,26:31:cancer	HPV-positive status ( In HNSCC patients only)
NCT02433626	1:11:clinical_variable,13:21:lower_bound	Hemoglobin ≥9.0 g/dL
NCT02433626	51:66:chronic_disease	History of clinically significant or uncontrolled cardiac disease
NCT02433626	1:19:treatment,54:67:lower_bound,99:105:cancer	Hormone treatments must be discontinued for at least 28 days prior to the first administration of COTI-2
NCT02433626	23:39:treatment	Inability to tolerate oral medications
NCT02433626	1:42:clinical_variable,44:47:lower_bound,115:119:treatment	Left ventricular ejection fraction (LVEF) ≥55% (or the institutional lower limit of normal [LLN]) as evidenced on ECHO
NCT02433626	1:16:clinical_variable,18:26:lower_bound	Life expectancy ≥3 months
NCT02433626	1:14:treatment,26:101:treatment,110:123:upper_bound,140:146:treatment	Major surgery, excluding skin biopsies and procedures for insertion of central venous access devices, within 28 days prior to the start of COTI-2
NCT02433626	1:22:chronic_disease	Myocardial infarction
NCT02433626	9:16:cancer,18:32:cancer,34:52:cancer,54:65:cancer,70:85:cancer	Part 1: Ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer
NCT02433626	9:14:cancer	Part 2: HNSCC, with confirmed p53 mutations
NCT02433626	9:35:cancer,37:42:cancer,44:54:cancer,56:60:cancer,62:79:cancer,90:96:cancer	Part 3: Gynecological malignancies, HNSCC, colorectal, lung, pancreatic cancer, or other tumors with Sponsor approval
NCT02433626	1:34:clinical_variable,42:68:upper_bound	Partial thromboplastin time (PTT) within 1.5x upper limit of normal
NCT02433626	90:98:treatment	Patients enrolled in the expansion phase must be willing to undergo pre and post-Cycle 1 biopsies
NCT02433626	30:47:pregnancy,68:86:pregnancy,96:131:contraception_consent,139:157:contraception_consent,159:180:contraception_consent,182:202:contraception_consent,204:232:contraception_consent	Physiologically incapable of becoming pregnant, postmenopausal, or negative pregnancy test and agree to use adequate contraception (e.g., oral contraceptive, double barrier method, intra-uterine device, intra-muscular contraceptive)
NCT02433626	1:15:clinical_variable,17:28:lower_bound	Platelet count ≥100 x 109/L
NCT02433626	1:9:pregnancy	Pregnant
NCT02433626	1:19:treatment,27:49:treatment,54:63:treatment,98:111:lower_bound,143:149:treatment	Prior chemotherapy, other investigational agents, or radiation must be discontinued for at least 28 days prior to the first administration of COTI-2
NCT02433626	1:22:clinical_variable,26:60:clinical_variable,68:94:upper_bound	Prothrombin time (PT) or international normalize rate (INR) within 1.5x upper limit of normal
NCT02433626	1:29:chronic_disease,40:59:chronic_disease	Supraventricular arrhythmias including atrial fibrillation, which are uncontrolled
NCT02433626	43:61:chronic_disease,70:82:treatment	The presence of or imminent occurrence of airway obstruction, unless tracheostomy in place
NCT02433626	1:16:clinical_variable	Total bilirubin within normal limits
NCT02433626	1:9:clinical_variable,15:28:treatment,37:45:chronic_disease,64:71:upper_bound	Toxicity from prior therapy (except alopecia) has resolved to ≤Grade 1
NCT02433626	1:14:clinical_variable,16:22:upper_bound,26:39:clinical_variable	Urine protein <500 mg or urine protein
NCT02433626	1:24:chronic_disease,46:53:treatment	Ventricular arrhythmias requiring continuous therapy
NCT02433626	1:23:clinical_variable,25:28:upper_bound	creatinine ratio (UPC) <1.0
NCT02433626	2:10:lower_bound,14:17:age	≥18 years of age
NCT02430051	14:20:chronic_disease,27:31:treatment	Diagnosis of autism using ADOS
NCT02430051	58:74:upper_bound	In need of an oral cleaning (no previous cleaning within past four months)
NCT02430051	9:33:language_fluency	Parents speak English or Spanish
NCT02430051	17:39:treatment	Prescription of anti-cholinergic drugs (which may alter EDA)
NCT02430051	13:29:chronic_disease	Significant motor impairment
NCT02430051	1:15:chronic_disease	cerebral palsy
NCT02425566	31:44:clinical_variable,47:58:lower_bound	Current smokers or history of heavy smoking (>2 packs/day)
NCT02425566	1:13:chronic_disease,35:46:clinical_variable,48:57:lower_bound,67:79:clinical_variable,82:90:lower_bound,133:134:lower_bound	Hypertension will be defined as a systolic BP ≥140 mm Hg and/or a diastolic BP ≥ 90 mm Hg, taken in the seated position in at least 2 separate occasions
NCT02425566	1:5:treatment	Lean
NCT02425566	1:10:pregnancy	Pregnancy
NCT02425566	19:34:chronic_disease	Subjects with any chronic disease
NCT02425566	15:29:clinical_variable,31:34:clinical_variable,37:45:lower_bound	Subjects with morbid obesity (BMI > 40 kg/m2)
NCT02425566	9:11:lower_bound,16:24:upper_bound,28:31:age	between 18 and 65 years of age
NCT02425566	1:23:chronic_disease	cardiovascular disease
NCT02425566	1:9:chronic_disease	diabetes
NCT02425566	14:25:chronic_disease	diagnosis of sleep apnea or a high score in the Berlin questionnaire for sleep apnea
NCT02425566	1:16:gender	female subjects
NCT02425566	1:13:chronic_disease	hypertension
NCT02425566	1:5:gender	male
NCT02425566	1:6:chronic_disease	obese
NCT02424968	67:77:cancer	Active central nervous system (CNS) involvement of the underlying malignancy
NCT02424968	1:15:cancer	Acute leukemia not in remission
NCT02424968	1:35:chronic_disease	Chronic myelogenous leukemia (CML)
NCT02424968	1:11:clinical_variable,15:22:upper_bound,36:56:clinical_variable,60:68:lower_bound	Creatinine =< 3 mg/dL or estimated creatinine clearance >= 40ml/min
NCT02424968	1:11:clinical_variable,14:21:lower_bound,29:59:clinical_variable,63:72:upper_bound	Creatinine > 2 mg/dL and an estimated creatinine clearance =< 40 mL/min
NCT02424968	1:58:clinical_variable,61:64:upper_bound	Diffusing capacity of the lung for carbon monoxide (DLCO) < 40% predicted
NCT02424968	1:18:clinical_variable,21:24:upper_bound	Ejection fraction < 30%
NCT02424968	1:8:gender,9:29:pregnancy	Females must not be pregnant or lactating
NCT02424968	8:31:chronic_disease,35:63:chronic_disease,163:173:treatment	Have a psychiatric disorder(s) or psychosocial circumstance(s) which in the opinion of the primary physician would place the patient at an unacceptable risk from transplant
NCT02424968	1:35:chronic_disease	Human immunodeficiency virus (HIV) positive
NCT02424968	1:35:clinical_variable,38:41:upper_bound	Karnofsky performance status (KPS) < 60%
NCT02424968	9:11:lower_bound,12:20:upper_bound,24:27:age	Must be 18-75 years of age, inclusive
NCT02424968	72:82:treatment	Must be an HLA-matched or single allele mismatched sibling of enrolled transplant patient
NCT02424968	31:44:treatment	Must be capable of undergoing leukapheresis
NCT02424968	147:154:upper_bound,171:210:treatment	Must be in a state of general good health and have completed a donor evaluation with history, medical examination and standard blood tests within 35 days of starting the hematopoietic cell collection procedure
NCT02424968	24:42:cancer,72:75:treatment,80:83:treatment,119:140:treatment,163:166:cancer,168:198:cancer,200:232:cancer,234:237:cancer,239:254:cancer,252:254:cancer	Must have a myeloid or lymphoid malignant disease that is treated with TLI and ATG reduced intensity conditioning for allogeneic transplant (any of the following AML, myelodysplastic syndrome [MDS], myeloproliferative disease [MPD], CLL, B or T-cell NHL, HL)
NCT02424968	13:35:clinical_variable,38:54:lower_bound,56:65:clinical_variable,68:84:lower_bound,89:99:clinical_variable,102:105:lower_bound	Must have a white blood cell count > 3.5 x 10^9/liter, platelets > 150 x 10^9/liter and hematocrit > 35%
NCT02424968	30:41:chronic_disease,43:54:chronic_disease,72:83:chronic_disease,94:127:chronic_disease,138:182:chronic_disease	Must not be seropositive for HIV 1 and 2, hepatitis B surface antigen, hepatitis C antibody, human T-lymphotropic virus (HTLV) antibody, cytomegalovirus (CMV) immunoglobulin M (IgM), or rapid plasma reagin (RPR) (Treponema)
NCT02424968	31:41:cancer,52:64:treatment,68:77:treatment,100:109:treatment	Must not have developed a new malignancy requiring chemotherapy or radiation in the interval since apheresis for initial hematocrit (HCT)
NCT02424968	15:28:chronic_disease,56:74:chronic_disease	Must not have psychological traits or psychological or medical conditions which make them unlikely to tolerate the procedure
NCT02424968	25:31:lower_bound,43:49:upper_bound,50:66:treatment	Patients must be beyond day 30 and before day 60 after transplant
NCT02424968	21:93:treatment,109:136:treatment	Patients must be on single immune suppression therapy with either tacrolimus or cyclosporine at the time of CD8+ memory T-cell infusion
NCT02424968	22:50:clinical_variable,57:60:lower_bound,80:107:treatment	Patients must have a Karnofsky performance status of >= 60% at the time of the CD8+ memory T-cell infusion
NCT02424968	86:113:treatment	Patients must have adequate organ function and performance status at the time of the CD8+ memory T-cell infusion
NCT02424968	38:58:clinical_variable,117:119:lower_bound,127:130:upper_bound	Patients must have evidence of mixed CD3 T-cell chimerism based on the day +28 (+/- 7 days) blood sample showing >= 5% and =< 95% donor type cells
NCT02424968	42:67:chronic_disease,87:114:treatment	Patients must have no evidence of active graft-versus-host disease at the time of the CD8+ memory T-cell infusion
NCT02424968	40:49:chronic_disease,51:57:chronic_disease,61:76:chronic_disease,118:125:treatment,146:173:treatment	Patients must not have an uncontrolled bacterial, fungal or viral infection, defined as progressive symptoms despite therapy, at the time of the CD8+ memory T-cell infusion
NCT02424968	21:24:age,39:57:chronic_disease,63:76:treatment	Patients who due to age, pre-existing medical conditions, or, prior therapy are considered to be at high risk for regimen related toxicity associated with fully ablative transplant conditioning, and therefore reduced intensity conditioning is recommended
NCT02424968	19:31:chronic_disease,49:76:treatment	Poorly controlled hypertension despite multiple antihypertensive medication
NCT02424968	1:9:pregnancy	Pregnant
NCT02424968	7:17:cancer	Prior malignancy
NCT02424968	13:39:cancer,48:68:treatment	Progressive hemato-lymphoid malignancy despite conventional therapy
NCT02424968	1:5:clinical_variable,9:13:clinical_variable,17:24:upper_bound	SGOT or SGPT =< 4 x ULN
NCT02424968	1:47:clinical_variable,51:95:clinical_variable,98:129:lower_bound	Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) > 4 x upper limit of normal (ULN)
NCT02424968	1:16:clinical_variable,20:27:upper_bound	Total bilirubin =< 4 mg/dL
NCT02424968	1:16:clinical_variable,19:26:lower_bound	Total bilirubin > 3 mg/dL
NCT02424968	14:23:chronic_disease,25:30:chronic_disease,34:50:chronic_disease,79:89:treatment	Uncontrolled bacterial, viral or fungal infection defined as currently taking medication and progression of clinical symptoms
NCT02424968	14:21:chronic_disease	asymptomatic viremia
NCT02424968	104:107:lower_bound,118:133:clinical_variable,157:167:cancer	diagnosed > 5 years ago without evidence of disease, OR treated =< 5 years ago but have a greater than 50% chance of life expectancy of >= 5 years for that malignancy
NCT02424968	24:35:chronic_disease	donors with a positive hepatitis B PCR test
NCT02424968	31:42:chronic_disease,80:111:treatment,138:159:chronic_disease	donors with prior evidence of hepatitis B core antibody positivity will have a polymerase chain reaction (PCR) test done to evaluate for hepatitis B infection
NCT02424968	28:38:chronic_disease	patients with a history of acute GVHD overall grade II based on skin only involvement or upper gastrointestinal (GI) tract involvement only
NCT02424968	28:51:chronic_disease,52:56:chronic_disease	patients with a history of liver or lower GI tract GVHD
NCT02424968	1:11:treatment,37:49:upper_bound	prednisone at a physiologic dose of 5 mg per day or less is allowed
NCT02424968	14:29:chronic_disease	uncontrolled cardiac failure
NCT02424929	12:25:language_fluency	Ability to speak English well
NCT02424929	45:64:chronic_disease	All patients will have moderate to advanced Parkinson's disease
NCT02424929	1:17:chronic_disease,23:49:chronic_disease	Essential Tremor, and Parkinson's plus disorders
NCT02424929	1:12:chronic_disease,38:46:chronic_disease,62:84:treatment,106:113:chronic_disease,128:131:treatment	Parkinson's patients with concurrent dementia as measured by neurocognitive testing, or with significant strokes identified on MRI
NCT02424929	37:43:treatment,47:60:treatment	Patients must be medically safe for asleep or awake surgery
NCT02424929	19:24:chronic_disease	Patients that are obese or that have severe potential airway issues
NCT02409810	1:16:chronic_disease	Acute hepatitis
NCT02409810	1:20:chronic_disease	Acute liver failure
NCT02409810	1:28:chronic_disease	Acute myocardial infarction
NCT02409810	7:15:chronic_disease	Acute seizures
NCT02409810	1:13:chronic_disease	Acute stroke
NCT02409810	1:24:clinical_variable,26:40:upper_bound	Burn injury experienced <48 hours prior to admission to the Burn Center for care
NCT02409810	1:9:chronic_disease,13:35:chronic_disease	Chemical or electrical burn injury
NCT02409810	38:52:lower_bound	Expected stay on the Burn Center for 3 or more days
NCT02409810	10:13:age,14:16:lower_bound,18:20:upper_bound	Patients age 18- 89
NCT02409810	14:26:pregnancy	Patients who are pregnant
NCT02409810	23:46:chronic_disease,56:91:clinical_variable,93:101:upper_bound,103:123:clinical_variable,126:138:upper_bound,160:183:chronic_disease,188:222:chronic_disease	Patients with current hemodynamic instability (current hypotension systolic blood pressure <100 mmHg, sustained heart rate < 60 beats/min without a pacemaker, symptomatic bradycardia, or second or third degree heart block)
NCT02409810	1:30:language_fluency	Read, write and speak English
NCT02409810	55:59:chronic_disease,96:104:chronic_disease,106:126:language_fluency	Severe cognition or communication difficulties (e.g., coma, deafness without signing literacy, dementia, non-English speaking)
NCT02409810	88:90:lower_bound,91:114:clinical_variable	admitted for initial management of a thermal burn injury (flame, scald, contact) with >1% total body surface area
NCT02409316	10:18:lower_bound,22:25:age	At least 18 years of age
NCT02409316	10:13:lower_bound,90:92:treatment,94:103:treatment,105:108:treatment,110:120:treatment	At least one site of disease outside of the liver that is seen on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT)
NCT02409316	1:8:gender,13:25:pregnancy	Females who are pregnant at the time of screening
NCT02409316	53:60:treatment,64:70:treatment,82:95:cancer,99:110:cancer,130:157:treatment,159:176:treatment	History of ER+ pathology (ER+ may be confirmed from surgery or biopsy of primary breast cancer or lymph nodes, and/or surgery or biopsy of a metastatic site, metastatic biopsy is not required)
NCT02409316	12:36:cancer	History of HER2/neu positive cancer (IHC 3+ and/or FISH positive) as assessed by medical record review at screening
NCT02409316	61:87:treatment,147:160:cancer	History of progression or recurrence of disease while on an endocrine targeted therapy containing regimen as assessed by medical record review of breast cancer history at screening
NCT02409316	1:10:cancer,14:31:cancer,85:91:treatment,139:141:treatment,143:152:treatment,154:157:treatment,159:169:treatment	Recurrent or metastatic cancer that is of known or suspected breast origin - may be biopsy proven or identified on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT)
NCT02409316	7:16:pregnancy,56:61:gender	urine pregnancy test will be performed at screening in women of child-bearing potential
NCT02404688	1:3:lower_bound,7:15:upper_bound,19:22:age	21 to 55 years of age
NCT02404688	1:6:gender	Males
NCT02404688	1:19:pregnancy	Positive pregnancy screen
NCT02404688	1:8:gender	females
NCT02404012	26:30:treatment,34:56:treatment,66:74:lower_bound	Subject has a history of RYGB or SG weight loss surgery at least 6 months ago
NCT02404012	26:41:treatment,46:59:chronic_disease,67:84:upper_bound	Subject has a history of hospitalization for acute illness in the previous 3 months
NCT02404012	28:46:cancer	Subject has current active malignant neoplasm
NCT02404012	94:109:chronic_disease,111:129:chronic_disease	Subject has gastrointestinal disease that involve increased inflammation or blood loss (e.g. Crohn's disease, Ulcerative colitis)
NCT02404012	17:32:treatment,43:52:upper_bound	Subject has had parenteral iron less than one month before screening visit
NCT02404012	24:41:treatment,59:78:treatment	Subject has history of surgical revision or conversion of bariatric procedure
NCT02404012	20:26:chronic_disease,35:45:clinical_variable,48:56:lower_bound	Subject has severe anemia, with a hemoglobin > 7.0 g/dL
NCT02404012	21:23:lower_bound,42:50:upper_bound,54:57:age	Subject is at least 18 but not more than 65 years of age
NCT02404012	12:18:gender	Subject is female
NCT02404012	12:20:pregnancy	Subject is pregnant
NCT02404012	22:59:treatment,69:81:treatment	Subject is taking an erythropoietin stimulating medication or is on hemodialysis
NCT02404012	20:37:treatment,52:72:treatment	Subject is under a treatment regimen that requires iron supplementation greater than standard of care
NCT02404012	24:25:lower_bound,33:34:upper_bound	Subject meets at least 2 of the 4 previously mentioned conditions classifying them as iron deficient
NCT02404012	12:22:cancer,44:69:cancer,77:93:upper_bound	history of malignancy other than localized basal cell cancer of skin during previous 5 years
NCT02402907	3:11:lower_bound	> 24 weeks gestation
NCT02402907	12:25:allergy_name	allergy to chlorhexidine
NCT02402907	17:51:treatment	scheduled for a primary or repeat cesarean section
NCT02402907	24:40:treatment	unplanned or emergency cesarean section
NCT02402907	1:6:gender	women
NCT02400463	1:9:lower_bound,13:16:age	18 years of age or older at the time of enrollment
NCT02400463	8:19:chronic_disease,23:34:chronic_disease	Active hepatitis B or hepatitis C
NCT02400463	1:31:clinical_variable,33:41:upper_bound	Estimated creatinine clearance <15mL/min
NCT02400463	18:40:treatment,52:67:treatment,76:82:upper_bound,87:99:upper_bound,104:113:treatment	Has received any prior systemic therapy, excluding corticosteroids, within 7 days (or 5 half-lives) of treatment
NCT02400463	17:46:chronic_disease,81:103:cancer	Known secondary HPS (Hemophagocytic Syndrome) that is otherwise treatable (e.g. non-Hodgkin's lymphoma)
NCT02400463	1:14:chronic_disease	Malabsorption
NCT02400463	1:6:gender	Males
NCT02400463	11:21:cancer,56:80:cancer,84:101:cancer	No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ
NCT02400463	48:51:chronic_disease	Patients must meet the diagnostic criteria for HPS
NCT02400463	34:44:cancer,154:162:treatment,166:191:treatment	Patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies
NCT02400463	1:9:pregnancy	Pregnant
NCT02400463	1:26:clinical_variable,28:35:upper_bound	absolute neutrophil count <1000/μL)
NCT02400463	5:12:gender,52:76:pregnancy,89:95:upper_bound,99:108:treatment	all females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment
NCT02400463	1:8:gender	females
NCT02400463	1:6:clinical_variable,8:20:clinical_variable,22:31:clinical_variable,43:44:lower_bound,57:67:clinical_variable,69:75:upper_bound	fever, splenomegaly, cytopenia involving ≥2 cell lines (Hemoglobin <9 g/dL
NCT02400463	1:21:chronic_disease,25:43:chronic_disease	hypertriglyceridemia or hypofibrinogenemia
NCT02400463	7:10:chronic_disease	known HIV infection
NCT02400463	11:17:gender	lactating female
NCT02400463	11:18:gender	lactating females must discontinue breast feeding
NCT02400463	15:39:chronic_disease	low or absent NK (Natural Killer) cell activity
NCT02400463	1:10:clinical_variable,12:22:upper_bound	platelets <100,000/μL
NCT02400463	27:36:chronic_disease,44:90:clinical_variable,92:94:lower_bound	reported history of liver cirrhosis with a Model for End-stage Liver Disease (MELD) score >20
NCT02400463	1:15:clinical_variable,17:26:lower_bound	serum ferritin ≥3000 ug/L
NCT02400463	1:29:clinical_variable,31:40:lower_bound	soluble IL-2 receptor (CD25) >2400 U/mL
NCT02400463	25:41:cancer	tissue demonstration of hemophagocytosis
NCT02397889	1:3:lower_bound,4:12:upper_bound,16:19:age	18-65 years of age
NCT02397889	3:17:clinical_variable	A blood pressure of one reading over 160/90 or two separate readings over 140/90 at screen or baseline visits
NCT02397889	22:37:chronic_disease,41:57:chronic_disease	Current diagnosis of bulimia nervosa or anorexia nervosa
NCT02397889	14:25:chronic_disease,29:60:chronic_disease	Diagnosis of schizotypal or antisocial personality disorder
NCT02397889	12:23:chronic_disease	History of (hypo)mania
NCT02397889	12:18:chronic_disease,20:38:chronic_disease,40:73:chronic_disease,78:97:chronic_disease	History of autism, mental retardation, pervasive developmental disorders, or Tourette's syndrome
NCT02397889	12:15:lower_bound,24:32:chronic_disease	History of one or more seizures without a clear and resolved etiology
NCT02397889	1:19:treatment,27:35:treatment,80:88:treatment	Hormonal treatment (e.g., estrogen) started in the 3 months prior to the first infusion day
NCT02397889	1:4:gender	Men
NCT02397889	27:32:clinical_variable,81:85:chronic_disease	Participants must fulfill DSM-5 criteria for current civilian or combat-related PTSD
NCT02397889	29:38:chronic_disease	Past or current presence of psychotic symptoms
NCT02397889	58:84:chronic_disease	Patients judged clinically to be at serious and imminent suicidal or homicidal risk
NCT02397889	46:60:treatment,65:82:treatment,89:104:treatment,114:127:treatment,131:138:treatment,147:160:upper_bound	Patients who report current treatment with a benzodiazepine, an opioid medication, or a mood stabilizer (such as valproic acid or lithium) within 2 weeks prior to randomization
NCT02397889	27:60:chronic_disease	Patients with uncorrected hypothyroidism or hyperthyroidism
NCT02397889	30:38:treatment,42:45:treatment	Previous recreational use of ketamine or PCP
NCT02397889	1:17:chronic_disease,37:40:clinical_variable,42:50:lower_bound	Renal impairment, as reflected by a BUN >20 mg/dL
NCT02397889	34:47:treatment	Use of evidence-based individual psychotherapy (such as prolonged exposure) during the study
NCT02397889	1:6:gender,45:63:pregnancy,100:120:treatment	Women of childbearing potential must have a negative pregnancy test at screening and prior to each intravenous infusion
NCT02397889	1:15:chronic_disease	cardiovascular
NCT02397889	1:20:clinical_variable,25:34:upper_bound	creatinin clearance of >1.3 mg/dL
NCT02397889	23:41:upper_bound	dependence within the preceding 3 months
NCT02397889	25:43:chronic_disease,54:67:chronic_disease,71:95:chronic_disease	diagnosis of a lifetime psychotic disorder including schizophrenia or schizoaffective disorder
NCT02397889	1:33:chronic_disease	gastro-esophageal reflux disease
NCT02397889	1:20:chronic_disease	hematologic disease
NCT02397889	62:73:treatment,75:97:chronic_disease,102:127:chronic_disease	history of difficulty with airway management during previous anesthetics, ischemic heart disease and uncontrolled hypertension
NCT02397889	19:30:chronic_disease	history of severe head injury
NCT02397889	1:18:chronic_disease,36:39:clinical_variable,41:49:lower_bound	hyroid impairment, as reflected by TSH> 4.2 mU/L
NCT02397889	1:24:chronic_disease	obstructive sleep apnea
NCT02397889	1:5:gender,10:33:pregnancy	omen who plan to become pregnant
NCT02397889	1:9:pregnancy	pregnant
NCT02397889	1:6:gender	women
NCT02391987	8:26:chronic_disease	Active systemic infection
NCT02391987	17:25:lower_bound	Adult patients >18 years old
NCT02391987	11:24:chronic_disease,28:36:treatment	End stage renal disease on dialysis
NCT02391987	1:13:treatment,53:86:chronic_disease	Hospitalized with primary or secondary diagnosis of Acute Decompensated Heart Failure
NCT02391987	1:31:technology_access	Inadequate cell phone coverage (including international patients or international travel during study period)
NCT02391987	23:32:allergy_name,34:46:allergy_name,48:56:allergy_name,58:65:allergy_name	Known skin allergy to adhesives (hydrocolloid, silicone, acrylic)
NCT02391987	9:24:clinical_variable,27:33:upper_bound	Overall life expectancy < 1 year
NCT02391987	1:9:pregnancy	Pregnant
NCT02391987	25:71:technology_access	Subject or caregiver is not visually and tactile capable of smartphone and home device usage
NCT02391987	1:6:chronic_disease,8:24:chronic_disease,26:33:chronic_disease,38:67:chronic_disease,71:88:treatment	rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography)
NCT02391987	1:20:chronic_disease,22:31:chronic_disease,35:40:chronic_disease	shortness of breath, orthopnea or edema
NCT02391402	1:9:lower_bound,13:16:age	55 years of age enrolled at participating VA sites able to provide informed consent
NCT02391402	8:23:chronic_disease,89:98:treatment	Active suicidal intent indicating significant clinical risk, which would suggest that a treatment specifically targeting this intent was indicated
NCT02391402	1:9:chronic_disease,13:31:chronic_disease	Auditory or visual impairments that would compromise ability to participate or benefit
NCT02391402	20:37:chronic_disease	Clients who report suicidal ideation without imminent risk will be admitted into the study
NCT02391402	106:118:upper_bound	Current diagnosis of moderate or severe substance (alcohol) use disorder using DSM-5 criteria within the past 30 days
NCT02391402	14:18:chronic_disease	Diagnosis of PTSD based on the Clinician Administered PTSD Scale
NCT02391402	1:17:language_fluency,73:84:upper_bound	English speaking, able to travel to the primary care clinics weekly for 10 sessions and for the follow-up assessments
NCT02391402	50:69:treatment,58:69:treatment	Enrollees will be asked to hold the doses of the current medications stable over the course of enrollment (though changes in medications after enrollment will not exclude them from on-going participation)
NCT02391402	24:35:chronic_disease,78:94:chronic_disease,99:118:chronic_disease,159:169:treatment	Individuals with other psychiatric diagnoses will not be excluded except for bipolar disorder and psychotic disorders (requirement to refrain from additional treatments might be harmful)
NCT02391402	11:34:treatment,46:54:treatment,63:70:upper_bound,96:109:upper_bound,186:195:treatment,284:300:treatment,319:343:treatment,347:356:treatment,382:394:upper_bound	Initiated psychotropic medication, including Prazosin, within 4 weeks or changed dosage within 2 weeks prior to the first assessment, as this would make it difficult to determine which treatment contributed to change in the CABA condition; additionally, started or changed dosage of sleep medication or low dosages of tricyclic antidepressant or trazodone for pain or sleep within 1 week prior to the first assessment
NCT02391402	71:81:treatment	Participants could be reconsidered for eligibility after stability on medication was achieved
NCT02391402	111:114:chronic_disease,230:258:clinical_variable,272:280:lower_bound,284:311:clinical_variable,325:335:lower_bound	Veterans with a history indicated by medical record review of a diagnosis of moderate, severe, or penetrating TBI, or self-reported history on the Structured Interview for Collecting Head Trauma Event Characteristics of TBI with Post-Traumatic Amnesia (PTA) greater than 24 hours or loss of consciousness (LOC) greater than 30 minutes
NCT02391402	21:60:clinical_variable	endorsed any of the Neurobehavioral Symptom Inventory (NSI) cognitive symptoms items
NCT02389959	36:79:chronic_disease	The patient carries a diagnosis of hereditary hemorrhagic telangiectasia (HHT)
NCT02389959	30:33:chronic_disease,60:77:treatment	The patient has a history of HIV or another known cause of immunosuppression
NCT02389959	21:36:treatment,54:71:treatment,83:92:upper_bound	The patient has had prior treatment with systemic or nasal bevacizumab within the past year
NCT02389959	27:41:treatment,46:55:chronic_disease,67:81:upper_bound	The patient has undergone electrocautery for epistaxis within the 6 months prior to study enrollment
NCT02389959	25:33:lower_bound	The patient is at least 18 years old
NCT02389959	16:24:pregnancy	The patient is pregnant
NCT02389959	27:36:treatment,42:56:treatment	The patient is to undergo treatment with electrocautery in the operating room under endoscopic visualization
NCT02389959	17:46:treatment,54:75:treatment,77:95:chronic_disease	actively taking immunosuppressive medications due to organ transplantation, rheumatoid disease, or other medical conditions
NCT02377089	1:3:lower_bound,4:16:upper_bound	21-65 years old
NCT02377089	14:21:chronic_disease,23:36:chronic_disease,44:62:chronic_disease,67:75:chronic_disease	a history of bipolar, schizophrenia, other psychotic disorder, or dementia
NCT02377089	39:57:treatment	consent to be randomized to active or sham TNS treatment
NCT02377089	55:63:lower_bound	current substance abuse not in remission for at least 3 months
NCT02377089	9:17:chronic_disease,21:39:chronic_disease	current suicidal or homicidal ideation requiring hospitalization
NCT02377089	23:37:treatment,39:50:treatment,52:65:treatment,70:96:treatment,149:164:lower_bound	evidence of receiving antidepressant, antianxiety, antipsychotic, or mood-stabilizer medication where the dose has not been stable for a minimum of six weeks prior to entering the randomization
NCT02377089	23:59:treatment	evidence of receiving psychosocial or medication treatment through a clinic or facility other than the VA GLA PTSD Clinic
NCT02377089	28:38:treatment,84:88:chronic_disease,103:113:upper_bound	have completed a course of PE therapy in the Resident Psychotherapy Program in the PTSD Clinic within six months of enrollment
NCT02377089	83:91:lower_bound	meet DSM-IV criteria for current warzone-related PTSD with a duration of at least 3 months
NCT02377089	18:21:chronic_disease,27:40:clinical_variable,42:52:lower_bound	report of severe TBI with coma duration (30 minutes or more) during the screening interview and/or duration of post
NCT02377089	1:16:chronic_disease,24:34:upper_bound	suicide attempt within six months
NCT02377089	1:18:chronic_disease,20:25:lower_bound,45:67:chronic_disease	traumatic amnesia (1hour or greater) on the Post-traumatic Amnesia Questionnaire (PTAQ)
NCT02377089	27:31:chronic_disease,59:69:clinical_variable,71:73:lower_bound	with significant residual PTSD symptoms as evidenced by a CAPS score >50
NCT02359864	52:72:chronic_disease,79:104:chronic_disease,106:122:chronic_disease,124:137:chronic_disease	Current presence of a clinically significant major psychiatric disorder (e.g. major depressive disorder, bipolar disorder, schizophrenia, etc., according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV
NCT02359864	16:28:chronic_disease	Dermatological skin disease of the scalp
NCT02359864	12:30:chronic_disease,33:43:chronic_disease	History of cerebral infection / hemorrhage
NCT02359864	12:25:chronic_disease	History of hydrocephalus
NCT02359864	12:28:chronic_disease,31:48:chronic_disease	History of subdural hygroma / subdural hematoma
NCT02359864	9:17:lower_bound,21:24:age	Must be 55 years of age or older
NCT02359864	1:23:chronic_disease	Non-Alzheimer dementia
NCT02359864	36:58:treatment	Patient currently participating in another Clinical Trial
NCT02359864	15:25:treatment,37:39:lower_bound,40:42:upper_bound	Patient has a MMSE score of between 10-20
NCT02359864	13:31:clinical_variable,48:57:lower_bound	Patient has estimated survival of greater than 12 months
NCT02359864	89:107:upper_bound	Patient has evidence of substance abuse (alcohol / or other drugs of dependence) during previous 12 months
NCT02359864	19:44:treatment	Patient is taking anti-epileptic medication
NCT02359864	45:64:chronic_disease	Patient must meet NINCDS-ADRDA criteria for Alzheimer's Disease
NCT02359864	16:36:treatment,43:49:treatment,51:58:treatment,60:67:treatment,69:76:treatment,80:85:treatment	Patient taking Alzheimer medication, i.e. Exelon, Aricept, Namenda, Reminyl or Ebixa
NCT02359864	25:52:chronic_disease,76:107:chronic_disease	Patient with history of focal neurological deficits (with the exception of vibratory peripheral neuropathy
NCT02359864	30:36:cancer,44:68:cancer	The patient has a history of cancer except non-melanoma skin cancer
NCT02358850	1:9:lower_bound	18 years and older
NCT02358850	12:31:treatment,38:70:treatment,72:83:treatment,85:113:treatment,127:134:treatment	Additional surgical procedures (i.e. UPPP (uvulopalatopharyngoplasty), septoplasty, inferior turbinate reduction) during same surgery
NCT02358850	35:46:treatment,48:55:treatment,57:62:treatment,64:72:treatment,74:82:treatment	Contraindications to pain regimen medications (Tylenol, Norco, Percocet, Dilaudid)
NCT02358850	35:43:treatment	Contraindications to preoperative Decadron
NCT02358850	12:24:chronic_disease,39:49:treatment	History of chronic pain or daily pain medication used for another medical problem
NCT02358850	12:25:chronic_disease	History of liver disease
NCT02358850	24:34:cancer	Indications: Suspected malignancy
NCT02358850	1:9:pregnancy,10:17:gender	Pregnant females
NCT02358850	23:42:chronic_disease,44:51:chronic_disease,53:64:chronic_disease	Surgical indications: Chronic tonsillitis, Snoring, Sleep apnea
NCT02358850	1:19:treatment,21:57:treatment,59:115:treatment	Surgical procedure: Tonsillectomy with monopolar cautery, hemostasis with monopolar cautery and/or suction cautery
NCT02358850	5:13:treatment,41:54:treatment	The surgical procedure can also include Adenoidectomy with suction cautery
NCT02356861	1:5:age,6:8:lower_bound,11:23:upper_bound	Ages 18 - 65 years old
NCT02356861	1:8:gender	Females
NCT02356861	5:40:chronic_disease	Had Gulf War Veterans' Illnesses (GWVI), but did not answer 'Yes' to the following questions: 1) Difficulty concentrating and/or 2) Difficulty remembering recent information
NCT02356861	11:14:age,15:17:upper_bound,39:41:lower_bound	Less than age 18, or greater than age 60
NCT02356861	1:6:gender	Males
NCT02356861	90:116:treatment,121:148:treatment	Must be physically able to travel to the VA Boston Healthcare System, Jamaica Plain, for Neuropsychological testing and transcranial LED treatments
NCT02356861	36:40:chronic_disease	Must meet screening criteria for a PTSD diagnosis
NCT02356861	26:55:treatment	Not meeting criteria for post-traumatic stress disorder and for mild or moderate traumatic brain injury
NCT02356861	106:132:treatment,137:164:treatment	Physical limitations that would prevent traveling to the VA Boston Healthcare System, Jamaica Plain, for Neuropsychological testing and transcranial LED treatments
NCT02356861	48:54:cancer	Presence of a life-threatening disease such as cancer
NCT02356861	15:40:chronic_disease,49:84:chronic_disease,86:97:chronic_disease,99:107:chronic_disease	Presence of a neurodegenerative disease such as Amyotrophic Lateral Sclerosis (ALS), Parkinson's, Dementia
NCT02356861	22:37:chronic_disease,46:59:chronic_disease,71:81:chronic_disease	Presence of a severe mental disorder such as schizophrenia, or severe depression
NCT02349035	3:24:treatment	A upper limb amputation at the transradial level
NCT02349035	1:21:chronic_disease	Cognitive impairment sufficient to adversely affect understanding of or compliance with study requirements
NCT02349035	52:62:treatment	Significant new injury that would prevent use of a prosthesis: The ability to consistently wear a prosthesis and perform activities of daily living and specific performance tasks is necessary to evaluate the relative benefits of the interventions
NCT02347111	23:25:chronic_disease,33:47:chronic_disease	A reversible cause of AF (e.g., thyrotoxicosis)
NCT02347111	1:3:chronic_disease,30:44:lower_bound	AF symptoms present at least once per month
NCT02347111	21:30:ethnicity	Any race other than Caucasian
NCT02347111	1:28:treatment,40:57:upper_bound	Cardiac or thoracic surgery within the previous 6 months
NCT02347111	24:37:allergy_name	Contra-indication to a class III AAD
NCT02347111	1:21:clinical_variable,23:32:upper_bound	Creatinine clearance <40 ml/min
NCT02347111	1:4:clinical_variable,30:39:upper_bound	ECG that was recorded within 12 months of randomization showing AF
NCT02347111	1:8:gender,17:25:pregnancy	Females who are pregnant
NCT02347111	12:38:chronic_disease	History of severe AV node dysfunction unless an electronic pacemaker is present
NCT02347111	23:42:chronic_disease	History of typical or lone symptomatic AF
NCT02347111	59:67:upper_bound	Medical condition that is likely to be fatal in less than one year
NCT02347111	11:13:chronic_disease,26:40:chronic_disease	Permanent AF or isolated atrial flutter
NCT02347111	17:27:treatment,73:83:chronic_disease	Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital)
NCT02347111	25:32:treatment,37:67:treatment	Previously treated with class I and class III antiarrhythmic drugs
NCT02347111	10:11:lower_bound,20:24:treatment	Received 2 or more AADs in past
NCT02347111	24:40:chronic_disease,46:49:clinical_variable,50:56:lower_bound	congenital or acquired long QT syndrome with QTc>450 ms at baseline
NCT02347111	12:14:chronic_disease	history of MI
NCT02347111	1:25:chronic_disease	structural heart disease
NCT02347111	3:11:lower_bound,15:18:age	≥ 18 years of age
NCT02343367	16:30:chronic_disease,32:41:chronic_disease,46:63:chronic_disease	a diagnosis of cardiovascular, pulmonary, or digestive disease
NCT02343367	1:4:age,5:6:lower_bound,7:9:upper_bound	age 6-11
NCT02343367	43:51:ethnicity	identified by parent or legal guardian as Hispanic
NCT02343367	1:11:chronic_disease,15:20:chronic_disease,22:25:bmi,38:42:lower_bound,47:55:upper_bound,58:62:upper_bound,79:82:age	overweight or obese (BMI between the 85th and 99.9thth (<99th) percentile for age and gender
NCT02343367	41:54:technology_access	parent unable or not willing to receive text messages
NCT02343367	8:28:technology_access	parent without a cell phone
NCT02340650	1:4:age,5:13:lower_bound	Age 18 years and older
NCT02340650	37:57:chronic_disease	Patient with sufficient evidence of cognitive impairment that limits the subject's ability to understand the protocol
NCT02340650	17:32:chronic_disease	Patients having acute infection
NCT02340650	13:22:allergy_name	Person with Lidocaine sensitivity
NCT02340650	1:6:gender,23:26:age,40:69:pregnancy,82:100:pregnancy	Women of childbearing age who have the possibility of being pregnant must have a negative pregnancy test prior to participation
NCT02340650	1:6:gender,42:51:pregnancy	Women with the possibility of having the pregnancy
NCT02340650	20:30:treatment	who are undergoing cystoscopy as part of their routine clinical care
NCT02340156	22:31:chronic_disease,43:60:chronic_disease,72:88:treatment	Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
NCT02340156	74:81:treatment	Any condition that prevents compliance with the protocol or adherence to therapy
NCT02340156	1:8:gender,17:25:pregnancy,42:65:pregnancy	Females who are pregnant or lactating or plan to become pregnant during the course of this study
NCT02340156	1:6:clinical_variable,10:16:lower_bound	Fever (> 38.1°C)
NCT02340156	1:13:cancer,17:28:cancer,42:54:cancer	Glioblastoma or gliosarcoma disease with leptomeningeal spread
NCT02340156	60:68:upper_bound	Had prior exposure to gene vector delivery products within 6 months
NCT02340156	73:85:allergy_name	Have a history of hypersensitivity reaction to any of the components of Temozolomide
NCT02340156	39:57:allergy_name	Have a history of hypersensitivity to dacarbazine (DTIC)
NCT02340156	6:30:clinical_variable,36:44:lower_bound,73:83:treatment	Have diastolic blood pressure of > 90 mm Hg resting at baseline despite medication
NCT02340156	34:41:treatment	Have recovered from any previous therapy side effects or toxicities
NCT02340156	26:38:cancer,42:53:cancer	Histologically confirmed glioblastoma or gliosarcoma in 1st, 2nd or 3rd relapse
NCT02340156	22:42:cancer	Histology other than astrocytoma grade IV
NCT02340156	1:29:clinical_variable,32:35:lower_bound	Karnofsky performance status ≥ 60%
NCT02340156	1:5:gender	Male
NCT02340156	1:6:gender,55:69:gender,102:152:contraception_consent,178:191:upper_bound,217:226:treatment	Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment
NCT02340156	23:26:treatment,44:57:upper_bound	Measurable disease on MRI performed within 14 days prior to registration
NCT02340156	13:38:chronic_disease	Moderate to severe hepatic impairment
NCT02340156	1:15:clinical_variable,35:42:upper_bound	Organ function characterized by ≤ Grade 1
NCT02340156	1:3:clinical_variable,8:11:clinical_variable,14:23:upper_bound	PT and PTT ≤ 1.5 X ULN
NCT02340156	42:51:treatment,56:74:treatment,78:95:treatment,108:113:cancer	Patients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study
NCT02340156	35:43:treatment,47:67:treatment	Patients who are currently taking Coumadin or Coumadin derivatives other than to maintain patency of venous access lines
NCT02340156	38:44:cancer,88:95:treatment,130:137:lower_bound	Patients with a history of any other cancer, unless in complete remission, and off all therapy for that disease for a minimum of 5 years
NCT02340156	15:47:clinical_variable,49:73:clinical_variable,76:113:lower_bound,118:127:clinical_variable,129:136:lower_bound	Patients with serum aspartate aminotransferase, alanine aminotransferase > 2.5 X the upper limit of normal (ULN) and bilirubin >1.5 ULN
NCT02340156	1:18:treatment,9:18:treatment,42:62:treatment,70:83:upper_bound	Planned treatment, or treatment with any investigational drug within 4 weeks prior to screening
NCT02340156	23:26:chronic_disease	Positive results from HIV serology testing, if any available
NCT02340156	1:19:treatment,34:37:cancer,43:64:treatment,75:90:treatment,94:105:treatment	Prior chemotherapy for recurrent GBM with nitrosourea compounds including Gliadel® wafers or bevacizumab
NCT02340156	1:25:treatment,33:41:upper_bound	Prior focal radiotherapy within 3 months of screening
NCT02340156	61:74:treatment	Radiographic demonstration of disease progression following prior therapy
NCT02340156	11:39:treatment	Receiving hematopoietic growth factors
NCT02340156	1:40:clinical_variable,42:51:lower_bound	Renal insufficiency or serum creatinine >1.5 X ULN at screening
NCT02340156	11:25:treatment	Requiring renal dialysis
NCT02340156	9:29:chronic_disease	Serious nonmalignant disease
NCT02340156	50:65:upper_bound	Substance or alcohol abuse or dependence, within 12 months prior to screening
NCT02340156	1:31:clinical_variable,34:42:upper_bound,46:77:clinical_variable,80:87:upper_bound	Supine systolic blood pressure < 100 mmHg or supine diastolic blood pressure < 50 mmHg at screening and baseline
NCT02340156	14:25:treatment,30:39:chronic_disease,47:61:upper_bound	Treated with antibiotics for infection within one week prior to study entry
NCT02340156	1:6:cancer	Tumor foci detected below the tentorium or beyond the cranial vault
NCT02340156	1:11:treatment	Urinalysis: No clinically significant abnormalities
NCT02340156	1:6:gender,38:88:contraception_consent,114:121:upper_bound,147:162:treatment	Women of childbearing potential must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment
NCT02340156	1:6:gender,45:78:pregnancy,102:114:upper_bound	Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 3 days prior to study initiation
NCT02340156	1:16:gender	female patients
NCT02340156	3:11:lower_bound,15:18:age	≥ 18 years of age
NCT02335242	15:39:treatment,24:27:treatment	A review of a previous MRI examination may help confirm the entry criteria on subjects selected to come to Stanford for the MRI screening
NCT02335242	1:15:treatment	Alpha-blockers
NCT02335242	38:54:treatment,56:70:treatment,72:82:treatment,87:97:treatment	Also excluded are concomitant use of organic nitrates, alpha-blockers, amlodipine, or cimetidine
NCT02335242	1:11:treatment	Amlodipine
NCT02335242	30:31:lower_bound,34:42:upper_bound	Assent obtained for subjects 7 - 10 years old
NCT02335242	19:25:clinical_variable,29:33:lower_bound	Be at the minimum weight of 8 kg at the time of enrollment
NCT02335242	47:69:chronic_disease,94:119:lower_bound	Be required to have the clinical diagnosis of lymphatic malformation that appears to be over 3 cm in greatest diameter in order to be evaluated for entry
NCT02335242	37:59:chronic_disease,103:107:lower_bound,124:132:clinical_variable,144:147:treatment	Cannot confirm that the lesion is a lymphatic malformation or the lymphatic malformation is less than 3 cm in its greatest diameter during the MRI screening
NCT02335242	1:11:treatment	Cimetidine
NCT02335242	20:76:treatment	Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended
NCT02335242	69:79:treatment,131:139:treatment	Consistent with its known effects on the nitric oxide/cGMP pathway, sildenafil was shown to potentiate the hypotensive effects of nitrates
NCT02335242	18:26:chronic_disease,48:66:chronic_disease	Has a history of priapism or is diagnosed with sickle cell anemia or any other disorder which may predispose to priapism
NCT02335242	22:39:cancer,43:45:chronic_disease	Has diagnosis of the soft tissue tumor as LM not clinically certain
NCT02335242	19:32:treatment,36:49:treatment,59:61:chronic_disease,115:124:treatment,135:145:treatment	Has had extensive prior surgery or sclerotherapy to treat LM such that scarring may interfere with evaluation and treatment effect of sildenafil
NCT02335242	34:52:chronic_disease	Has one or more of the following medical conditions
NCT02335242	23:26:lower_bound,44:55:treatment,92:102:treatment,110:117:upper_bound	Has received at least one of the following medications contraindicated in association with sildenafil within 15 days of inclusion
NCT02335242	37:40:chronic_disease	Has ulcerated or currently infected LMs
NCT02335242	17:20:treatment,53:75:cancer,107:111:lower_bound,115:123:clinical_variable,161:171:treatment	Have a required MRI examination to confirm that the lymphatic malformation is present and is greater than 3 cm in diameter in order for the subjects to receive medication, which happens during the initial screening evaluation portion of the trial
NCT02335242	10:29:chronic_disease,167:176:treatment,187:197:treatment	Have had recurrent infection and significant scarring of the lesion secondary to infection to such an extent that the that scarring may interfere with evaluation and treatment effect of sildenafil
NCT02335242	29:32:treatment	Have no contraindication to MRI examinations such as metal implants, etc
NCT02335242	42:52:treatment	Have no contraindications for the use of sildenafil
NCT02335242	10:32:chronic_disease,104:120:treatment	Have the lymphatic malformation cause enough disability for the subject that requires them to consider systemic therapy
NCT02335242	1:19:chronic_disease,28:44:chronic_disease,46:67:chronic_disease,76:90:chronic_disease,92:108:chronic_disease,110:127:chronic_disease,129:146:chronic_disease,148:165:chronic_disease,171:184:chronic_disease,186:197:chronic_disease,226:234:chronic_disease	Hepatic impairment, severe renal impairment, lymphedema conditions such as Milroy disease, Meige lymphedema, Hennekam syndrome, Njolstad syndrome, Aagenaes syndrome, and Fabry disease, hypotension or at risk for hypotension, seizures or history of seizures
NCT02335242	29:39:allergy_name	Known to have an allergy to sildenafil
NCT02335242	1:17:treatment	Organic nitrates in any form, either regularly or intermittently
NCT02335242	18:40:treatment	Participating in another clinical study which may interfere
NCT02335242	29:66:treatment,76:88:treatment,90:102:treatment,104:116:treatment,118:128:treatment,153:162:treatment	Requires concomitant use of potent cytochrome P450 3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin, saquinavir), or concomitant use of ritonavir
NCT02335242	1:10:treatment,21:44:treatment	Ritonavir and other Potent CYP3A Inhibitors
NCT02335242	202:258:chronic_disease,299:307:chronic_disease,309:321:chronic_disease,323:346:chronic_disease,351:365:chronic_disease,384:397:chronic_disease,399:414:chronic_disease,419:434:chronic_disease	any significant cardiovascular risk factors and any condition which requires participants to use nitric oxide donors or nitrates in any form, underlying anatomic or vascular risk factor for developing non-arteritic anterior ischemic optic neuropathy (NAION) including low ocular cup to disc ratio, diabetes, hypertension, coronary artery disease, or hyperlipidemia Participants with Down syndrome, Turner syndrome and Noonan syndrome will be considered on a case-by-case basis
NCT02335242	13:17:age,13:16:age,21:29:lower_bound,32:40:upper_bound	between the ages of 6 months - 10 years of age at the time of entry into the study
NCT02335242	18:32:treatment,38:45:treatment	co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects
NCT02335242	1:16:gender	female subjects
NCT02335242	13:21:pregnancy	must not be pregnant or breast-feeding
NCT02329327	19:43:chronic_disease	A patient with an intracerebral hemorrhage
NCT02329327	42:58:clinical_variable,63:69:lower_bound	Acute bleeding associated with a fall in hemoglobin level by ≥2 g/dL
NCT02329327	1:15:chronic_disease,34:44:clinical_variable,34:50:clinical_variable,55:61:upper_bound	Acute bleeding associated with a hemoglobin level of ≤8 g/dL if no baseline hemoglobin is available
NCT02329327	1:15:chronic_disease	Acute bleeding in a critical area or organ such as intraspinal, pericardial, or intracranial
NCT02329327	1:15:chronic_disease	Acute bleeding that is potentially life-threatening
NCT02329327	1:11:treatment	Dabigatran
NCT02329327	32:39:upper_bound	Expected survival of less than 1 month
NCT02329327	19:40:chronic_disease,86:105:treatment,127:134:upper_bound	For patients with intracranial bleeding, there must be a reasonable expectation that andexanet treatment will commence within 2 hours of the baseline imaging evaluation
NCT02329327	1:19:clinical_variable,22:23:upper_bound	Glasgow coma score < 7
NCT02329327	1:23:clinical_variable,26:31:lower_bound	Intracerebral hematoma > 60 cc as assessed by CT or MRI
NCT02329327	43:66:treatment,74:80:upper_bound	Patient has received any of the following drugs or blood products within 7 days of Screening
NCT02329327	78:92:upper_bound,96:105:treatment,122:130:treatment,132:143:treatment,145:153:treatment,157:167:treatment	Patient received or is believed to have received one of the following within 18 hours prior to andexanet administration: apixaban, rivaroxaban, edoxaban or enoxaparin
NCT02329327	27:30:treatment,32:57:treatment,61:67:treatment,96:104:upper_bound,126:144:treatment	Planned administration of PCC, fresh frozen plasma (FFP) or rfVIIa from Screening until within 12 hours after the end of the andexanet infusion
NCT02329327	1:9:pregnancy	Pregnant
NCT02329327	1:47:treatment,51:83:treatment	Prothrombin Complex Concentrate products (PCC) or recombinant factor VIIa (rfVIIa)
NCT02329327	24:31:upper_bound	Recent history (within 2 weeks) of a diagnosed thrombotic event (TE)
NCT02329327	1:14:chronic_disease,18:30:chronic_disease	Severe sepsis or septic shock at the time of Screening
NCT02329327	37:44:treatment,58:66:upper_bound	The patient is scheduled to undergo surgery in less than 12 hours
NCT02329327	17:37:clinical_variable,39:52:upper_bound	Treated with an investigational drug <30 days prior to Screening
NCT02329327	1:27:treatment	Vitamin K antagonist (VKA)
NCT02329327	11:17:gender	lactating female
NCT02329327	11:38:treatment	minimally invasive surgery/procedures
NCT02329327	1:23:chronic_disease,25:46:chronic_disease,48:92:chronic_disease,122:147:chronic_disease,149:173:chronic_disease,200:227:chronic_disease,235:248:upper_bound	venous thromboembolism, myocardial infarction, disseminated intravascular coagulation (DIC), cerebral vascular accident, transient ischemic attack, unstable angina pectoris hospitalization or severe peripheral vascular disease within 2 weeks prior to screening
NCT02324608	11:26:clinical_variable,39:47:lower_bound	Estimated life expectancy of at least 12 weeks
NCT02324608	102:111:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or other agents used in the study
NCT02324608	1:10:clinical_variable,13:22:upper_bound,26:36:upper_bound,43:50:lower_bound,54:65:lower_bound	Magnesium < 1.4 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels
NCT02324608	1:19:pregnancy	Negative pregnancy test
NCT02324608	48:56:treatment	Patients must agree to pre- and post-treatment biopsies
NCT02324608	23:83:clinical_variable,87:88:upper_bound	Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2
NCT02324608	131:137:cancer,138:142:lower_bound	Patients must have untreated or relapsed SCCS that is considered to be aggressive and locally advanced by the following criteria: tumors 2 cm or more, tumors invading deep tissues such as muscle, cartilage or bone; tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes; patients may have had prior surgical interventions or been treated with investigational agents with residual or recurrent disease
NCT02324608	1:10:clinical_variable,13:23:upper_bound,29:37:lower_bound	Potassium < 3.5 mmol/L or > 6 mmol/L despite intervention to normalize levels
NCT02324608	1:24:treatment,7:16:treatment	Prior radiation therapy is not an exclusion however, patient must have documented progression at the radiation site
NCT02324608	8:26:cancer,35:44:treatment	Second primary malignancy only if treatment would interfere with the patient's participation in this trial in the opinion of the treating physician
NCT02324608	21:39:chronic_disease,51:68:chronic_disease	Serious concomitant systemic disorders (including active infections) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator
NCT02324608	1:48:clinical_variable,51:72:upper_bound,78:103:lower_bound	Serum calcium (ionized or adjusted for albumin) < 8 mg/dl (1.75 mmol/L) or > 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels
NCT02324608	1:6:gender,15:23:pregnancy	Women who are pregnant
NCT02324608	1:4:age,29:38:pregnancy,53:60:treatment,68:94:contraception_consent,96:139:contraception_consent,141:151:contraception_consent,223:231:upper_bound,248:253:gender,254:269:pregnancy,261:269:pregnancy	age must agree to undergo a pregnancy test prior to therapy and to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
NCT02324608	15:40:cancer,92:99:lower_bound	patient had a second primary malignancy but has been treated and disease free for at least 3 years
NCT02324608	1:6:gender	women of childbearing
NCT02318342	1:4:age,5:13:lower_bound	Age 18 years or older
NCT02318342	18:43:allergy_name	Known allergy to iodinated contrast agents
NCT02318342	13:65:treatment,85:99:lower_bound	Presence of transcatheter or surgical bioprosthetic aortic valve implanted at least 48 hours prior to enrollment
NCT02318342	1:20:chronic_disease,22:32:clinical_variable,35:44:lower_bound	Renal insufficiency (creatinine > 1.5 mg/dL)
NCT02317523	1:5:age,6:14:lower_bound	Aged 55 years or older
NCT02317523	1:15:clinical_variable,17:30:lower_bound	Blood pressure >200/120 mm Hg
NCT02317523	64:77:treatment	Caregivers enrolled in another intervention study or receiving psychotherapy to improve well-being or reduce distress
NCT02317523	1:21:chronic_disease	Cognitive impairment
NCT02317523	1:15:treatment,27:40:upper_bound	Glucocorticoid use in the 2 weeks prior to enrollment
NCT02317523	27:36:chronic_disease,95:110:clinical_variable,124:130:upper_bound	Neither the caregiver nor Alzheimer's patient can be diagnosed with a terminal illness with a life expectancy of less than 1 year
NCT02317523	41:49:chronic_disease	Providing in-home care to a spouse with dementia
NCT02317523	8:15:treatment,19:28:treatment	Taking Aldomet or labetalol
NCT02317523	8:31:treatment	Taking Coumarin anticoagulants
NCT02317523	8:16:treatment,20:26:treatment	Taking nitrates or niacin
NCT02317523	8:32:treatment	Taking non-selective β-blockers
NCT02316574	28:48:chronic_disease,60:80:chronic_disease,87:112:chronic_disease,114:142:chronic_disease,219:265:treatment	A diagnosis of any current psychiatric disorder other than Alcohol Use Disorder (e.g. Major Depressive Disorder, Generalized Anxiety Disorder) that in the investigator's judgment might require intervention with either pharmacological or non-pharmacological therapy over the course of the study
NCT02316574	30:39:treatment	Agree to not seek additional treatment
NCT02316574	21:24:lower_bound,48:51:gender,52:57:gender,65:76:upper_bound	Currently drinking >5/4 or more drinks/day for men/women in the last 28 day
NCT02316574	22:46:treatment	Currently taking any psychotropic medications
NCT02316574	1:17:language_fluency	English-speaking and able to provide informed consent and comply with study procedures
NCT02316574	44:51:chronic_disease	History of severe alcohol withdrawal (e.g. seizure, delirium tremens, multiple detoxifications or ER visits for alcohol withdrawal)
NCT02316574	29:38:treatment	Legally mandated to receive treatment
NCT02316574	21:37:chronic_disease	Lifetime history of Bipolar Disorder
NCT02316574	34:54:chronic_disease	Meets DSM-V criteria for current Alcohol Use Disorder
NCT02316574	1:13:chronic_disease,17:35:chronic_disease,62:65:treatment,92:98:chronic_disease,100:107:chronic_disease,109:120:cancer,122:137:chronic_disease,139:157:chronic_disease,159:171:treatment,181:190:pregnancy,192:206:chronic_disease	Neurological or medical conditions that would interfere with MRI scanning (e.g. history of stroke, seizure, brain tumor, brain infection, multiple sclerosis, metal device in body, pregnancy, claustrophobia)
NCT02316574	1:14:chronic_disease,18:42:chronic_disease	Schizophrenia or Schizoaffective Disorder
NCT02316574	9:18:treatment	Seeking treatment for Alcohol Use Disorder
NCT02316574	13:33:chronic_disease	Significant cognitive impairment
NCT02316574	22:29:chronic_disease	Significant risk for suicide or violence
NCT02316574	48:56:upper_bound	Willing to abstain from alcohol completely for 24 hours on 3 separate occasions
NCT02315196	1:32:clinical_variable,36:52:lower_bound	Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
NCT02315196	1:33:clinical_variable,35:81:clinical_variable,83:113:clinical_variable,115:159:clinical_variable,163:186:upper_bound	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional ULN
NCT02315196	22:43:treatment,64:65:lower_bound,66:73:upper_bound	Before administering liposomal doxorubicin, patients must wait 4-6 weeks after surgery
NCT02315196	1:20:treatment,56:62:treatment,95:108:upper_bound,149:167:cancer	Computed tomography of the chest, abdomen, and pelvis (CT CAP) and bone scan performed within 30 days prior to study entry and does not demonstrate metastatic disease
NCT02315196	1:11:clinical_variable,14:23:upper_bound	Creatinine < 2.5 mg/dL
NCT02315196	47:65:cancer	Definitive clinical or radiologic evidence of metastatic disease
NCT02315196	14:40:cancer	Diagnosis of inflammatory breast cancer
NCT02315196	13:31:chronic_disease,35:47:chronic_disease	Evidence of bleeding diathesis or coagulopathy
NCT02315196	1:11:clinical_variable,14:22:lower_bound	Hemoglobin > 9.0 g/dL
NCT02315196	14:35:treatment,59:84:treatment,147:166:chronic_disease	History of a major organ allograft or condition requiring chronic immunosuppression, e.g., kidney, liver, lung, heart, bone marrow transplant, or autoimmune diseases
NCT02315196	83:114:allergy_name,136:141:allergy_name,143:153:allergy_name,158:169:allergy_name	History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride (HCL) or the components of doxil, paclitaxel, or carboplatin
NCT02315196	142:149:upper_bound	Imaging by magnetic resonance imaging (MRI), ultrasound and/or mammogram and physical exam to document lesions size must be performed within 30 days of study entry
NCT02315196	1:23:chronic_disease,56:63:chronic_disease	Intrinsic lung disease resulting in moderate to severe dyspnea
NCT02315196	17:33:chronic_disease,39:62:chronic_disease	Known or active hepatitis B or C with abnormal liver function tests
NCT02315196	1:16:clinical_variable,20:28:lower_bound,58:71:cancer	Life expectancy >= 52 weeks excluding their diagnosis of breast cancer
NCT02315196	1:19:chronic_disease,23:38:chronic_disease,32:38:chronic_disease,46:54:upper_bound,74:107:clinical_variable,108:116:lower_bound,128:141:chronic_disease,184:207:chronic_disease,232:251:chronic_disease,253:269:chronic_disease,321:341:treatment,354:368:chronic_disease,372:410:chronic_disease	Myocardial infarct or unstable angina within 6 months before enrollment, New York Heart Association (NYHA) class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, valvular disease with documented compromise in cardiac function, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities
NCT02315196	1:74:pregnancy,140:154:upper_bound	Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential within one week prior to enrollment
NCT02315196	1:24:chronic_disease,26:38:chronic_disease,40:67:chronic_disease,72:101:chronic_disease,106:113:lower_bound	Nervous system disorder (paresthesias, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
NCT02315196	37:46:treatment,58:96:treatment,120:133:cancer	Patients may not receive concurrent treatment with other investigational or commercial agent(s) for treatment of their breast cancer
NCT02315196	38:45:treatment,54:64:treatment,68:78:treatment,83:98:treatment,106:119:cancer	Patients must be eligible to undergo surgery, either lumpectomy or mastectomy for local treatment of the breast cancer
NCT02315196	23:83:clinical_variable,86:87:upper_bound	Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status < 2
NCT02315196	43:79:contraception_consent,86:96:contraception_consent,98:117:contraception_consent,119:138:contraception_consent,140:170:contraception_consent,174:196:contraception_consent,205:214:treatment,223:235:upper_bound	Patients with reproductive potential must use an adequate contraceptive method (e.g. abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment
NCT02315196	1:10:clinical_variable,14:32:lower_bound	Platelets >= 100,000 cells/mm^3
NCT02315196	7:20:treatment,40:46:treatment,55:65:cancer	Prior anthracycline, platinum salt, or taxane for any malignancy
NCT02315196	1:26:cancer,16:26:cancer,39:53:cancer,60:91:cancer,112:150:cancer,189:196:lower_bound	Second primary malignancy except most situ carcinoma (e.g. in situ carcinoma of the cervix, adequately treated non-melanomatous carcinoma of the skin) or other malignancy treated at least 5 years previously with no evidence of recurrence
NCT02315196	9:39:chronic_disease,51:68:chronic_disease,72:89:chronic_disease,100:123:treatment	Serious concomitant systemic disorders (including active infections or chronic infection requiring suppressive antibiotics) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator
NCT02315196	13:29:chronic_disease,37:52:chronic_disease,54:71:chronic_disease	Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
NCT02315196	15:20:cancer,49:55:treatment,60:74:treatment	Submission of tumor samples from the diagnostic biopsy and breast surgery is required for all patients
NCT02315196	13:40:chronic_disease	Symptomatic peripheral vascular disease
NCT02315196	7:16:clinical_variable,19:52:upper_bound	Total bilirubin < 1.5 X upper limit of normal (ULN)
NCT02315196	1:6:gender,11:23:pregnancy	Women who are pregnant
NCT02315196	1:6:gender,45:53:lower_bound,54:57:upper_bound,58:71:cancer,73:75:clinical_variable,76:79:clinical_variable,80:84:clinical_variable,101:103:upper_bound,121:122:lower_bound,123:124:upper_bound,129:155:treatment,159:200:treatment,204:207:upper_bound,246:251:cancer,275:281:lower_bound,318:328:treatment	Women with previously untreated, unilateral stage II-III breast cancer, ER/PgR/HER2 negative (ER =< 5%, PgR =< 5%, HER2 0-1+ by immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH] =< 2.0); if clinically negative lymph nodes, tumor size should be minimum 1.0 cm and identifiable under office-based ultrasound guidance
NCT02315196	1:21:treatment,121:128:treatment	axillary exploration at discretion of surgeon but all patients minimally have sentinel lymph node evaluation at time of surgery
NCT02315196	50:63:upper_bound,81:93:treatment	imaging must have been performed no greater than 30 days prior to initiation of chemotherapy
NCT02315196	28:47:treatment,49:61:treatment,66:82:treatment	patients who have received corneal transplants, cadaver skin, or bone transplants are eligible
NCT02315196	15:24:treatment,30:45:treatment,37:45:treatment,53:62:upper_bound,75:84:lower_bound,85:103:treatment	this includes treatment with corticosteroids within one month (dose of >= 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids)
NCT02311621	28:42:treatment,53:64:treatment	For patients with positive Hepatitis C Ab, negative PCR testing must be documented
NCT02311621	21:34:chronic_disease,82:98:chronic_disease,117:143:treatment,145:152:chronic_disease,154:161:chronic_disease,163:187:chronic_disease,188:198:chronic_disease,207:221:chronic_disease,223:231:chronic_disease,233:251:chronic_disease,253:275:chronic_disease,277:286:chronic_disease,288:321:chronic_disease	History of relevant CNS pathology or current relevant CNS pathology (non-febrile seizure disorder requiring ongoing anti-epileptic medications, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder)
NCT02311621	1:45:clinical_variable,51:53:lower_bound	Lansky or Karnofsky performance status score of ≥ 50
NCT02311621	1:16:clinical_variable,22:29:lower_bound	Life expectancy of ≥ 8 weeks
NCT02311621	1:5:gender	Male
NCT02311621	23:54:treatment	Must not be receiving external beam radiation therapy at the time of study enrollment
NCT02311621	10:13:chronic_disease,36:47:chronic_disease,68:79:chronic_disease,96:110:upper_bound	Negative HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C antibody within 3 months prior to enrollment
NCT02311621	4:43:treatment,72:89:treatment	No prior genetically modified cell therapy that is still detectable or prior virotherapy
NCT02311621	4:28:treatment,76:82:upper_bound	No systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollment
NCT02311621	34:85:treatment	Patient must NOT have received a prior allogeneic hematopoietic stem cell transplant
NCT02311621	19:41:cancer	Patients may have CNS intracranial tumor
NCT02311621	23:41:treatment,52:78:treatment	Patients who received stem cell infusion following non-myelo-ablative therapy
NCT02311621	1:9:pregnancy	Pregnant
NCT02311621	23:39:chronic_disease,40:68:chronic_disease	Presence of a primary immunodeficiency/bone marrow failure syndrome
NCT02311621	13:30:cancer,42:44:cancer	Presence of active malignancy other than NB
NCT02311621	20:36:chronic_disease	Presence of active severe infection
NCT02311621	141:163:treatment	Presence of any concurrent medical condition that, in the opinion of the protocol PI or designee, would prevent the patient from undergoing protocol-based therapy
NCT02311621	19:56:chronic_disease	Presence of known intracranial metastatic neuroblastoma
NCT02311621	20:46:cancer,105:110:cancer	Prior diagnosis of NB or ganglioneuroblastoma either by histologic verification and/or demonstration of tumor cells in the bone marrow with increased catecholamine levels
NCT02311621	21:39:treatment,43:55:treatment	Receiving any other anti-cancer agents or radiotherapy at the time of study entry
NCT02311621	61:73:treatment,75:88:treatment,93:105:treatment	Recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment onto this study
NCT02311621	1:20:cancer	Skull based disease with soft tissue extension
NCT02311621	20:29:treatment,73:91:treatment	Unable to tolerate apheresis procedure including placement of temporary apheresis catheter
NCT02311621	1:16:gender	female subjects
NCT02311621	3:11:upper_bound,15:18:age	≤ 26 years of age
NCT02311621	3:11:lower_bound,17:40:treatment	≥ 12 weeks from prior I131 MIBG therapy
NCT02311621	3:15:lower_bound,19:26:lower_bound,53:89:treatment	≥ 3 half-lives or 30 days from time of last dose of anti-tumor directed antibody therapy, whichever is shorter from time of enrollment
NCT02311621	3:10:lower_bound,16:37:treatment,42:73:treatment,86:104:treatment	≥ 6 weeks from myeloablative therapy and autologous stem cell transplant (timed from stem cell infusion)
NCT02311621	3:9:lower_bound,21:33:treatment,37:53:treatment	≥ 7 days since last chemotherapy or biologic therapy administration
NCT02307058	38:44:treatment,80:116:clinical_variable	A suspicious central gland lesion on MP-MRI must have a distinct lesion on the apparent diffusion coefficient (ADC)
NCT02307058	1:4:age,7:9:lower_bound,16:24:upper_bound	Age ≥ 35 and ≤ 85 years at signing of consent
NCT02307058	4:17:treatment,25:37:treatment,41:54:upper_bound,92:114:treatment,136:161:treatment	An anti-androgen (e.g., bicalutamide at 50 mg per day po) is recommended to start prior to LHRH agonist injection (not recommended for LHRH antagonist injection) and is recommended to not be administered
NCT02307058	1:35:treatment	Androgen deprivation therapy (ADT) is at the discretion of the treating physician
NCT02307058	1:7:treatment,18:32:cancer	Biopsy confirmed adenocarcinoma (including ductal) of the prostate
NCT02307058	20:59:treatment	Distinct lesion on dynamic contrast-enhanced MRI (DCE-MRI) with early enhancement and later washout
NCT02307058	1:8:clinical_variable,9:10:lower_bound,11:13:upper_bound,19:22:clinical_variable,27:35:lower_bound	Gleason 8-10 or a PSA of >15 ng/ml
NCT02307058	1:14:clinical_variable,15:16:lower_bound,17:19:upper_bound	Gleason score 6-10
NCT02307058	34:48:upper_bound	It may be initiated no more than 3 months prior to the signing of consent
NCT02307058	42:54:treatment	It must be started prior to the start of radiotherapy
NCT02307058	1:10:clinical_variable,14:74:clinical_variable,99:105:clinical_variable	Karnofsky or Eastern Cooperative Oncology Group (ECOG) performance status may be used to estimate Zubrod
NCT02307058	23:33:cancer,46:71:cancer,87:115:cancer,137:168:cancer	No concurrent, active malignancy, other than nonmetastatic skin cancer or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma)
NCT02307058	16:26:cancer,65:83:treatment	No evidence of metastasis by any clinical criteria or available radiographic tests (N0M0 by clinical or imaging criteria)
NCT02307058	24:51:treatment,53:77:treatment	No previous history of radical/total prostatectomy (suprapubic prostatectomy is acceptable)
NCT02307058	13:32:treatment	No previous pelvic radiotherapy
NCT02307058	1:32:clinical_variable,35:44:upper_bound,58:66:upper_bound	Prostate-specific Antigen (PSA) ≤ 100 ng/mL within (+/-) 4 months of signing of consent
NCT02307058	15:25:chronic_disease	Subjects with T3 disease based on digital rectal exam (DRE)
NCT02307058	55:61:treatment	Suspicious peripheral zone or central gland lesion on MP-MRI
NCT02307058	1:3:lower_bound,4:6:upper_bound	T1-T3 disease based on digital rectal exam
NCT02307058	36:45:upper_bound	The total length planned must be ≤ 30 months
NCT02307058	1:26:clinical_variable,29:30:upper_bound	Zubrod performance status ≤ 2
NCT02307058	24:27:clinical_variable,33:38:clinical_variable,40:44:upper_bound	distinct lesion on the ADC map (Value <1000)
NCT02307058	13:17:upper_bound	map (Value <1000)
NCT02307058	68:120:treatment,124:144:treatment	must be decided (none, short-term or long-term as counted from the luteinizing hormone-releasing hormone (LHRH) agonist or antagonist injection) prior to enrollment
NCT02307058	15:24:treatment,38:46:upper_bound,97:107:cancer	should have a bone scan within (+/-) 4 months of signing of consent that is without evidence of metastasis
NCT02298491	32:43:chronic_disease	A highly probable diagnosis of sarcoidosis, as determined using the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Sarcoidosis Organ Assessment Instrument (Judson et al., 2014), with involvement not limited to the central nervous system
NCT02298491	7:15:treatment,65:73:lower_bound	If on steroids, on a stable dose of the medication for at least 3 months
NCT02277782	17:28:lower_bound,32:35:upper_bound,36:60:clinical_variable	Patients with a Category II or III fetal heart rate tracing
NCT02277782	1:5:age,9:11:lower_bound,16:24:upper_bound	ages of 18 and 45 years
NCT02277782	9:18:clinical_variable,22:30:lower_bound	at term gestation (≥ 37 weeks)
NCT02277782	1:9:pregnancy,10:17:gender	pregnant females
NCT02277782	1:31:chronic_disease	prolonged rupture of membranes
NCT02277548	1:4:age,14:22:lower_bound	Age at least 18 years old
NCT02277548	1:21:clinical_variable,35:44:upper_bound	Creatinine clearance of less than 30 mL/min by Cockcroft-Gault estimate
NCT02277548	56:72:treatment,74:84:treatment,89:99:treatment	Has another painful condition requiring chronic use of opioid analgesic, gabapentin, or pregabalin
NCT02277548	12:22:chronic_disease	History of angioedema
NCT02277548	32:42:allergy_name,46:56:allergy_name	History of hypersensitivity to pregabalin or gabapentin
NCT02277548	12:19:chronic_disease,40:65:treatment	History of seizure or currently taking anti-epileptic medication
NCT02277548	20:33:chronic_disease,37:54:chronic_disease,118:128:chronic_disease	History of serious mood disorder or attempted suicide as determined by patients history and physical and by using theDepression Screening
NCT02277548	1:33:clinical_variable,34:37:lower_bound,41:43:upper_bound,44:57:chronic_disease	New York Heart Association class III or IV heart failure
NCT02277548	33:50:treatment	Patients anticipated to receive radiation therapy with Protons
NCT02277548	28:48:cancer,76:88:treatment,93:110:treatment,153:176:cancer	Patients being treated for oropharyngeal cancer with undergoing concurrent chemotherapy and radiation therapy (photons) for a histological diagnosis of squamous cell carcinoma to the head and neck at the University of Pennsylvania
NCT02277548	1:10:clinical_variable,24:33:upper_bound,48:64:chronic_disease	Platelets of less than 150 mg/dL or history of thrombocytopenia
NCT02277548	39:41:lower_bound,40:41:lower_bound	Subjects with a score of greater than 10 or those answering #5 with scores greater than a 0 will be deemed ineligible to be enrolled on study
NCT02277548	84:103:chronic_disease	The patient has any uncontrolled intercurrent illness including but not limited to psychiatric illness/social situations that would limit compliance or interfere with their ability to participate
NCT02277548	1:10:treatment,40:61:chronic_disease,80:96:treatment	Treatment entails significant risk for symptomatic mucositis likely to require opioid analgesia, as per the discretion of treating physician/NP
NCT02273362	3:9:treatment,17:32:chronic_disease	A biopsy of the cirrhotic liver (non-surgical cohort)
NCT02273362	3:24:treatment,84:98:upper_bound	A clinical liver biopsy (with research tissue specimens available for analysis) =< 3 months prior to pre-registration
NCT02273362	19:43:treatment	An indication for surgical liver resection
NCT02273362	5:20:treatment,26:35:treatment	Any prior treatment with erlotinib or other agent whose primary mechanism of action is known to inhibit EGFR
NCT02273362	1:33:clinical_variable,34:82:clinical_variable,87:117:clinical_variable,118:164:clinical_variable,168:189:upper_bound	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x institutional ULN
NCT02273362	1:11:clinical_variable,15:38:upper_bound	Creatinine =< 1.5 x institutional ULN
NCT02273362	1:61:clinical_variable,62:63:lower_bound,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
NCT02273362	102:121:treatment	History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (Tarceva)
NCT02273362	39:47:chronic_disease,51:73:chronic_disease,117:142:clinical_variable,146:147:upper_bound	Individuals with a clinical diagnosis fibrosis or cirrhosis of the liver (no more than Child-Pugh classification A; Child-Pugh-Turcotte score of 6 or less) who have
NCT02273362	1:37:clinical_variable,41:44:upper_bound	International normalized ratio (INR) =< 1.5
NCT02273362	58:70:treatment,75:89:upper_bound,168:185:chronic_disease,187:202:chronic_disease,204:212:chronic_disease,217:226:chronic_disease	Non-surgical cohort only: pathology report from clinical liver biopsy (=< 3 months prior to pre-registration) demonstrates no histologic abnormalities associated with chronic hepatitis, steatohepatitis, fibrosis, or cirrhosis
NCT02273362	64:67:lower_bound,68:82:clinical_variable,110:140:treatment	Non-surgical cohort only: positive phospho-EGFR assessment (>= 100 stained pixels) from tissue obtained from previous clinical liver biopsy
NCT02273362	1:13:pregnancy	Not pregnant or breast feeding
NCT02273362	36:44:treatment,46:53:treatment,55:61:treatment,72:94:treatment,104:145:treatment,150:157:treatment	Participants who cannot have their warfarin, Lovenox, Plavix, or other comparable medications held for percutaneous or transjugular liver biopsy and surgery if so indicated
NCT02273362	32:39:lower_bound,122:150:treatment,155:163:treatment	Participants who regularly (>= 2 times per week) use drugs that alter the pH of the gastrointestinal (GI) tract, such as proton pump inhibitors (PPI) and antacids
NCT02273362	40:74:chronic_disease	Participants with a known diagnosis of human immunodeficiency virus (HIV)
NCT02273362	1:13:treatment,17:36:treatment,40:55:chronic_disease,65:77:lower_bound,81:96:treatment,98:113:treatment	Percutaneous or transjugular biopsy of cirrhotic liver at least 7 days prior to liver resection (surgical cohort)
NCT02273362	1:10:clinical_variable,14:29:lower_bound	Platelets >= 50 B/L (10^9/L)
NCT02273362	18:24:treatment	Pre-intervention biopsy sample collected
NCT02273362	21:43:treatment,47:61:upper_bound	Receiving any other investigational agents =< 6 months prior to registration
NCT02273362	1:9:treatment,34:46:treatment,50:69:treatment	Surgical cohort (cohort A only): percutaneous or transjugular biopsy incomplete or not performed
NCT02273362	1:16:clinical_variable,20:65:upper_bound	Total bilirubin =< 3 x institutional upper limit of normal (ULN)
NCT02273362	14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,162:181:chronic_disease,182:199:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02273362	42:54:treatment,56:66:treatment,68:82:treatment,84:93:treatment,95:107:treatment,109:119:treatment,121:131:treatment,133:142:treatment,144:154:treatment,156:169:treatment,171:185:treatment,187:199:treatment,205:215:treatment,219:235:treatment	Use of potent CYP3A4 inhibitors, such as ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice
NCT02273362	52:77:treatment,90:102:treatment	Willingness to authorize collection of tissue from surgically-resected liver or clinical liver biopsy for analyses
NCT02273362	53:68:upper_bound,134:150:treatment	Willingness to discontinue smoking during the study two weeks prior to beginning the study and willingness to not smoke while taking study medication
NCT02273362	1:42:contraception_consent,52:61:pregnancy,65:77:pregnancy,84:97:upper_bound,112:123:treatment	Willingness to use adequate contraception to avoid pregnancy or impregnation until 2 weeks after discontinuing study agent
NCT02273362	34:38:treatment,181:195:treatment,207:245:chronic_disease,246:272:chronic_disease	individuals who use prescription PPIs and have approval from their primary health care provider to discontinue for the duration of clinical trial participation may be enrolled; an alternate drug to control gastroesophageal reflux disease (GERD)/peptic ulcer disease (PUD) symptoms will be suggested
NCT02273362	7:22:treatment,31:41:treatment,43:52:treatment,54:65:treatment,67:76:treatment,78:91:treatment,93:106:treatment,112:127:treatment	se of CYP3A4 inducers such as rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's wort
NCT02273362	1:6:gender,3:6:gender,47:140:contraception_consent	women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
NCT02266784	74:78:chronic_disease	(Inattentive Symptoms, Hyperactive-Impulsive Symptoms, Total Symptoms or ADHD Index) on both the Self-Report
NCT02266784	1:3:lower_bound,4:12:upper_bound,16:19:age	18-55 years of age
NCT02266784	1:5:chronic_disease	ADHD Diagnosis
NCT02266784	1:5:chronic_disease	ADHD Symptom Ratings
NCT02266784	1:22:clinical_variable,25:27:lower_bound	Cognitive functioning > 80 as assessed by the KBIT-II
NCT02266784	11:13:clinical_variable,16:18:upper_bound,22:54:clinical_variable	Estimated IQ < 80 on Kaufmann Brief Intelligence Test, Second Edition
NCT02266784	5:9:chronic_disease,18:25:clinical_variable,28:30:lower_bound	For ADHD Groups: T-Score > 65 on one of the DSM-IV relevant scales
NCT02266784	36:40:chronic_disease	For Control Group: NO diagnosis of ADHD as determined by clinician administered CAADID and clinical interview
NCT02266784	20:27:clinical_variable,30:32:upper_bound	For Control Group: T-Score < 60 on all of the DSM-IV relevant scales
NCT02266784	32:48:chronic_disease	Has a primary diagnosis of any Axis II Disorder
NCT02266784	38:53:chronic_disease	Has a primary diagnosis of any other Axis I Disorder (determined by the Structured Diagnostic Interview for DSM; SCID) that is significantly impairing and would contraindicate participation in the present study
NCT02266784	1:5:gender	Male
NCT02266784	23:54:clinical_variable,67:73:lower_bound	Provides an afternoon exhaled carbon monoxide reading of at least 10 ppm
NCT02266784	30:47:lower_bound	Self-report smoking at least 10 cigarettes/day
NCT02266784	12:35:treatment,43:57:upper_bound,70:93:treatment,102:106:chronic_disease	Use of any psychoactive medication in the past 12 months, other than FDA-approved medication for the ADHD group only
NCT02266784	1:7:gender	female
NCT02259504	1:9:chronic_disease,89:97:chronic_disease,165:171:upper_bound	Aneurysm size [largest measurement from the cross sectional images to determine overall aneurysm size, not just the lumen, and including any thrombosed portions] ≤ 4.9 mm
NCT02259504	13:21:chronic_disease,23:36:clinical_variable,37:38:lower_bound,39:40:upper_bound	If ruptured aneurysm: Hunt and Hess 0-3
NCT02259504	39:64:clinical_variable,65:66:lower_bound,69:70:upper_bound	If unruptured aneurysm: Subject grade Modified Rankin Scale mRS 0 - 2 The investigator believes the aneurysm is appropriate for the designated Phase coiling paradigm
NCT02259504	21:66:treatment	Intended or planned aneurysm treatment by parent vessel occlusion
NCT02259504	1:16:clinical_variable,27:36:upper_bound	Life expectancy less than 12 months
NCT02259504	23:26:lower_bound,27:35:chronic_disease,126:135:chronic_disease	Patient has more than one aneurysm requiring treatment in the current treatment session, and only one of those to be treated aneurysms fits the current Study inclusion criteria
NCT02259504	57:74:chronic_disease	Presence of fusiform, mycotic, traumatic, dissecting or tumoral aneurysms in any location 10
NCT02259504	7:16:treatment,58:66:chronic_disease	Prior treatment (surgical or endovascular) of the target aneurysm
NCT02259504	9:12:age,15:17:lower_bound,24:26:upper_bound	Subject age ≥ 18 and ≤ 80
NCT02259504	79:88:treatment	Subject with social, medical, or psychological conditions that interfere with treatment and follow-up evaluation
NCT02259504	27:50:treatment,58:67:treatment,82:90:chronic_disease	Use (current or prior) of liquid embolic material in the treatment of the target aneurysm
NCT02259504	30:36:treatment,38:48:treatment,52:65:treatment	Use of other modified coils (Matrix, HydroCoil® or fibered coils)
NCT02259504	1:6:gender,11:23:pregnancy	Women who are pregnant
NCT02259504	1:24:pregnancy	plan to become pregnant during the Study
NCT02259504	21:74:chronic_disease,95:145:treatment	with a diagnosis of ruptured or unruptured saccular intracranial aneurysm judged suitable for selective endovascular treatment by coil occlusion
NCT02253368	1:4:age,6:8:lower_bound,9:17:upper_bound	Age: 21-40 years
NCT02253368	36:45:upper_bound	Average habitual sleep duration of 6.5 hours or less per night
NCT02253368	1:16:bmi,18:22:lower_bound,26:36:upper_bound	Body mass index: 25.0 to 29.9 kg/m2
NCT02253368	1:15:chronic_disease	claustrophobia
NCT02253368	1:9:chronic_disease	diabetes
NCT02253368	1:24:chronic_disease,49:63:chronic_disease	obstructive sleep apnea or history of any other sleep disorder
NCT02253368	1:10:pregnancy	pregnancy
NCT02253368	18:24:chronic_disease,28:49:chronic_disease	prior or current eating or psychiatric disorders
NCT02253368	11:17:upper_bound	recent (< 4 week) travel across time zones
NCT02253368	29:42:upper_bound	stable sleep habits for the past 6 months
NCT02253368	23:25:treatment,34:47:treatment,55:67:upper_bound	subjects who have received iv or oral contrast in the past 2 weeks
NCT02253316	1:32:clinical_variable,36:46:lower_bound,47:61:clinical_variable,65:76:lower_bound	Absolute neutrophil count (ANC) >= 1,000 mm^3 Platelet count >= 75,000/mm^3
NCT02253316	8:27:chronic_disease,28:43:chronic_disease,54:88:chronic_disease	Active hepatitis A, B or C virus infection, or known human immunodeficiency virus (HIV) positive
NCT02253316	67:79:treatment,81:94:treatment,96:108:treatment,117:134:treatment,163:172:treatment,176:192:cancer,207:222:treatment	Administration or planned administration of any other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy which would be considered a treatment of multiple myeloma until Day +28 post-transplant through discontinuation from study
NCT02253316	54:61:lower_bound,68:77:pregnancy	All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure
NCT02253316	13:20:chronic_disease,24:43:chronic_disease,132:141:treatment	Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
NCT02253316	13:16:age,13:17:age,21:23:lower_bound,28:36:upper_bound	Between the ages of 18 and 70 years of age (inclusive) at time of enrollment
NCT02253316	1:16:chronic_disease	Cardiac syncope
NCT02253316	12:23:cancer,27:53:cancer,64:73:treatment	Concurrent hematologic or non-hematologic malignancy requiring treatment
NCT02253316	1:61:clinical_variable	Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or
NCT02253316	13:15:cancer	Evidence of MM disease progression any time prior to enrollment
NCT02253316	1:16:gender,45:69:pregnancy	Female patients who are lactating or have a positive serum pregnancy test during the screening period
NCT02253316	1:6:clinical_variable	Grade >= 3 peripheral neuropathy
NCT02253316	51:67:cancer	Histologically confirmed diagnosis of symptomatic multiple myeloma
NCT02253316	12:32:cancer,36:42:cancer	History of plasma cell leukemia or MM CNS involvement
NCT02253316	1:10:chronic_disease,21:48:treatment,66:75:chronic_disease,83:96:upper_bound,115:124:treatment	Infection requiring systemic antibiotic therapy or other serious infection within 14 days prior to start of study treatment
NCT02253316	7:17:chronic_disease,21:33:treatment,96:104:treatment	Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib
NCT02253316	29:46:allergy_name	Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
NCT02253316	1:14:treatment,22:35:upper_bound,54:63:treatment	Major surgery within 14 days prior to start of study treatment
NCT02253316	24:39:treatment,68:90:treatment,126:139:upper_bound,152:167:treatment	Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days prior to start of study treatment and throughout the duration of this trial
NCT02253316	20:35:treatment,85:101:cancer,109:130:chronic_disease,132:152:chronic_disease	Patients may be on corticosteroids if they are being given for disorders other than multiple myeloma (e.g., adrenal insufficiency, rheumatoid arthritis, etc.)
NCT02253316	24:31:cancer,47:58:chronic_disease	Patients with multiple myeloma with secondary amyloidosis
NCT02253316	14:35:treatment,79:91:treatment	Per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS program
NCT02253316	1:23:treatment,34:59:treatment	Prior organ transplant requiring immunosuppressive therapy
NCT02253316	42:44:cancer	Progression from smoldering/asymptomatic MM to symptomatic MM
NCT02253316	19:22:lower_bound,37:44:treatment,56:72:treatment,77:93:cancer,109:110:lower_bound,111:120:upper_bound,142:157:treatment	Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-16 months of the first dose of initial therapy
NCT02253316	10:15:gender,23:31:pregnancy,35:58:pregnancy	Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
NCT02253316	1:34:treatment	Tandem autologous transplantation
NCT02253316	27:144:contraception_consent,237:244:upper_bound,237:250:lower_bound,267:279:treatment	This is defined as either committing to continued abstinence from heterosexual intercourse or beginning TWO acceptable methods of contraception (one highly effective method and one additional effective method AT THE SAME TIME) at least 28 days prior to the start of lenalidomide, for the duration of study participation, and for 28 days following the last dose of lenalidomide
NCT02253316	1:6:gender,60:69:pregnancy	Women of childbearing potential must also agree to ongoing pregnancy testing
NCT02253316	1:6:gender,45:54:pregnancy	Women of childbearing potential must follow pregnancy testing requirements as outlined in the Revlimid REMS program material
NCT02253316	22:39:chronic_disease	clinically important autonomic disease
NCT02253316	35:58:chronic_disease,67:91:treatment	clinically significant repetitive ventricular arrhythmias despite antiarrhythmic treatment
NCT02253316	1:17:cancer	multiple myeloma
NCT02253316	1:22:chronic_disease,34:53:upper_bound	myocardial infarction within the previous six months
NCT02253316	1:22:chronic_disease	secondary amyloidosis
NCT02253316	8:31:chronic_disease	severe orthostatic hypotension
NCT02253316	15:19:clinical_variable,20:27:lower_bound,31:32:upper_bound,33:57:chronic_disease	uncompensated NYHA Class 3 or 4 congestive heart failure
NCT02253316	1:25:chronic_disease	unstable angina pectoris
NCT02250664	23:35:upper_bound,62:68:lower_bound	A quit attempt in the past 30 days resulting in greater than 3 days of abstinence
NCT02250664	36:51:chronic_disease,101:110:treatment,114:127:treatment,141:158:upper_bound	Be in good physical health without serious illness or change in health or medication (not including methadone or buprenorphine dose) in the past three months as determined by the license medical professional at each site
NCT02250664	43:66:chronic_disease	Be without current (within the past year) serious mental disorder that would interfere with study results or completion as determined by the licensed medical professional or PI
NCT02250664	1:10:clinical_variable,13:19:lower_bound	Breath CO > 80 ppm
NCT02250664	1:21:clinical_variable,24:28:lower_bound	Breath alcohol level > 0.01 ( participants with a positive screen will be allowed to re-screen once)
NCT02250664	21:30:chronic_disease,34:42:chronic_disease,47:52:chronic_disease	Current symptoms of psychosis or dementia, or mania
NCT02250664	18:44:treatment	Currently taking anticonvulsant medications
NCT02250664	11:31:treatment,33:42:treatment,52:69:treatment	Have used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month
NCT02250664	1:11:clinical_variable,40:47:lower_bound,61:67:upper_bound	Heart rate is greater than or equal to 115 bpm or less than 45 bpm
NCT02250664	1:4:gender	Men
NCT02250664	29:38:treatment,51:57:treatment,106:115:treatment,119:132:treatment	Not currently enrolled in a treatment program for opioid dependence and/or not currently stable on their methadone or buprenorphine dose
NCT02250664	1:13:pregnancy,37:93:contraception_consent	Not pregnant or nursing, and report using oral, implant, injection or barrier contraceptives, or report being surgically sterile, or post menopausal
NCT02250664	45:54:treatment,58:71:treatment,146:149:upper_bound,159:168:clinical_variable,176:188:upper_bound	Participants must be maintained on a stable methadone or buprenorphine dose for the past month, with no evidence of regular illicit-drug abuse (<30% positive specimens in the past 30 days)
NCT02250664	36:41:lower_bound,67:79:upper_bound	Participants must provide at least three urine samples within the last 30 days
NCT02250664	48:60:upper_bound	Participation in another research study in the past 30 days
NCT02250664	38:45:upper_bound	Planning to quit smoking in the next 30 days
NCT02250664	19:35:clinical_variable,37:42:lower_bound	Provide an intake breath CO sample >8 ppm
NCT02250664	98:104:lower_bound,112:119:upper_bound	Report no significant use of other tobacco or nicotine products within the past month (more than 9 days in the past 30)
NCT02250664	8:15:clinical_variable,18:38:lower_bound	Report smoking ≥ 5 cigarettes per day
NCT02250664	50:56:lower_bound,64:76:upper_bound,111:124:gender	Self-report of binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks in a 2 hour period in females/males)
NCT02250664	1:18:chronic_disease	Suicidal ideation in the past month
NCT02250664	1:16:chronic_disease,24:37:upper_bound	Suicide attempt in the past 6 months
NCT02250664	1:5:age,6:8:lower_bound,9:11:upper_bound	ages 18-70
NCT02250664	38:50:lower_bound,60:70:lower_bound	pressure is greater than or equal to 160/100 mmHg or below 90/50 mmHg
NCT02250664	29:38:treatment,42:55:treatment,68:77:treatment	who are currently receiving methadone or buprenorphine maintenance treatment for opioid dependence
NCT02250664	1:6:gender	women
NCT02243813	23:52:treatment	Agree not to take any Pro-re-nata (PRN) medications on the mornings of drug sessions
NCT02243813	19:39:treatment,41:50:treatment,63:74:treatment,82:90:upper_bound	Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of each drug administration
NCT02243813	197:215:treatment	Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of psilocybin session days
NCT02243813	33:51:treatment,97:105:upper_bound	Agree to refrain from using any psychoactive drugs, including alcoholic beverages and nicotine, 24 hours before and after each drug administration
NCT02243813	82:102:chronic_disease,181:204:treatment	Be healthy and psychologically stable as determined by screening for medical and psychiatric problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests
NCT02243813	1:26:chronic_disease,28:51:chronic_disease,53:59:chronic_disease,61:67:chronic_disease,82:94:chronic_disease,121:144:treatment,164:195:chronic_disease,201:232:chronic_disease,240:249:upper_bound	Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant Electrocardiogram (ECG) abnormality (e.g., symptomatic atrial fibrillation), or Transient Ischemic Attack (TIA) in the past year
NCT02243813	90:103:chronic_disease	Current or past history of meeting Diagnostic and Statistics Manual (DSM)-5 criteria for Schizophrenia
NCT02243813	36:48:upper_bound,157:173:chronic_disease	Current or past history within the last 5 years of meeting DSM-5 criteria for alcohol or substance use disorder (excluding caffeine and nicotine) or severe major depression
NCT02243813	55:66:treatment,127:136:treatment,169:204:treatment	Currently taking on a regular (e.g., daily) basis any medications having a primary centrally-acting pharmacological effect on serotonin neurons or medications that are Mono amine Oxidase (MAO) inhibitors
NCT02243813	18:54:treatment	Currently taking psychoactive prescription medication on a regular (e.g., daily) basis
NCT02243813	1:9:chronic_disease,26:34:chronic_disease	Epilepsy with history of seizures
NCT02243813	74:87:treatment,89:126:treatment	Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals
NCT02243813	7:28:chronic_disease	Has a psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin
NCT02243813	45:58:chronic_disease,60:78:chronic_disease,140:164:chronic_disease	Have a first or second-degree relative with Schizophrenia, Psychotic Disorder (unless substance induced or due to a medical condition), or Bipolar I or II Disorder
NCT02243813	1:27:chronic_disease,39:56:treatment,83:95:chronic_disease	Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
NCT02243813	11:14:lower_bound,57:68:clinical_variable	More than 20% outside the upper or lower range of ideal body weight according to Metropolitan Life height and weight table
NCT02243813	1:19:chronic_disease,81:105:chronic_disease	Psychotic Disorder (unless substance-induced or due to a medical condition), or Bipolar I or II Disorder
NCT02243813	1:6:gender,11:23:pregnancy,43:67:pregnancy	Women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing
NCT02243813	1:6:gender,70:120:contraception_consent	women who are of child-bearing potential and sexually active who are not practicing an effective means of birth control
NCT02232516	1:32:clinical_variable,36:43:lower_bound	Absolute neutrophil count (ANC) >= 750/mcl
NCT02232516	1:38:cancer	Adult T-cell lymphoma/leukemia (ATLL)
NCT02232516	1:4:age,8:16:lower_bound,22:30:upper_bound	Age >= 18 years to < 60 years
NCT02232516	19:55:contraception_consent	All patients must agree to use effective contraception while on study
NCT02232516	62:84:treatment,71:84:treatment	All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program
NCT02232516	1:31:cancer	Anaplastic large cell lymphoma
NCT02232516	1:31:cancer,33:36:treatment	Anaplastic large cell lymphoma, ALK-positive
NCT02232516	1:31:cancer	Anaplastic large-cell lymphoma, primary cutaneous type
NCT02232516	1:35:cancer	Angioimmunoblastic T-cell lymphoma
NCT02232516	1:33:clinical_variable,35:81:clinical_variable,87:117:clinical_variable,119:163:clinical_variable,168:175:upper_bound	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum pyruvate glutamate transaminase [SPGT]) =< 3 x ULN
NCT02232516	1:19:chronic_disease	Cardiac arrhythmia
NCT02232516	1:11:clinical_variable,15:22:upper_bound	Creatinine =< 2 x ULN
NCT02232516	1:33:cancer	Enteropathy-type T-cell lymphoma
NCT02232516	1:59:cancer	Extranodal natural killer (NK)/T-cell lymphoma, nasal type
NCT02232516	18:51:pregnancy,42:51:pregnancy,64:76:upper_bound	FCPB must have a negative urine or serum pregnancy test within 7 days prior to registration, and be willing to adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS®) program
NCT02232516	1:8:gender,54:114:contraception_consent,118:163:contraception_consent,256:270:lower_bound,256:263:lower_bound,280:292:treatment,301:321:treatment	Females of childbearing potential (FCBP) must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, during lenalidomide therapy, during dose interruptions, and for at least 28 days following discontinuation of lenalidomide therapy
NCT02232516	1:11:clinical_variable,15:21:lower_bound	Hemoglobin >= 8 g/dl
NCT02232516	1:42:cancer	Hepatosplenic gamma-delta T-cell lymphoma
NCT02232516	39:43:cancer	Histologically confirmed diagnosis of PTCL (using the most recent edition of the World Health Organization [WHO] Classification of Tumors of Hematopoietic and Lymphoid Tissues as guidance)
NCT02232516	1:18:cancer,19:34:cancer	Mycosis fungoides/Sezary syndrome
NCT02232516	1:17:cancer	NK-cell leukemia
NCT02232516	12:28:chronic_disease	Ongoing or active infection
NCT02232516	36:48:cancer,56:62:lower_bound	Patients must be free of any prior malignancies for >= 1 year
NCT02232516	74:87:upper_bound	Patients must have adequate organ and marrow function (documented within 14 days prior to registration)
NCT02232516	23:83:clinical_variable,87:88:upper_bound	Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2
NCT02232516	20:55:clinical_variable,60:64:lower_bound,69:71:treatment	Patients must have bi-dimensionally measurable disease (>= 1 cm) by CT imaging
NCT02232516	33:55:treatment,48:55:treatment,60:64:cancer,77:92:treatment,97:99:upper_bound	Patients must not have received prior systemic therapy for PTCL (except for corticosteroids for 10 or fewer days at any dose, no washout period required as long as they discontinue prior to starting study therapy)
NCT02232516	20:37:treatment,53:75:treatment	Patients receiving ongoing treatment with any other investigational agents
NCT02232516	18:26:pregnancy	Patients who are pregnant or actively nursing an infant
NCT02232516	69:77:cancer	Patients who have known central nervous system (CNS) involvement of lymphoma
NCT02232516	23:35:treatment,47:68:treatment,73:85:treatment,126:139:upper_bound	Patients who received chemotherapy (including monoclonal antibodies) or radiotherapy, administered for any condition, within 4 weeks prior to registration are not eligible
NCT02232516	45:88:treatment,92:122:treatment	Patients who received prior exposure to any other histone deacetylase (HDAC) inhibitors or immunomodulatory (IMID) agents for any reason
NCT02232516	17:28:clinical_variable,31:39:lower_bound,76:89:upper_bound	Patients with a QT interval > 500 msec (using the Bazett's formula) within 28 days prior to registration
NCT02232516	23:51:chronic_disease	Patients with a known human immunodeficiency (HIV) infection
NCT02232516	66:72:treatment	Patients with adequate archived (well-preserved, formalin-fixed) biopsy tissue remaining will be required to submit a portion for exploratory studies
NCT02232516	15:34:chronic_disease	Patients with marrow-only disease
NCT02232516	1:27:cancer	Peripheral T-cell lymphoma, unspecified (not otherwise specified [NOS])
NCT02232516	1:10:clinical_variable,14:24:lower_bound	Platelets >= 50,000/mcl
NCT02232516	1:35:cancer,36:44:cancer	Precursor T-lymphoblastic lymphoma/leukemia
NCT02232516	1:20:chronic_disease	Psychiatric illness/social situations that would limit compliance with study requirements
NCT02232516	1:47:cancer	Subcutaneous panniculitis-like T-cell lymphoma
NCT02232516	13:37:chronic_disease	Symptomatic congestive heart failure
NCT02232516	1:37:cancer	T-cell granular lymphocytic leukemia
NCT02232516	1:31:cancer	T-cell prolymphocytic leukemia
NCT02232516	1:16:clinical_variable,20:48:upper_bound	Total bilirubin =< 2 x upper limit normal (ULN)
NCT02232516	13:30:cancer	Transformed mycosis fungoides
NCT02232516	1:25:chronic_disease	Unstable angina pectoris
NCT02232516	36:55:treatment,62:69:upper_bound,76:85:pregnancy	all patients must agree to undergo counseling sessions every 28 days about pregnancy precautions and risks of fetal exposure
NCT02232516	1:44:cancer	anaplastic large cell kinase (ALK)-negative
NCT02232516	19:32:cancer,37:69:cancer,71:102:cancer,104:110:cancer,115:122:cancer,146:174:cancer	currently treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or surgically removed melanoma in situ of the skin (stage 0) with histologically confirmed free margins of excision
NCT02232516	7:24:treatment	these topical therapies should be stopped at time of registration
NCT02232516	1:18:chronic_disease,62:80:cancer,112:116:cancer	topical treatment may have been given for prior existence of cutaneous lymphoma that has since become systemic PTCL
NCT02232516	13:35:cancer	transformed Mycosis fungoides [MF]
NCT02232516	8:52:clinical_variable,56:57:lower_bound,83:105:treatment	with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator
NCT02221830	1:22:chronic_disease,24:30:chronic_disease,32:39:chronic_disease	abnormal placentation (previa, accreta, etc)
NCT02221830	1:21:chronic_disease	antenatal hemorrhage
NCT02221830	21:29:allergy_name	contraindication to oxytocin
NCT02221830	14:26:chronic_disease,145:154:pregnancy,164:187:clinical_variable,201:210:lower_bound,201:202:lower_bound,216:240:clinical_variable,254:262:lower_bound,275:276:lower_bound,296:303:lower_bound,310:324:upper_bound,339:350:clinical_variable,356:380:lower_bound,392:400:clinical_variable	diagnosis of preeclampsia (PE defined using standard definitions based on the ACOG bulletin and the NIH Working Group on High Blood Pressure in Pregnancy (i.e., a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of > 300mg per 24 hour period or > 1+ on dipstick)
NCT02221830	23:40:treatment,45:53:upper_bound,134:153:treatment	patients treated with magnesium sulfate for 24 hours post partum at 2g/hr (standard of care when deemed appropriate by clinician for seizure prophylaxis)
NCT02221830	35:50:clinical_variable,76:84:lower_bound	vaginal or cesarean delivery at a gestational age greater than or equal to 20 weeks gestational age
NCT02214550	37:39:lower_bound,40:46:upper_bound,48:64:clinical_variable,81:90:lower_bound	Participants must have had regular (22-45 day) menstrual cycles over at least a two month period preceding testing
NCT02214550	14:17:age,18:23:gender,25:27:lower_bound,28:30:upper_bound	Reproductive age women (18-45)
NCT02214550	46:55:pregnancy	absence of regular menses (including current pregnancy, recent pregnancy, or active breast feeding) unwilling to take either cyclic or combined OCs
NCT02214550	8:31:chronic_disease,39:54:upper_bound	active genitourinary infection in the last four weeks
NCT02214550	20:52:cancer	presence of active pelvic or abdominal malignancies (primary or metastatic)
NCT02214550	13:25:chronic_disease	presence of hypertension or risk for developing hypertension
NCT02214550	1:61:language_fluency	unable to read or comprehend the informed consent in English
NCT02214550	36:52:upper_bound	unwilling to withdraw from OCs for two months prior to the Aim #1 study visit
NCT02207439	1:26:clinical_variable,29:41:upper_bound	Absolute Neutrophil Count ≤ 1500 per mm3
NCT02207439	1:16:treatment,1:17:treatment,19:32:treatment,34:47:treatment,65:74:treatment,76:94:treatment,95:104:treatment,106:121:treatment,123:133:treatment,135:145:treatment,147:156:treatment,158:165:treatment,167:187:treatment,189:201:treatment,203:215:treatment,217:236:treatment,238:250:treatment,251:261:treatment,263:272:treatment,274:292:treatment,294:303:treatment,305:323:treatment,324:341:treatment,343:363:treatment,364:376:treatment,378:411:treatment,413:427:treatment,429:438:treatment	Anti-Convulsants: carbamazepine, Phenobarbital, Anti-Convulsant:phenytoin, Anti-Mycobacterial:rifabutin, PDE5 Inhibitors: sildenafil, vardenafil, tadalafil, HMG-CoA: Reductase Inhibitors: atorvastatin, rosuvastatin, Immuno-suppressants: cyclosporine,tacrolimus, sirolimus, Narcotic Analgesic: methadone, Oral Contraceptive:ethinyl estradiol, Macrolide Antibiotic:azithromycin, Inhaled/nasal steroid fluticasone, Antidepressant: trazodone
NCT02207439	1:16:treatment,17:27:treatment,29:38:treatment,40:57:treatment,59:67:treatment,69:86:treatment,87:104:treatment,94:104:treatment,106:116:treatment,130:146:treatment,148:163:treatment	Antiarrhythmics:amiodarone, quinidine, Antimycobacterial: rifampin, Ergot Derivatives:dihydroergotamine, ergonovine, ergotamine, methylergonovine, Herbal Products
NCT02207439	89:110:treatment,115:132:treatment	Determined by the treating physician to be a candidate for organ preserving, concurrent standard chemotherapy and radiation therapy to the head and neck with definitive intent
NCT02207439	1:19:cancer	Distant metastases
NCT02207439	1:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	ECOG Performance Status 0-2
NCT02207439	39:62:cancer,159:179:treatment	Histologically confirmed diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx stages III, IVa, or IVb, p16-negative on immunohistochemistry
NCT02207439	44:50:allergy_name,52:65:allergy_name,110:115:allergy_name	History of allergic reactionsattributed to Flagyl (metronidazole), which has a chemical structure similar to FMISO
NCT02207439	116:125:treatment	Patients must sign an informed consent document that indicates they are aware of the investigational nature of the treatment in this protocol as well as the potential risks and benefits
NCT02207439	34:39:treatment,90:100:treatment	Patients receiving the following drugs will be clinically evaluated as to whether dosage/medication can be changed to permit patient on study
NCT02207439	21:32:chronic_disease	Patients with known HIV disease
NCT02207439	12:20:lower_bound	Patients ≥ 18 years old
NCT02207439	1:15:clinical_variable,18:33:upper_bound	Platelet count ≤ 100,000 per mm3
NCT02207439	1:9:pregnancy	Pregnant
NCT02207439	10:17:treatment,25:59:chronic_disease,60:78:treatment	Previous therapy with a human immunodeficiency virus (HIV) protease inhibitor
NCT02207439	1:19:treatment,31:43:upper_bound	Prior chemotherapy within the past 5 years
NCT02207439	1:45:treatment	Prior radiation therapy to the head and neck
NCT02207439	1:10:clinical_variable,14:17:clinical_variable,20:53:lower_bound	Serum AST or ALT > 2 times the upper limit of normal
NCT02207439	1:16:clinical_variable,19:28:lower_bound	Serum bilirubin > 1.2 mg/dl
NCT02207439	1:17:clinical_variable,20:55:lower_bound	Serum creatinine > 1.5 times the upper limit of normal
NCT02207439	7:16:pregnancy,46:51:gender	Serum pregnancy testing will be required for women of childbearing potential
NCT02207439	10:15:gender,16:31:pregnancy,23:31:pregnancy	Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
NCT02207439	1:38:treatment,40:68:treatment,70:80:treatment,81:92:treatment,94:105:treatment,106:114:treatment,116:138:treatment,140:158:treatment,160:169:treatment,171:180:treatment	St.John's wort (hypericum perforatum), HMG-CoA Reductase Inhibitors: lovastatin,simvastatin, Neuroleptic:pimozide, Proton Pump Inhibitors, Sedative/Hypnotics: midazolam, triazolam
NCT02207439	31:44:chronic_disease	Subjects with moderate-severe renal disease
NCT02207439	43:81:treatment,110:120:treatment	These patients have a high probability of treatment with anti-retroviral therapy which may interact with the nelfinavir
NCT02207439	77:101:chronic_disease,103:127:chronic_disease,132:151:chronic_disease	Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02207439	1:7:clinical_variable,18:21:lower_bound,31:44:upper_bound,61:83:chronic_disease	Weight loss of > 10% over the past 6 months which is due to tumor wasting syndrome
NCT02207439	1:6:gender,73:88:pregnancy	Women of childbearing potential who have a positive result on screening urine pregnancy test
NCT02207439	1:6:gender,3:6:gender,46:81:contraception_consent,83:126:contraception_consent,170:183:upper_bound,208:225:treatment	women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, during study, until 1 month after completion of the final FMISO PET/CT scan
NCT02197351	17:39:treatment,50:61:treatment,63:74:treatment,76:84:treatment,86:93:treatment,95:105:treatment,111:120:treatment,124:137:treatment	Patients taking anti-thrombotic agents including clopidogrel, ticlopidine, coumadin, heparin, enoxaparin, and direct II or Xa inhibitors
NCT02197351	38:63:chronic_disease	Patients who have evidence of active gastrointestinal bleeding will be excluded
NCT02197351	15:18:clinical_variable,20:23:lower_bound,25:39:clinical_variable,41:47:upper_bound	Patients with INR >1.5, platelet count <75,000
NCT02197351	101:107:chronic_disease,116:121:chronic_disease	gastric indications include upper abdominal pain dyspepsia abnormal gastric imaging iron deficiency anemia gastric ulcer management of GI blood loss without active bleeding reflux weight loss
NCT02197351	16:31:treatment	presenting for upper endoscopy for gastric indications
NCT02197351	14:16:upper_bound	younger than 18
NCT02184520	49:53:lower_bound,66:71:upper_bound	Able to meet the proposed follow-up schedule at 6 mo, 12 mo, and 24 mo
NCT02184520	8:16:chronic_disease,20:35:chronic_disease	Active systemic or local infection
NCT02184520	1:21:chronic_disease	Acute mental illness or substance abuse
NCT02184520	1:4:age,5:7:lower_bound	Age 18 or older at the time of consent
NCT02184520	8:25:cancer,15:25:cancer,54:73:cancer,82:106:cancer,132:160:treatment,241:248:lower_bound	Has an active malignancy defined as a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there has been no clinical signs or symptoms of the malignancy for at least 5 years
NCT02184520	35:43:allergy_name,45:64:allergy_name,66:97:allergy_name,102:121:allergy_name	Known allergy to device materials titanium, polycarbonate (PCU), polyethylene terepthalate (PET), or hydroxyapatite (HA)
NCT02184520	1:24:chronic_disease	Lytic spondylolisthesis at the index level(s)
NCT02184520	1:15:chronic_disease,29:44:bmi,47:49:lower_bound,56:62:clinical_variable,73:80:lower_bound	Morbid obesity defined as a body mass index > 40, or a weight more than 100 lbs over ideal body weight
NCT02184520	1:24:chronic_disease,33:51:chronic_disease,53:76:chronic_disease,78:107:chronic_disease	Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, etc
NCT02184520	21:43:treatment,47:67:treatment,75:82:upper_bound,86:93:treatment	Participation in an investigational device or drug clinical trials within 30 days of surgery
NCT02184520	1:9:pregnancy,27:44:pregnancy,56:68:upper_bound	Pregnant or interested in becoming pregnant within the next 2 years
NCT02184520	1:21:treatment,33:46:treatment	Prior fusion surgery or another spinal device implanted in the thoracic, lumbar or sacral spine
NCT02184520	10:19:treatment	Requires treatment of more than two vertebral levels
NCT02184520	28:32:chronic_disease,34:37:chronic_disease,39:50:chronic_disease	Systemic disease including AIDS, HIV, Hepatitis C
NCT02184520	8:19:treatment,68:92:treatment,100:108:treatment,128:134:treatment	Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids, excluding routine NSAIDs)
NCT02184520	1:31:chronic_disease,59:80:chronic_disease	degenerative spondylolisthesis with objective evidence of neurologic impairment
NCT02184520	1:9:chronic_disease	kyphosis
NCT02184520	1:16:chronic_disease	pseudoarthrosis (failed previous fusion)
NCT02180412	16:33:chronic_disease,68:84:clinical_variable	A diagnosis of diabetes mellitus, which might increase the risk of glucose infusion
NCT02180412	17:23:upper_bound,149:158:chronic_disease	Acute symptoms (7 days duration or less to time of enrollment) such as abdominal, back and/or limb pain, diagnosed by the investigator as caused by porphyria after initial evaluation has excluded other causes
NCT02180412	87:108:chronic_disease	Diagnosis of acute porphyria documented by a substantial increase in urinary or serum porphobilinogen (PBG)
NCT02180412	5:39:chronic_disease	For acute intermittent porphyria (AIP): Normal or only slight increases in plasma and fecal porphyrins
NCT02180412	5:36:chronic_disease,63:79:treatment	For hereditary coproporphyria (HCP): Substantial increases in fecal porphyrins (almost entirely coproporphyrin III)
NCT02180412	5:29:chronic_disease,302:334:treatment	For variegate porphyria (VP): Substantial increases in fecal porphyrins (mostly coproporphyrin III and protoporphyrin), increased plasma total porphyrins and a fluorescence emission maximum of diluted plasma at neutral pH near 626 nm. Almost all (~95 percent) will have a demonstrable disease-causing protoporphyrinogen oxidase (PPO) mutation
NCT02180412	1:14:chronic_disease,36:42:chronic_disease	Heart failure, significant chronic anemia or any disease or condition that the investigator judges would lead to an unacceptable risk to the patient or interfere with the successful collection of date for the trial
NCT02180412	31:41:allergy_name	Known or suspected allergy to Panhematin™ or related products
NCT02180412	1:5:gender	Male
NCT02180412	52:96:treatment,115:125:lower_bound	Most (~90 percent) will have deficient activity of erythrocyte porphobilinogen deaminase (PBGD), and almost all (>95 percent) will have a demonstrable disease-causing PBGD mutation
NCT02180412	46:55:treatment,64:77:treatment	Preexisting coagulation defect or concurrent treatment with an anticoagulant
NCT02180412	23:39:chronic_disease,53:69:clinical_variable,76:85:lower_bound,89:99:lower_bound	Previously documented renal impairment defined as a serum creatinine above 1.7 mg/dL or 150 mmol/L
NCT02180412	1:19:treatment,27:39:upper_bound	Therapy with hemin within 7 days prior to enrollment in this study
NCT02180412	9:24:chronic_disease,128:137:treatment,151:163:treatment	Type of acute porphyria confirmed by additional testing (in addition to increased PBG), which may be completed before or after treatment begins using pretreatment samples
NCT02180412	1:5:age,6:14:lower_bound	aged 18 years
NCT02180412	1:7:gender	female
NCT02180243	26:36:treatment	Current involvement in a meditation or acupuncture group
NCT02180243	11:16:chronic_disease	Currently manic
NCT02180243	24:50:chronic_disease,57:64:chronic_disease,66:70:chronic_disease,72:92:chronic_disease	Currently suffers from Gulf War Veterans' Illness (i.e. fatigue, pain, cognitive impairment)
NCT02180243	11:19:chronic_disease	Currently suicidal
NCT02180243	34:38:lower_bound,39:43:upper_bound	Deployed to the Gulf War between 1990-1991
NCT02176967	3:12:upper_bound,16:24:upper_bound,29:32:age,51:64:cancer	< 12 months (< 365 days) of age at diagnosis with INRG stage L1
NCT02176967	3:12:upper_bound,16:19:age,27:51:clinical_variable,54:79:upper_bound	< 12 months of age with a non-adrenal primary site < 5 cm in greatest diameter
NCT02176967	3:12:upper_bound,16:24:upper_bound,29:32:age,77:90:cancer,91:111:cancer	< 18 months (< 547 days) of age at diagnosis with INRG stage L2 or stage Ms neuroblastoma/ganglioneuroblastoma
NCT02176967	4:12:upper_bound,16:19:age,28:58:clinical_variable,62:68:upper_bound	=< 6 months of age with an adrenal primary site and tumor =< 3.1 cm in greatest diameter
NCT02176967	3:11:lower_bound,18:27:upper_bound,31:34:age,51:64:cancer,67:71:upper_bound	> 6 months and < 12 months of age with an adrenal primary tumor < 5 cm in greatest diameter
NCT02176967	15:23:treatment,27:35:treatment	Enrollment on ANBL00B1 or APEC14B1 is required for all newly diagnosed patients
NCT02176967	10:24:clinical_variable,27:31:upper_bound	Greatest tumor diameter < 5 cm of adrenal or non-adrenal origin
NCT02176967	49:54:cancer,55:61:treatment,100:107:upper_bound	Group A and C patients, not required to undergo tumor biopsy, who do not enroll on ANBL1232 within 4 weeks of confirmatory imaging study
NCT02176967	61:68:upper_bound	Group B and C patients who do not enroll on ANBL1232 within 4 weeks of definitive diagnostic procedure
NCT02176967	98:106:cancer,110:128:cancer,156:177:chronic_disease,245:269:chronic_disease,342:372:chronic_disease,374:393:chronic_disease,403:418:chronic_disease	No life threatening symptoms or no impending neurologic or other organ function compromise (e.g. epidural or intraspinal tumors with existing or impending neurologic impairment, periorbital or calvarial-based lesions with existing or impending cranial nerve impairment, anatomic or mechanical compromise of critical organ function by tumor [abdominal compartment syndrome, urinary obstruction, etc.]); horner syndrome is not considered neurologic compromise
NCT02176967	4:22:treatment,26:38:treatment,62:75:treatment	No prior radiotherapy or chemotherapy, with the exception of dexamethasone, which is allowed
NCT02176967	4:25:treatment,29:35:treatment	No prior tumor resection or biopsy
NCT02176967	4:25:treatment,27:39:treatment	No prior tumor resection, tumor biopsy ONLY
NCT02176967	20:45:cancer	Only patients with MYCN non-amplified tumors
NCT02176967	20:28:upper_bound,32:35:age,44:65:cancer,68:71:lower_bound,78:82:upper_bound	Patients less than 6 months of age with an adrenal primary tumor > 3.1 and < 5 cm in greatest diameter
NCT02176967	48:64:cancer,80:93:cancer,249:269:cancer	Patients must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma (International Classification of Diseases for Oncology [ICD-O] morphology 9500/3) or MYCN non-amplified ganglioneuroblastoma verified by histology
NCT02176967	58:67:treatment	Patients must meet the specified criteria for one of the treatment groups defined below; genomic features include MYCN gene amplification, segmental chromosome aberrations (somatic copy number loss at 1p, 3p, 4p, or 11q or somatic copy number gain at 1q, 2p, or 17q) and deoxyribonucleic acid (DNA) index
NCT02176967	30:36:cancer	Patients with MYCN amplified tumors
NCT02176967	84:114:treatment,132:145:clinical_variable,203:216:cancer	Patients with non-adrenal primaries are eligible, but must have positive uptake on metaiodobenzylguanidine (MIBG) scan or elevated catecholamine metabolites (urine or serum) to support the diagnosis of neuroblastoma
NCT02176967	33:36:lower_bound,71:89:cancer,91:100:clinical_variable,103:104:lower_bound	genomic features are defined by one or more whole-chromosome gains or hyperdiploid tumor (DNA index > 1) in the absence of segmental chromosome aberrations
NCT02176967	53:84:chronic_disease,183:196:cancer,198:207:clinical_variable	genomic features are defined by the presence of any segmental chromosome aberration (somatic copy number loss at 1p, 3p, 4p, or 11q or somatic copy number gain at 1q, 2p, or 17q) or diploid tumor (DNA index = 1); this includes copy neutral loss of heterozygosity (LOH)
NCT02176967	12:21:upper_bound,25:33:upper_bound,38:41:age,77:90:cancer,91:111:cancer	patients < 12 months (< 365 days) of age with newly diagnosed INRG stage L1 neuroblastoma/ganglioneuroblastoma
NCT02176967	12:21:upper_bound,25:33:upper_bound,38:41:age,77:90:cancer,91:111:cancer	patients < 18 months (< 547 days) of age with newly diagnosed INRG stage L2 neuroblastoma/ganglioneuroblastoma
NCT02176967	12:21:upper_bound,25:33:upper_bound,38:41:age,77:90:cancer,91:111:cancer	patients < 18 months (< 547 days) of age with newly diagnosed INRG stage Ms neuroblastoma/ganglioneuroblastoma
NCT02169037	2:17:clinical_variable,20:28:lower_bound	(LA volume index > 60 ml/m2)
NCT02169037	40:55:chronic_disease	AF secondary to electrolyte imbalance, thyroid disease
NCT02169037	1:19:treatment,21:39:treatment,41:77:treatment	ASD closure device, LAA closure device, prosthetic mitral or tricuspid valve
NCT02169037	1:25:chronic_disease	Congestive heart failure (1 point)
NCT02169037	21:29:treatment,39:64:treatment	Contraindication to Warfarin or other novel oral anticoagulants
NCT02169037	1:5:clinical_variable,10:13:lower_bound	LVEF >or=40%
NCT02169037	1:11:clinical_variable,12:13:lower_bound,17:19:upper_bound,30:45:treatment,52:59:lower_bound	NYHA Class 0,I, II stable on medical therapy for > 3months
NCT02169037	1:13:clinical_variable,14:17:lower_bound,19:21:upper_bound	NYHA classes III, IV
NCT02169037	1:23:chronic_disease,50:58:treatment,80:105:chronic_disease,111:132:chronic_disease	acquired heart disease that may increase risk of ablation, such as significant ventricular septal defect post myocardial infarction
NCT02169037	1:14:chronic_disease,18:43:chronic_disease,47:53:chronic_disease	acute illness or active systemic infection or sepsis that may ordinarily warrant postponement of the procedure
NCT02169037	1:4:age,5:13:lower_bound	age 65 years or older (1 point)
NCT02169037	1:4:age,5:13:lower_bound	age 75 years or older (2 points)
NCT02169037	12:30:treatment,12:20:treatment	at time of ablation procedure, clinically significant abnormalities in serum potassium, sodium, magnesium or other electrolytes that affect the suitability of the patient for ablation at that time
NCT02169037	1:21:chronic_disease,46:83:treatment,91:99:upper_bound	atrial clot/thrombus on imaging such as on a trans-esophageal echocardiogram (TEE) within 72 hours of the procedure
NCT02169037	1:20:chronic_disease,52:59:treatment,61:76:chronic_disease,78:90:chronic_disease	atrial fibrillation from a reversible cause (e.g., surgery, hyperthyroidism, pericarditis)
NCT02169037	1:8:treatment,12:28:treatment,40:53:upper_bound	cardiac or thoracic surgery within the past 180 days
NCT02169037	1:24:treatment,34:49:treatment,69:77:upper_bound	cardiac transplantation or other cardiac surgery planned within the 12 month followup period of the trial
NCT02169037	1:25:chronic_disease,99:107:treatment	congenital heart disease where the abnormality or its correction prohibit or increase the risk of ablation
NCT02169037	21:28:treatment	contraindication to Heparin
NCT02169037	1:9:chronic_disease	diabetes (1 point)
NCT02169037	9:32:chronic_disease	extreme left atrial enlargement
NCT02169037	1:14:chronic_disease,37:52:treatment	heart failure that is not stable on medical therapy
NCT02169037	19:42:chronic_disease,44:50:chronic_disease,54:57:chronic_disease,62:86:clinical_variable,96:104:upper_bound	history of recent cerebrovascular disease (stroke or TIA) or systemic thromboembolism within < 6 months
NCT02169037	24:46:chronic_disease	history of significant bleeding abnormalities
NCT02169037	24:52:chronic_disease,54:70:chronic_disease,74:95:chronic_disease	history of significant blood clotting abnormalities, systemic thrombi or systemic embolization
NCT02169037	1:13:chronic_disease	hypertention (1 point)
NCT02169037	9:12:treatment	in whom PVI has low success and 55 mm baskets are too small for the atria
NCT02169037	1:20:chronic_disease,30:42:cancer,69:77:treatment	intramural thrombus or other cardiac mass that may adversely effect catheter introduction or manipulation
NCT02169037	1:21:clinical_variable,27:32:upper_bound	left atrial diameter <or= 5.5cm
NCT02169037	1:16:clinical_variable,27:36:upper_bound	life expectancy less than 12 months (the followup period of the trial)
NCT02169037	1:5:gender,9:15:gender	male or female
NCT02169037	1:27:chronic_disease,39:56:upper_bound	myocardial infarction (MI) within the past three months
NCT02169037	1:21:treatment,70:73:lower_bound,115:125:clinical_variable	oral anticoagulation required for those subjects who have a score of two or more based on the following criteria (CHAD score)
NCT02169037	7:13:chronic_disease,17:42:chronic_disease	prior stroke or transient ischemic attack (2 points)
NCT02169037	1:16:chronic_disease,40:50:treatment,54:62:treatment	pulmonary edema, that may make planned anesthesia or sedation difficult
NCT02169037	24:27:lower_bound,28:35:lower_bound,39:42:upper_bound,43:70:treatment	refractory to at least one Class I or III anti-arrhythmic medications
NCT02169037	32:35:lower_bound,71:106:chronic_disease,118:140:upper_bound,163:164:lower_bound,187:198:treatment,202:218:treatment	reported incidence of at least two documented episodes of symptomatic paroxysmal atrial fibrillation (AF) during the three months preceding trial entry (at least 1 episode documented by 12-lead ECG or ECG rhythm strip)
NCT02169037	1:24:chronic_disease	rheumatic valve disease, since this produces a unique AF phenotype
NCT02169037	15:21:gender	sex category: female (1 point)
NCT02169037	13:30:chronic_disease,38:42:chronic_disease	significant pulmonary disease (e.g., COPD) or any other disease that significantly increase the risk to the patient from sedation or anesthesia
NCT02169037	13:30:chronic_disease,38:46:upper_bound	significant pulmonary embolus within 6 months of enrollment
NCT02169037	1:23:chronic_disease,35:54:treatment	stable/unstable angina or ongoing myocardial ischemia
NCT02169037	1:25:chronic_disease	structural heart disease of clinical significance
NCT02169037	11:13:chronic_disease	sustained AF during the procedure
NCT02169037	24:38:allergy_name	untreatable allergy to contrast media
NCT02169037	1:17:chronic_disease	vascular disease (1 point)
NCT02169037	115:137:treatment	willingness, ability and commitment to participate in baseline and follow-up evaluations without participation in another clinical trial (unless documented approval received from both sponsors)
NCT02169037	1:6:gender,81:93:pregnancy	women without childbearing potential or women of childbearing potential who are not pregnant per a serum HCG test
NCT02161380	58:70:treatment	A previous CLIA certified genetic lab result showing the LHON G11778A mutation will be accepted for inclusion
NCT02161380	1:4:age,5:7:lower_bound	Age 15 or older
NCT02161380	12:32:allergy_name,36:74:allergy_name	Allergy to pupil dilating drops or narrow angles precluding safe dilation
NCT02161380	1:29:clinical_variable,30:56:clinical_variable,58:91:lower_bound,93:108:clinical_variable,110:117:lower_bound,119:129:clinical_variable,132:138:upper_bound,140:156:clinical_variable,158:169:upper_bound,174:188:clinical_variable,191:201:upper_bound	Aspartate transaminase (AST)/alanine transaminase (ALT) >5.0 x upper limit of normal (ULN); Total bilirubin >3 x ULN; Hemoglobin < 8 g/dL; neutrophil count <1.0 x 109/L; or platelet count < 50 x 109/L
NCT02161380	12:33:chronic_disease,40:68:chronic_disease	History of autoimmune conditions (e.g. systemic lupus erythematosus)
NCT02161380	12:18:cancer,26:36:upper_bound,58:63:cancer,67:90:cancer	History of cancer within five years other than localized basal or squamous cell carcinoma not near the orbital area
NCT02161380	12:40:chronic_disease,47:65:chronic_disease,67:87:chronic_disease,89:106:chronic_disease	History of neurodegenerative conditions (e.g. multiple sclerosis, neuromyelitis optica, Parkinson disease)
NCT02161380	1:16:chronic_disease,20:38:chronic_disease,61:77:chronic_disease,84:93:chronic_disease,95:103:chronic_disease	Ocular diseases or visual dysfunction conditions other than refractive error (e.g. amblyopia, glaucoma, etc.) in the eye selected for the injection
NCT02161380	15:19:chronic_disease,28:49:clinical_variable	Patients with LHON and the G11778A mitochondrial DNA mutation
NCT02161380	34:40:cancer,129:136:lower_bound	Patients with a prior history of cancer will need documentation from their cancer specialist that the cancer was cured at least 5 years before study entry
NCT02161380	1:9:pregnancy,21:26:gender,30:104:contraception_consent	Pregnant or nursing women or unwillingness for subject with childbearing potential to use contraception during the first year of the study
NCT02161380	1:21:treatment	Previous eye surgery in the eye selected for injection
NCT02161380	1:16:chronic_disease,36:56:chronic_disease	Type I diabetes or the presence of diabetic retinopathy
NCT02145260	1:24:chronic_disease,32:42:upper_bound	Acute coronary syndrome within seven days
NCT02145260	1:13:chronic_disease	Acute stroke
NCT02145260	1:4:age,6:9:lower_bound	Age ≥18y
NCT02145260	1:11:chronic_disease,14:21:lower_bound	Chronic HD (>90 days)
NCT02145260	26:34:upper_bound	Expected length of stay <24 hours (e.g. admission for HD access procedure)
NCT02145260	1:13:treatment,14:17:clinical_variable,19:27:lower_bound	Pre-dialysis SBP >180 mmHg
NCT02145260	1:26:clinical_variable,29:38:upper_bound,44:54:lower_bound	Pre-dialysis serum sodium <=128mmol/L or > 145 mmol/L
NCT02145260	1:10:pregnancy	Pregnancy
NCT02145260	8:16:treatment	Use of pressors
NCT02132598	11:18:chronic_disease	Abdominal fistula
NCT02132598	1:32:clinical_variable,34:43:lower_bound	Absolute Neutrophil Count (ANC) ≥1,500/mm3 (no CSF support)
NCT02132598	8:28:chronic_disease	Active peptic ulcer disease
NCT02132598	1:4:age,6:14:lower_bound	Age ≥18 years
NCT02132598	1:38:clinical_variable,40:49:upper_bound	Alanine Aminotransferase (ALT) (SGPT) ≤3.0 × ULN
NCT02132598	32:43:chronic_disease	Any history of congenital long QT syndrome
NCT02132598	29:37:upper_bound,69:78:treatment	Any of the following within 6 months before the first dose of study treatment
NCT02132598	31:51:chronic_disease,59:67:upper_bound,99:108:treatment	Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
NCT02132598	1:40:clinical_variable,42:51:upper_bound	Aspartate Aminotransferase (AST) (SGOT) ≤3.0 × ULN
NCT02132598	1:10:clinical_variable,12:29:chronic_disease,33:42:upper_bound	Bilirubin (Gilbert's Disease) < 3.0 mg/dL
NCT02132598	1:10:clinical_variable,13:46:upper_bound	Bilirubin ≤ 1.5 x upper limit of normal (ULN)
NCT02132598	1:18:chronic_disease,22:48:chronic_disease	Bowel obstruction or gastric outlet obstruction
NCT02132598	1:25:chronic_disease	Cardiovascular disorders
NCT02132598	24:49:chronic_disease,57:72:upper_bound,97:106:treatment,109:119:clinical_variable,125:145:lower_bound,166:181:upper_bound	Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment b.Hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment
NCT02132598	26:40:chronic_disease,44:63:chronic_disease,71:84:upper_bound,109:118:treatment	Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
NCT02132598	12:37:chronic_disease,59:61:clinical_variable,64:73:lower_bound,89:97:lower_bound,116:150:treatment,141:150:treatment,158:164:upper_bound	Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment
NCT02132598	1:31:chronic_disease,33:66:clinical_variable,67:76:lower_bound,91:99:upper_bound	Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening
NCT02132598	1:28:clinical_variable,30:39:lower_bound	Creatinine clearance (CrCl) ≥40 mL/min
NCT02132598	1:61:clinical_variable,63:64:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status ≤2
NCT02132598	1:7:gender,34:38:lower_bound,41:50:upper_bound	Female: Multiply above result by 0.85 ≤ 1.5 x ULN
NCT02132598	15:27:treatment,44:51:lower_bound,58:65:treatment	First dose of cabozantinib occurs at least 28 days after surgery, and the subject has recovered from the effects of surgery
NCT02132598	17:22:gender,19:22:gender,63:156:contraception_consent,186:200:upper_bound,218:228:treatment	For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after the last dose of study drug, even if oral contraceptives are used
NCT02132598	1:27:chronic_disease,78:89:chronic_disease,93:110:chronic_disease	Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation
NCT02132598	1:29:chronic_disease	Gastrointestinal perforation
NCT02132598	1:11:clinical_variable,13:19:lower_bound	Hemoglobin ≥9 g/dL
NCT02132598	12:28:treatment	History of organ transplant
NCT02132598	12:19:treatment	History of surgery
NCT02132598	1:27:chronic_disease,39:57:chronic_disease,62:77:chronic_disease,80:94:chronic_disease,96:109:chronic_disease,123:134:chronic_disease,138:150:chronic_disease	Inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis
NCT02132598	1:24:chronic_disease	Intra-abdominal abscess
NCT02132598	17:22:cancer,23:33:cancer	Intra-abdominal tumor/metastases invading GI mucosa
NCT02132598	1:10:clinical_variable,12:15:lower_bound	Karnofsky ≥60%
NCT02132598	1:7:clinical_variable,47:59:chronic_disease,63:72:upper_bound	Lipase (no radiologic or clinical evidence of pancreatitis) < 2.0 x ULN
NCT02132598	1:23:chronic_disease	Malabsorption syndrome
NCT02132598	1:5:gender,30:33:age,37:39:clinical_variable	Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72)
NCT02132598	7:16:chronic_disease,76:132:treatment,140:155:upper_bound,174:187:treatment	Other disorders associated with a high risk of fistula formation including Percutaneous Endoscopic Gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy
NCT02132598	48:62:upper_bound,81:93:treatment,102:110:treatment,112:121:treatment,123:133:treatment,139:154:treatment	Other enzyme inducing agents prohibited within 2 weeks before the first dose of cabozantinib include rifampin, rifabutin, rifapentin, and St. John's Wort
NCT02132598	7:20:treatment,28:35:upper_bound,57:69:treatment	Other minor surgery within 28 days of the first dose of cabozantinib if there were no wound healing complications
NCT02132598	79:85:upper_bound,99:108:treatment	Patients must have normal organ and marrow function as defined below: (within 4 days of beginning treatment unless noted otherwise)
NCT02132598	54:70:chronic_disease,84:93:treatment,97:135:treatment	Patients must have received at least one regimen for systemic disease which may be cytotoxic or oral tyrosine kinase inhibitor therapy
NCT02132598	20:25:cancer,95:136:treatment	Patients must have tumor tissue available for submission that is sufficient to complete c-MET Fluorescence in Situ Hybridization (FISH) studies as well as routine molecular profiling at the UPMC
NCT02132598	20:35:treatment,91:103:upper_bound,120:133:treatment	Patients receiving glucocorticoids must be on a stable dose of glucocorticoids during the 5 days prior to the baseline brain imaging
NCT02132598	29:38:treatment,49:65:treatment,71:95:treatment,97:122:treatment,127:145:treatment	Patients who have undergone treatment for their brain metastases with whole brain radiotherapy, stereotactic radiosurgery, or surgical resection must be clinically stable and recovered from all procedures at the time of study enrollment
NCT02132598	49:65:cancer	Patients with clinically asymptomatic untreated brain metastases will be allowed on trial at the discretion of the treating physician
NCT02132598	11:17:cancer,43:99:treatment,101:132:treatment,138:170:treatment	Patients' tumors must undergo testing for Epidermal Growth Factor Receptor (EGFR) exon 19 deletion, EGFR exon 21 L858R substitution, and anaplastic lymphoma kinase (ALK) rearrangements
NCT02132598	1:10:clinical_variable,12:23:lower_bound	Platelets ≥100,000/mm3
NCT02132598	34:52:cancer,66:82:cancer,105:114:treatment	Previously treated patients with non-squamous NSCLC who have had brain metastases at any point in their treatment history
NCT02132598	1:34:treatment,44:66:treatment	Prior treatment with cabozantinib or other c-MET directed therapy
NCT02132598	9:25:chronic_disease,36:54:treatment,45:54:treatment,62:69:upper_bound	Serious active infection requiring systemic treatment within 28 days before the first dose of study treatment
NCT02132598	1:26:chronic_disease,27:32:chronic_disease,54:68:upper_bound,93:102:treatment	Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
NCT02132598	1:17:clinical_variable,20:29:upper_bound	Serum creatinine ≤ 1.5 x ULN
NCT02132598	1:17:clinical_variable,19:26:clinical_variable,28:37:clinical_variable,42:51:clinical_variable	Serum phosphorus, calcium, magnesium and potassium ≥ LLN
NCT02132598	60:90:cancer,98:105:upper_bound,128:137:treatment	Subjects with a history of early stage or locally advanced non-metastatic prostate cancer within 2 years of the start of study treatment may be included in the study
NCT02132598	29:84:clinical_variable,86:92:lower_bound,100:114:upper_bound	The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) >500 ms within 28 days before randomization
NCT02132598	72:117:allergy_name	The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
NCT02132598	35:74:chronic_disease,85:88:treatment,92:125:treatment	The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan
NCT02132598	29:34:cancer,156:168:cancer,172:191:cancer,199:213:upper_bound,232:244:treatment	The subject has evidence of tumor invading the Gastro Intestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib
NCT02132598	42:62:chronic_disease,79:112:treatment,114:145:treatment,151:160:treatment,184:198:upper_bound,217:229:treatment	The subject has had an assessment of all extracranial disease sites (e.g., by computerized tomography (CT) scan, positron emission tomography-CT, and bone scan as appropriate) within 28 days before the first dose of cabozantinib
NCT02132598	37:44:upper_bound,67:76:treatment,88:98:cancer,114:132:treatment	The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
NCT02132598	46:51:clinical_variable,54:61:upper_bound,87:102:treatment	The subject has not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies
NCT02132598	17:38:clinical_variable,40:113:clinical_variable,121:145:lower_bound,153:166:upper_bound,191:200:treatment	The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 7 days before the first dose of study treatment
NCT02132598	26:48:treatment,60:98:treatment,103:118:treatment,126:135:treatment,139:149:treatment,161:192:treatment,201:208:upper_bound,213:225:treatment,227:238:treatment,246:260:upper_bound,285:294:treatment	The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies; including investigational biologic agents) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatment
NCT02132598	17:63:treatment,71:78:upper_bound,104:116:treatment,124:137:treatment,139:148:treatment,150:163:treatment,165:174:treatment	The subject has received enzyme-inducing anti-epileptic agents within 2 weeks before the first dose of cabozantinib (e.g., carbamazepine, phenytoin, phenobarbital, primidone)
NCT02132598	26:41:treatment,32:41:treatment,49:80:treatment,86:102:treatment,114:159:treatment,168:175:upper_bound	The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
NCT02132598	26:43:treatment	The subject has received radiation therapy
NCT02132598	26:48:treatment,39:48:treatment,56:63:upper_bound	The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment
NCT02132598	17:22:cancer	The subject has tumor abutting, invading or encasing any major blood vessels
NCT02132598	38:61:treatment,63:86:treatment,91:126:treatment,121:125:treatment,176:193:treatment,197:205:upper_bound	The subject is receiving concomitant treatment with warfarin, warfarin-related agents, or low molecular weight heparin (LMWH) at the time of study entry at therapeutic doses. Low-dose warfarin (≤ 1 mg/day) or LMWH at prophylactic doses
NCT02132598	40:43:treatment,40:48:treatment,52:71:treatment,117:130:upper_bound,148:160:treatment	The subject must have a baseline brain MRI scan or CT scan of the head (in patients unable to obtain an MRI) within 14 days prior to first dose of cabozantinib
NCT02132598	29:36:upper_bound,58:73:treatment	To any other site(s) within 28 days of the first dose of study treatment
NCT02132598	4:8:cancer,12:28:cancer,36:43:upper_bound,71:80:treatment	To bone or brain metastasis within 14 days of the first dose of study treatment
NCT02132598	50:58:upper_bound,86:95:treatment,179:202:treatment	To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has with ongoing complications or is without complete recovery and healing from prior radiation therapy
NCT02132598	1:38:clinical_variable,40:41:upper_bound	Urine protein/creatinine ratio (UPCR) ≤1
NCT02132598	1:6:gender,45:69:pregnancy	Women of childbearing potential must have a negative serum pregnancy test at screening
NCT02132598	43:47:treatment,55:65:clinical_variable,69:72:lower_bound,106:111:cancer,127:145:cancer	c-MET amplification will be determined by FISH ratio (c-MET/CEP7) > 2.0, based on testing of the primary tumor and/or site of metastatic disease
NCT02132598	32:43:chronic_disease	clinically-significant cardiac arrhythmias
NCT02132598	1:27:chronic_disease	myocardial infarction (MI)
NCT02132598	1:9:pregnancy	pregnant
NCT02132598	1:7:chronic_disease,19:50:chronic_disease	stroke (including Transient Ischemic Attack (TIA), or other ischemic event
NCT02132598	1:15:chronic_disease,32:59:treatment	thromboembolic event requiring therapeutic anticoagulation
NCT02132598	10:25:chronic_disease	unstable angina pectoris
NCT02128100	71:81:cancer	A reasonable attempt should be made to make a pathologic diagnosis of malignancy
NCT02128100	1:43:chronic_disease	Acquired Immune Deficiency Syndrome (AIDS) based on CDC criteria
NCT02128100	24:37:upper_bound	Additional labs within 14 days prior to registration
NCT02128100	1:4:age,9:17:lower_bound	Age >/= 18 years
NCT02128100	1:4:clinical_variable,34:47:upper_bound	CBC/differential obtained within 14 days prior to registration with adequate bone marrow function
NCT02128100	75:82:upper_bound	CT scan of the chest, abdomen and pelvis with IV and oral contrast within 8 weeks of registration
NCT02128100	1:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	ECOG performance status 0-1
NCT02128100	1:4:chronic_disease	HIV testing is not manditory for this protocol
NCT02128100	1:22:chronic_disease,45:53:chronic_disease,61:80:chronic_disease	Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
NCT02128100	1:19:cancer	Metastatic disease as defined by the multi-disciplinary team
NCT02128100	1:25:pregnancy,38:51:upper_bound,72:77:gender	Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
NCT02128100	43:68:cancer	Pathologic or clinical diagnosis of a new pancreatic adenocarcinoma
NCT02128100	1:9:pregnancy,10:15:gender	Pregnant women or lactating women
NCT02128100	1:26:treatment,33:49:cancer	Prior anti-cancer therapy for a pancreatic tumor
NCT02128100	7:17:cancer,29:41:upper_bound	Prior malignancy within the last 3 years
NCT02128100	1:20:treatment,28:35:upper_bound	Whole body PET scan within 8 weeks of registration
NCT02124174	1:35:chronic_disease	Active and uncontrolled infections will cause patients to be excluded
NCT02124174	26:33:lower_bound,37:40:age	All allograft patients > 2 years of age
NCT02124174	20:27:upper_bound,31:34:age,69:83:chronic_disease,89:102:treatment	Children less than 2 years of age will be excluded due to increased hepatotoxicity from valproic acid in this age group
NCT02124174	1:16:clinical_variable,42:45:lower_bound,49:67:clinical_variable,78:79:upper_bound,87:134:clinical_variable	Karnofsky score greater than or equal to 70% or Performance status of < or = 2 by the Eastern Cooperative Oncology Group (ECOG) scale
NCT02124174	10:13:cancer	Low risk AML in complete remission 1, will not be candidates for this study
NCT02124174	28:41:treatment,61:76:treatment	Patients already receiving valproic acid or receiving other anticonvulsants will be excluded
NCT02124174	30:61:treatment,69:71:lower_bound,72:79:upper_bound,96:105:treatment,168:190:chronic_disease	Patients must have undergone allogeneic stem cell transplant within 40-60 days before starting treatment and be self-sufficient in caloric intake along with no active graft vs. host disease
NCT02124174	18:43:clinical_variable,54:58:upper_bound	Patients with an absolute neutrophil count less than 1500 will be excluded
NCT02124174	15:24:clinical_variable,35:41:upper_bound	Patients with platelets less than 50,000 will be excluded
NCT02124174	39:71:cancer,114:154:cancer	Patients with refractory or relapsed: acute myelogenous leukemia (AML) (including inv16, t(8;21) or t(15;17)) or high risk myelodysplastic syndrome (MDS)
NCT02124174	1:10:clinical_variable,16:22:upper_bound,24:61:clinical_variable,64:71:upper_bound	bilirubin of < 2mg/dL, serum glutamate pyruvate transaminase < 3 * ULN
NCT02124174	1:11:clinical_variable,14:20:upper_bound	creatinine < 2mg/dL
NCT02124174	12:30:clinical_variable,38:40:lower_bound	defined as bone marrow blasts > or = 5%
NCT02124174	1:9:pregnancy,10:17:gender	pregnant females are excluded
NCT02122172	1:26:clinical_variable,30:39:lower_bound	Absolute neutrophil count >= 1,000/mcL
NCT02122172	35:90:treatment,41:68:treatment,94:111:cancer,213:240:treatment,255:269:treatment,273:291:treatment	All patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting
NCT02122172	1:82:clinical_variable,83:159:clinical_variable,163:173:upper_bound	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X IULN
NCT02122172	1:32:clinical_variable,36:45:lower_bound,93:119:clinical_variable,123:156:lower_bound	Calculated creatinine clearance >= 30 mL/min by the modified Cockcroft and Gault Formula OR glomerular filtration rate >= 30 mL/min/body surface area (BSA) by Modification of Diet in Renal Disease or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
NCT02122172	1:61:clinical_variable,62:63:lower_bound,64:65:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status 0-1
NCT02122172	1:11:clinical_variable,15:22:lower_bound	Hemoglobin >= 8.5g/dL
NCT02122172	19:35:treatment	Inability to take oral medications
NCT02122172	41:63:treatment	Patients may not be receiving any other investigational agents
NCT02122172	62:88:cancer	Patients must have histologically or cytologically confirmed urothelial tract carcinoma
NCT02122172	40:68:cancer,93:111:treatment	Patients must have locally advanced or metastatic urothelial cancer that is not amenable to surgical treatment
NCT02122172	60:63:lower_bound,169:174:lower_bound,213:218:lower_bound,224:260:treatment,335:347:cancer	Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan for the evaluation of measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1])
NCT02122172	27:61:chronic_disease,57:60:chronic_disease,81:115:treatment,171:175:clinical_variable,179:187:upper_bound	Patients with known prior human immunodeficiency virus (HIV)-positive status on combination antiretroviral therapy are ineligible; known prior HIV-positive patients with CD4+ =< 500/mm^3 are ineligible (HIV testing is not required as part of this study)
NCT02122172	31:47:cancer	Patients with untreated known brain metastases, or treated brain metastases that are clinically unstable
NCT02122172	1:10:clinical_variable,14:25:lower_bound	Platelets >= 100,000/mcL
NCT02122172	14:39:chronic_disease	Pre-existing interstitial lung disease
NCT02122172	1:28:treatment	Prior therapy with afatinib
NCT02122172	1:16:clinical_variable,20:66:upper_bound	Total bilirubin =< 1.5 institutional upper limit of normal (IULN)
NCT02122172	14:34:chronic_disease,77:93:chronic_disease,107:131:chronic_disease,142:157:treatment,162:181:treatment	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02122172	1:6:gender	Women
NCT02122172	1:6:gender,19:27:pregnancy	Women known to be pregnant
NCT02122172	1:6:gender	Women who are breastfeeding and who are unwilling to stop breastfeeding prior to study entry
NCT02122172	30:65:contraception_consent,67:75:contraception_consent,79:110:contraception_consent	child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control
NCT02122172	1:4:gender	men
NCT02122172	15:35:cancer	patients with urothelial carcinoma of the bladder, upper tract, or urethra
NCT02122172	10:15:gender,16:31:pregnancy,47:58:pregnancy	should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
NCT02120222	1:32:clinical_variable,36:45:lower_bound	Absolute neutrophil count (ANC) >= 1500/mm^3
NCT02120222	1:31:clinical_variable,27:30:clinical_variable,34:47:upper_bound,91:97:treatment,110:126:cancer,134:147:upper_bound	Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable
NCT02120222	1:10:clinical_variable,13:52:upper_bound,75:93:chronic_disease,110:125:clinical_variable,131:142:upper_bound	Bilirubin < 2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 times ULN)
NCT02120222	1:19:treatment,37:75:treatment	Concurrent therapy with approved or investigational anticancer therapeutic
NCT02120222	1:31:chronic_disease,35:74:clinical_variable,78:79:lower_bound	Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3
NCT02120222	1:61:clinical_variable,65:66:lower_bound,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
NCT02120222	1:31:clinical_variable,38:47:lower_bound	Estimated creatinine clearance of >= 50 mL/min, calculated using the formula of Cockroft and Gault
NCT02120222	1:16:gender,49:91:contraception_consent,103:127:pregnancy	Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening
NCT02120222	1:6:clinical_variable,10:11:lower_bound,12:33:chronic_disease,41:54:upper_bound,72:79:treatment	Grade >= 2 peripheral neuropathy within 14 days prior to initiation of therapy
NCT02120222	8:31:chronic_disease	HBsAg (hepatitis B virus [HBV] surface antigen)
NCT02120222	12:20:chronic_disease,22:40:chronic_disease,44:59:chronic_disease,80:92:upper_bound	History of seizures, movement disorders or cerebrovascular accident within the past 5 years
NCT02120222	219:235:treatment	If patient did not receive such agents, rationale for not treating the patients with the 629 agent must be cleared with the study PI (ie no V600e/k BRAF mutation or patient with autoimmunity, thus 630 not eligible for biologic therapy)
NCT02120222	7:44:chronic_disease	Known active hepatitis A, B, or C infection
NCT02120222	13:47:chronic_disease	Known to be human immunodeficiency virus (HIV) seropositive
NCT02120222	1:14:treatment,22:32:upper_bound,54:61:treatment	Major surgery within four weeks before initiation of therapy
NCT02120222	1:27:chronic_disease,35:43:upper_bound,61:68:treatment	Myocardial infarction (MI) within 3 months of initiation of therapy
NCT02120222	21:48:treatment,62:75:upper_bound,93:100:treatment	Participation in an investigational anti-cancer study within 3 weeks prior to initiation of therapy
NCT02120222	31:47:treatment,54:67:treatment	Patients must have received a biologic therapy (e.g. interleukin 2)
NCT02120222	18:26:pregnancy	Patients who are pregnant or lactating
NCT02120222	46:74:treatment	Patients will be excluded if they have had a major resection of the bowel that could influence absorption
NCT02120222	22:61:cancer	Patients with active central nervous system (CNS) malignancy
NCT02120222	21:41:chronic_disease,58:66:chronic_disease	Patients with known macular degeneration or uncontrolled glaucoma
NCT02120222	28:36:cancer	Patients with unresectable melanoma
NCT02120222	1:15:clinical_variable,19:31:lower_bound	Platelet count >= 100,000/mm^3
NCT02120222	1:10:treatment,12:24:treatment,17:24:treatment,26:39:treatment,53:80:treatment,84:97:upper_bound	Radiation, chemotherapy, immunotherapy or any other systemic anticancer therapy =< 2 weeks prior to initiation of therapy
NCT02120222	1:20:chronic_disease	Serious psychiatric or medical conditions that could interfere with treatment
NCT02120222	1:21:chronic_disease	Symptomatic ischemia
NCT02120222	1:35:clinical_variable,39:48:lower_bound	Total white blood cell (WBC) count >= 3000/mm^3
NCT02120222	14:30:chronic_disease	Uncontrolled active infection within one week prior to first dose
NCT02120222	69:92:chronic_disease,96:111:treatment,129:167:chronic_disease,184:221:chronic_disease,222:254:chronic_disease	Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch block [RBBB]
NCT02120222	1:24:chronic_disease	Unstable cardiovascular
NCT02120222	3:7:treatment,15:28:treatment,33:38:cancer,52:57:clinical_variable,61:75:clinical_variable,85:95:cancer	a BRAF and/or MEK inhibitor (if tumor contains the V600E or V600K mutation) for 628 metastatic disease
NCT02120222	6:30:gender,32:79:contraception_consent	both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose
NCT02120222	1:29:chronic_disease,37:50:upper_bound	gastrointestinal perforation within 28 days prior to beginning study treatment
NCT02120222	12:29:chronic_disease	history of abdominal fistula
NCT02120222	1:27:chronic_disease	inflammatory bowel disease
NCT02120222	26:49:chronic_disease,50:72:clinical_variable	known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA)
NCT02120222	1:14:gender,20:68:contraception_consent,95:101:gender	male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential
NCT02120222	7:34:chronic_disease	other gastrointestinal conditions with increased risk of perforation
NCT02111850	43:53:upper_bound,76:88:upper_bound	A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2 years)
NCT02111850	1:26:clinical_variable,40:49:lower_bound,73:83:treatment	Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
NCT02111850	8:27:chronic_disease,46:70:treatment,73:94:chronic_disease	Active systemic infections, (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnesses
NCT02111850	13:37:chronic_disease,47:87:chronic_disease	Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease)
NCT02111850	1:28:clinical_variable,32:36:clinical_variable,37:38:lower_bound,42:43:upper_bound	Clinical performance status of ECOG 0 or 1
NCT02111850	24:30:chronic_disease,38:61:chronic_disease,92:111:chronic_disease,113:136:chronic_disease,161:172:chronic_disease,194:216:chronic_disease	Clinically significant atrial and or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or have a history of ischemic heart disease, or chest pain
NCT02111850	1:36:chronic_disease,42:64:treatment	Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
NCT02111850	1:36:treatment	Concurrent systemic steroid therapy
NCT02111850	12:16:clinical_variable,39:42:upper_bound	Documented FEV1 less than or equal to 60% predicted tested in patients with
NCT02111850	12:16:clinical_variable,42:45:upper_bound	Documented LVEF of less than or equal to 45% testing is required in patients who are
NCT02111850	26:34:lower_bound,38:41:age	Greater than or equal to 18 years of age and less than or equal to age
NCT02111850	16:30:chronic_disease,41:67:treatment	History of any cardiac events including coronary revascularization or ischemic symptoms
NCT02111850	58:94:allergy_name	History of severe immediate hypersensitivity reaction to any of the agents used in this study
NCT02111850	4:24:treatment,116:123:treatment	If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative
NCT02111850	37:62:treatment,93:106:upper_bound,107:116:treatment,183:199:cancer	Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible
NCT02111850	1:18:cancer	Metastatic cancer diagnosis will be confirmed by the Laboratory of Pathology at the NCI
NCT02111850	1:42:cancer,53:59:cancer,138:143:cancer	Metastatic or locally advanced refractory/recurrent cancer that expresses MAGE-A3 as assessed by one of the following methods: RT-PCR on tumor tissue defined as 30,000 copies of MAGE-A3 per 10^6 GAPDH copies
NCT02111850	11:21:lower_bound,50:72:treatment,110:129:treatment,181:188:upper_bound,228:236:chronic_disease,240:248:chronic_disease	More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)
NCT02111850	18:25:clinical_variable	Patients must be HLA-DP4 positive
NCT02111850	40:73:treatment,88:117:treatment	Patients must have previously received prior first line standard therapy (or effective salvage chemotherapy regimens) for their disease, if known to be effective for that disease, and have been either non-responders (progressive disease) or have recurred
NCT02111850	34:67:contraception_consent,124:135:upper_bound,142:151:treatment	Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
NCT02111850	38:60:treatment	Patients who are receiving any other investigational agents
NCT02111850	39:49:treatment,70:81:chronic_disease,101:112:treatment,125:141:treatment	Patients who have previously received ipilimumab and have documented GI toxicity must have a normal colonoscopy with normal colonic biopsies
NCT02111850	15:16:upper_bound,26:42:clinical_variable,62:78:upper_bound	Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible
NCT02111850	1:15:clinical_variable,41:53:lower_bound	Platelet count greater than or equal to 100,000/mm^3
NCT02111850	1:9:treatment	Serology
NCT02111850	18:21:chronic_disease,50:59:treatment	Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.)
NCT02111850	18:29:chronic_disease,60:71:chronic_disease	Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody
NCT02111850	1:14:clinical_variable,37:72:upper_bound	Serum ALT/AST less than or equal to 2.5 times the upper limit of normal
NCT02111850	1:17:clinical_variable,40:49:upper_bound	Serum creatinine less than or equal to 1.6 mg/dl
NCT02111850	18:51:treatment	Subjects must be co-enrolled in protocol 03-C-0277
NCT02111850	13:36:chronic_disease	Symptoms of respiratory dysfunction
NCT02111850	1:16:clinical_variable,39:48:upper_bound,74:92:chronic_disease,109:124:clinical_variable,135:144:upper_bound	Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dl
NCT02111850	1:4:clinical_variable,30:39:lower_bound	WBC greater than or equal to 3000/mm^3
NCT02111850	1:6:gender,46:64:pregnancy,122:131:treatment	Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
NCT02111850	1:6:gender,38:50:pregnancy,120:129:treatment	Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
NCT02111850	4:24:treatment,55:58:lower_bound,73:84:cancer,91:92:lower_bound,93:95:upper_bound,100:107:clinical_variable	by immunohistochemistry of resected tissue defined as 10% or greater of tumor cells being 2-3+ for MAGE-A3, or serum antibody reactive with MAGE-A3
NCT02111850	26:34:lower_bound	greater than or equal to 65 years old
NCT02106754	1:4:age,8:9:upper_bound,12:20:lower_bound	Age (< 9, >18 years)
NCT02106754	8:9:lower_bound,10:18:upper_bound	Youths 9-18 years old
NCT02101554	3:18:clinical_variable,59:67:upper_bound	A life expectancy (assessed by investigator) of less than 6 months
NCT02101554	68:82:treatment,108:113:lower_bound,125:133:treatment	Be an experienced opioid user, defined as any subject treated with opioid therapy, equivalent or equal to >20 mg per day of morphine, for a period of 3 consecutive days immediately prior to first day of dosing
NCT02101554	1:48:clinical_variable,53:70:chronic_disease	Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation and behavior in past year
NCT02101554	21:29:allergy_name,31:41:allergy_name	Hypersensitivity to morphine, naltrexone
NCT02101554	11:18:treatment,26:38:upper_bound	Undergone surgery within 3 days prior to the first day of dosing
NCT02101554	57:91:treatment	with moderate to severe pain requiring around the clock treatment with an opioid analgesic
NCT02100722	1:4:age,7:15:lower_bound	Age ≥ 21 years
NCT02100722	1:18:chronic_disease	Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support
NCT02100722	24:44:treatment,49:59:upper_bound	Inability to take dual antiplatelet therapy for six months
NCT02100722	7:41:clinical_variable,43:46:upper_bound	Known left ventricular ejection fraction <30%
NCT02100722	1:18:chronic_disease,29:46:treatment	Left main disease requiring revascularization
NCT02100722	1:16:clinical_variable,19:26:upper_bound	Life expectancy < 2 years
NCT02100722	13:18:chronic_disease	Ongoing Non STEMI with biomarkers (cardiac troponin) still rising
NCT02100722	17:51:chronic_disease,80:117:clinical_variable,122:137:clinical_variable,144:147:lower_bound	Patients with a non-dominant right coronary artery may be included if only the left anterior descending artery (LAD) and left circumflex have ≥50% stenosis
NCT02100722	1:10:pregnancy	Pregnancy
NCT02100722	10:14:treatment	Previous CABG
NCT02100722	8:13:clinical_variable,16:28:upper_bound	Recent STEMI (<5 days prior to randomization)
NCT02100722	23:64:treatment,72:89:treatment,91:116:treatment	Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve replacement, carotid revascularization)
NCT02100722	11:36:treatment	Requiring renal replacement therapy
NCT02100722	1:17:clinical_variable,32:44:lower_bound,206:223:treatment,232:235:treatment,240:244:treatment	Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each of the three major epicardial vessels or major side branches, but not involving left main coronary artery, and amenable to revascularization by both PCI and CABG as determined by the Heart Team
NCT02100722	27:48:treatment	Undergoing evaluation for organ transplantation
NCT02100722	6:12:chronic_disease,32:51:chronic_disease	with angina and/or evidence of myocardial ischemia
NCT02094794	1:27:cancer,31:57:cancer,128:145:treatment,190:203:treatment,209:214:treatment,219:226:treatment	Acute lymphocytic leukemia or acute myelogenous leukemia who are not in first remission or second remission i.e. after failing induction therapy, or in relapse or beyond second remission; (prior therapy with VP-16 and Cytoxan is allowed)
NCT02094794	14:27:gender,58:84:chronic_disease,86:94:contraception_consent,98:129:contraception_consent,133:143:contraception_consent,174:184:upper_bound,237:242:gender,250:258:pregnancy	Agreement of men AND women-of-child-bearing-potential to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
NCT02094794	43:72:treatment	All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical siblings who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele matched unrelated donor
NCT02094794	1:13:treatment,27:34:upper_bound	Chemotherapy given within 14 days of planned study enrollment for the purpose of controlling counts is permitted
NCT02094794	1:22:treatment,26:61:treatment,63:80:clinical_variable,87:90:lower_bound	Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50%
NCT02094794	1:29:clinical_variable,33:36:lower_bound,40:41:upper_bound	Karnofsky performance status >= 70% =< 2
NCT02094794	1:30:clinical_variable,34:43:lower_bound,76:92:clinical_variable,96:105:upper_bound	Measured creatinine clearance >= 80 ml/min per 24 hour urine collection OR serum creatinine =< 1.3 mg/dL
NCT02094794	57:79:treatment,107:119:treatment,124:141:treatment	Plans during the trial to receive any other (non-trial) investigational agents, or concurrent biological, chemotherapy, or radiation therapy
NCT02094794	1:24:treatment	Prior radiation therapy that would exclude the use of TMLI
NCT02094794	27:72:clinical_variable,77:118:clinical_variable,133:135:clinical_variable,140:143:lower_bound	Pulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted normal value
NCT02094794	1:47:clinical_variable,52:96:clinical_variable,100:107:upper_bound	Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 5 x ULN
NCT02094794	56:77:clinical_variable,113:120:lower_bound,149:158:treatment	The time from the end last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days from planned start of study treatment
NCT02094794	1:16:clinical_variable,20:53:upper_bound,57:64:upper_bound,69:86:chronic_disease	Total bilirubin =< 1.5 x upper limit of normal (ULN) OR 3 x ULN for Gilbert's disease
NCT02094794	14:21:chronic_disease,50:59:chronic_disease	Uncontrolled illness including ongoing or active infection
NCT02094794	1:6:gender,64:73:pregnancy	Women of child bearing potential only: Negative urine or serum pregnancy test
NCT02094794	32:42:treatment	the patient, family member and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure
NCT02086448	1:10:pregnancy,23:26:bmi,29:31:lower_bound	Pregnancy and current BMI >=30
NCT02086448	35:42:lower_bound	Self-reported frequent snoring (>=3x/week over past month) or self-reported non-snorer
NCT02086448	14:37:chronic_disease	diagnosis of pregestational diabetes
NCT02086448	26:37:chronic_disease,100:110:treatment	self-report a history of sleep apena and who are using or were receommended by a physican to use a PAP device already
NCT02086448	1:6:gender,15:21:lower_bound,26:48:upper_bound	women between 14 0/7 and 20 6/7 weeks gestation at the time of their initial PSG assessment
NCT02085941	1:26:clinical_variable,29:38:lower_bound	Absolute neutrophil count ≥ 1,500/mcL
NCT02085941	1:4:age,5:13:lower_bound	Age 18 years or older
NCT02085941	1:33:clinical_variable,34:64:clinical_variable,67:108:upper_bound	Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤ 2.5 X institutional upper limit of normal
NCT02085941	1:11:clinical_variable,50:70:clinical_variable,73:90:lower_bound,109:126:clinical_variable	Creatinine within normal institutional limits or creatinine clearance ≥ 60 mL/min/1.73 m2 for subjects with creatinine levels about institutional normal
NCT02085941	1:13:treatment,90:95:cancer,121:158:treatment	Cryoablation can be performed near vessels of the head and neck, and if deemed necessary tumor may be displaced using a saline injection (hydro-displacement)
NCT02085941	1:61:clinical_variable,64:65:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
NCT02085941	102:128:allergy_name	History of allergic reactions attributed to compounds of similar chemical or biologic composition to gadolinium contrast agents, if contrast use is anticipated during the procedure
NCT02085941	1:11:clinical_variable,14:36:lower_bound	Leukocytes ≥ 3,000/microliter (mcL)
NCT02085941	1:16:clinical_variable,33:40:lower_bound	Life expectancy of greater than 8 weeks in the opinion of the referring clinician
NCT02085941	19:28:cancer,54:71:cancer	Participants with malignant locally recurrent and/or metastatic tumors
NCT02085941	19:25:cancer	Participants with tumors involving the optic chiasm, brain, or spinal cord
NCT02085941	1:10:clinical_variable,13:37:lower_bound	Platelets ≥ 100,000/microliter (mcL)
NCT02085941	1:9:pregnancy,10:15:gender	Pregnant women
NCT02085941	7:64:treatment,188:191:treatment	Since positron emission tomography-computed tomography (PET-CT) guidance requires the nuclear medicine department to administer a radionuclide material, the default will be to try to use MRI guidance
NCT02085941	1:16:clinical_variable	Total bilirubin within normal institutional limits
NCT02085941	1:6:cancer	Tumor displacement from nerves may be required and will be performed as deemed appropriate to avoid nerve injury
NCT02085941	1:7:cancer,37:40:treatment,56:59:treatment,60:62:treatment	Tumors that are not clearly seen by MRI but showing on PET/CT will be ablated with PET/CT guidance
NCT02085941	14:34:chronic_disease,76:92:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,158:176:chronic_disease,181:200:chronic_disease,201:218:chronic_disease	Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02085941	1:24:chronic_disease,26:30:clinical_variable,33:41:upper_bound	impaired renal function (eGFR < 60ml/min)
NCT02085941	7:23:chronic_disease	known ischemic disease
NCT02085941	32:44:treatment	may not be receiving any other study agents
NCT02085941	1:4:gender	men
NCT02085941	6:41:contraception_consent,43:86:contraception_consent,88:98:contraception_consent	must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
NCT02085941	48:51:treatment,52:54:treatment	must have a mass that is well visualized under PET/CT
NCT02085941	48:51:treatment	must have a mass that is well-visualized under MRI
NCT02085941	23:27:cancer,29:33:cancer,37:58:cancer	must have an advanced head, neck or spine malignant tumor that would potentially benefit from a minimally invasive procedure
NCT02085941	36:51:cancer,60:70:cancer	must have histologically confirmed malignant tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
NCT02085941	35:44:treatment,54:63:treatment,65:77:treatment,79:86:treatment	must have sustained all available treatment options (radiation, chemotherapy, surgery) as verified by the Dana Farber Cancer Institute's Head and Neck Tumor Board
NCT02085941	1:7:cancer	tumors that encase any major blood vessel (carotid, jugular, vertebral)
NCT02085941	14:26:treatment,30:42:treatment,59:66:upper_bound,71:83:treatment,87:98:treatment	who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
NCT02085941	8:27:clinical_variable,33:47:lower_bound	with a blood glucose level of > 200mg/dl prior to the baseline study
NCT02085941	12:28:cancer,136:170:chronic_disease	with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
NCT02085941	1:6:gender	women of child-bearing potential
NCT02076906	1:4:age,8:16:upper_bound,20:23:age	AGE: ≤ 30 years of age
NCT02076906	1:4:age,21:37:clinical_variable	Age-adjusted normal serum creatinine
NCT02076906	10:18:lower_bound,35:55:treatment,68:76:lower_bound,82:103:treatment	At least 2 months post-autologous stem cell transplant or at least 3 months post-allogeneic transplant
NCT02076906	1:29:treatment	Biologic (anti-cancer agent)
NCT02076906	34:50:chronic_disease	Clinically significant unrelated systemic illness
NCT02076906	10:17:treatment,30:37:treatment,39:56:treatment,58:70:treatment	Curative therapy may include surgery, radiation therapy, chemotherapy, or any combination of these modalities
NCT02076906	15:22:chronic_disease	Defined as no dyspnea at rest
NCT02076906	36:48:cancer,42:48:cancer,91:107:cancer,118:138:cancer,140:155:cancer,174:186:cancer,188:201:cancer,203:215:cancer,217:231:cancer,233:249:cancer,255:269:cancer	Histologically confirmed malignant solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors, and desmoid tumors
NCT02076906	1:14:treatment	Immunotherapy
NCT02076906	1:8:treatment,12:22:treatment,61:70:treatment	Implant or prosthesis or scar tissue within the path of the HIFU beam
NCT02076906	50:54:treatment	Inability to tolerate stationary position during HIFU
NCT02076906	22:25:treatment	Inability to undergo MRI and/or contraindication for MRI
NCT02076906	1:20:cancer	Lesion in the skull
NCT02076906	1:30:treatment	Myelosuppressive chemotherapy
NCT02076906	32:59:treatment	No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry
NCT02076906	10:29:treatment,31:43:treatment,45:63:treatment,65:82:treatment,104:118:treatment,109:118:treatment	No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted during HIFU treatment and post treatment follow up for tolerability
NCT02076906	1:10:clinical_variable,12:15:clinical_variable,20:23:clinical_variable,26:35:upper_bound	Normal PT, PTT and INR < 1.5 x ULN
NCT02076906	12:20:lower_bound	Patients > 10 years old
NCT02076906	36:53:treatment	Patients currently receiving other anticancer agents
NCT02076906	36:58:treatment	Patients currently receiving other investigational agents
NCT02076906	72:90:treatment,92:105:treatment,110:122:treatment	Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study
NCT02076906	44:53:chronic_disease	Patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score
NCT02076906	12:43:clinical_variable,48:54:lower_bound	Peripheral absolute neutrophil count (ANC) of ≥750/µL
NCT02076906	1:15:clinical_variable,17:26:lower_bound	Platelet count ≥75,000/µL
NCT02076906	1:18:treatment	Radiation therapy
NCT02076906	42:53:cancer	Radiographically evaluable or measurable solid tumor target lesion(s)
NCT02076906	1:26:treatment	Stem Cell Transplantation
NCT02076906	9:13:upper_bound,19:31:clinical_variable	Target <1 cm from nerve plexus
NCT02076906	1:15:cancer,25:49:cancer,53:63:cancer	Target lesions that are pulmonary primary tumors or metastases
NCT02076906	22:37:treatment,46:55:treatment,73:79:cancer,89:98:cancer,102:128:treatment	The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors)
NCT02076906	22:55:treatment	The last dose of all myelosuppressive anticancer drugs
NCT02076906	28:69:treatment	The last dose of all other local palliative (limited port) radiation
NCT02076906	18:44:treatment	The last dose of colony stimulating factors
NCT02076906	18:31:treatment,33:52:treatment,56:63:treatment	The last dose of immunotherapy (monoclonal antibody or vaccine)
NCT02076906	18:27:treatment,41:45:lower_bound	The last dose of radiation to more than 25 % of marrow containing bones (pelvis, spine, skull)
NCT02076906	15:21:cancer,90:97:treatment,147:156:treatment	The patient's cancer must have relapsed after or failed to respond to frontline curative therapy and there must not be other potentially curative treatment options available
NCT02076906	3:23:clinical_variable,25:42:lower_bound	a creatinine clearance ≥60 mL/min/1.73 m2
NCT02076906	12:20:upper_bound	children ≤ 10 years old
NCT02076906	1:11:treatment,13:25:treatment,31:45:treatment	filgrastim, sargramostim, and erythropoietin
NCT02076906	13:25:treatment	may receive transfusions
NCT02076906	18:30:lower_bound	must be at least 1 week prior to study entry
NCT02076906	18:31:lower_bound	must be at least 2 weeks prior to study entry
NCT02076906	18:31:lower_bound	must be at least 3 weeks prior to study entry
NCT02076906	18:31:lower_bound	must be at least 4 weeks prior to study entry
NCT02076906	13:40:clinical_variable,43:46:lower_bound	must have a Karnofsky performance level ≥ 50%
NCT02076906	13:37:clinical_variable,40:43:lower_bound	must have a Lansky performance level ≥ 50%
NCT02076906	1:14:treatment	pegfilgrastim
NCT02076906	1:19:chronic_disease,21:28:chronic_disease,30:35:chronic_disease,45:62:chronic_disease	serious infections, hepatic, renal or other organ dysfunction, which in the judgment of the Principal or Associate Investigator would compromise the patient's ability to tolerate the general anesthetic required for the procedure
NCT02072356	1:30:chronic_disease	Active uncontrolled infection
NCT02072356	1:33:clinical_variable,37:67:clinical_variable,70:105:lower_bound	Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limit of normal (UNL)
NCT02072356	1:19:chronic_disease,55:62:treatment	Bleeding diathesis, not correctable by usual forms of therapy
NCT02072356	69:90:treatment	Co-morbid disease of condition that would preclude safe delivery of TheraSphere treatment or, in the judgment of the physician, place the patient at undue risk
NCT02072356	14:37:cancer,67:70:cancer,235:241:cancer,254:259:cancer,276:299:treatment	Diagnosis of intrahepatic malignancy including but not limited to HCC; the histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as alpha-fetoprotein (AFP) and clinical findings
NCT02072356	1:67:clinical_variable,68:69:lower_bound,72:73:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2
NCT02072356	28:85:treatment,156:168:treatment	Evidence of any detectable technetium-99m macroaggregated serum albumin (Tc-99m MAA) flow to the stomach or duodenum, not correctable by using established angiographic techniques to stop or mitigate such flow
NCT02072356	48:56:lower_bound,58:63:lower_bound,117:126:treatment	Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs in a single treatment
NCT02072356	13:36:chronic_disease	Evidence of pulmonary insufficiency
NCT02072356	49:63:allergy_name,65:74:allergy_name,76:85:allergy_name,90:98:allergy_name	History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine that cannot be corrected or premedicated
NCT02072356	25:34:treatment	Ineligible for surgical resection
NCT02072356	1:10:pregnancy	Pregnancy
NCT02072356	1:16:clinical_variable,19:28:lower_bound	Serum bilirubin > 2.0 mg/dl (unless segmental infusion is planned)
NCT02072356	8:35:chronic_disease,56:71:treatment	Severe peripheral vascular disease that would preclude catheterization
NCT02072356	13:33:chronic_disease	Significant extrahepatic disease representing an imminent life-threatening outcome
NCT02072356	35:54:chronic_disease	Significant underlying medical or psychiatric illness
NCT02072356	25:36:treatment,41:71:treatment	ny contraindications to angiography and hepatic artery catheterization
NCT02048722	1:26:clinical_variable,29:38:lower_bound	Absolute neutrophil count > 1500/mm^3
NCT02048722	1:31:chronic_disease	Active coronary artery disease
NCT02048722	34:49:chronic_disease	Active or clinically significant cardiac disease
NCT02048722	2:31:clinical_variable,36:68:clinical_variable,72:81:upper_bound,74:81:lower_bound	Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
NCT02048722	1:27:clinical_variable,31:40:upper_bound,33:40:upper_bound,98:104:cancer	Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
NCT02048722	49:62:upper_bound	Any hemorrhage or bleeding event grade 3 within 4 weeks prior to registration
NCT02048722	5:18:chronic_disease	Any malabsorption condition
NCT02048722	1:20:chronic_disease,31:54:treatment,66:79:treatment,83:90:treatment	Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin
NCT02048722	12:31:treatment,33:45:treatment,47:54:treatment,56:69:treatment,71:87:treatment,92:110:treatment,140:151:treatment	Concurrent anti-cancer therapy (chemotherapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib)
NCT02048722	1:25:chronic_disease	Congestive heart failure - New York Heart Association > class II
NCT02048722	1:12:clinical_variable,15:22:lower_bound	Dehydration > grade 1
NCT02048722	1:66:clinical_variable,67:68:lower_bound,72:73:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
NCT02048722	13:30:chronic_disease,32:65:chronic_disease,69:91:chronic_disease	Evidence of abdominal fistula, gastrointestinal (GI) perforation or intraabdominal abscess
NCT02048722	25:55:chronic_disease,66:82:chronic_disease,105:133:cancer,137:153:cancer	Evidence of significant central nervous system disease including seizure disorder requiring medication, symptomatic metastatic brain or meningeal tumors
NCT02048722	24:42:chronic_disease,46:58:chronic_disease	Evidence or history of bleeding diathesis or coagulopathy
NCT02048722	20:43:cancer,53:73:cancer,78:103:cancer	Exceptions include cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor
NCT02048722	1:11:clinical_variable,14:20:lower_bound	Hemoglobin > 9 g/dL
NCT02048722	26:38:cancer	Histologically confirmed angiosarcoma
NCT02048722	12:27:treatment,39:57:treatment	History of organ allograft (including corneal transplant)
NCT02048722	1:37:clinical_variable,38:71:clinical_variable,74:83:upper_bound	International normalized ratio (INR)/partial thromboplastin time (PTT) < 1.5 x ULN
NCT02048722	1:26:chronic_disease	Interstitial lung disease with ongoing signs and symptoms at the time of registration
NCT02048722	18:62:chronic_disease,92:118:chronic_disease,144:161:treatment	Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
NCT02048722	1:16:clinical_variable,29:37:lower_bound	Life expectancy of at least 4 months
NCT02048722	1:7:clinical_variable,11:24:upper_bound	Lipase =< 1.5 x the ULN
NCT02048722	10:17:clinical_variable,22:34:upper_bound	Low dose aspirin (=< 100 mg daily)
NCT02048722	10:18:treatment,50:108:clinical_variable,112:121:upper_bound	Low dose warfarin (1 mg orally, once daily) with prothrombin time (PT)-international normalized ratio (INR) =< 1.5 x ULN is permitted
NCT02048722	27:38:treatment,79:86:upper_bound	Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before registration
NCT02048722	9:18:clinical_variable,21:28:lower_bound	Ongoing infection > grade 2
NCT02048722	18:42:treatment,65:73:treatment,77:84:treatment	Patients who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists
NCT02048722	15:31:cancer	Patients with pheochromocytoma
NCT02048722	15:40:chronic_disease,42:52:clinical_variable	Patients with severe hepatic impairment (Child-Pugh class C)
NCT02048722	1:15:clinical_variable,18:29:lower_bound	Platelet count > 100000/mm^3
NCT02048722	1:17:chronic_disease,21:28:chronic_disease,68:75:lower_bound,76:83:clinical_variable	Pleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea)
NCT02048722	15:32:chronic_disease,34:51:chronic_disease,56:69:chronic_disease	Presence of a non-healing wound, non-healing ulcer, or bone fracture
NCT02048722	14:25:treatment	Prior use of regorafenib
NCT02048722	14:23:treatment	Prior use of sorafenib
NCT02048722	1:20:chronic_disease,32:50:treatment,75:85:treatment	Progressive disease under last palliative therapy with a history of prior ifosfamide
NCT02048722	23:30:treatment	Prophylactic doses of heparin
NCT02048722	1:10:treatment,30:36:chronic_disease,44:51:upper_bound	Radiation directed at target lesion within 28 days of registration
NCT02048722	1:14:chronic_disease,25:52:treatment	Renal failure requiring hemo-or peritoneal dialysis
NCT02048722	1:17:clinical_variable,21:34:upper_bound	Serum creatinine =< 1.5 x the ULN
NCT02048722	11:24:gender,57:92:contraception_consent,134:142:lower_bound	Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at registration until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator
NCT02048722	54:60:cancer,74:86:cancer	Subjects with any previously untreated or concurrent cancer unrelated to angiosarcoma
NCT02048722	15:25:chronic_disease,27:34:chronic_disease	Subjects with thrombotic, embolic, venous, or arterial events
NCT02048722	1:55:treatment,63:71:treatment,81:89:treatment,94:105:treatment	Therapeutic anticoagulation with Vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids
NCT02048722	7:16:clinical_variable,20:58:upper_bound	Total bilirubin =< 1.5 x the upper limits of normal (ULN)
NCT02048722	1:6:cancer	Tumor deemed unresectable or metastatic
NCT02048722	14:26:chronic_disease,28:45:clinical_variable,48:56:lower_bound,60:78:clinical_variable,81:88:lower_bound	Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
NCT02048722	1:16:chronic_disease,10:16:chronic_disease,69:77:upper_bound,102:123:chronic_disease,131:139:upper_bound	Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before registration, or myocardial infarction within 6 months before registration
NCT02048722	8:30:treatment,38:45:upper_bound	Use of cytotoxic chemotherapy within 21 days of registration
NCT02048722	8:24:treatment,32:46:upper_bound	Use of targeted therapy within two half-lives of registration
NCT02048722	1:6:gender,45:74:pregnancy,92:104:upper_bound	Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug
NCT02048722	1:6:gender,11:23:pregnancy	Women who are pregnant
NCT02048722	50:63:upper_bound	all treatments must have been completed at least 3 years prior to registration
NCT02048722	1:25:chronic_disease,37:63:chronic_disease,66:86:chronic_disease,90:108:chronic_disease,116:124:upper_bound	cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent
NCT02048722	1:12:treatment,16:30:treatment,35:47:cancer	doxorubicin or taxane therapy for angiosarcoma
NCT02048722	38:40:treatment,38:44:treatment,88:96:treatment,106:125:treatment,154:174:treatment	infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy; therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes
NCT02048722	22:49:clinical_variable,52:59:upper_bound,63:77:lower_bound	patients must have a 24-hour urine protein value < grade 3 (> 3.5 g/24 hours) to be eligible
NCT02048722	17:22:gender,35:38:age,42:50:lower_bound,78:84:lower_bound	post-menopausal women (defined as age >= 50 years and no menses for at least 1 year)
NCT02048722	103:110:lower_bound	subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed
NCT02048722	23:28:gender	surgically sterilized women are not required to undergo a pregnancy test
NCT02048722	7:8:upper_bound,9:24:treatment	up to 4 prior therapies are allowed
NCT02047721	1:4:bmi,6:8:lower_bound,9:11:upper_bound	BMI: 27-35
NCT02047721	1:4:age,6:8:lower_bound,9:15:upper_bound	age: 21-45 yrs
NCT02047721	1:18:treatment	bariatric surgery
NCT02047721	21:24:treatment	contraindication to MRI
NCT02047721	1:19:pregnancy,44:52:upper_bound	currently pregnant, lactating or less than 6 months post-partum
NCT02047721	12:40:chronic_disease,42:59:chronic_disease,61:86:chronic_disease,98:113:chronic_disease,115:128:chronic_disease,130:145:chronic_disease	history of cardiovascular disease (CVD), diabetes mellitus, uncontrolled hypertension, untreated thyroid disease, renal disease, hepatic disease, or any other medical condition affecting weight or energy metabolism
NCT02047721	7:27:chronic_disease,77:87:chronic_disease,115:117:lower_bound,128:185:clinical_variable,198:214:chronic_disease,234:236:lower_bound,244:251:clinical_variable	major psychiatric disorder, presence of alcohol or substance abuse, current depression by history and/or a score >21 on the he Center for Epidemiologic Studies Depression Scale (CES-D), history of eating disorders and/or a score of >20 on the EATS-26
NCT02047721	1:12:treatment,53:76:clinical_variable,84:97:upper_bound	medications affecting weight, Energy Intake (EI) or Energy Expenditure (EE) in the last 6 months
NCT02047721	22:28:upper_bound	sedentary (less than 1 hour of planned physical activity by self-report)
NCT02047721	33:56:treatment	unable to pass screening graded exercise treadmill test
NCT02047721	1:12:clinical_variable,16:27:clinical_variable,32:41:lower_bound,45:58:upper_bound	weight loss or weight gain of >5 percent in past 6 months
NCT02047721	1:7:clinical_variable,22:35:upper_bound,43:56:upper_bound	weight stable within +/- 5 percent in the last 6 months
NCT02047474	3:10:lower_bound,17:30:treatment	> 4 weeks since major surgery
NCT02047474	1:26:clinical_variable,30:38:lower_bound	Absolute neutrophil count >= 1,500/uL
NCT02047474	1:33:clinical_variable,38:68:clinical_variable,72:79:upper_bound	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
NCT02047474	1:10:clinical_variable,14:23:upper_bound	Bilirubin =< 1.5 X ULN
NCT02047474	1:11:clinical_variable,14:47:upper_bound	Creatinine < 1.5 X upper limit of normal (ULN)
NCT02047474	1:61:clinical_variable,63:64:lower_bound,65:66:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status: 0-1
NCT02047474	11:43:clinical_variable,46:55:lower_bound	Estimated glomerular filtration rate (GFR) > 30 ml/min
NCT02047474	1:11:clinical_variable,15:21:lower_bound	Hemoglobin >= 9 g/dL
NCT02047474	1:19:pregnancy,28:33:gender,50:53:age	Negative pregnancy test in women of childbearing age
NCT02047474	7:14:lower_bound,23:44:chronic_disease	No >= grade 2 sensory peripheral neuropathy
NCT02047474	16:39:chronic_disease,43:66:treatment,68:76:treatment,81:92:treatment,171:181:cancer	No evidence of extrapancreatic disease by cross sectional imaging, PET scan, or laparoscopy, including nodal involvement beyond the peripancreatic tissues and/or distant metastases
NCT02047474	16:21:cancer,264:288:treatment,285:287:treatment,295:314:treatment,319:351:treatment,391:394:treatment	No evidence of tumor extension to superior mesenteric artery, hepatic artery, celiac axis, aorta, or inferior vena cava, and no evidence of occlusion or encasement of the superior mesenteric vein or superior mesenteric vein/portal vein confluence, as assessed by computed tomography (CT) using pancreatic protocol (or magnetic resonance imaging [MRI] in patients who cannot undergo CT) and EUS
NCT02047474	15:31:chronic_disease	No history of chronic diarrhea
NCT02047474	4:26:chronic_disease,56:89:chronic_disease	No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
NCT02047474	21:39:treatment	No other concurrent anticancer therapy
NCT02047474	10:20:cancer,28:43:upper_bound	No other malignancy within past five years
NCT02047474	4:19:treatment,21:33:treatment,35:53:treatment,58:70:treatment,87:104:cancer	No prior treatment (chemotherapy, biological therapy, or radiotherapy) for resectable pancreatic cancer
NCT02047474	4:105:treatment	No prior treatment with oxaliplatin, irinotecan (irinotecan hydrochloride), fluorouracil or capecitabine
NCT02047474	16:31:chronic_disease,58:73:chronic_disease,75:107:clinical_variable,108:110:lower_bound,111:113:upper_bound,114:138:chronic_disease,140:161:chronic_disease,169:185:treatment	No significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment
NCT02047474	17:33:chronic_disease,42:62:chronic_disease,73:109:chronic_disease	No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease
NCT02047474	1:13:pregnancy	Not pregnant and not nursing
NCT02047474	42:67:cancer	Pathologic or cytologic documentation of pancreatic adenocarcinoma
NCT02047474	23:35:treatment,38:49:lower_bound,54:66:cancer,78:95:cancer	Patients who received chemotherapy > 5 years ago for malignancies other than pancreatic cancer are eligible
NCT02047474	1:15:clinical_variable,19:29:lower_bound	Platelet count >= 100,000/uL
NCT02047474	1:45:cancer	Resectable pancreatic adenocarcinoma disease
NCT02047474	36:46:cancer	There is no evidence of the second malignancy at the time of study entry
NCT02047474	1:33:cancer,35:61:cancer,66:96:cancer	basal cell carcinoma of the skin, cervical carcinoma in situ, or non-metastatic prostate cancer
NCT02031250	2:4:lower_bound,29:38:upper_bound	>70 (see Appendix A) within two weeks of enrollment
NCT02031250	83:84:lower_bound,88:91:upper_bound	A measure of general well being and activities of daily living; scores range from 0 to 100 where 100 represents perfect health)
NCT02031250	24:42:cancer	Documented evidence of distant metastases
NCT02031250	1:4:chronic_disease,58:63:cancer	EBV (+) Nasopharyngeal Carcinoma in the protocol treated tumor
NCT02031250	1:31:clinical_variable,33:41:lower_bound	Estimated Creatinine clearance >30cc/min
NCT02031250	1:4:chronic_disease,46:77:cancer	HPV(+) or p16(+) locally/regionally advanced (T4 or N3) oropharyngeal cancer
NCT02031250	1:4:chronic_disease,9:29:chronic_disease,69:104:cancer	HPV(‐) (Human Papillomavirus) or p16(-) locally/regionally advanced (T3‐4 or N2‐3) oropharyngeal cancer
NCT02031250	30:40:cancer,48:50:cancer,52:73:cancer,83:111:chronic_disease	Locally/regionally advanced (stage T3‐4 and/or N3) nasopharyngeal cancer which is EBV (‐) (Epstein‐Barr Virus)
NCT02031250	22:25:age,27:29:lower_bound	Patients are adults (Age >18)
NCT02031250	43:55:treatment	Patients must be able to receive protocol chemotherapy in the judgment of the treating Medical Oncologist
NCT02031250	73:81:treatment	Patients should have no contraindications to having a contrast enhanced MRI scan
NCT02031250	15:31:chronic_disease	Patients with active infection
NCT02031250	1:9:pregnancy,10:15:gender	Pregnant women
NCT02031250	1:14:treatment	Pre‐treatment laboratory criteria within four weeks of enrollment
NCT02031250	1:19:cancer,36:58:cancer	Primary tumor (T4) with or without metastatic lymph nodes
NCT02031250	1:30:treatment	Prior head and neck radiation
NCT02031250	1:10:lower_bound,11:13:lower_bound,29:52:cancer,76:83:treatment	Stage III/IV oral cavity or paranasal sinus cancers in patients who refuse surgery or are unfit for surgery
NCT02031250	1:3:cancer,7:19:cancer,23:44:cancer	T3 or T4 laryngeal or hypopharyngeal cancer that is locally advanced
NCT02031250	7:16:clinical_variable,19:28:upper_bound	Total Bilirubin < 1.5 X ULN
NCT02031250	1:6:clinical_variable,8:14:lower_bound	bulky (>40 cc*)
NCT02031250	1:15:cancer,35:67:cancer	non‐metastatic locally/regionally advanced squamous cell carcinoma of the head and neck
NCT02031250	17:24:treatment	patient refuses surgery, or surgery is not possible due to comorbidities
NCT02031250	14:33:treatment	referred for definitive chemo‐RT
NCT02031250	35:42:treatment	unresectable, or patient declines surgery
NCT02030990	13:27:gender	Active duty male or female, of any race
NCT02030990	8:26:chronic_disease,28:60:chronic_disease,68:72:upper_bound	Active ophthalmic disease, neovascularization of the cornea within 1 mm of the intended ablation zone, or lens opacity
NCT02030990	5:34:chronic_disease	Any physical or mental impairment which would preclude participation in any of the examinations, such as inability to give verbal responses to eye charts
NCT02030990	6:39:clinical_variable,43:48:upper_bound	Best spectacle corrected visual acuity of 20/25 or better in both eyes
NCT02030990	1:19:treatment,23:43:treatment,80:95:treatment,97:112:treatment,114:126:treatment,128:139:treatment,141:178:treatment,187:209:treatment	Concurrent topical or systemic medications which may impair healing, including corticosteroids, antimetabolites, isotretinoin, (Accutane™), amiodarone hydrochloride (Cordarone™), and/or sumatriptan (Imitrex™)
NCT02030990	13:21:chronic_disease,28:48:clinical_variable,62:82:lower_bound	Evidence of glaucoma or an intraocular pressure greater than 22 mm Hg at baseline
NCT02030990	13:24:chronic_disease,26:46:chronic_disease,60:77:treatment	Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye
NCT02030990	1:16:gender,21:33:pregnancy,54:79:pregnancy	Female subjects who are pregnant, breast-feeding, or intend to become pregnant during the course of the study
NCT02030990	102:122:lower_bound	Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least four (4) weeks prior to baseline measurements
NCT02030990	1:36:clinical_variable,42:49:lower_bound,43:49:upper_bound,53:59:upper_bound,65:84:clinical_variable	Manifest spherical equivalent (MSE) from +3.00 D to -11.0D with refractive cylinder of up to 3.00 D
NCT02030990	113:130:chronic_disease,135:143:chronic_disease	Medical conditions which, in the judgment of the investigator, may impair healing, including but not limited to thyroid disorders and diabetes
NCT02030990	79:124:allergy_name	Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course
NCT02030990	53:72:lower_bound	Soft contact lenses must have been removed at least two (2) weeks prior to baseline measurements
NCT02030990	156:162:lower_bound,174:183:upper_bound,262:266:lower_bound	Stable spectacle refraction, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50 D during the six-month period immediately preceding the baseline examination for myopic patients and 0.75 for hyperopic patients
NCT02030990	116:129:lower_bound	Strong motivation for attending the follow-up visits and orders to remain in the area for the duration of at least twelve months of follow up
NCT02030990	10:18:lower_bound	at least 21 years old at the time of the pre-operative examination
NCT02025543	21:47:treatment	contraindication to magnetic resonance imaging
NCT02016430	1:17:chronic_disease,30:41:treatment,49:57:upper_bound	Active infection or received antibiotics within 2 months of study enrollment
NCT02016430	10:27:clinical_variable,30:34:lower_bound	Elevated TMAO metabolizers (>5 µM) based on screening test
NCT02016430	18:38:treatment,42:51:treatment,60:75:treatment,79:85:treatment	Having undergone bariatric procedures or surgeries such as gastric banding or bypass
NCT02016430	1:4:gender	Men
NCT02016430	1:10:pregnancy	Pregnancy
NCT02016430	13:28:chronic_disease,32:53:chronic_disease,82:109:chronic_disease,111:124:chronic_disease,126:143:chronic_disease,145:165:chronic_disease	Significant chronic illness or end-organ dysfunction, including known history of uncompensated heart failure, renal failure, pulmonary disease, hematologic diseases
NCT02016430	84:95:upper_bound	Use of over-the-counter probiotic within past month, or ingestion of yogurt within past 7 days
NCT02016430	22:29:treatment,59:75:treatment,80:92:upper_bound,135:150:treatment,178:185:upper_bound	Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting study and staying on the same aspirin regimen during the duration of the 12-week study
NCT02016430	1:4:age,5:13:lower_bound	age 18 years or above
NCT02016430	1:6:gender	women
NCT02013492	1:8:clinical_variable,10:21:upper_bound	AST/ALT <6 times ULN
NCT02013492	10:26:clinical_variable,30:39:lower_bound	Absolute neutrophil count >= 1,500/mcL
NCT02013492	42:46:cancer,43:44:upper_bound,47:55:lower_bound,92:122:cancer	An additional cohort of 10 patients with BCLC stages A to C locally advanced or metastatic hepatocellular carcinoma (HCC) that is not surgically resectable will also be enrolled (See appendix for BCLC staging system)
NCT02013492	1:33:clinical_variable,34:80:clinical_variable,82:112:clinical_variable,113:157:clinical_variable,162:167:upper_bound,168:203:clinical_variable	Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
NCT02013492	10:13:lower_bound,36:61:cancer,86:89:clinical_variable,113:117:lower_bound,179:207:treatment,211:243:treatment,262:271:chronic_disease,275:299:chronic_disease	At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) > 1 cm with arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis
NCT02013492	1:21:clinical_variable,25:43:lower_bound,62:79:clinical_variable	Creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
NCT02013492	1:11:clinical_variable	Creatinine within normal institutional limits
NCT02013492	1:61:clinical_variable,65:66:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status =< 2
NCT02013492	64:83:chronic_disease,197:212:treatment,216:219:treatment,245:248:cancer	For patients whose CURRENT disease is vascular only: Enhancing vascular thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early arterial enhancement and delayed washout on multi-phasic CT or MRI, in a patient with known HCC (diagnosed according to criteria in (a) or (b)
NCT02013492	102:113:treatment	History of allergic reactions attributed to compounds of similar chemical or biologic composition to propranolol
NCT02013492	1:4:clinical_variable,12:15:upper_bound	INR < or = 1.7
NCT02013492	1:10:clinical_variable,14:17:lower_bound	Karnofsky >= 60%
NCT02013492	1:11:clinical_variable,15:24:lower_bound	Leukocytes >= 3,000/mcL
NCT02013492	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 6 months
NCT02013492	20:23:cancer	Parameters for the HCC cohort
NCT02013492	70:73:cancer	Pathologically (histologically or cytologically) proven diagnosis of HCC
NCT02013492	26:29:cancer	Patients (except for the HCC cohort) must have normal organ and marrow function
NCT02013492	52:61:treatment	Patients may have had any number of prior systemic therapies
NCT02013492	35:63:treatment	Patients may not be receiving any other investigational agents
NCT02013492	63:85:cancer	Patients must have histologically-proven locally-recurrent or metastatic solid tumor
NCT02013492	40:52:treatment	Patients who are currently receiving a beta-blocker for another medical condition
NCT02013492	23:35:treatment,39:51:treatment,59:66:upper_bound,68:75:upper_bound,80:92:treatment,96:107:treatment,226:241:lower_bound	Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
NCT02013492	15:31:cancer,56:70:treatment,129:138:treatment,158:169:treatment	Patients with brain metastases may participate in this clinical study provided that symptoms have been controlled with standard therapies and/or appropriate medications
NCT02013492	15:36:treatment	Patients with liver transplantation
NCT02013492	27:39:chronic_disease,44:61:clinical_variable,72:75:upper_bound,82:100:clinical_variable,111:117:upper_bound	Patients with significant lung disease, an ejection fraction less than 40%, or a resting heart rate less than 60/min will not be enrolled
NCT02013492	25:35:chronic_disease	Patients with worsening depression that has not been addressed clinically
NCT02013492	1:10:clinical_variable,14:25:lower_bound	Platelets >= 100,000/mcL
NCT02013492	1:9:pregnancy,10:15:gender	Pregnant women
NCT02013492	16:27:treatment	The effects of propranolol on the developing human fetus may be detrimental
NCT02013492	1:16:clinical_variable	Total bilirubin within normal institutional limits
NCT02013492	14:26:chronic_disease	Uncontrolled hypertension
NCT02013492	77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT02013492	1:26:clinical_variable,33:41:lower_bound	absolute neutrophil count > or =1000/mcl
NCT02013492	1:21:clinical_variable,29:44:lower_bound,63:80:clinical_variable	creatinine clearance > or = 60mL/min/1.73m2 for patients with creatinine levels above institutional normal level
NCT02013492	1:11:clinical_variable	creatinine within normal institutional limits
NCT02013492	1:11:clinical_variable,19:27:lower_bound	leukocytes > or = 3000/mcl
NCT02013492	43:50:treatment	patients need not have exhausted standard therapy for their disease, but must be stable and must not have actively progressing
NCT02013492	1:10:clinical_variable,18:24:lower_bound	platelets > or = 70,000
NCT02013492	43:68:cancer,70:83:cancer,89:107:cancer,118:130:cancer	preference will be given to patients with metastatic ovarian cancer, breast cancer, and malignant melanoma, as these malignancies have been shown to be sensitive to manipulation of the beta-adrenergic receptor
NCT02013492	77:106:cancer	the final twenty-five patients to be accrued must have locally-recurrent or metastatic malignant melanoma that is not surgically resectable
NCT02013492	32:38:cancer	the first 10 patients may have cancer of any histology
NCT02013492	7:16:clinical_variable,24:30:upper_bound	total bilirubin < or = 2mg/dL
NCT02013492	1:6:gender,47:82:contraception_consent,84:92:contraception_consent,96:127:contraception_consent	women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control
NCT02006069	15:35:treatment	Already had a CRT device implanted
NCT02006069	1:20:chronic_disease	Atrial Fibrillation
NCT02006069	1:31:chronic_disease,35:66:chronic_disease,74:88:upper_bound	Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) in the 3 months prior the enrollmen
NCT02006069	32:55:treatment,40:55:treatment,102:116:lower_bound	Classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 12 months
NCT02006069	25:35:chronic_disease,39:52:chronic_disease,60:73:upper_bound	History or incidence of Paroxysmal or Persistent AF within 30 days prior the enrollment
NCT02006069	11:19:upper_bound,23:26:age	Less than 18 years of age
NCT02006069	1:16:clinical_variable,19:28:upper_bound	Life expectancy < 12 months
NCT02006069	1:22:chronic_disease	Myocardial Infarction
NCT02006069	11:13:chronic_disease,31:47:treatment,55:62:upper_bound,72:83:treatment	Permanent AF not treated with AV node ablation within 2 weeks from the CRT implant
NCT02006069	1:14:chronic_disease	Persistent AF at the time of enrollment
NCT02006069	1:9:pregnancy,17:44:pregnancy	Pregnant or are planning to become pregnant during the duration of the investigatio
NCT02006069	9:25:chronic_disease	Primary valvular disease
NCT02006069	8:33:treatment,35:39:treatment,41:46:treatment,50:54:treatment,63:76:upper_bound,110:118:upper_bound	Recent cardiac revascularization (PTCA, Stent or CABG) in the 4 weeks prior to enrollment or planned for the 3 months following
NCT02006069	13:36:treatment	Undergone a cardiac transplantation
NCT02006069	1:16:chronic_disease,24:37:upper_bound	unstable angina within 40 days prior the enrollment
NCT01994538	34:37:lower_bound	Admission to the hospital (for > 24h) at the time of diagnosis
NCT01994538	1:12:gender	Male gender
NCT01994538	19:25:upper_bound,79:86:chronic_disease,88:105:chronic_disease,107:114:chronic_disease,116:125:chronic_disease,127:140:chronic_disease,143:158:chronic_disease,160:191:chronic_disease,196:206:chronic_disease	New-onset (within 7 days) of at least one of the following symptoms/findings: dysuria, urinary frequency, urgency, hematuria, perineal pain, supra-pubic pain, costovertebral angle tenderness, or flank pain
NCT01994538	7:28:treatment,67:70:chronic_disease,88:98:chronic_disease,100:109:chronic_disease	Other antimicrobial therapy (new or ongoing) prescribed for a non-UTI diagnosis (e.g., cellulitis, pneumonia, etc.)
NCT01994538	36:42:lower_bound,62:69:upper_bound,81:94:treatment,98:105:treatment	Prescribed treatment with at least 7 days, but not more than 14 days, of either ciprofloxacin or TMP-SMZ
NCT01994538	52:55:chronic_disease,73:89:chronic_disease,91:121:chronic_disease	Symptoms thought more likely to be caused by a non-UTI diagnosis (e.g., urinary calculus, sexually transmitted infection, etc.)
NCT01994538	80:88:upper_bound	Treated as an outpatient (Primary Care Center or Emergency Department), with < 24 hours observation in the hospital or Emergency Department following the time of initial diagnosis
NCT01994538	15:18:chronic_disease,22:34:upper_bound	Treatment for UTI in past 14 days
NCT01994538	1:10:treatment,29:58:treatment	Treatment initiated with an empiric antimicrobial regimen that is underdosed, based on current guidelines and reviews
NCT01994538	29:50:treatment	Treatment initiated with an empiric antimicrobial to which the organism isolated in the urine culture is non-susceptible based on standard laboratory criteria
NCT01992861	1:16:clinical_variable,30:38:upper_bound	Life expectancy of less than 6 months
NCT01992861	18:37:chronic_disease,103:112:treatment	Major medical or psychiatric illness that, in the investigator's opinion, would prevent completion of treatment, completion of the study protocol, or interfere with follow-up
NCT01992861	29:39:treatment,46:56:treatment,58:75:treatment,77:91:treatment,119:138:treatment,140:149:pregnancy,168:174:clinical_variable,188:198:lower_bound,200:203:clinical_variable,206:208:upper_bound	Medical contraindication to MR imaging (e.g. pacemakers, metallic implants, aneurysm clips, known contrast allergy to gadolinium contrast, pregnancy, nursing mothers, weight greater than 350 pounds, GFR < 30)
NCT01992861	45:54:lower_bound,55:58:upper_bound,59:93:cancer,105:118:cancer,120:158:cancer,174:209:cancer,228:245:treatment,250:265:cancer	Patients must have histologically confirmed stage IB2-IVA epithelial carcinoma of the cervix, including squamous cell, adeno-, and undifferentiated carcinoma, and excluding small cell/neuroendocrine carcinoma, who will undergo radiation therapy for cervical cancer with curative intent
NCT01992861	32:62:treatment,38:54:treatment,82:87:cancer	Patients who have received any prior pelvic radiation therapy in the area of the tumor that precludes the delivery of a curative dose of pelvic radiation
NCT01992861	36:53:treatment,70:98:treatment,103:118:cancer	Patients who will undergo standard radiation therapy with concurrent cisplatin-based chemotherapy for cervical cancer
NCT01992861	40:71:treatment	Patients with no contra-indications to magnetic resonance (MR) imaging
NCT01992861	24:41:treatment	Patients with no prior radiation therapy to the pelvis
NCT01992861	15:59:cancer	Patients with small cell/neuroendocrine cervical carcinoma
NCT01992861	1:17:treatment,23:46:treatment,51:66:treatment	Surgical staging with retroperitoneal staging and lymphadenectomy
NCT01992861	31:34:treatment,57:60:clinical_variable,66:83:lower_bound	for the test-retest sub-study MRI, patients must have a GFR of > 60 mL/min/1.73m^2
NCT01992861	1:33:clinical_variable,36:54:lower_bound	glomerular filtration rate (GFR) > 30 mL/min/1.73 m^2
NCT01989546	1:10:clinical_variable,11:20:clinical_variable,43:86:upper_bound	AST(SGOT)/ALT(SGPT) less than or equal to 3 times institutional upper limit of normal
NCT01989546	1:4:age,30:38:lower_bound,42:45:age	Age greater than or equal to 18 years of age
NCT01989546	5:29:chronic_disease	Any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
NCT01989546	1:24:clinical_variable,47:48:upper_bound	ECOG performance status less than or equal to 2
NCT01989546	39:50:treatment,130:137:treatment	Eligibility of subjects receiving any medications or substances with the potential to affect the activity or pharmacokinetics of BMN 673 will be determined following review by the principal investigator
NCT01989546	1:4:chronic_disease,26:60:treatment	HIV-positive patients on combination antiretroviral therapy are ineligible
NCT01989546	1:16:clinical_variable,33:41:lower_bound	Life expectancy of greater than 3 months
NCT01989546	38:60:treatment	Patients who are receiving any other investigational agents
NCT01989546	23:35:treatment,39:51:treatment	Patients who have had chemotherapy or radiotherapy
NCT01989546	23:63:treatment	Patients who have had prior treatment with any PARP inhibitors are ineligible
NCT01989546	49:63:treatment,72:80:treatment	Patients who require use of coumarin-derivative anticoagulants such as warfarin are excluded
NCT01989546	16:40:cancer,97:104:lower_bound,115:124:treatment,128:144:cancer	Patients whose brain metastatic disease status has remained stable for greater than or equal to 4 weeks following treatment of brain metastases are eligible to participate at the discretion of the principal investigator
NCT01989546	15:19:cancer,38:51:cancer,55:69:cancer,122:129:treatment	Patients with HER2-positive advanced breast cancer or ovarian cancer should have received at least two lines of systemic therapy in the advanced setting
NCT01989546	28:44:cancer,48:72:cancer	Patients with known active brain metastases or carcinomatous meningitis are excluded from this clinical trial
NCT01989546	1:9:pregnancy,10:15:gender	Pregnant women are excluded from this study
NCT01989546	77:93:chronic_disease,95:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:201:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT01989546	1:6:gender	Women who are currently lactating
NCT01989546	1:26:clinical_variable,52:61:lower_bound	absolute neutrophil count greater than or equal to 1,500/mcL
NCT01989546	1:21:clinical_variable,47:56:lower_bound,75:92:clinical_variable	creatinine clearance greater than or equal to 60 mL/min for patients with creatinine levels above institutional normal
NCT01989546	1:11:clinical_variable,34:79:upper_bound	creatinine less than or equal to 1.5 times institutional upper limit of normal
NCT01989546	81:90:treatment	for the duration of study participation, and for 30 days after completing study treatment
NCT01989546	1:11:clinical_variable,37:46:lower_bound	leukocytes greater than or equal to 3,000/mcL
NCT01989546	1:10:clinical_variable,36:47:lower_bound	platelets greater than or equal to 100,000/mcL
NCT01989546	7:16:clinical_variable,39:48:upper_bound,49:84:clinical_variable	total bilirubin less than or equal to 1.5 times institutional upper limit of normal
NCT01989546	17:24:upper_bound,29:41:treatment,45:56:treatment	within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
NCT01989546	1:6:gender,3:6:gender,46:139:contraception_consent	women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry
NCT01983475	1:37:treatment,76:86:lower_bound	Anabolic or Steroid hormonal therapy; within the past year and longer than six months
NCT01983475	45:59:treatment,45:60:treatment,63:70:lower_bound,71:81:treatment,145:153:lower_bound,250:259:chronic_disease	Any patient receiving moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid) for longer than one week, not including drug administered in an attempt to preserve neurological function at the time of acute SCI
NCT01983475	22:36:treatment,41:70:chronic_disease	Any patient taking a bisphosphonate for heterotopic ossification (HO)
NCT01983475	22:28:cancer	Current diagnosis of cancer
NCT01983475	1:30:chronic_disease	Cushing's disease or syndrome
NCT01983475	14:26:chronic_disease	Diagnosis of Hypocalcemia
NCT01983475	21:29:upper_bound	Duration of injury <12 weeks
NCT01983475	52:55:chronic_disease	Extensive life-threatening injuries in addition to SCI
NCT01983475	1:25:chronic_disease	Heterotopic ossification of the knee region
NCT01983475	12:33:chronic_disease	History of chronic alcohol abuse
NCT01983475	18:30:chronic_disease,32:59:chronic_disease,61:73:chronic_disease	History of prior bone disease (Paget's hyperparathyroidism, osteoporosis, etc.)
NCT01983475	1:16:chronic_disease	Hyperthyroidism
NCT01983475	1:6:gender	Males
NCT01983475	1:4:gender,16:28:chronic_disease	Men with known hypogonadism prior to SCI
NCT01983475	17:22:gender	Post menopausal women
NCT01983475	1:10:pregnancy	Pregnancy
NCT01983475	13:17:age,21:23:lower_bound,28:40:upper_bound	between the ages of 18 and 50 years old
NCT01983475	13:17:age,21:23:lower_bound,28:36:upper_bound	between the ages of 18 and 65 years old
NCT01983475	1:8:gender	females
NCT01983475	12:18:cancer	history of cancer
NCT01983462	18:29:clinical_variable,49:70:chronic_disease,72:100:chronic_disease,102:126:chronic_disease,128:131:lower_bound,135:138:upper_bound,146:154:chronic_disease,156:175:chronic_disease	Abnormal resting 12-lead ECG (e.g., evidence of myocardial infarction, left ventricular hypertrophy, left-bundle branch block, 2nd or 3rd degree AV block, atrial fibrillation/flutter)
NCT01983462	1:4:age,15:17:lower_bound,29:37:upper_bound,41:44:age	Age is > or = 18 and < or = 79 years of age
NCT01983462	84:93:treatment	Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study
NCT01983462	5:12:treatment,20:27:upper_bound	Any surgery within 30 days of screening
NCT01983462	1:29:treatment,47:57:clinical_variable,59:68:upper_bound,79:98:upper_bound,103:106:clinical_variable,108:111:clinical_variable,136:139:clinical_variable,148:151:lower_bound,154:162:upper_bound	Blood chemistries indicative of normal renal (creatinine <2.0 mg/dl), liver (<3 times upper limit for ALT, AST), and thyroid function (TSH between 0.4 - 5.0 mU/L)
NCT01983462	84:87:clinical_variable	Healthy, as determined by health history questionnaire, blood chemistries, 12-lead ECG
NCT01983462	12:15:chronic_disease,27:44:chronic_disease,64:77:chronic_disease,96:107:chronic_disease,111:112:chronic_disease	History of HIV infection, hepatic cirrhosis, other preexisting liver disease, or positive HIV, Hepatitis B or C test at screening
NCT01983462	30:57:lower_bound	History of alcohol abuse or >10 alcoholic units per week (1 unit= 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 oz alcohol)
NCT01983462	12:34:chronic_disease,43:60:treatment,61:84:treatment,86:107:chronic_disease,109:115:chronic_disease,117:130:chronic_disease,147:181:clinical_variable,183:186:upper_bound,188:202:chronic_disease,204:226:chronic_disease,244:265:treatment,267:293:chronic_disease	History of cardiovascular disease such as heart angioplasty/stent or bypass surgery, myocardial infarction, stroke, heart failure with or without left ventricular ejection fraction <40%, cardiomyopathy, valvular heart disease, cardiomyopathy, heart transplantation, Type 2 and Type 1 diabetes
NCT01983462	12:56:chronic_disease	History of chronic obstructive pulmonary disease (COPD)
NCT01983462	49:64:clinical_variable,70:78:upper_bound	History of co-morbid condition that would limit life expectancy to < 6 months
NCT01983462	12:26:chronic_disease,28:46:chronic_disease,48:57:chronic_disease,66:104:chronic_disease,109:127:chronic_disease	History of gastric ulcers, bleeding disorders, dyspepsia, severe gastroesophageal reflux disease (GERD), or metabolic acidosis
NCT01983462	19:30:chronic_disease,32:40:chronic_disease,44:53:chronic_disease,68:83:chronic_disease	History of recent chicken pox, shingles or influenza (ie., risk of Reye's syndrome)
NCT01983462	12:25:chronic_disease,27:35:chronic_disease,39:56:treatment	History of renal failure, dialysis or kidney transplant
NCT01983462	12:32:chronic_disease,34:49:chronic_disease,51:79:chronic_disease,85:109:chronic_disease	History of rheumatoid arthritis, Grave's disease, systemic lupus erythematosis, and Wegener's granulomatosis
NCT01983462	24:33:treatment,134:147:upper_bound,185:197:treatment,232:246:treatment,251:270:treatment	If currently receiving treatment with or taking any of the following supplements, be willing and able to discontinue taking them for 2 weeks prior and throughout the treatment period: Vitamin C, E or other multivitamins containing vitamin C or E; or omega-3 fatty acids
NCT01983462	15:37:chronic_disease,45:57:chronic_disease,59:65:chronic_disease,67:80:chronic_disease,82:104:chronic_disease,106:120:chronic_disease,123:129:chronic_disease,133:148:chronic_disease,153:180:chronic_disease	No history of cardiovascular disease (e.g., heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy), Type 1 or Type 2 diabetes, or peripheral arterial disease
NCT01983462	78:89:lower_bound	Non-smokers, defined as no history of smoking or no smoking for at least the past 1 year
NCT01983462	24:27:treatment,44:65:chronic_disease,67:95:chronic_disease,97:121:chronic_disease,123:149:chronic_disease,151:178:chronic_disease	Normal resting 12-lead ECG (no evidence of myocardial infarction, left ventricular hypertrophy, left-bundle branch block, 2nd or 3rd degree AV block, atrial fibrillation/flutter)
NCT01983462	4:21:treatment,29:36:treatment,38:46:treatment,49:56:treatment,58:69:treatment,72:79:treatment,81:101:treatment,115:143:treatment,152:160:upper_bound	On weight loss drugs (e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications) within 3 months of screening
NCT01983462	1:9:pregnancy	Pregnant
NCT01983462	37:49:upper_bound	Recent flu-like symptoms within the past 2 weeks
NCT01983462	9:29:chronic_disease,40:48:chronic_disease	Serious neurologic disorders including seizures
NCT01983462	1:17:clinical_variable,20:29:lower_bound	Serum creatinine > 2.0 mg/dL
NCT01983462	38:51:upper_bound	Smoking or history of smoking within past one year
NCT01983462	1:24:clinical_variable,29:37:lower_bound,43:51:upper_bound	Systolic blood pressure >/= 130 mmHg and <180 mmHg
NCT01983462	1:24:clinical_variable,28:36:lower_bound,40:64:clinical_variable,66:74:lower_bound	Systolic blood pressure >/=180 mmHg or diastolic blood pressure >110 mmHg
NCT01983462	8:44:treatment,52:59:treatment,61:68:treatment,70:78:treatment,83:91:treatment,94:110:treatment,118:128:treatment,130:139:treatment,144:155:treatment,158:165:treatment	Taking Phosphodiesterase (PDE) 5 inhibitors (e.g., Viagra®, Cialis®, Levitra®, or Revatio®); PDE 3 inhibitors (e.g., cilostazol, milrinone, or vesnarinone); lithium
NCT01983462	8:22:treatment,31:39:treatment,41:49:treatment,52:62:treatment,64:71:treatment,74:85:treatment,87:93:treatment,96:108:treatment,110:120:treatment,123:130:treatment	Taking blood thinners such as coumadin (Warfarin), enoxaparin (Lovenox); clopidogrel (Plavix); dipyridamole (Persantine); heparin
NCT01983462	8:62:treatment,71:78:treatment,80:92:treatment,94:102:treatment,104:127:treatment,129:138:treatment,140:145:treatment,147:153:treatment,196:209:upper_bound	Taking chronic non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, indomethacin, naproxen, acetaminophen (Tylenol), ibuprofen (Advil, Motrin) and not able or willing to go off of for 2 weeks prior and during the study
NCT01983462	8:24:treatment,26:34:treatment,36:41:treatment,51:62:treatment,64:72:treatment,74:81:treatment,83:92:treatment	Taking cox-2 inhibitors (Celebrex, Vioxx, etc) or allopurinol (Zyloprim, Lopurin, Allopurin)
NCT01983462	30:39:treatment,41:50:treatment,52:59:treatment,68:86:treatment,88:95:treatment,97:104:treatment,106:111:treatment	Taking diabetic medications (Metformin, glyburide, insulin, etc.), thiazolidinediones (Avandia, Rezulin, Actos)
NCT01983462	30:37:treatment,39:45:treatment,71:80:treatment,82:89:treatment,92:107:treatment,109:121:treatment,123:138:treatment,142:162:treatment	Taking lipid lowering (e.g., statins, niacin), glycemic control (e.g. metformin, insulin), anticoagulation, anti-seizure, anti-depression or antipsychotic agents
NCT01983462	8:16:treatment,20:29:treatment,32:47:treatment,49:59:treatment,62:74:treatment,76:96:treatment,99:118:treatment,120:128:treatment	Taking steroids or biologics : corticosteroids (prednisone); methotrexate, infliximab (Remicade), etanercept (Enbrel); anakinra
NCT01983462	8:27:treatment,36:49:treatment,51:58:treatment,60:69:treatment,80:89:treatment,92:100:treatment	Taking thyroid medications such as levothyroxine (Levoxyl, Synthroid, Levoxyl, Unithroid); Levodopa
NCT01983462	12:35:treatment,39:69:treatment,77:90:upper_bound,128:149:treatment	Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments
NCT01983462	1:14:clinical_variable,35:52:upper_bound	Weight stable (+/- 5 lbs) for the previous 3 months
NCT01983462	1:15:clinical_variable,17:24:clinical_variable,43:76:lower_bound	hepatic enzyme (ALT/AST) concentrations > 3 times the upper limit of normal
NCT01983462	1:28:pregnancy	planning to become pregnant (self or partner) at any time during the study
NCT01973270	2:14:lower_bound	>500 mg po qd
NCT01973270	67:74:lower_bound	Achieved clinical stability (e.g., outpatient status for at least 1 month before study entry)
NCT01973270	5:26:chronic_disease	Any neurological disorder
NCT01973270	20:31:treatment,33:48:treatment,67:76:treatment	Being treated with benztropine, diphenhydramine, or high doses of clozapine
NCT01973270	9:11:lower_bound,16:24:upper_bound,28:31:age	Between 18 and 35 years of age
NCT01973270	23:36:chronic_disease,38:62:chronic_disease,64:73:chronic_disease,105:130:chronic_disease,117:148:chronic_disease,131:148:chronic_disease	Clinical diagnosis of schizophrenia, schizoaffective disorder, psychosis Not Otherwise Specified (NOS), Unspecified Schizophrenia Spectrum Disorder, Schizophrenia Spectrum Disorder, Specified
NCT01973270	4:49:language_fluency	Is fluent and proficient in the English language
NCT01973270	1:11:treatment	olanzapine(to be determined on a case by case basis)
NCT01973270	1:26:chronic_disease,47:64:chronic_disease,76:88:upper_bound	schizophreniform disorder with onset of first psychotic episode within the last 2 years
NCT01969643	30:34:cancer,70:71:upper_bound,72:141:treatment	-positive and/or PR-positive/HER2- disease and received no more than 1 prior non-hormonally-directed or cytotoxic therapy in the MBC setting
NCT01969643	18:39:cancer,62:69:lower_bound	Combination Arm: HER2-positive disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting (not enrolling new patients)
NCT01969643	38:49:allergy_name	Combination Arm: hypersensitivity to trastuzumab
NCT01969643	1:54:clinical_variable,55:56:lower_bound,60:61:upper_bound	Eastern Cooperative Oncology Group performance status 0 or 1
NCT01969643	1:22:cancer	Malignant CNS disease that has not been definitively treated
NCT01969643	39:52:cancer,128:146:cancer	Pathologically confirmed diagnosis of breast cancer with radiographic evidence of incurable, unresectable, locally advanced or metastatic disease (LA/MBC)
NCT01969643	1:24:clinical_variable,25:32:lower_bound	Pre-existing neuropathy Grade 2 or higher
NCT01969643	22:31:treatment	Prior treatment with SGN-LIV1A
NCT01969643	1:24:cancer,35:36:lower_bound,71:95:treatment,330:346:treatment	Triple-negative disease (ER/PR/HER2-negative) and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting; or ER-positive and/or PR-positive/HER2-negative disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, LA/MBC setting and are no longer a candidate for hormonal therapy (not enrolling new patients)
NCT01969643	1:24:cancer,73:90:treatment	Triple-negative disease and received 1 prior non-hormonally-directed or cytotoxic therapy in the MBC setting
NCT01969643	1:16:cancer,38:39:lower_bound,40:47:upper_bound,48:81:treatment,89:92:clinical_variable	Triple-negative disease and received 2-4 prior non-hormonally-directed therapies in the MBC setting (not enrolling new patients)
NCT01969643	25:48:treatment	prior treatment with an MMAE-containing therapy
NCT01937884	16:38:chronic_disease	A pre-existing bronchopleural fistula
NCT01937884	7:10:bmi,12:14:lower_bound	Admit BMI >30
NCT01937884	25:44:treatment,52:60:upper_bound	Anticipate placement of central venous line within 24 hours of admission
NCT01937884	1:21:chronic_disease	Anuric renal failure
NCT01937884	32:40:upper_bound	Cannot be enterally fed within 24 hours of admission according to the admitting physician
NCT01937884	10:45:chronic_disease	Exhibits Acute Hypoxemic Respiratory Failure
NCT01937884	1:18:clinical_variable,20:28:upper_bound	Expected survival <24 hours or limitations to aggressive ICU care (DNR)
NCT01937884	18:27:allergy_name,31:39:allergy_name	Known allergy to lactulose or mannitol
NCT01937884	16:35:chronic_disease	No evidence of cardiac dysfunction
NCT01937884	4:46:treatment	On extracorporeal membrane oxygenation (ECMO)
NCT01937884	1:10:lower_bound,14:22:upper_bound,26:29:age	One month to 16 years of age
NCT01937884	1:10:clinical_variable,13:16:upper_bound	PaO2/FiO2 ≤ 300
NCT01937884	1:9:pregnancy	Pregnant
NCT01937884	34:42:upper_bound,65:68:age	Premature infants and neonates < 37 weeks corrected gestational age
NCT01937884	18:21:treatment	Receiving active CPR when admitted to the PICU
NCT01937884	9:29:treatment	Require artificial nutrition
NCT01937884	1:5:clinical_variable,6:10:clinical_variable,13:16:upper_bound	SpO2/FiO2 ≤ 260
NCT01937884	10:23:treatment	previous bowel surgery
NCT01937884	1:19:chronic_disease	short gut syndrome
NCT01919619	1:32:clinical_variable,36:48:lower_bound	Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
NCT01919619	1:12:chronic_disease,8:12:chronic_disease,43:48:lower_bound,49:59:treatment	Active GVHD or recent GVHD and still on > 10 mg prednisone (or equivalent)
NCT01919619	8:32:chronic_disease	Active congestive heart failure (New York Heart Association [NYHA] class III to IV)
NCT01919619	1:43:chronic_disease	Active life-threatening autoimmune disease
NCT01919619	1:23:chronic_disease,34:57:treatment	Acute active infection requiring intravenous antibiotics
NCT01919619	1:4:age,9:17:lower_bound,25:33:upper_bound	Age >/= 18 years to </= 80 years
NCT01919619	1:31:clinical_variable,35:38:lower_bound,42:80:treatment,88:96:upper_bound,123:130:upper_bound,143:155:treatment,167:180:upper_bound	Cardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-ECHO) within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
NCT01919619	1:21:chronic_disease,25:43:chronic_disease,51:59:upper_bound	Deep vein thrombosis or pulmonary embolism within 3 months of study entry
NCT01919619	1:17:clinical_variable,20:23:upper_bound,43:60:chronic_disease	Direct bilirubin < 1.6 (unless related to Gilbert's disease or medications)
NCT01919619	1:8:gender,54:87:pregnancy,124:133:lower_bound,141:143:lower_bound,144:157:upper_bound	Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to study entry
NCT01919619	1:46:clinical_variable	Forced expiratory volume in one second (FEV1)
NCT01919619	1:35:cancer	Hematologic or lymphoid malignancy
NCT01919619	1:14:treatment,18:30:treatment,95:102:upper_bound	Immunotherapy or chemotherapy with approved or investigational anticancer therapeutics within 4 weeks of first dose
NCT01919619	7:41:chronic_disease	Known human immunodeficiency virus (HIV) seropositive
NCT01919619	27:38:allergy_name,40:52:allergy_name,56:66:allergy_name	Known hypersensitivity to thalidomide, lenalidomide or ipilimumab
NCT01919619	4:20:chronic_disease	No active infection
NCT01919619	13:24:treatment,32:45:upper_bound	Patients on alemtuzumab within 6 weeks prior to consenting
NCT01919619	27:39:cancer,51:67:upper_bound	Patients with other known malignancies within the past three years
NCT01919619	21:62:clinical_variable,63:64:upper_bound,76:85:clinical_variable,98:100:lower_bound	Performance status: Eastern Cooperative Oncology Group (ECOG) 2 or less or Karnofsky of at least 60
NCT01919619	1:10:clinical_variable,13:24:lower_bound	Platelets > 75 x 10^9/L
NCT01919619	1:9:pregnancy	Pregnant
NCT01919619	7:26:chronic_disease	Prior auto-immune disease
NCT01919619	1:17:clinical_variable,21:30:upper_bound,35:55:clinical_variable,59:68:lower_bound	Serum creatinine =< 1.6 mg/dL and creatinine clearance >= 30 ml/min
NCT01919619	1:45:clinical_variable,47:93:clinical_variable,104:139:upper_bound,159:176:chronic_disease	Serum glutamate pyruvate transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT) less than 2 x the upper limit of normal range (unless related to Gilbert's disease or medications)
NCT01919619	13:23:chronic_disease,25:33:lower_bound,37:38:upper_bound	Significant neuropathy (grades 3 to 4 or grade 2 pain)
NCT01919619	20:54:cancer	adequately treated basal or squamous cell skin cancer
NCT01919619	1:18:treatment,26:33:upper_bound	antifungal agents within 14 days of first dose
NCT01919619	41:52:chronic_disease	antiviral (except antiviral directed at hepatitis B)
NCT01919619	1:22:cancer,28:51:treatment	breast cancer in situ with full surgical resection
NCT01919619	16:23:gender	breast-feeding females
NCT01919619	1:32:cancer	carcinoma in situ of the cervix
NCT01919619	1:21:clinical_variable,51:75:clinical_variable	creatinine clearance will be calculated using the Cockcroft-Gault equation
NCT01919619	1:58:clinical_variable,62:65:lower_bound,73:81:upper_bound,108:115:upper_bound,128:140:treatment,152:165:upper_bound	diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
NCT01919619	1:28:clinical_variable	forced vital capacity (FVC)
NCT01919619	1:12:chronic_disease	hepatitis B
NCT01919619	1:12:chronic_disease	hepatitis C infection
NCT01919619	11:18:gender,62:74:treatment	lactating females must agree not to breast-feed while taking lenalidomide
NCT01919619	1:22:chronic_disease,30:38:upper_bound	myocardial infarction within 6 months of study entry
NCT01919619	15:42:chronic_disease,15:26:chronic_disease,94:111:treatment	patients with hepatitis B surface antigen [Sag] or core antibody receiving and responding to antiviral therapy directed at hepatitis B
NCT01919619	1:16:cancer,22:35:clinical_variable,38:39:upper_bound,52:83:clinical_variable,93:110:upper_bound	prostate cancer with Gleason score < 6 with stable prostate-specific antigen (PSA) over the past three months
NCT01919619	1:21:chronic_disease	symptomatic ischemia or conduction abnormalities uncontrolled by conventional interventions
NCT01910818	8:22:chronic_disease,26:32:chronic_disease,90:95:lower_bound,125:140:chronic_disease	Active Herpes Simplex or Zoster at the time of treatment or having experienced more than three episodes of Herpes Simplex / Zoster eruption within a year of study enrollment
NCT01910818	61:65:allergy_name,67:74:allergy_name,78:95:allergy_name	Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists
NCT01910818	64:74:lower_bound	All wounds in the area of interest must be closed for at least two months
NCT01910818	1:23:clinical_variable,24:25:lower_bound,26:28:upper_bound	Fitzpatrick skin types I-VI
NCT01910818	9:14:gender	Healthy males
NCT01910818	12:37:chronic_disease	History of collagen vascular disease
NCT01910818	12:57:chronic_disease,69:113:chronic_disease,117:158:chronic_disease,169:198:treatment	History of immunosuppression/immune deficiency disorders (including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) or use of immunosuppressive medications
NCT01910818	105:117:upper_bound	Participation in another interventional study with potential exposure to an investigational drug within past 30 days
NCT01910818	12:24:treatment,34:43:treatment,103:106:clinical_variable	Patient on chemotherapy (but not tamoxifen or other things that affect wound healing) and also active XRT
NCT01910818	1:9:pregnancy,10:15:gender	Pregnant woman can be included because study involves local intervention, no new drugs
NCT01910818	1:49:treatment,77:89:upper_bound,93:110:treatment	Prior skin treatment with laser or other devices in the treated area within three months of initial treatment or during the course of the study
NCT01910818	41:62:chronic_disease,71:85:clinical_variable,99:100:lower_bound,192:202:treatment,204:213:treatment,236:256:chronic_disease	Significant concurrent illness, such as uncontrolled diabetes (with a hemoglobin A1C of more than 8) (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process); Mentally incompetent, prisoner or evidence of active substance or alcohol abuse
NCT01910818	49:57:upper_bound,184:197:chronic_disease	The scars must be deemed stable for a period of 3 months or have a suitable contralateral control before initiation of treatment. This will be determined by objective measurements of scar erythema, pliability, induration, thickness at enrollment and again at 3 months
NCT01910818	9:11:lower_bound,16:24:upper_bound,28:31:age	between 18 and 80 years of age
NCT01910818	1:8:gender	females
NCT01910818	6:32:chronic_disease,24:32:chronic_disease,37:51:chronic_disease,94:106:lower_bound	with radiation-induced fibrosis and depigmentation. The fibrosis must have occurred at least 1 year prior to the date of enrollment
NCT01902810	18:26:upper_bound	Admission within 72 hours of injury
NCT01902810	1:4:age,6:8:upper_bound	Age <18
NCT01902810	1:4:age,7:15:lower_bound	Age ≥ 18 years
NCT01902810	23:67:chronic_disease,69:75:chronic_disease,85:113:chronic_disease	Currently treated for Chronic Obstructive Pulmonary Disease (COPD), asthma or other chronic pulmonary conditions
NCT01902810	12:42:chronic_disease,44:61:clinical_variable,64:67:upper_bound	History of Congestive Heart Failure (CHF) (ejection fraction < 20%)
NCT01902810	12:15:chronic_disease,19:23:chronic_disease	History of HIV or AIDS
NCT01902810	12:30:chronic_disease	History of cardiac arrhythmia requiring medication
NCT01902810	1:11:cancer,33:42:treatment,57:73:treatment,81:88:upper_bound	Malignancy currently undergoing treatment or history of cancer treatment within 5 years
NCT01902810	29:53:treatment	Medical condition requiring glucocorticoid treatment
NCT01902810	46:49:age,52:67:clinical_variable,70:73:lower_bound	Patients unlikely to survive injury or with ;age = total burn size ≥ 130
NCT01902810	34:65:treatment,75:96:treatment	Pre-injury medications including blocking agents (alpha or beta) or other anti-arrhythmic drugs
NCT01902810	1:9:pregnancy,10:15:gender	Pregnant women
NCT01902810	3:6:lower_bound,7:37:clinical_variable	≥ 20% Total Body Surface Area (TBSA) burn with anticipated operation need on admission
NCT01873131	118:135:treatment,139:157:chronic_disease	Any infant who, in the opinion of his or her pediatrician or the investigators, has a major medical problem (such as cardiac pathology or airway obstruction) that makes participation in the study difficult
NCT01873131	37:48:cancer	Infant with one or more superficial hemangiomas in the preproliferative phase or very early proliferative growth phase
NCT01873131	26:35:treatment,52:70:treatment,82:89:treatment,91:108:treatment,112:124:treatment	Infants already on other treatment prior to PDL or timolol treatments (including topical, systemic steroids or other agents)
NCT01873131	14:25:cancer	Infants with hemangiomas that threaten vital functions (e.g. obstructing the airway or impairing hearing or vision)
NCT01873131	35:42:upper_bound	More pronounced appearance within 1 month of birth
NCT01873131	15:21:chronic_disease,46:83:chronic_disease,87:109:chronic_disease,121:138:chronic_disease,140:185:chronic_disease,187:208:chronic_disease,214:231:chronic_disease,270:277:allergy_name,338:351:allergy_name,355:369:allergy_name	Patients with asthma or a history of asthma, chronic obstructive pulmonary disease or cardiovascular disease, including sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock; hypersensitivity to any component of timolol; and in those patients receiving systemic administration of beta-blockers or ace inhibitors
NCT01873131	13:22:chronic_disease	Scarring or infection of the area to be treated
NCT01873131	46:55:treatment	Willingness of parent/guardian to follow the treatment schedule and post treatment care requirements
NCT01873131	43:91:treatment,99:109:chronic_disease	Willingness of parent/guardian to not use topical or systemic (oral) TREATMENT medications of the hemangioma other than those prescribed by the investigators during the study period
NCT01873131	56:65:treatment	Willingness of parent/guardian to receive EXPERIMENTAL treatment
NCT01873131	1:5:age,16:24:upper_bound	aged less than 3 months
NCT01873131	1:7:gender	female
NCT01873131	1:5:gender	male
NCT01873131	9:26:chronic_disease	who are immunocompromised
NCT01873131	48:57:treatment	whose parent/guardian is unable to comply with treatment, home care or follow-up visits
NCT01829958	1:4:age,7:9:upper_bound,7:15:lower_bound,19:22:clinical_variable	Age ≥ 70 years OR KPS ≤ 70
NCT01829958	5:35:clinical_variable,37:40:lower_bound	Any nodal or extranodal tumor mass ≥7cm in greatest dimension
NCT01829958	28:37:treatment,41:51:treatment	Contraindication to use of rituximab or prednisone
NCT01829958	1:11:chronic_disease,13:23:clinical_variable,25:34:upper_bound,42:51:clinical_variable,53:64:upper_bound	Cytopenias (leukocytes <1 × 109/L and/or platelets ,100 × 109/L)
NCT01829958	17:30:treatment	Enrollment in a Phase I trial
NCT01829958	20:31:chronic_disease,20:41:chronic_disease,118:130:treatment	Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B surface antigen or viral DNA by PCR analysis)
NCT01829958	1:18:language_fluency	Fluent in English (because not all components of the GA have been validated in other languages)
NCT01829958	53:67:treatment,71:80:treatment,95:123:clinical_variable,126:133:upper_bound	History of any serious adverse reaction to either a corticosteroid or rituximab not including rituximab infusion reactions ≤ Grade 3
NCT01829958	63:68:cancer	Indolent histology with one of the following markers of large tumor burden (67)
NCT01829958	18:27:treatment,52:58:treatment,60:67:treatment,71:77:treatment,128:146:treatment	Intended initial treatment to include ≥2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days
NCT01829958	1:15:cancer,17:32:clinical_variable,34:43:lower_bound	Leukemic phase (malignant cells ≥5 x 109/L)
NCT01829958	24:44:treatment,61:78:treatment,91:113:treatment,122:134:treatment,138:168:treatment,177:186:treatment,190:200:treatment	Must be starting a new chemotherapy regimen (patients whose treatment regimen includes an immunomodulatory agent such as lenalidomide or small molecule targeted agents such as Ibrutinib or Idelelasib
NCT01829958	38:47:treatment	Must meet criteria for initiation of treatment
NCT01829958	26:29:clinical_variable	Pathologically confirmed NHL
NCT01829958	39:44:cancer,98:106:cancer	Pathologically confirmed diagnosis of DLBCL, with or without simultaneous or antecedent indolent lymphoma
NCT01829958	82:89:treatment	Patients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its components
NCT01829958	1:17:clinical_variable,20:22:lower_bound,45:65:chronic_disease	Patients scoring ≥ 11 on the BOMC (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Subjects meeting the following criteria will be excluded from enrollment in the pre-phase arm of the study, but may be included in the GA only arm
NCT01829958	32:41:chronic_disease,57:64:chronic_disease,80:91:chronic_disease,116:143:chronic_disease,169:176:clinical_variable,199:208:treatment	Patients with evidence of past infection without active viremia (i.e. positive hepatitis B core antibody, negative hepatitis B surface antigen and negative hepatitis B DNA PCR) will be treated with entecavir as per institutional guidelines
NCT01829958	26:31:cancer	Previously untreated for DLBCL
NCT01829958	1:16:chronic_disease,18:33:chronic_disease,37:55:chronic_disease	Serous effusion (plural effusion or peritoneal ascites)
NCT01829958	13:25:chronic_disease	Substantial splenomegaly
NCT01829958	1:26:chronic_disease	Systemic fungal infection
NCT01829958	14:31:chronic_disease	Uncontrolled diabetes mellitus
NCT01829958	1:21:chronic_disease	Ureteral compression
NCT01829958	31:63:treatment	patients being treated with a single agent monoclonal antibody
NCT01829958	2:3:lower_bound,32:36:lower_bound	≥3 nodal masses that are each ≥3 cm in greatest dimension
NCT01829958	2:10:lower_bound	≥60 years old
NCT01821781	5:13:upper_bound,17:20:age	</= 21 years of age
NCT01821781	1:5:clinical_variable,10:13:lower_bound	DLCO >/= 40%
NCT01821781	20:28:chronic_disease	Known diagnosis of HIV I/II
NCT01821781	1:5:clinical_variable,9:12:lower_bound,16:20:clinical_variable,24:27:lower_bound	LVEF >/=40% or LVSF >/=26%
NCT01821781	1:14:clinical_variable,19:25:upper_bound	Liver enzymes </= 5x ULN
NCT01821781	1:19:pregnancy	Negative pregnancy test
NCT01821781	1:19:clinical_variable,24:26:lower_bound	Performance status >/= 40
NCT01821781	1:9:pregnancy	Pregnant
NCT01821781	1:17:clinical_variable,20:26:upper_bound	Serum creatinine < 2x ULN
NCT01821781	14:29:clinical_variable,33:53:clinical_variable,61:74:upper_bound,87:98:treatment	Uncontrolled invasive fungal or bacterial infections within 1 month prior to starting alemtuzumab
NCT01821781	20:29:chronic_disease,37:49:upper_bound,62:73:treatment	Uncontrolled viral infection within 1 week prior to starting alemtuzumab
NCT01795573	1:4:cancer,6:9:cancer,29:54:clinical_variable,57:68:lower_bound,74:88:clinical_variable,91:105:lower_bound,134:142:cancer,154:175:upper_bound	AML, ALL: Normal values for absolute neutrophil count (>1000/microL) and platelet count (>100,000/microL); Absence of extramedullary leukemia; Less than 5 percent blast cells present in the bone marrow
NCT01795573	32:73:clinical_variable,76:79:lower_bound,83:117:treatment,121:135:treatment,137:182:clinical_variable,184:211:clinical_variable,217:259:clinical_variable,262:265:lower_bound,289:313:treatment,315:328:clinical_variable,330:333:clinical_variable,335:338:clinical_variable,342:371:upper_bound,380:400:clinical_variable,403:411:lower_bound	Adequate vital organ function: Left ventricular ejection fraction (LVEF) ≥ 45% by multigated acquisition (MUGA) scan or echocardiogram; Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing lung capacity oxygenation (DLCO) ≥ 50% of predicted values on pulmonary function tests; Transaminases (AST, ALT) < 3 times upper limit of normal values; Creatinine clearance ≥ 50cc/min
NCT01795573	1:45:contraception_consent	Agreement to utilize effective contraceptive methods during the study (for one year)
NCT01795573	1:29:treatment	Antithymocyte globulin (ATG) as part of the conditioning regimen
NCT01795573	1:4:cancer,65:76:clinical_variable,78:84:lower_bound,88:96:clinical_variable,100:119:treatment,177:202:clinical_variable,204:215:lower_bound,217:231:clinical_variable,233:247:lower_bound,298:315:treatment,349:359:cancer,364:378:treatment,386:406:treatment	CLL: Absence of constitutional symptoms attributable to CLL; No lymph nodes >1.5 cm in diameter on computed tomography; No hepatomegaly or splenomegaly by computed tomography; Absolute neutrophil count >1500/microL; Platelet count >100,000/microL; No clonal lymphocytes in the peripheral blood by immunophenotyping; Bone marrow with no evidence of clonal CLL (by flow cytometry and/or immunohistochemistry
NCT01795573	39:42:age,45:47:lower_bound	Eligible donors will include siblings age ≥ 18 matched with the recipient at HLA-A, B, C, and DRB1
NCT01795573	1:4:chronic_disease,17:22:treatment,26:82:treatment,75:81:treatment	HIV negative by ELISA or reverse transcription polymerase chain reaction (RT-PCR) [if ELISA is positive and RT-PCR is negative, the ELISA is considered false positive]
NCT01795573	73:82:treatment,217:249:treatment,267:294:treatment,385:405:treatment	HL: No clinical evidence of disease or disease-related symptoms; A post-treatment residual mass of any size is permitted as long as it is PET negative; Spleen and liver must be non-palpable and without nodules; If a pre-treatment bone marrow biopsy was positive, an adequate bone marrow biopsy from the same site must be cleared of infiltrate; if this is indeterminate by morphology, immunohistochemistry should be negative
NCT01795573	1:25:cancer,28:60:cancer,62:96:cancer,98:128:cancer,130:164:cancer,166:192:cancer,194:215:cancer,217:238:cancer,244:267:treatment,269:287:treatment	Hematologic malignancies - Acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM) - in complete remission (CR). Complete remission is defined per morphologic, cytogenetic, FISH, molecular, and radiographic imaging studies appropriate for each condition listed
NCT01795573	1:18:chronic_disease,31:39:treatment,43:49:treatment	Hepatitis B and C negative by serology or RT-PCR
NCT01795573	6:17:clinical_variable,24:45:upper_bound,118:128:clinical_variable,130:137:lower_bound,139:148:clinical_variable,150:162:lower_bound,164:175:clinical_variable,177:187:lower_bound	MDS: Bone marrow with ≤5 percent myeloblasts with normal maturation of all cell lines; Peripheral blood demonstrates hemoglobin ≥11 g/dL, platelets ≥100 x 10^9/L, neutrophils ≥1 x 10^9/L, and no circulating blasts
NCT01795573	1:4:cancer,91:104:treatment,112:123:treatment	MDS: Low/intermediate-1 IPSS risk category patients are eligible only if they have failed prior therapy or are transfusion-dependent
NCT01795573	1:4:cancer,42:71:treatment,73:95:treatment,100:113:treatment	MDS: May have achieved CR through either hypomethylating agent therapy, induction chemotherapy, or other therapy
NCT01795573	126:146:treatment,151:157:treatment,185:194:upper_bound,308:318:clinical_variable,373:401:clinical_variable	MM: Absence of monoclonal protein in serum and urine by immunofixation with no current evidence of soft tissue plasmacytoma; Bone marrow aspirate and biopsy must demonstrate less than 5 percent clonal plasma cells; In patients who lack measurable M proteins in the serum and urine being monitored using the FLC levels, the definition of CR requires a normalization of the free light chain (FLC) ratio in addition to the above criteria
NCT01795573	37:40:chronic_disease,59:65:treatment,67:128:treatment,130:164:treatment,166:199:treatment,201:231:treatment,233:268:treatment,270:309:treatment	Must complete full screening panel: HIV 1, 2 serology and RT-PCR; human T cell lymphotropic virus types 1/2 (HTLV-1/2) serology; rapid plasma reagin (RPR) serology; Epstein-Barr virus (EBV) serology; Cytomegalovirus (CMV) serology; herpes simplex virus (HSV) serology; Varicella-. Zoster Virus (VZV) serology
NCT01795573	77:80:treatment,77:94:cancer,77:95:cancer,104:113:treatment,263:265:treatment,321:352:treatment,334:352:treatment,445:465:treatment	NHL: No clinical evidence of disease or disease-related symptoms; Typically FDG-avid lymphomas: a post-treatment residual mass of any size is permitted as long as it is PET negative; Variably FDG-avid lymphoma/FDG avidity unknown: all lymph nodes normal size by CT; Spleen and liver non-palpable and without nodules; If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative
NCT01795573	11:20:chronic_disease,62:69:treatment	No active infection; infection controlled with antimicrobial therapy is not excluded
NCT01795573	1:19:clinical_variable,21:55:clinical_variable,58:61:lower_bound	Performance status: Karnofsky Performance Status Score ≥ 60%
NCT01795573	18:41:clinical_variable,55:75:lower_bound	Peripheral blood white blood count (WBC) greater than 2,000 per microliter (required for collection of dendritic cell precursors)
NCT01783795	48:60:chronic_disease	The patient has a family member diagnosed with Dent Disease
NCT01783795	75:87:chronic_disease	The patient has been diagnosed, or in the process of being diagnosed with Dent Disease
NCT01774019	1:4:age,5:7:lower_bound	Age 18 or older
NCT01774019	1:29:chronic_disease	Biliary obstructive symptoms or signs
NCT01774019	1:19:chronic_disease,40:53:chronic_disease	Biliary strictures caused by confirmed benign tumors
NCT01774019	30:42:cancer,54:71:cancer,73:102:cancer,113:134:cancer	Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD cholangiocarcinoma and other periampullary cancers
NCT01774019	1:16:clinical_variable,26:44:lower_bound	Bilirubin level at/above 100 umol per liter (5.8 mg/dL)
NCT01774019	23:40:cancer,49:90:cancer,101:122:cancer	Diagnosis of probable pancreatic cancer, distal common bile duct (CBD) cholangiocarcinoma and other periampullary cancers (histology not required)
NCT01774019	8:27:chronic_disease,44:61:cancer,63:92:cancer,102:126:cancer	Distal biliary obstruction consistent with pancreatic cancer, distal CBD cholangiocarcinoma or other periampullary malignancy
NCT01774019	1:11:treatment,16:34:treatment	Endoscopic and surgical treatment to be provided by same team
NCT01774019	13:39:chronic_disease,122:125:lower_bound	Location of distal biliary obstruction is such that it would allow the proximal end of a stent to be positioned at least 2cm from the hilum
NCT01774019	1:25:treatment,38:48:cancer	Neoadjuvant chemotherapy for current malignancy
NCT01774019	55:62:upper_bound	Participation in another investigational trial within 90 days
NCT01774019	1:10:pregnancy	Pregnancy
NCT01774019	1:38:treatment	Previous biliary drainage by ERCP/PTC
NCT01774019	1:8:treatment,23:30:upper_bound	Surgery intent within 4 weeks
NCT01774019	57:78:treatment	Surgically altered biliary tract anatomy, not including prior cholecystectomy
NCT01754298	1:4:chronic_disease	AVN
NCT01754298	23:43:treatment	Completed a course of conservative therapy
NCT01754298	14:18:chronic_disease	Diagnosis of JOCD
NCT01754298	14:37:chronic_disease	Diagnosis of metabolic bone disorder
NCT01754298	14:33:chronic_disease	Diagnosis of sickle cell disease
NCT01754298	22:36:treatment	History of prolonged corticosteroid
NCT01754298	45:48:treatment	Patient deemed skeletally immature based on MRI
NCT01754298	1:13:treatment	chemotherapy treatment
NCT01754298	1:8:chronic_disease	discoid/meniscal tear
NCT01754298	1:23:chronic_disease	inflammatory arthritis
NCT01754298	1:24:chronic_disease	osteogenesis imperfecta
NCT01737502	4:11:lower_bound,12:32:clinical_variable	>= Grade 2 hypercholesterolemia
NCT01737502	4:11:lower_bound,12:32:clinical_variable	>= Grade 2 hypertriglyceridemia
NCT01737502	1:32:clinical_variable,36:43:lower_bound	Absolute neutrophil count (ANC) >= 1500 uL
NCT01737502	29:39:chronic_disease	Active or recent history of hemoptysis
NCT01737502	1:16:chronic_disease	Angina pectoris
NCT01737502	126:140:treatment	Any illness that in the opinion of the investigator would compromise the ability of the patient to participate safely in the clinical trial
NCT01737502	1:19:chronic_disease	Cardiac arrhythmia
NCT01737502	1:66:clinical_variable,67:68:lower_bound,73:74:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2
NCT01737502	1:17:clinical_variable,21:27:lower_bound	Hemoglobin (Hgb) >= 9 g/dL
NCT01737502	41:52:cancer,54:62:cancer,64:90:cancer,94:116:cancer	Histologic or cytologic confirmation of lung cancer (squamous, ras-mutated adenocarcinoma or small cell lung cancer)
NCT01737502	12:36:clinical_variable,40:48:upper_bound	History of congestive heart failure =< 3 months
NCT01737502	1:35:chronic_disease,76:99:treatment	Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy
NCT01737502	1:13:chronic_disease	Hypertension
NCT01737502	1:23:chronic_disease,27:86:chronic_disease	Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
NCT01737502	1:16:clinical_variable,20:28:lower_bound	Life expectancy >= 12 weeks
NCT01737502	1:14:treatment,22:32:treatment,35:46:treatment,63:79:chronic_disease,83:96:upper_bound,114:127:treatment,131:144:upper_bound,177:199:treatment,218:240:treatment	Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regard
NCT01737502	1:4:gender,8:13:gender,48:90:contraception_consent	Men or women of childbearing potential who are unwilling to employ adequate contraception
NCT01737502	1:22:chronic_disease,26:40:upper_bound	Myocardial infarction =< 6 months prior to registration
NCT01737502	1:25:pregnancy,39:51:upper_bound,73:78:gender	Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
NCT01737502	1:25:cancer	Non-melanoma skin cancer
NCT01737502	9:14:gender	Nursing women
NCT01737502	14:24:cancer	Other active malignancy
NCT01737502	38:41:lower_bound,52:64:treatment,135:144:treatment	Patients must have received at least one course of chemotherapy consisting of a platinum doublet and must have no acceptable standard treatment options
NCT01737502	1:16:clinical_variable,20:30:lower_bound	Platelets (PLT) >= 100,000 uL
NCT01737502	1:27:chronic_disease	Poorly controlled diabetes
NCT01737502	1:9:pregnancy,10:15:gender	Pregnant women
NCT01737502	1:24:treatment	Prior radiation therapy
NCT01737502	1:10:treatment,17:35:lower_bound	Radiation to >= 25% of bone marrow
NCT01737502	37:56:treatment	Recovered from the toxic effects of radiation treatment before study entry
NCT01737502	41:80:cancer,84:100:chronic_disease	Symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases or seizure disorder
NCT01737502	1:16:clinical_variable,20:53:upper_bound,57:73:clinical_variable	Total bilirubin =< 1.5 x upper limit of normal (ULN) or direct bilirubin =< ULN
NCT01737502	37:52:treatment,54:62:treatment,64:75:treatment,77:119:treatment	Unable to discontinue use of potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors/inducers
NCT01737502	8:23:treatment	Use of St. John's Wort because of its effects on hepatic drug metabolism
NCT01737502	1:9:chronic_disease	alopecia
NCT01737502	1:18:cancer	carcinoma-in-situ of the cervix
NCT01737502	1:18:clinical_variable,21:24:lower_bound	ejection fraction > 40%
NCT01737502	33:60:treatment	history of poor compliance with antihypertensive medication
NCT01737502	1:20:chronic_disease	labile hypertension
NCT01737502	1:26:cancer	localized prostate cancer
NCT01737502	23:37:cancer,116:124:treatment	patients with treated CNS metastases without evidence of progression and without uncontrolled symptoms or need for steroids may enroll
NCT01720836	1:21:clinical_variable,24:32:lower_bound	Absolute Neutrophils > 1,500/µL
NCT01720836	1:21:clinical_variable,24:41:lower_bound,73:76:clinical_variable,81:84:clinical_variable,90:110:clinical_variable,120:151:upper_bound	Creatinine clearance > 60 mL/min/1.73 m2 for subjects with above normal AST and ALT with alkaline phosphatase within < 1.5 times upper limit of normal
NCT01720836	1:11:clinical_variable	Creatinine within normal institutional limits
NCT01720836	1:24:clinical_variable,25:26:lower_bound,27:28:upper_bound	ECOG performance status 0-1(Appendix A)
NCT01720836	1:11:clinical_variable,14:21:lower_bound	Hemoglobin > 10 g/dL
NCT01720836	1:3:cancer,5:9:cancer,12:14:cancer,17:21:cancer,23:25:clinical_variable	IB (T2NO), II & IIIA (N2 negative)
NCT01720836	7:18:chronic_disease,22:38:treatment,45:55:treatment	Known Hepatitis B on immunomodulators (i.e. interferon)
NCT01720836	45:55:treatment	Known Hepatitis C on immunomodulators (i.e. interferon)
NCT01720836	1:11:clinical_variable,14:22:lower_bound	Leukocytes > 3,000/µL
NCT01720836	4:25:treatment	No prior vaccine therapy
NCT01720836	35:43:treatment,53:72:treatment	Patients may not be receiving any steroids or other anti-immune therapy at the time of registration
NCT01720836	1:10:clinical_variable,13:23:lower_bound	Platelets > 100,000/µL
NCT01720836	1:9:pregnancy,10:15:gender	Pregnant women
NCT01720836	1:15:cancer	Stage IA(T1NO)
NCT01720836	41:63:treatment	Subjects may not be receiving any other investigational agents
NCT01720836	25:26:lower_bound,30:38:upper_bound,59:68:treatment	Subjects must be within 4 to 12 weeks of standard of care treatment for their particular stage of disease
NCT01720836	62:95:cancer	Subjects must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC
NCT01720836	32:40:lower_bound,63:72:treatment	Subjects must not be more than 12 weeks from standard of care treatment for their particular stage of disease
NCT01720836	24:50:chronic_disease,60:77:chronic_disease,218:227:treatment	Subjects must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the subjects to receive protocol treatment
NCT01720836	34:44:chronic_disease	Subjects with a history of known autoimmune
NCT01720836	1:16:clinical_variable	Total Bilirubin within normal institutional limits
NCT01720836	77:93:chronic_disease,107:131:chronic_disease,133:148:chronic_disease,159:177:chronic_disease,182:201:chronic_disease	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
NCT01720836	1:6:gender	Women
NCT01720836	10:18:lower_bound,22:25:age	at least 18 years of age
NCT01720836	7:10:chronic_disease	known HIV-positive patients
NCT01720836	1:4:gender	men
NCT01715571	12:20:chronic_disease	History of priapism
NCT01715571	1:11:clinical_variable,22:24:upper_bound	IIEF score less than 13
NCT01715571	1:4:gender,10:30:chronic_disease	Men with neurological disease
NCT01715571	1:18:chronic_disease	Pelvic neuropathy
NCT01715571	24:30:chronic_disease	Penile skin lesions or ulcers
NCT01715571	6:19:treatment	Post-prostatectomy
NCT01715571	1:19:chronic_disease	Spinal cord injury
NCT01715571	15:35:chronic_disease,45:116:clinical_variable,117:119:lower_bound,120:122:upper_bound	mild-moderate erectile dysfunction based on International Index of Erectile Function (IIEF) erectile function score 13-25
NCT01697865	39:49:upper_bound	Active forward elevation of less than 90 degrees
NCT01697865	1:18:chronic_disease	Advanced dementia
NCT01697865	1:21:chronic_disease,51:58:treatment,60:78:chronic_disease	Chronic rotator cuff tear with severe retraction, atrophy, fatty infiltration
NCT01697865	1:24:chronic_disease,30:41:chronic_disease	Neuro-muscular disorder (ie: Parkinson's)
NCT01697865	10:28:chronic_disease	Previous shoulder infection
NCT01697865	1:22:treatment	Revision arthroplasty
NCT01697865	1:25:chronic_disease,33:65:chronic_disease,82:104:chronic_disease	Shoulder pseudoparalysis due to chronic rotator cuff dysfunction with or without glenohumeral arthritis
NCT01697865	1:24:chronic_disease	Teres minor dysfunction
NCT01686659	45:60:treatment	Adult patients undergoing one of the listed major surgeries associated with possibility of significant blood loss
NCT01686659	25:54:treatment	Any patients undergoing Cardio-Pulmonary Bypass (CPB)
NCT01686659	68:85:treatment	Any patients who cannot be transfused or has refused consent for a blood transfusion
NCT01686659	27:43:chronic_disease	Any patients with a known hemoglobinopathy
NCT01686659	110:125:clinical_variable,139:142:lower_bound	At least one finger available and accessible for performing non-invasive hemoglobin monitoring (preoperative perfusion index greater than 0.5)
NCT01686659	65:72:upper_bound	Patients being treated by any artificial oxygen carriers within 30 days of hospital stay
NCT01686659	49:56:upper_bound	Patients who are actively enrolled in or within 30 days of completion of any other study (except for purely observational studies with no intervention)
NCT01686659	18:26:pregnancy	Patients who are pregnant
NCT01686659	23:31:upper_bound	Patients younger than 18 years old
NCT01624090	1:11:clinical_variable,34:47:upper_bound	ALT (SGPT) less than or equal to 3.0 times ULN
NCT01624090	1:4:age,6:8:lower_bound	Age >18
NCT01624090	1:8:clinical_variable,11:17:lower_bound	Albumin > 2 g/dL
NCT01624090	1:8:treatment,12:42:treatment,71:81:chronic_disease	Aspirin or salicylate-containing products, which may increase risk of hemorrhage
NCT01624090	10:11:lower_bound,47:76:treatment	At least 3 half-lives must have elapsed since monoclonal antibody treatment
NCT01624090	10:19:lower_bound,46:57:treatment,61:82:treatment	At least six weeks must have elapsed between mitomycin C or nitrosourea treatment
NCT01624090	1:18:clinical_variable,21:58:upper_bound	Bilirubin (total) < 1.5 times upper limit of normal (ULN)
NCT01624090	19:58:clinical_variable,60:63:lower_bound,67:81:treatment,83:87:treatment,92:102:treatment	Cardiac Function: Left ventricular ejection fraction (EF) >40% by Echocardiogram, MUGA, or cardiac MR
NCT01624090	55:72:chronic_disease,88:95:chronic_disease,97:106:chronic_disease,108:115:chronic_disease,125:142:chronic_disease,236:243:treatment	Clinically significant systemic illness (e.g. serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the judgment of the PI would compromise the patient s ability to tolerate protocol therapy or significantly increase the risk of complications
NCT01624090	1:12:treatment	Clopidogrel
NCT01624090	1:11:clinical_variable,19:46:clinical_variable,50:70:clinical_variable,96:114:lower_bound,133:150:clinical_variable,157:177:clinical_variable	Creatinine within normal institutional limits or creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
NCT01624090	1:5:clinical_variable,9:12:upper_bound,24:43:treatment	DLCO, < 30% predicted (post-bronchodilator)
NCT01624090	1:8:treatment	Dextran
NCT01624090	1:13:treatment	Dipyridamole
NCT01624090	21:44:treatment,63:92:treatment,101:113:treatment,115:127:treatment,129:140:treatment,145:157:treatment	Disease amenable to biopsy via percutaneous approach or other minimally invasive procedures such as thoracoscopy, bronchoscopy, laparoscopy, or GI endoscopy
NCT01624090	1:12:clinical_variable,13:14:lower_bound,15:16:upper_bound	ECOG status 0-2
NCT01624090	1:4:clinical_variable,8:11:upper_bound	FEV, < 30% predicted
NCT01624090	1:11:clinical_variable,37:43:lower_bound,45:62:treatment	Hemoglobin greater than or equal to 8 g/dL (PRBC transfusions permitted)
NCT01624090	1:17:treatment	Hepatic Function
NCT01624090	21:32:allergy_name	Hypersensitivity to mithramycin
NCT01624090	61:81:treatment	Normal ionized calcium, magnesium and phosphorus (can be on oral supplementation)
NCT01624090	1:18:clinical_variable,32:35:lower_bound	Oxygen saturation greater than 92% on room air
NCT01624090	1:7:clinical_variable	PT/PTT within normal limits
NCT01624090	38:55:treatment,48:55:treatment,96:108:treatment,122:135:upper_bound	Patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed 14 days prior to commencing therapy, and the patient has recovered from any toxicity
NCT01624090	39:44:cancer,45:53:treatment	Patients must be willing to undergo 2 tumor biopsies
NCT01624090	27:39:treatment,41:57:treatment,62:79:treatment,90:100:cancer,114:127:lower_bound,131:140:treatment	Patients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy for at least 30 days prior to treatment
NCT01624090	55:67:treatment,78:101:cancer	Patients must have had or refused first-line standard chemotherapy for their inoperable malignancies
NCT01624090	13:40:treatment	Patients on therapeutic anticoagulation
NCT01624090	115:126:treatment,155:165:chronic_disease	Patients who are concurrently receiving or requiring any of the following agents, which may increase the risk for mithramycin related toxicities, such as hemorrhage
NCT01624090	15:20:treatment,22:28:treatment,30:35:treatment,39:45:treatment,72:107:treatment	Patients with ABCB4, ABCB11, RALBP or CYP851 genotypes associated with mithramycin-mediated hepatotoxicity
NCT01624090	36:68:chronic_disease	Patients with any of the following pulmonary function abnormalities
NCT01624090	15:34:cancer	Patients with cerebral metastases
NCT01624090	27:42:chronic_disease,44:67:chronic_disease,82:100:chronic_disease	Patients with evidence of active bleeding, intratumoral hemorrhage or history of bleeding diatheses
NCT01624090	26:29:chronic_disease,31:34:chronic_disease,38:41:chronic_disease	Patients with history of HIV, HBV or HCV due to potentially increased risk of mithramycin toxicity in this population
NCT01624090	63:75:cancer,80:101:cancer,103:119:cancer,121:137:cancer,139:170:cancer,174:193:cancer	Patients with measurable inoperable, histologically confirmed primary lung and esophageal carcinomas, thymic neoplasms, germ cell tumors, malignant pleural mesotheliomas or chest wall sarcomas
NCT01624090	1:15:clinical_variable,41:50:lower_bound	Peripheral ANC greater than or equal to 1500/mm^3
NCT01624090	1:10:clinical_variable,36:49:lower_bound,51:62:treatment	Platelets greater than or equal to 100,000/ mm^3 (transfusion independent)
NCT01624090	1:15:treatment	Sulfinpyrazone
NCT01624090	1:20:treatment	Thrombolytic agents
NCT01624090	1:14:treatment	Valproic acid
NCT01624090	15:22:cancer,24:34:cancer,38:51:cancer,56:89:cancer	patients with gastric, colorectal or renal cancers and sarcomas metastatic to the thorax
NCT01624090	1:9:pregnancy,10:17:gender	pregnant females (due to risk to fetus or newborn, and lack of testing for excretion in breast milk)
NCT01624090	1:29:treatment,36:56:treatment	prophylactic anticoagulation (i.e. intralumenal heparin) for venous or arterial access devices
NCT01624090	66:78:treatment,87:103:chronic_disease	specifically occurring as an isolated incident during reversible chemotherapy induced thrombocytopenia
NCT01595061	1:32:clinical_variable,36:45:lower_bound	Absolute neutrophil count (ANC) >= 1,500/mcl
NCT01595061	1:21:clinical_variable,25:32:upper_bound	Alkaline phosphatase =< 3 x ULN
NCT01595061	1:32:clinical_variable	Aspartate aminotransferase (AST
NCT01595061	1:10:clinical_variable,14:23:upper_bound	Bilirubin =< 1.5 x ULN
NCT01595061	1:11:clinical_variable,15:66:upper_bound	Creatinine =< 1.5 times institutional upper limit of normal (ULN)
NCT01595061	59:81:treatment	Patients judged capable of tolerating a radical course of chemoradiation therapy
NCT01595061	28:50:treatment,54:76:treatment	Patients who have received prior pelvic radiation or cytotoxic chemotherapy
NCT01595061	15:49:cancer,66:84:treatment,97:115:treatment	Patients with T2 or T3 primary tumors (N0-3, M0) not amenable to surgical resection by standard radical vulvectomy
NCT01595061	17:39:clinical_variable,43:44:lower_bound,52:53:upper_bound	Patients with a GOG performance status of 0, 1, or 2
NCT01595061	34:44:chronic_disease,53:62:chronic_disease,64:89:chronic_disease,100:125:chronic_disease,136:163:treatment	Patients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy
NCT01595061	54:90:cancer	Patients with locally advanced, previously untreated squamous cell carcinoma of the vulva
NCT01595061	25:47:cancer,71:80:treatment	Patients with recurrent carcinoma of the vulva regardless of previous treatment
NCT01595061	15:31:cancer,35:43:cancer	Patients with vulvar melanomas or sarcomas
NCT01595061	1:10:clinical_variable,14:25:lower_bound	Platelets >= 100,000/mcl
NCT01595061	1:31:clinical_variable,35:44:upper_bound	alanine aminotransferase (ALT) =< 3.0 x ULN
NCT01595061	12:32:clinical_variable,36:45:lower_bound	calculated creatinine clearance >= 60 mL/min
NCT01584076	1:4:age,6:13:lower_bound	Age ≥8 years
NCT01584076	1:10:chronic_disease,27:37:chronic_disease,45:58:chronic_disease	Amblyopia associated with strabismus and/or anisometropia
NCT01584076	1:28:clinical_variable,32:37:lower_bound,40:46:upper_bound	Amblyopic eye visual acuity of 20/50 - 20/400
NCT01584076	24:32:lower_bound	Available for at least 6 months of follow-up
NCT01584076	33:47:upper_bound	Complete eye examination within 6 months prior to enrollment
NCT01584076	16:26:treatment,35:44:treatment,48:52:chronic_disease,56:79:chronic_disease	Current use of medication for the treatment of ADHD or psychological disorders
NCT01584076	9:23:treatment,27:37:treatment	Current vision therapy or orthoptics
NCT01584076	1:8:gender,13:25:pregnancy	Females who are pregnant
NCT01584076	5:6:lower_bound,10:11:upper_bound,10:17:upper_bound,32:51:treatment,42:51:treatment,64:71:lower_bound,103:110:lower_bound,182:209:clinical_variable,212:221:upper_bound	For 8 to 17 year olds, current amblyopia treatment of at least 2 hours of daily patching for at least 4 weeks during the pre-enrollment period with no improvement in best-corrected amblyopic eye visual acuity (<5 letters or 1 logMAR line between 2 consecutive visual acuity measurements at least 4 weeks apart while on current treatment)
NCT01584076	6:13:lower_bound	For ≥18 year olds
NCT01584076	12:37:chronic_disease,43:63:chronic_disease	History of gastrointestinal bleeding from peptic ulcer disease
NCT01584076	59:75:treatment	Inability to swallow pills equivalent in size to the 5 mg donepezil tablet
NCT01584076	52:83:allergy_name	Known allergies or contraindications to the use of acetylcholinesterase inhibitors
NCT01584076	7:29:chronic_disease	Known psychological problems
NCT01584076	24:29:allergy_name,33:50:allergy_name,55:56:lower_bound,60:67:upper_bound	Known skin reaction to patch or bandage adhesives for 8 to 17 year olds
NCT01584076	1:7:chronic_disease,19:25:lower_bound	Myopia more than -6.00 D spherical equivalent
NCT01584076	13:20:chronic_disease,32:38:chronic_disease,40:69:chronic_disease,71:87:chronic_disease,89:109:chronic_disease,118:138:chronic_disease,160:166:treatment	Presence of cardiac condition, asthma, obstructive pulmonary disease, seizure disorder, urinary incontinence, and/or peptic ulcer disease receiving concurrent NSAIDs
NCT01584076	1:21:treatment,25:43:treatment	Previous intraocular or refractive surgery
NCT01584076	1:47:treatment	Prior acetylcholinesterase inhibitor treatment
NCT01584076	1:24:clinical_variable,29:34:lower_bound	Sound eye visual acuity of ≥20/25
NCT01584076	1:19:treatment,35:43:upper_bound	Strabismus surgery planned within 22 weeks
NCT01584076	1:10:treatment,44:56:upper_bound	Treatment with topical atropine within the past 4 weeks
NCT01584076	78:79:upper_bound,91:92:upper_bound,177:184:lower_bound	Wearing optimal optical correction with stable amblyopic eye visual acuity (<5 letters or 1 logMAR line of improvement during 2 consecutive visual acuity measurements at least 4 weeks apart)
NCT01584076	6:23:technology_access	have access to a phone
NCT01584076	12:51:treatment	history of prior amblyopia treatment with patching
NCT01584076	14:29:pregnancy,41:54:upper_bound	intending to become pregnant within the next 6 months
NCT01560637	17:53:treatment	Participated in United Therapeutics Study TDE-PH-310
NCT01542879	22:41:cancer,47:65:cancer,69:86:cancer	Diagnosis of a solid extra-cranial tumor like malignant lymphoma or malignant sarcoma
NCT01542879	1:14:chronic_disease,15:30:chronic_disease,85:96:treatment	Hemosiderosis/hemochromatosis (patients can still be included in 2nd branch without ferumoxytol)
NCT01542879	1:9:pregnancy,10:15:gender	Pregnant women
NCT01542879	40:51:treatment	Pt with iron-overload will not receive Ferumoxytol
NCT01542879	30:83:treatment	Scheduled for or completed a 18F-FDG-PET or 18F-FDG-PET/CT tumor staging procedure
NCT01542879	30:38:treatment,42:52:treatment	Very young children who need sedation or anesthesia
NCT01542879	9:17:treatment,21:35:chronic_disease	need of sedation or claustrophobia
NCT01542879	58:72:allergy_name	patients with a positive history of allergic reaction to iron compounds or other severe allergic reactions
NCT01536522	10:21:clinical_variable,23:32:lower_bound	(fasting blood sugar >110 mg/dL)
NCT01536522	5:9:allergy_name	Any milk allergies
NCT01536522	23:34:chronic_disease,38:53:chronic_disease,133:156:chronic_disease,179:192:chronic_disease	Any other significant respiratory or cardiac disease or the presence of clinically important comorbidities, including, uncontrolled coronary artery disease, acute or and chronic renal failure
NCT01536522	1:7:chronic_disease,94:107:clinical_variable,112:115:lower_bound,119:123:clinical_variable	Asthma diagnosed by a medical specialist and/or history of positive methacholine rest and/or reversibility of >10% of FEV1
NCT01536522	1:4:bmi,6:14:lower_bound	BMI >40 kg/m2
NCT01536522	1:8:allergy_name	Coconut allergies
NCT01536522	52:65:lower_bound	Current smoking or smoking history of greater than 10 pack-years
NCT01536522	1:9:chronic_disease	Diabetes
NCT01536522	1:5:clinical_variable	FEV1 is within acceptable limits
NCT01532687	4:12:lower_bound,16:46:clinical_variable,53:59:lower_bound	>= 140 mmHg or diastolic blood pressure (DBP) of >= 90mmHg
NCT01532687	3:25:treatment,27:38:treatment	A bilateral oophorectomy (ovariectomy)
NCT01532687	3:15:treatment	A hysterectomy
NCT01532687	1:32:clinical_variable,36:48:lower_bound	Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
NCT01532687	1:45:clinical_variable,49:58:upper_bound	Activated partial thromboplastin time (aPTT) =< 1.2 x ULN
NCT01532687	1:28:chronic_disease	Active peptic ulcer disease
NCT01532687	1:17:treatment,41:56:treatment,61:79:cancer	Adjuvant therapy will not count towards prior treatment for metastatic disease, unless the patient relapsed
NCT01532687	1:31:clinical_variable,36:68:clinical_variable,72:81:upper_bound	Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
NCT01532687	27:52:treatment	Any ongoing toxicity from prior anti-cancer therapy
NCT01532687	5:37:treatment	Any prior treatment with gemcitabine
NCT01532687	5:35:treatment,39:80:clinical_variable,84:152:treatment,158:167:treatment,169:178:treatment,184:195:treatment	Any prior treatment with pazopanib or vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)-targeting agents (eg. sorafenib, sunitinib, and bevacizumab)
NCT01532687	42:49:chronic_disease,51:62:chronic_disease	Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures
NCT01532687	1:20:treatment,24:32:treatment	Cardiac angioplasty or stenting
NCT01532687	1:13:treatment,15:28:treatment,30:46:treatment,48:71:treatment,75:91:treatment	Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy
NCT01532687	39:45:gender,60:84:pregnancy	Childbearing potential, including any female who has had a negative serum pregnancy test
NCT01532687	1:10:lower_bound,14:16:upper_bound,17:41:chronic_disease,61:94:clinical_variable	Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
NCT01532687	24:54:chronic_disease,85:107:treatment	Clinically significant gastrointestinal abnormalities that may affect absorption of investigational produc
NCT01532687	1:37:treatment	Coronary artery bypass graft surgery
NCT01532687	1:28:clinical_variable,31:55:lower_bound	Corrected QT interval (QTc) > 480 milliseconds (msecs) using Bazett's formula
NCT01532687	1:61:clinical_variable,65:66:lower_bound,67:68:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
NCT01532687	13:28:chronic_disease,32:50:chronic_disease	Evidence of active bleeding or bleeding diathesis
NCT01532687	1:16:gender,89:99:treatment,147:156:treatment	Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period
NCT01532687	1:11:clinical_variable,15:34:lower_bound	Hemoglobin >= 9 g/dL (5.6 mmol/L)
NCT01532687	1:11:chronic_disease,62:69:upper_bound	Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug
NCT01532687	39:49:cancer,66:85:cancer,97:128:cancer,130:146:cancer,148:172:cancer,178:187:cancer,191:216:cancer	Histologically confirmed diagnosis of metastatic or unresectable soft tissue sarcoma, excluding gastrointestinal stromal tumors, Kaposi's sarcoma, Ewing's family of tumors, and embryonal or alveolar rhabdomyosarcoma
NCT01532687	12:29:chronic_disease,31:59:chronic_disease,64:87:chronic_disease	History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
NCT01532687	45:59:chronic_disease	History of any one or more of the following cardiovascular conditions
NCT01532687	12:36:chronic_disease,47:78:chronic_disease,80:98:chronic_disease,112:140:chronic_disease	History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT)
NCT01532687	33:72:cancer,76:105:cancer,158:172:cancer	History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic
NCT01532687	13:27:treatment	Implants of levonorgestrel
NCT01532687	1:27:chronic_disease,34:52:chronic_disease,54:69:chronic_disease,81:108:chronic_disease,132:143:chronic_disease	Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation
NCT01532687	1:24:treatment	Injectable progesterone
NCT01532687	1:26:contraception_consent,30:55:contraception_consent,100:111:upper_bound	Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year
NCT01532687	7:28:cancer,107:127:chronic_disease	Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage
NCT01532687	7:30:cancer	Known intraluminal metastatic lesion/s with risk of bleeding
NCT01532687	1:16:treatment	Major resection of the stomach or small bowel
NCT01532687	1:23:chronic_disease	Malabsorption syndrome
NCT01532687	1:5:gender,14:27:treatment,29:38:treatment,61:72:chronic_disease,87:103:gender,89:93:gender	Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject
NCT01532687	24:81:treatment	Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
NCT01532687	1:22:chronic_disease	Myocardial infarction
NCT01532687	1:19:contraception_consent	Oral contraceptive, either combined or progesterone alone
NCT01532687	38:41:lower_bound,61:66:upper_bound,68:85:treatment,90:99:treatment,103:133:cancer	Patients must have received at least one, but not more than three, systemic regimens for treatment of metastatic soft tissue sarcoma
NCT01532687	1:35:contraception_consent	Percutaneous contraceptive patches
NCT01532687	1:10:clinical_variable,14:26:lower_bound	Platelets >= 100 x 10^9/L
NCT01532687	19:31:chronic_disease,44:73:clinical_variable	Poorly controlled hypertension (defined as systolic blood pressure (SBP)
NCT01532687	13:35:chronic_disease	Presence of uncontrolled infection
NCT01532687	1:20:treatment,24:30:chronic_disease	Prior major surgery or trauma
NCT01532687	7:17:cancer	Prior malignancy
NCT01532687	1:22:clinical_variable,26:62:clinical_variable,66:99:upper_bound	Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN)
NCT01532687	1:18:treatment,20:27:treatment,31:49:treatment	Radiation therapy, surgery or tumor embolization
NCT01532687	1:17:clinical_variable,21:43:upper_bound	Serum creatinine =< 1.5 mg/dL (133 umol/L)
NCT01532687	20:53:treatment	Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses
NCT01532687	16:19:treatment,48:67:chronic_disease	Subjects using HRT must have experienced total cessation of menses
NCT01532687	13:40:chronic_disease	Symptomatic peripheral vascular disease
NCT01532687	7:16:clinical_variable,20:29:upper_bound	Total bilirubin =< 1.5 x ULN
NCT01532687	54:65:treatment	Unable or unwilling to discontinue use of prohibited medications
NCT01532687	1:16:chronic_disease	Unstable angina
NCT01532687	1:40:clinical_variable,43:44:upper_bound	Urine protein to creatinine ratio (UPC) < 1
NCT01532687	37:57:treatment	administration of any non-oncologic investigational drug
NCT01532687	27:36:clinical_variable,41:44:clinical_variable,45:48:clinical_variable,55:88:lower_bound	concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
NCT01532687	5:19:upper_bound,32:55:treatment	for 14 days before exposure to investigational product, through the dosing period
NCT01532687	5:12:upper_bound	for 14 days following the last dose of study drug
NCT01532687	5:19:upper_bound,37:47:treatment	for 6 months prior to first dose of study drug
NCT01532687	8:14:lower_bound,35:43:lower_bound,47:50:age	for >= 1 year and be greater than 45 years in age
NCT01532687	8:14:lower_bound,35:43:lower_bound,47:50:age	for >= 1 year and be greater than 45 years of age
NCT01532687	14:21:lower_bound,25:50:lower_bound	for at least 14 days or five half-lives of a drug (whichever is longer)
NCT01532687	14:21:lower_bound,45:68:treatment	for at least 21 days after the last dose of investigational product
NCT01532687	14:21:lower_bound	for at least 6 weeks are eligible
NCT01532687	52:55:treatment,60:84:clinical_variable,108:111:treatment	have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT
NCT01532687	29:37:treatment,41:64:treatment	have had no requirement for steroids or anti-seizure medication
NCT01532687	32:41:treatment	must be willing to comply with treatment and follow-up
NCT01532687	26:45:treatment,72:82:cancer	patients must have had a prior anthracycline in either the adjuvant or metastatic setting unless medically inappropriate for the patient
NCT01532687	17:34:chronic_disease,36:44:chronic_disease,49:54:chronic_disease,75:93:treatment	presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major
NCT01532687	1:38:treatment	prior to the first dose of study drug and for the duration of the study
NCT01532687	29:40:treatment,48:54:upper_bound	subjects may not have had a transfusion within 7 days of screening assessment
NCT01532687	22:49:clinical_variable,52:55:upper_bound	subjects must have a 24-hour urine protein value < 1 g to be eligible
NCT01532687	31:41:cancer	subjects who have had another malignancy and have been disease-free
NCT01532687	48:79:cancer,102:119:cancer,145:159:cancer	subjects with a history of completely resected non-melanomatous skin carcinoma, successfully treated in situ carcinoma, or successfully treated bladder cancer are eligible
NCT01532687	22:25:chronic_disease,53:88:treatment	subjects with recent DVT who have been treated with therapeutic anti-coagulating agents
NCT01532687	8:22:treatment	use of urine dipstick for renal function assessment is not acceptable
NCT01532687	8:14:upper_bound,29:45:treatment	within 1 year of completing adjuvant therapy
NCT01532687	8:15:upper_bound,94:103:treatment	within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
NCT01532687	8:21:upper_bound,43:52:treatment	within 14 days prior to the first dose of pazopanib
NCT01532687	8:21:upper_bound,35:50:treatment	within 28 days prior to beginning study treatment
NCT01532687	8:21:upper_bound,39:49:treatment	within 28 days prior to first dose of study drug
NCT01532687	8:15:upper_bound,19:31:upper_bound,89:104:treatment	within 30 days or 5 half-lives whichever is longer prior to receiving the first dose of study treatment
NCT01532687	8:20:upper_bound,42:57:treatment	within 7 days prior to the first dose of study treatment
NCT01532687	12:25:upper_bound	within the past 6 months
NCT01459107	1:20:chronic_disease	Active tuberculosis
NCT01459107	1:5:age,6:8:lower_bound,11:19:upper_bound	Aged 16 - 65 years
NCT01459107	1:5:age,6:8:lower_bound,9:17:upper_bound	Aged 18-69 years
NCT01459107	1:26:treatment	Below-shoulder amputation
NCT01459107	58:79:chronic_disease,84:95:chronic_disease,131:161:chronic_disease,167:180:chronic_disease	Conditions that may impact functional outcomes including Lipopolysaccharidosis and amyloidosis (may impact nerve regeneration) or rare disorders of bone healing like osteopetrosis
NCT01459107	158:168:chronic_disease,170:194:chronic_disease,196:222:chronic_disease,224:240:chronic_disease,242:254:chronic_disease,256:275:chronic_disease	Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc
NCT01459107	158:185:treatment	Conditions that, in the opinion of the study team, may impact the immunomodulatory protocol potentially exposing the recipient to an unacceptable risk under immunosuppressive treatment
NCT01459107	13:33:treatment,49:65:treatment	Consents to bone marrow infusion as part of the treatment regime
NCT01459107	24:32:upper_bound	Current/recent (within 3 months of donation/screening consent) IV drug abuse
NCT01459107	116:131:treatment	Functionless or minimally functional hand desiring removal of functionless / minimally functional hand followed by transplantation
NCT01459107	1:4:chronic_disease	HIV (active or seropositive)
NCT01459107	1:17:chronic_disease	Hepatitis B or C
NCT01459107	47:53:chronic_disease,57:70:chronic_disease,72:82:chronic_disease	Infectious, post infectious, or inflammatory (axonal or demyelinating) neuropathy
NCT01459107	11:32:chronic_disease	Inherited peripheral neuropathy
NCT01459107	1:5:gender,9:15:gender	Male or female and of any race, color or ethnicity
NCT01459107	1:11:cancer,20:32:upper_bound	Malignancy (within past 5 years)
NCT01459107	1:32:chronic_disease	Mixed connective tissue disease
NCT01459107	7:33:chronic_disease,38:55:chronic_disease,95:102:treatment	Mixed connective tissue diseases and collagen diseases can result in poor wound healing after surgery
NCT01459107	14:17:chronic_disease,21:31:treatment	Negative for HIV at transplant
NCT01459107	14:24:cancer,29:41:upper_bound	Negative for malignancy for past 5 years
NCT01459107	10:36:treatment	Negative lymphocytotoxic crossmatch
NCT01459107	119:137:treatment,244:253:treatment,356:387:treatment	No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results (see Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of upper extremity transplantation.)
NCT01459107	32:45:upper_bound	Non-professional tattoo within last 6 months
NCT01459107	1:22:chronic_disease	Paralysis of ischemic or traumatic origin
NCT01459107	75:108:treatment	Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime
NCT01459107	54:74:treatment	Personally identifiable tattoo (i.e., donor name) on potential transplant
NCT01459107	10:18:lower_bound,68:93:chronic_disease,124:144:treatment	Recent (≥6 months) or remote (i.e., several decades) unilateral or bilateral upper limb loss (below the shoulder) desiring limb transplantation
NCT01459107	64:93:clinical_variable	Sensitized recipients with high levels (50%) of panel-reactive human leukocyte antigen (HLA) antibodies
NCT01459107	18:28:chronic_disease,32:46:chronic_disease	Severe deforming rheumatoid or osteoarthritis in the limb
NCT01459107	48:60:treatment	Stable donor (i.e., does not require excessive vasopressors to maintain blood pressure)
NCT01459107	1:17:chronic_disease	Toxic neuropathy (i.e. heavy metal poisoning, drug toxicity, industrial agent exposure)
NCT01459107	1:14:chronic_disease	Toxoplasmosis
NCT01459107	1:45:chronic_disease	Type I (insulin-dependent) diabetes mellitus
NCT01459107	82:92:treatment	USA citizen or equivalent, or foreigner with documentation of ability to pay for transplant and required follow-up care
NCT01459107	11:17:chronic_disease	Untreated sepsis
NCT01459107	1:19:chronic_disease	Viral encephalitis
NCT01429337	54:57:gender,92:104:gender	A condom is required to be used also by vasectomized men as well during intercourse with a male partner in order to prevent delivery of the drug via semen
NCT01429337	31:43:upper_bound	Consumption of alcohol within 3 days prior to dosing or during the study
NCT01429337	17:22:gender,35:45:contraception_consent,78:89:treatment,107:121:upper_bound	Sexually active males unless they use condom during intercourse while taking midostaurin and for at least 3 months after the last exposure to drug
NCT01429337	13:23:chronic_disease,27:47:chronic_disease	Significant neurologic or psychiatric disorder which could compromise participation in the study
NCT01429337	15:30:clinical_variable,44:52:lower_bound	Subjects with cotinine levels greater than 500ng/mL are considered as smokers and will not be enrolled
NCT01429337	62:75:upper_bound	Subjects with known ongoing alcohol and/or drug abuse within 1 month prior to dosing or evidence of such abuse
NCT01373112	16:46:chronic_disease,52:83:treatment	Diagnosis of a periprosthetic joint infection of a primary total knee arthroplasty with a planned two-stage exchange procedure
NCT01373112	46:65:treatment	Extensive bone loss preventing the use of an articulating spacer
NCT01373112	1:10:chronic_disease,41:72:treatment	Infection of a revision as opposed to a primary total knee arthroplasty
NCT01373112	18:40:allergy_name,42:52:allergy_name,56:66:allergy_name	Known allergy to polymethylmethacrylate, tobramycin or vancomycin
NCT01373112	21:43:treatment	Medically unfit for operative intervention
NCT01373112	1:20:chronic_disease,48:67:treatment	Soft tissue defects that prevent the use of an articulating spacer
NCT01367444	27:61:chronic_disease,65:95:chronic_disease	A past medical history of human immunodeficiency virus (HIV) or hepatitis A, B, or C infection
NCT01367444	5:28:treatment,107:121:upper_bound	Any injectable intravitreal treatment to the treated eye or intravitreal device in the treated eye within 6 months prior to screening
NCT01367444	5:24:treatment,28:33:treatment,63:71:upper_bound	Any intraocular surgery or laser in either eye planned within 6 months of Day 0
NCT01367444	107:118:treatment,206:221:treatment	Any known allergy to any component of the delivery vehicle or diagnostic agents used during the study, or medications planned for use in the perioperative period particularly topical, injected or systemic corticosteroids
NCT01367444	5:45:treatment,72:86:upper_bound	Any periocular injections of corticosteroids to the treated eye within 4 months prior to screening
NCT01367444	1:8:treatment,12:28:treatment	Aphakia or prior vitrectomy in the study eye
NCT01367444	1:17:treatment,35:52:treatment,60:68:upper_bound	Cataract surgery with intraocular lens implantation within 6 months of enrolment
NCT01367444	13:30:chronic_disease,83:92:treatment	Concomitant systemic diseases including those in which the disease itself, or the treatment for the disease, can alter ocular function
NCT01367444	12:35:treatment,62:83:treatment	Concurrent anti-retroviral therapy that would inactivate the investigational agent
NCT01367444	29:39:treatment	Contraindications to use of anesthesia (local or general, as appropriate)
NCT01367444	24:33:treatment,39:60:treatment,75:98:treatment,110:126:upper_bound,130:137:treatment	Current or anticipated treatment with anticoagulant therapy or the use of anticoagulation therapy within the four weeks prior to surgery
NCT01367444	14:52:chronic_disease,68:71:lower_bound	Diagnosis of Stargardt's Macular Degeneration (SMD), with at least one pathogenic mutant ABCA4 allele on each chromosome
NCT01367444	83:110:treatment,116:120:clinical_variable,125:133:lower_bound	Enlargement in the area of central macular retinal thinning/photoreceptor loss by ocular coherence tomography at a rate of ≥0.5 mm^2
NCT01367444	51:74:clinical_variable,89:97:lower_bound	Enlargement in the area of macular RPE atrophy by fundus autofluorescence at a rate of ≥0.5 mm^2
NCT01367444	33:42:treatment	Enrolment in any other clinical treatment study throughout the duration of the SAR422459 study
NCT01367444	16:37:treatment,45:58:upper_bound,62:71:treatment	History of any investigational agent within 28 days prior to SAR422459 administration
NCT01367444	34:54:chronic_disease,56:66:chronic_disease,68:81:chronic_disease,86:106:treatment	History or signs consistent with unilateral amblyopia (strabismic, anisometropic, or stimulus deprivation)
NCT01367444	1:16:treatment,51:68:treatment,70:82:treatment	Laboratory test abnormalities or abnormalities in electrocardiogram, chest X-rays that in the opinion of the Principal Investigator would make the patient unsuitable for participation in the study
NCT01367444	10:11:lower_bound,20:41:clinical_variable	Loss of ≥1 line of Snellen visual acuity (equivalent to 5 ETDRS letters)
NCT01367444	1:6:gender,12:70:contraception_consent,84:96:lower_bound,107:131:treatment	Males must agree with their partner to use two forms of contraception for at least three months following SAR422459 administration
NCT01367444	20:54:treatment	Participation in a prior ocular gene transfer therapy study
NCT01367444	11:19:lower_bound,35:67:chronic_disease	Patients (18 years or older) with Stargardt's Macular Degeneration
NCT01367444	11:19:lower_bound,44:76:chronic_disease	Patients (18 years or older) with advanced Stargardt's Macular Degeneration
NCT01367444	160:163:lower_bound,250:263:upper_bound	Patients are anticipated to experience rapid deterioration in visual function and/or retinal structure as determined by an annual progression rate in at least one of the following parameters occurring in at least one eye (assessments recorded up to 2 years prior to the screening visit date may be considered to document evidence of rapid deterioration)
NCT01367444	80:92:lower_bound,103:112:treatment	Patients must agree to not donate blood, organs, tissues or cells for at least three months following SAR422459 administration
NCT01367444	14:28:chronic_disease,61:68:treatment	Pre-existing eye conditions that would preclude the planned surgery or interfere with the interpretation of study endpoints
NCT01367444	42:47:gender,56:107:contraception_consent,120:138:contraception_consent,142:161:contraception_consent	Pre-menopausal or non-surgically sterile women who are unwilling to use an effective form of contraception such as the contraceptive pill or intrauterine device
NCT01367444	1:38:clinical_variable,43:49:lower_bound,65:79:treatment	Reduction in macular mean sensitivity of ≥1.2 dB as assessed by microperimetry
NCT01367444	14:38:clinical_variable,43:47:lower_bound,51:78:clinical_variable,83:91:lower_bound,114:123:treatment	Reduction in macular mean sensitivity of ≥5 dB or reduction in hill of vision by >14 dB-sr as assessed by static perimetry
NCT01367444	8:28:chronic_disease,69:97:treatment	Severe cone-rod dysfunction with no detectable or severely abnormal full-field electroretinogram responses
NCT01367444	13:33:chronic_disease,58:71:upper_bound	Significant intercurrent illness or infection during the 28 days prior to enrolment
NCT01367444	28:35:lower_bound,39:47:upper_bound,88:91:age,110:118:upper_bound	Symptomatic patients (from 6 years to 26 years old) with early or childhood-onset SMD (age at disease onset <18 years) with at least one pathogenic mutant ABCA4 allele on each chromosome confirmed by direct sequencing and co-segregation analysis within the patient's family
NCT01367444	1:14:clinical_variable,16:22:upper_bound	Visual Acuity ≤20/200 in the worst eye
NCT01367444	1:14:clinical_variable,19:25:lower_bound	Visual acuity of ≥20/100 in both eyes at the time of screening visit
NCT01367444	1:14:clinical_variable,19:25:lower_bound	Visual acuity of ≥20/200 in both eyes at the time of the screening visit
NCT01367444	1:14:clinical_variable,16:22:upper_bound	Visual acuity ≤20/100 in the worst eye
NCT01367444	1:14:clinical_variable,16:22:upper_bound	Visual acuity ≤20/200 in the worst eye
NCT01367444	1:6:gender,45:63:pregnancy,84:131:contraception_consent,145:157:lower_bound,245:260:upper_bound	Women of childbearing potential must have a negative pregnancy test at Day -1, and agree to use an effective form of contraception for at least three months, or be surgically sterile or postmenopausal, with the last menstrual period being over two years prior to enrollment
NCT01367444	9:16:lower_bound,21:29:upper_bound	between 6 years and 17 years old
NCT01367444	1:9:pregnancy	pregnant
NCT01367444	31:34:chronic_disease,49:52:lower_bound	with early or childhood-onset SMD with at least one pathogenic mutant ABCA4 allele on each chromosome confirmed by direct sequencing and co-segregation analysis within the patient's family
NCT01245712	42:53:cancer,57:92:cancer	Axillary nodes with definite evidence of microscopic or macroscopic extracapsular extension
NCT01245712	47:57:treatment	Clear delineation of the extent of the target lumpectomy cavity not possible
NCT01245712	25:50:chronic_disease,65:80:chronic_disease,88:118:clinical_variable,156:165:chronic_disease,167:195:chronic_disease,200:211:chronic_disease	Documented diagnosis of collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma
NCT01245712	1:14:chronic_disease,65:69:cancer,71:76:cancer,82:86:upper_bound	Gross disease must be unifocal with pathologic (invasive and/or DCIS) tumor size 3 cm or less
NCT01245712	1:4:gender	Men are not eligible for this study
NCT01245712	11:12:lower_bound,37:51:cancer	More than 3 histologically positive axillary nodes
NCT01245712	1:35:cancer,44:51:cancer,55:63:cancer	Non-epithelial breast malignancies such as sarcoma or lymphoma
NCT01245712	34:39:cancer,48:79:cancer,92:120:cancer	On histological examination, the tumor must be ductal carcinoma in situ (DCIS) or invasive adenocarcinoma of the breast
NCT01245712	1:30:cancer	Paget's disease of the nipple
NCT01245712	56:78:chronic_disease,80:95:chronic_disease,97:112:chronic_disease,117:139:chronic_disease,236:241:cancer	Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes at time of enrollment unless there is histologic confirmation that these nodes are negative for tumor
NCT01245712	15:37:cancer,94:114:treatment,186:205:treatment,242:243:lower_bound,409:413:cancer	Patients with invasive breast cancer are required to have axillary staging which can include sentinel node biopsy alone (if sentinel node is negative), sentinel node biopsy followed by axillary dissection or sampling with a minimum total of 6 axillary nodes (if sentinel node is positive), or axillary dissection alone (with a minimum of 6 axillary nodes); axillary staging is not required for patients with DCIS
NCT01245712	1:10:pregnancy	Pregnancy
NCT01245712	1:36:treatment	Prior radiation to the index breast
NCT01245712	8:30:cancer,32:47:cancer,51:55:cancer,70:73:lower_bound,99:100:lower_bound	Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters
NCT01245712	1:19:treatment,49:59:treatment	Surgical treatment of the breast must have been lumpectomy
NCT01245712	1:31:cancer,107:116:treatment,120:137:treatment,146:154:treatment	Suspicious microcalcifications, or densities (in the ipsilateral or contralateral breast as documented on mammogram or breast ultrasound) unless biopsied and found to be benign
NCT01245712	1:31:cancer,35:61:cancer	Synchronous bilateral invasive or non-invasive breast cancer
NCT01245712	1:3:clinical_variable,7:13:lower_bound,16:18:clinical_variable,20:29:cancer,34:56:cancer	T2 (> 3.0 cm), T3, stage III, or stage IV breast cancer
NCT01245712	23:30:lower_bound,38:40:upper_bound,41:54:cancer,59:67:cancer,73:78:cancer,92:96:upper_bound	The patient must have stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or less
NCT01245712	12:22:treatment,150:153:upper_bound,196:225:treatment	The target lumpectomy cavity must be clearly delineated and the target lumpectomy cavity/whole breast reference volume must be less than or equal to 30% based on the postoperative/pre-enrollment computed tomography (CT) scan
NCT01245712	30:56:treatment	Treatment plan that includes regional nodal irradiation
NCT01245712	1:6:gender,38:100:contraception_consent	Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy
NCT01245712	71:87:clinical_variable,96:97:upper_bound	patients with microscopic multifocality are eligible as long as total pathologic tumor size is 3 cm or less
NCT01245712	1:31:treatment	reexcision of surgical margins
NCT01245712	50:60:treatment	surgical margins are rendered free of disease by reexcision
NCT01245712	69:74:cancer,76:80:cancer,85:93:cancer	the margins of the resected specimen must be histologically free of tumor (DCIS and invasive)
NCT01220583	1:32:clinical_variable,35:51:lower_bound	Absolute neutrophil count (ANC) ≥ 1,800 cells/mm^3
NCT01220583	1:43:chronic_disease,109:112:chronic_disease	Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition (HIV testing is not required for entry into this protocol)
NCT01220583	1:16:chronic_disease,20:36:chronic_disease,47:70:treatment	Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
NCT01220583	26:42:treatment,61:74:upper_bound	All patients must have a Medical Oncology evaluation within 4 weeks prior to registration
NCT01220583	1:33:clinical_variable,37:67:clinical_variable,70:95:upper_bound	Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN
NCT01220583	1:11:clinical_variable,14:22:lower_bound,35:46:treatment,80:90:clinical_variable	Hemoglobin ≥ 8.0 g/dL (the use of transfusion or other intervention to achieve hemoglobin ≥ 8.0 g/dL is acceptable)
NCT01220583	1:47:clinical_variable,50:53:lower_bound,71:95:cancer	High-grade acinic cell carcinoma or high-grade (>30% solid component) adenoid cystic carcinoma
NCT01220583	9:29:treatment,37:50:upper_bound	History/physical examination within 8 weeks prior to registration
NCT01220583	20:34:cancer,57:81:cancer	Intermediate-grade adenocarcinoma or intermediate-grade mucoepidermoid carcinoma
NCT01220583	1:25:pregnancy,38:51:upper_bound,72:77:gender	Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
NCT01220583	15:48:treatment	No concurrent erythropoiesis-stimulating agents
NCT01220583	15:43:treatment,51:56:treatment,60:73:treatment,82:94:treatment	No concurrent hematopoietic growth factors (e.g., G-CSF or pegfilgrastim) during radiotherapy
NCT01220583	18:46:chronic_disease,53:60:treatment	No patients with residual macroscopic disease after surgery
NCT01220583	10:29:cancer,38:66:cancer,105:112:lower_bound,127:158:cancer,160:171:cancer,176:182:cancer	No prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
NCT01220583	4:26:treatment	No prior organ transplant
NCT01220583	4:22:treatment,50:56:cancer,89:106:treatment	No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
NCT01220583	4:31:treatment,35:52:treatment,57:82:cancer	No prior systemic chemotherapy or radiation therapy for salivary gland malignancy
NCT01220583	4:31:treatment,35:52:treatment,57:82:cancer,84:102:treatment,119:125:cancer	No prior systemic chemotherapy or radiation therapy for salivary gland malignancy (prior chemotherapy for a different cancer is allowable)
NCT01220583	29:41:chronic_disease	No significant pre-existing hearing loss, as defined by the patient or treating physician
NCT01220583	1:13:pregnancy	Not pregnant or nursing
NCT01220583	1:22:cancer,59:62:upper_bound,92:100:treatment	Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (≤ 1mm) or microscopically positive surgical margin
NCT01220583	1:10:clinical_variable,13:31:lower_bound	Platelets ≥ 100,000 cells/mm^3
NCT01220583	16:23:lower_bound,24:34:chronic_disease	Pre-existing ≥ grade 2 neuropathy
NCT01220583	49:66:chronic_disease	Protocol-specific requirements may also exclude immunocompromised patients
NCT01220583	43:66:cancer,74:88:upper_bound,129:139:treatment,166:172:treatment	Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast CT imaging of the chest is required (PET/CT is acceptable)
NCT01220583	1:17:clinical_variable,20:29:upper_bound	Serum creatinine < 2.0 mg/dL
NCT01220583	1:19:treatment,48:61:upper_bound	Surgical resection with curative intent within 8 weeks prior to registration
NCT01220583	1:16:clinical_variable,19:68:upper_bound	Total bilirubin < 2 x the institutional upper limit of normal (ULN)
NCT01220583	1:33:chronic_disease,45:58:upper_bound	Transmural myocardial infarction within the last 6 months
NCT01220583	1:16:chronic_disease,24:48:chronic_disease,59:74:treatment,86:99:upper_bound	Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
NCT01220583	1:6:gender,37:54:gender,84:115:contraception_consent,123:132:treatment,141:148:upper_bound	Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment
NCT01220583	1:26:clinical_variable,27:28:lower_bound,29:30:upper_bound	Zubrod performance status 0-1
NCT01220583	26:44:cancer	patients must be free of distant metastases based upon the following minimum diagnostic workup
NCT01200940	1:4:clinical_variable,8:11:clinical_variable,22:57:lower_bound	ALT or AST more than 1.5 times the upper limit of normal
NCT01200940	1:27:clinical_variable,29:50:clinical_variable,54:63:lower_bound,78:105:lower_bound	Abnormal glucose tolerance (fasting blood glucose of 100 mg/dl or higher, or 2-hour blood glucose of 140 or higher on oral glucose tolerance testing)
NCT01200940	1:4:age,5:6:lower_bound,7:15:upper_bound	Age 6-12 years at enrollment
NCT01200940	1:4:age,30:38:lower_bound	Age greater than or equal to 18 years
NCT01200940	1:12:clinical_variable,22:27:lower_bound	Body weight at least 17 kg
NCT01200940	23:28:upper_bound	Body weight less than 50 kg
NCT01200940	45:64:treatment,69:77:treatment	Certain exceptions are permitted, including topical medications and vitamins
NCT01200940	45:64:treatment,66:74:treatment,80:103:treatment	Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives
NCT01200940	16:59:treatment	Current use of prescription or non-prescription medication
NCT01200940	1:9:chronic_disease,11:32:clinical_variable,36:45:lower_bound,60:80:clinical_variable,84:87:lower_bound	Diabetes (fasting blood glucose of 126 mg/dl or higher, or 2-hour blood glucose of 200 or higher on oral glucose tolerance testing)
NCT01200940	1:11:chronic_disease	Glycosuria
NCT01200940	61:71:allergy_name,75:79:allergy_name,87:94:allergy_name	Known allergy, sensitivity or other contraindication to any study food or drug or its vehicle
NCT01200940	7:18:treatment	Other medications may be permitted at the discretion of the investigators
NCT01200940	1:25:pregnancy	Positive urine pregnancy test
NCT01200940	40:45:gender,50:68:clinical_variable,91:95:upper_bound,99:103:gender	Prepubertal (Tanner stage I breasts in girls, or testicular volumes less than or equal to 3 mL in boys)
NCT01200940	1:12:chronic_disease,16:34:chronic_disease	Psychiatric or cognitive disorder that will, in the opinion of the investigators, limit the subject's ability to provide assent, and/or the subject s parent/guardian to provide informed consent, or to comply with study procedures
NCT01200940	1:34:chronic_disease	Psychiatric or cognitive disorder that will, in the opinion of the investigators, limit the subject's ability to provide informed consent, or to comply with study procedures
NCT01200940	9:22:upper_bound,73:82:treatment	Recent (past 2 months) use of drugs that alter glucose metabolism (e.g. metformin)
NCT01200940	9:22:upper_bound,73:82:treatment,108:130:treatment,158:172:treatment	Recent (past 2 months) use of drugs that alter glucose metabolism (e.g. metformin), alter gastric pH (e.g. proton pump inhibitors) or gastric emptying (e.g. metoclopramide)
NCT01200940	7:17:clinical_variable,24:46:treatment	alter gastric pH (e.g. proton pump inhibitors)
NCT01200940	1:17:treatment,24:38:treatment	gastric emptying (e.g. metoclopramide)
NCT01175044	1:4:age,7:9:upper_bound	Age ≤ 17
NCT01175044	12:27:allergy_name	Allergy to povidone iodine
NCT01175044	25:36:treatment,37:50:upper_bound,67:74:treatment	Any condition requiring antibiotics 14 days prior to arriving for surgery
NCT01175044	88:108:chronic_disease	Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance)
NCT01175044	31:63:treatment	Patients scheduled to undergo revision total knee arthroplasty for infectious reasons
NCT01175044	15:40:chronic_disease,50:53:chronic_disease,54:58:chronic_disease	Patients with chronic immunosuppression (such as HIV/AIDS)
NCT01175044	31:54:treatment	Scheduled to undergo revision total knee arthroplasty
NCT01107717	7:15:lower_bound,19:22:age	above 18 years of age
NCT01107717	29:38:treatment,49:57:upper_bound	drug naive, or have been on metformin less than 3 months
NCT01107717	15:30:chronic_disease,22:30:chronic_disease,34:37:chronic_disease,98:105:lower_bound,178:186:lower_bound	subjects with type 1 diabetes or GAD positive subjects or subjects with long standing diabetes (>2 years) or subjects who are not drug naive or have been on metformin more than 3 months
NCT01107717	15:30:chronic_disease,52:64:upper_bound	subjects with type 2 diabetes diagnosed during the past 2 years
NCT00975520	1:5:age,6:14:lower_bound	Aged 18 years or older
NCT00975520	1:9:chronic_disease	Albinism
NCT00975520	17:20:treatment,82:88:cancer	Clinical and/or MRI evidence of a named cranial or cervical nerve involvement by tumour
NCT00975520	10:31:treatment	Complete macroscopic resection of all known disease
NCT00975520	1:30:clinical_variable,34:35:upper_bound	ECOG performance status score of 2 or less
NCT00975520	36:43:treatment	High risk for poor compliance with therapy or follow-up as assessed by investigator
NCT00975520	26:54:cancer	Histologically confirmed neurotropic primary melanoma
NCT00975520	39:47:treatment	Inability to localise surgical bed on CT scans and/or surgical margins (cm) not known
NCT00975520	51:68:treatment,77:94:treatment,116:133:chronic_disease	Intercurrent illness that will interfere with the radiation therapy such as immunosuppression due to medication or medical condition
NCT00975520	1:16:clinical_variable,30:38:lower_bound	Life expectancy greater than 6 months
NCT00975520	1:13:chronic_disease,62:70:cancer	Neurotropism is identified pathologically by the presence of melanoma cells around nerve sheaths (perineural invasion) or within nerves (intraneural invasion)
NCT00975520	16:55:cancer,95:97:treatment,101:104:treatment	No evidence of in-transit, nodal or distant metastases as determined by clinical examination, CT or MRI
NCT00975520	13:20:treatment,25:33:cancer,55:76:treatment	No previous surgery for melanoma (other than complete macroscopic resection as stated above)(i.e. Not recurrent disease)
NCT00975520	19:25:cancer	Occasionally, the tumour itself may form neuroid structures (termed 'neural transformation'; this is also regarded as neurotropism)
NCT00975520	18:39:treatment	Participation in other clinical trials with the same primary endpoint
NCT00975520	38:66:contraception_consent	Patients capable of childbearing are using adequate contraception
NCT00975520	21:28:cancer,56:63:lower_bound,153:155:upper_bound,184:211:cancer,214:221:lower_bound,230:254:cancer,259:268:cancer	Patients with prior cancers, except: those diagnosed ≥ 5 years ago with no evidence of disease relapse and clinical expectation of relapse of less than 5%; prior successfully treated Level 1 cutaneous melanomas ≥ 2 years ago; or non-melanoma skin cancer; or carcinoma in situ of the cervix
NCT00975520	1:56:treatment,68:97:treatment,101:114:cancer,118:138:cancer,179:185:cancer	Previous radical radiation therapy to the head and neck, excluding superficial radiation therapy to cutaneous SCC or basal cell carcinoma, which is not within or overlapping the tumour bed
NCT00975520	1:7:cancer	Tumour located above the clavicle and below the jaw or occiput (neck primary) or above the jaw/occiput (head primary)
NCT00975520	1:6:gender,11:23:pregnancy	Women who are pregnant or lactating
NCT00969332	3:10:lower_bound,14:17:age,24:32:upper_bound	> 2 weeks of age and < 18 years of age
NCT00969332	3:6:lower_bound	> 60% calories from parenteral nutrition
NCT00969332	13:48:chronic_disease	Acquired or congenital gastrointestinal disease
NCT00969332	1:22:treatment	Anticoagulant therapy
NCT00969332	1:9:chronic_disease	Diabetes
NCT00969332	1:17:clinical_variable,38:45:lower_bound	Direct bilirubin greater or equal to 2 mg/dL on 2 consecutive measurements
NCT00969332	20:33:chronic_disease	Documented case of liver disease other than Parenteral Nutrition Associated Cholestasis
NCT00969332	10:37:clinical_variable,51:58:lower_bound	Expected parenteral nutrition course greater than 30 days
NCT00969332	1:36:treatment	Extracorporeal Membrane Oxygenation
NCT00969332	8:26:treatment,53:66:chronic_disease	Failed standard therapies to prevent progression of liver disease (Actigal, cyclic parenteral nutrition, avoidance of overfeeding, reduction/removal of copper from parenteral nutrition if elevated my laboratory analysis, advancement of enteral feeds)
NCT00969332	1:27:chronic_disease	Fatal chromosomal disorder
NCT00969332	33:53:treatment,57:64:upper_bound	Patient expected to weaned from parenteral nutrition in 30 days
NCT00969332	1:8:allergy_name,10:13:allergy_name,18:26:allergy_name	Seafood, egg, or Omegaven allergy
NCT00969332	1:7:chronic_disease	Stroke
NCT00969332	1:19:chronic_disease	pulmonary embolism
NCT00969332	8:29:chronic_disease	recent myocardial infarction
NCT00946192	1:3:lower_bound,4:12:upper_bound	14-21 years old
NCT00946192	16:28:clinical_variable,29:31:lower_bound,32:39:upper_bound,44:58:upper_bound	> nine menses (cycle length 21-35 days) in preceding year
NCT00946192	1:11:chronic_disease	Amenorrhea (for AA)
NCT00946192	1:4:bmi,13:17:lower_bound,18:34:upper_bound,39:42:age	BMI between 10th-90th percentiles for age
NCT00946192	1:14:clinical_variable,16:24:lower_bound	Bone age (BA) >15 years
NCT00946192	1:8:gender	Females
NCT00946192	25:42:lower_bound,62:76:chronic_disease,78:90:clinical_variable,93:102:lower_bound,109:119:lower_bound,148:156:lower_bound	absence of menses for > three months (74) within a period of oligomenorrhea (cycle length > six weeks) for >six months, or absence of menarche at >16 years
NCT00935090	26:37:cancer,41:63:cancer	Histologically confirmed solid tumor or hematologic malignancy
NCT00935090	1:19:pregnancy	Negative pregnancy test
NCT00935090	1:13:pregnancy	Not pregnant or nursing
NCT00870064	11:17:clinical_variable,31:38:lower_bound	fall from height greater than 10 feet
NCT00870064	22:29:upper_bound	falls from less than 10 feet
NCT00870064	44:76:treatment	open fracture that would typically require operative reduction and fixation
NCT00870064	20:23:lower_bound	wound greater than 1cm in length
NCT00870064	17:20:upper_bound	wound less than 1cm in length and the bone not visualized through the skin
NCT00738101	24:45:treatment,73:80:lower_bound	Be expected to require intravenous nutrition for at least an additional 28 days
NCT00738101	17:24:lower_bound,43:50:upper_bound	Be greater than 14 days old and less than 5 years old
NCT00738101	1:21:clinical_variable,35:42:lower_bound	Conjugated bilirubin greater than 2 mg/dL
NCT00738101	20:35:chronic_disease,39:60:chronic_disease	Have evidence of a viral hepatitis or primary liver disease as the primary etiology of their cholestasis
NCT00738101	90:101:chronic_disease	Have other health problems such that survival is extremely unlikely even if the infant's cholestasis improves
NCT00695214	21:24:chronic_disease,37:55:treatment	Adult patients with OSA considering surgical treatment
NCT00695214	12:20:allergy_name,22:33:allergy_name,35:47:allergy_name,51:59:allergy_name	Allergy to propofol, soybean oil, egg lecithin or glycerol
NCT00695214	34:42:treatment,56:72:treatment,76:92:treatment	Other contraindication to use of propofol (decision of anesthesiologist or otolaryngologist.)
NCT00695214	1:9:pregnancy,10:15:gender	Pregnant women
NCT00579514	68:81:cancer	All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites
NCT00579514	50:70:cancer,72:79:cancer,81:87:cancer,89:94:cancer,96:105:cancer,107:112:cancer,114:122:cancer,127:146:cancer,171:179:cancer	MSKCC patients without a histologic diagnosis of cancer of the breast, bladder, kidney, colon, testicles, lungs, prostate, or lymphoid malignancy (including all types of lymphoma) will not be eligible for the AMDeC sponsored component of the study
NCT00579514	70:76:cancer	Patients of Ashkenazi Jewish ancestry with a histologic diagnosis of cancer of any type
NCT00579514	41:47:cancer,55:60:cancer,62:68:cancer,70:77:cancer,79:85:cancer,87:96:cancer,98:103:cancer,105:113:cancer,115:128:cancer,133:148:cancer	Patients with a histologic diagnosis of cancer of the colon, breast, bladder, kidney, testicles, lungs, prostate, head and neck, or lymphoid organs, who have donated a diagnostic blood sample as either an inpatient or outpatient at MSKCC
NCT00542373	28:48:cancer,52:77:cancer	Patients with a history of head and neck cancer or oral premalignant disease but without any clinical evidence of disease
NCT00542373	52:63:cancer	Patients with either pre-malignant or a history of oral cancer based on patient history and clinical presentations
NCT00542373	43:56:chronic_disease,58:72:chronic_disease,129:140:cancer	Persons with any other condition (such as lichen planus, Fanconi anemia, heavy tobacco use, etc) making them at higher risk for oral cancer development
NCT00542373	15:34:cancer,99:110:chronic_disease,114:127:chronic_disease	Subjects with premalignant lesion, or potentially premalignant lesion, of the oral cavity mucosa (leukoplakia or erythroplakia)
NCT00501826	1:61:clinical_variable,84:85:upper_bound	Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3
NCT00501826	1:9:pregnancy	Pregnant
NCT00501826	22:32:cancer,43:72:cancer	Previously untreated T cell ALL including T cell lymphoblastic lymphoma
NCT00501826	7:16:clinical_variable,39:48:upper_bound,89:94:cancer	Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 5.0 mg/dL is acceptable
NCT00501826	1:17:clinical_variable,40:49:upper_bound,90:95:cancer,119:128:upper_bound	Serum creatinine less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 2.5 mg/dL is acceptable
NCT00501826	1:47:clinical_variable,51:95:clinical_variable,118:149:upper_bound	Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) less than or equal to 4 x upper limit of normal (ULN)
NCT00501826	36:48:treatment	failure to one induction course of chemotherapy are eligible
NCT00501826	9:14:gender	nursing women
NCT00501826	13:15:chronic_disease,25:26:upper_bound	patients in CR after =< 2 courses are also eligible
NCT00230607	24:38:treatment	agree to adhere to the Fabry Registry recommended schedule of assessments for medical history
NCT00230607	38:47:treatment	be born to a mother who is receiving Fabrazyme during lactation
NCT00230607	49:58:treatment	be enrolled in the Fabry Registry and receiving Fabrazyme while lactating
NCT00230607	1:11:treatment	genotyping
NCT00230607	1:10:pregnancy	pregnancy outcome
